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The management of chronic diseases is described as the “health challenge of the 
21st century” by the World Health Organization. Patients’ active role in managing their 
illness is considered, by many, as central in addressing this challenge. This study 
explored and described, through scleroderma patients’ own perceptions and 
understanding, their commitment to illness management, including how they were 
involved in dealing with their illness and how they learned to do so. The role of social 
interactions, in particular, support groups, in this process was also investigated. 
Using a mixed-methods approach, 201 patients were surveyed, and 25 in-depth 
interviews were conducted. The quantitative results of this study indicated that 64% of 
patients were committed in managing their illness by being highly active in dealing 
with their illness. An increase in activation was associated with longer disease duration 
in the first decade of illness. Additionally, the patients with high social support were 
more active. The qualitative findings showed patients engaged with various types of 
work to mitigate the physical, emotional, psychological, relational, and financial 
impact of the illness. In doing so, patients employed four problem-solving strategies 
that they had learned by confronting problems in daily lives. These strategies were at 
the heart of their incidental and tacit learning of how to manage their illness. 
Only 32% of patients participated in support groups. Support group participants 
showed higher activation and considered these groups as providing support, learning 
opportunities, and venues to help other patients. 
This study indicates that patients’ commitment to management of their illness, 
far from being a static characteristic of patients, is a spectrum where patients are 
engaged in a process of complex negotiation with multiple needs of their illness, in 
tandem with their illness trajectory. Illness uncertainty, learning, and strategies to solve 
problems in managing the illness frame patients’ commitment and engagement. A 
preliminary model delineating these elements is provided. 
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The World Health Organization (WHO, 2002) has called the management of 
chronic diseases the “health challenge of the 21st century” and predicted that chronic 
conditions will “be the leading cause of disability throughout the world by year 2020” 
(p. 6). Including patients in their care, WHO suggested, is one of the core elements of 
tackling this challenge:  
Because the management of chronic conditions requires lifestyle and 
daily behaviour change, emphasis must be upon the patient’s central role and 
responsibility in health care. Focusing on the patient in this way constitutes 
an important shift in current clinical practice. At present, systems relegate 
the patient to the role of passive recipient of care, missing the opportunity to 
leverage what he or she can do to promote personal health. Health care for 
chronic conditions must be re-oriented around the patient and family. (p. 5) 
Since this statement was put forth, a body of research on ways to encourage patients to 
have an active role in their own care has come to exist, notably for conditions like 
diabetes, asthma, and cardiovascular diseases. Despite these efforts, a fundamental 
understanding of this phenomenon of an active role, variably referred to as activation, 
engagement, participation, involvement, empowerment, self-care, self-management, 
among many other terms used, is lacking. This study investigated this phenomenon in 
patients with scleroderma, a rare autoimmune disease, with the purpose of inquiring into 
how it looked among these patients, what strategies patients used, and how they learned 
them, in order to add to the body of knowledge in this area and possible implications in 
health care practice and policies. 
  
2 
Context and Background 
According to the National Health Council (2012), chronic diseases, including 
chronic non-communicable diseases (CNCDs), affect approximately 45% of adult 
Americans and some 8% of children under the age of 18. In the U.S. annually, seven out 
of ten deaths and 75% of health care costs are attributed to chronic conditions. Chronic 
diseases are identified as those that have long durations (over 3 months), are not cured by 
medications, and are not preventable by vaccines. However, technical definitions vary 
considerably based on considered characteristics such as “duration or latency, need for 
medical attention, effect on function, pathology, departure from well-being, 
noncontagious nature, multiplicity of risk factors, and non-amenability to cure” 
(Goodman, Posner, Huang, Parekh, & Koh, 2013, p. 2). Some of the most prevalent 
chronic conditions are disorders such as high blood pressure, Alzheimer’s disease, 
cardiovascular disease (CVD), stroke, cancer, chronic respiratory diseases, diabetes, and 
arthritis (CDC, 2010). By the year 2020, the chronic disease contribution to mortality rate 
is “expected to rise to 73% of all deaths and 60% of global burden of disease” (WHO, 
2013), making it the “dominant global public health issue soon” (Greenberg, Raymond, 
& Leeder, 2011, p. 1386). 
The tremendous economic and human costs and the sheer worldwide magnitude 
make the problem of prevention, management, and cure of chronic diseases an urgent 
one. This problem is compounded by the realization that the prevalent health care 
systems are designed to cater to the needs of patients with acute illnesses, and conversely, 
are ill-equipped to address the needs of chronic disease patients the world over (Pan 
American Health Organization [PAHO], 2013). In acute and urgent care, “the emphasis is 
on diagnosis, ruling out serious disease, and curative or symptom-relieving treatments” 
(Wagner, Austin, & Von Korff, 1996, p. 513). These interventions constitute the totality 
of care needed for acute illnesses, which are characterized by being episodic and limited 
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in duration. For chronic diseases, the acute phase only marks the initial stage of a multi-
phase disease trajectory (Corbin & Strauss, 1988). Furthermore, the disease presentation 
at its earliest stages may be complex and baffling: some patients contend with MUS 
(medically unexplained symptoms) or contested illnesses (Barker, 2011; Daker-White, 
Sanders, Greenfield, Ealing, & Payne, 2011) for years or a decade in a state of 
“diagnostic limbo” (Corbin & Strauss, 1988, p. 27). More importantly, once diagnosed, 
many patients encounter medical practices that are not designed to provide for their 
ongoing needs. 
To date, the inability to meet these needs is deemed as the “single greatest 
challenge facing organized medical practice” (Wagner, n.d.), where “coverage gaps and 
poorly organized care” (Schoen, Osborn, How, Doty, & Peugh, 2009, p. w13) are viewed 
to be at the heart of the problem. Many experts concede that ecological and political 
changes at the policy and organizational levels are sorely needed to tackle the problem, 
but also acknowledge that the required multidisciplinary and boundary-crossing 
teamwork required “will necessarily take a lot of time, require cooperation among a 
variety of folks generally unaccustomed to working with one another, and require 
disparate stakeholders to develop new ways of doing business” (Vladeck, 2001, p. 175). 
The proposed organizational care models for the management of chronic diseases, such 
as the Chronic Care Model (Wagner et al., 2001), Innovative Care for Chronic Care 
framework (WHO, 2002), and the Expanded Chronic Care Model (Barr et al., 2003), 
depict the multiple stakeholders that ideally should be involved, and their roles and 
relationships within this complex enterprise. Engaging the patients in their care and 
having involved and activated patients (and caregivers) constitute important elements of 
these models. 
At the higher policy level, the National Research Council’s (2001) report 
recommends a restructuring of the healthcare system that is patient-centered by 
“providing care that is respectful of and responsive to individual patient preferences, 
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needs, and values and ensuring that patient values guide all clinical decisions” (p. 39). 
The Patient Protection and Affordable Care Act’s (2010) allocation of $3.5 billion in 
funding for a new Patient-Centered Outcomes Research Institute expands the patient and 
caregiver involvements to biomedical research. Globally, the Expert Patient program in 
the U.K. (Department of Health, 2001), the German der mündige (mature) patient 
(Dieterich, 2007), and the Canadian and Australian policy directives (Forbat, Hubbard, & 
Kearney, 2009) represent similar initiatives and debates, experimenting with and 
exploring patient involvement within a number of divergent and varied healthcare 
systems. 
These policy and organizational initiatives have accelerated a trend for a bottom-
up, patient-centric approach for service delivery (Wiig, Storm, Aase, & Gjestsen, 2013). 
In essence, they legitimize patients as active participants in their own care, in medical 
and cultural contexts that have traditionally treated them based on a paternalistic model 
of the patient-physician relationship (Emanuel & Emanuel, 1992; Robinson &Thomson, 
2001). A paternalistic model privileges the physician’s knowledge and views and 
decontextualizes the disease from the illness experience by considering the medical 
treatment as an objective and scientific undertaking to alleviate the symptoms. 
Such a view has taken hold, overtime, as the practice of medicine transitioned from 
bedside-medicine to hospital-medicine and then laboratory-medicine (Jewson, 1976). 
These transitions have shifted the sources of information for doctors and narrowed the 
roles that patients play in the diagnostic process and knowledge creation (Wilde, 2007). 
Under bedside-medicine, the experiential perception of sickness by the patient and 
observations of the extended family and neighbors might have been the basis of 
conceptualization of the illness; under hospital medicine, “the sick-man became a 
collection of synchronized organs, each with a specialized function” (Jewson, 1976, 
p. 229). With the advent of laboratory medicine and the utilization of pathology as the 
determinant of a disease state, the “patient was removed from the medical investigator’s 
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field of saliency altogether … by a relocation of the fundamental realities of pathology in 
microscopical events beyond the tangible detection of patients and practitioners alike” 
(p. 237). 
Nettleton (2004) argued that the anatomical science that was privileged in hospital 
medicine, along with the physiological science that was the basis of laboratory medicine, 
has started to give way to informational medicine. Propelled by information and systems 
theory sciences and advances in technology, the mechanistic view of body is replaced 
with a “somatic system,” where disease is “a form of information malfunction or 
‘communication pathology’” (p. 668). 
Patients are affected by these technological changes as well. Not only do they have 
access to unprecedented amounts of medical information that was only available to 
medical professionals just a few years earlier; they are also increasingly the producers of 
information in online communities and have become creators of what Fox and Ward 
(2006) call health identities ranging “from a relatively medicalized ‘expert patient’ to an 
independent consumer of health information” (p. 463). 
These technological changes, including self-tracking devices, information access, 
and connectivity to peer patients, have converged with a number of other factors to 
initiate a shift in how the current medical care models are viewed. Among these factors 
are: the worldwide scale of the problem of chronic conditions, the proposed health policy 
initiatives, the paradigmatic shift in how diseases are conceptualized, a move away from 
paternalistic models, the financially and economically unsustainable health delivery 
models, redefinition of patients as consumers, and an aging population often not with one 
but multiple chronic conditions. These factors have gathered force and contributed to a 
movement toward more inclusive and collaborative models of care where not having the 
patients involved is not an option (Greenhalgh, 2009; Reiser, 1993; Say & Thomson, 
2003; Swan, 2009). 
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Consequently, the real-world problem of understanding how patients should be 
involved or choose to have an active role increasingly is viewed as critical from research, 
practice, and policy perspectives. This begs the question: What does it mean for patients 
to play an active role? 
What Do We Know about the Active Roles Patients Play? 
A scoping search of literature was conducted using CINAHL, PsycINFO, Medline, 
and ERIC databases and the key words ‘patient,’ ‘involvement,’ ‘engagement,’ 
‘activation,’ and ‘participation’ for journal articles between 2000 and 2016. The 
following six categories were identified as areas where the notion of patient active role 
and involvement is explored in the literature: 
1. Biomedical and Health Research: patient involvement in research agenda 
setting, defining and assigning importance to treatment outcomes, review of 
effectiveness of research, lay membership in research ethics committees and 
scientific advisory process; participation in clinical, non-therapeutic, genomic, 
and translational research and trials; raising funds and doing medical charities. 
2. Social, Policy and Practice: patient involvement in enhancement of evidence-
based- practices, input into development of guidelines for clinical practice, 
setting priorities for healthcare improvement, assessing office consultation 
quality, and taking part in participatory action research. 
3. Patient Safety: including patient involvement in medical error disclosure, 
diagnostic error mitigation, and safety interventions and initiatives. 
4. Products and Service Development: patient involvement in health services 
design and quality improvement; health technology design and medical device 
development; development and evaluation of patient support tools, patient 
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reported outcome measures, information leaflets, and rehabilitation 
questionnaires. 
5. Education: patient involvement as educators in healthcare education curricula 
and health professional education programs for medical students and nurses, 
as lay-peer educators, and as participants in educational intervention / 
prevention / rehabilitation programs. 
6. Involvement in their own health through: health care consultations, treatment 
decision-making and goal-setting for care, engagement with health 
information, as participants in self-help groups, online social network and 
self-management programs, involvement in diagnostic process and health 
screening, self-monitoring and use of health technologies. 
The focus of this research is limited to item number 6 on this list: involvement of patients 
in their own care. The literature concerned with this type of involvement makes a number 
of assertions about patients who play an active role in their own care: 
•   These patients have better disease outcomes (Stewart, 1995), show higher self-
efficacy (Ritter, Lee, & Lorig, 2011), and express higher levels of satisfaction 
with their care (Ashraf, Colakoglu, & Nguyen, 2013; Glass et al., 2012). 
•   Patients’ education, age, race, gender, ethnicity and cultural background, and 
the severity of the illness have an impact on the levels of involvement. These 
levels may change over time and with increased knowledge. The younger, more 
educated, White, and female patients tend to be more involved. While those 
with lower education and those with severe life-threatening conditions prefer to 
defer to doctors (Arora & McHorney, 2000; Carey et al., 2012; DeWalt, Boone, 
& Pignone, 2007; Say, Murtagh, & Thomson, 2006; Smith, Dixon, Trevena, 
Nutbeam, & McCaffery, 2009). 
•   Across multiple chronic conditions that have been studied, all patients showed 
a high desire for getting information about their conditions and treatment 
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options, while levels of preference for being involved in decision-making 
varied (Chewning et al., 2012; Tariman, Berry, Cochrane, Doorenbos, & 
Schepp, 2010). 
•   The scope of active involvement goes beyond what occurs in clinical 
encounters and includes patients’ daily lives (Audulv, Asplund, & Norbergh, 
2012; Kralik, Koch, Price, & Howard, 2004). 
Contextual factors such as empowerment interventions, clinical setting and the 
physician’s communication style, patients’ social networks, patients’ 
psychological states and levels of depression, anxiety and distress exert an 
influence on the active role patients take on (Arora, Ayanian, & Guadagnoli, 
2005; Eldh, Ekman, & Ehnfors, 2008; Entwistle, Prior, Skea, & Francis, 2008; 
Sepucha & Mulley, 2009; Street, Gordon, Ward, Krupat, & Kravitz, 2005; 
Wensing & Grol, 1998). 
In spite of these understandings, the conceptualization and operationalization of the 
notion of active role and involvement in care have been fraught with difficulties. Forbat, 
Hubbard, and Kearney (2009), based on research done on cancer patients, concluded that 
“one of the greatest barriers to truly integrating patient involvement into the health 
service, policy and research is the conceptual muddle with which involvement is 
articulated, understood and actioned” (p. 2553). In addition to a lack of definitional 
clarity and consensus, many of these conceptualizations are not from the perspectives of 
the patients themselves (Barello, Graffigna, Vegni, & Bosio, 2014), but represent the 
professional and medical view of how patients should be active and involved.  
The Rationale for This Study 
First, the conceptual muddle noted by Forbat et al. (2009) and the perceived need 
for clarifying and describing patients’ involvement with their own care warrant further 
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research in this area at a conceptual level. Second, there is a need to understand these 
concepts from the patients’ point of view and through studies that solicit patients’ 
experience and commitment to the management of illness. Third, implications for 
practice and policy, including insights to facilitate participation, to remove barriers to 
involvement, and to deliver more responsive and tailored care, may be obtained through 
such explorations. Referring to patient engagement, Mostashari, the National Coordinator 
for Health Information Technology, is reported as stating “if it were a drug, it would be a 
blockbuster” (Schneider, 2012). This highlights the extent to which the significance of 
patients’ active role in their own care is underestimated at the practice and policy levels. 
Last, insights from such studies might be beneficial to patient groups in empowering their 
memberships to take on more active roles in their own care. As face-to-face and virtual 
social networks of patients are becoming more influential for obtaining information, 
getting provider referrals, and experimenting with alternative therapies, the practice 
implications expand beyond the traditional venues. Understanding patient involvement 
may expand our understanding of these non-traditional patient habitats in empowering 
patients. 
Problem Statement 
Despite a general agreement that patient involvement and activation are critical 
components of the types of care models needed for chronic conditions, our understanding 
and articulation of the concept of patients’ active role and involvement, and the 
operationalization of it as a construct are limited, in particular, from the perspective of 
patients themselves. In that light, this inquiry seeks to understand, from patients’ 
perspectives, in what ways their commitment to their illness management is perceived 




Although in many studies, the role of learning in patient involvement is implied, it 
is rarely explicitly explored. In some work, learning is referred to in the context of formal 
educational programs. For example, Lorig (1993) defines patient self-management “as 
learning and practicing the skills necessary to carry on an active and emotionally 
satisfying life in the face of a chronic condition” (p. 11). Charmaz (2003) refers to an 
illness experience as a conduit for learning “new definitions of self” and relinquishing the 
“‘old ones’” (p. 170). Corbin and Strauss (1988) note, “No one chooses an illness 
trajectory, but having been caught up in it, one must try to learn to live with it” (p. 75). 
Thorne, Paterson, and Russell (2003), regarding the expertise that many patients develop 
in illness decision-making, state, 
In short, we need to know what expertise in such decision-making 
entails beyond adherence to medical recommendations, understand how it is 
learned and sustained, and develop strategies for how we can best support it 
as it evolves over time and circumstance in the life trajectory. (p. 1338) 
Learning in this research is the explicit focus; the lens of adult learning theories is 
utilized as a framework for this exploration. 
Purpose of the Study 
The purpose of this study is to explore and describe, through scleroderma patients’ 
own perceptions and understanding, their commitment to illness management, including 
how they are involved in dealing with their illness and how they learned to do so. In this 
exploration, the significant areas of commitment in engaging with disease and living with 
the illness, and the patterns in involvement and possible meanings ascribed to them by 
patients are examined and described, and beliefs, feelings, attitude, strategies, and 
contextual factors that may have shaped these are scrutinized through a number of 
theoretical lenses. Such an examination in scleroderma patients is suspected to contribute 
to outlines of a general model of involvement in one’s care, applicable not only to this 
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group of patients, but also other chronic disease patients. The rationale for this argument 
is presented next. 
Significance of Studying Scleroderma Patients 
The rationale and significance of studying scleroderma patients are predicated on 
four characteristics of chronicity, autoimmunity, complexity, and the diversity of 
presentation in this disease. These are presented in this section, after a general 
introduction to scleroderma. 
Scleroderma 
Scleroderma, meaning hard skin, also known as systemic sclerosis (SSc), is an 
immune-mediated, connective tissue, inflammatory disease that involves fibrotic changes 
(scarring) in skin and/or the connective tissues of internal organs. An unknown trigger 
mechanism causes an inflammatory reaction by the immune system that is followed by 
fibrotic changes. Three processes in the pathology of the disease are observed: the 
fibroblast overproduction of extracellular matrix, vascular endothelial cell damage, and 
autoantibody productions due to immune response (Chung & Utz, 2004), although it has 
not been determined, to date, whether the autoimmune response is primary or secondary 
to the disease process.  
There are great variations in manifestation of the disease in terms of organ 
involvement, and the severity and progression that ensue. The subtypes include localized, 
limited cutaneous scleroderma (lcSSc), diffuse cutaneous scleroderma (dcSSc), and 
scleroderma sine scleroderma (ssSSc). In the localized form, skin below elbows and 
knees is the only affected area. In its limited form, the build-up of collagen manifests 
outwardly as shiny, thick, and tight skin on face, trunk, hands, and feet. In this form, the 
disease is not fatal, but the skin deformity, joint and muscle pain, and resulting 
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disabilities greatly impact the quality of patients’ lives. The systemic diffuse form of the 
disease progresses to one or more internal organs, such as lung, heart, kidney, and 
esophagus. Scleroderma sine lacks the skin manifestation, but similar to the diffuse form, 
impacts the internal organs. The end-stage organ failure is the cause of mortality in the 
progression of the systemic form of the disease.  
The etiology and pathogenesis of scleroderma are poorly understood, and hence no 
treatment to counteract the primary cause(s) of the disease exists. Clinically, scleroderma 
is managed by therapies that address the secondary symptoms and organs’ complications. 
For example, use of ACE inhibitors for kidney involvement and early treatment of 
pulmonary hypertension are attributed to considerable reduction of mortality in these 
subgroups of patients (Eckes, Hunzelmann, Moinzadeh, & Krieg, 2007). Largely 
experimental and with varying degrees of success, immunosuppressants such as 
chemotherapy and organ transplant anti-rejection drugs are used, off-label, to control the 
immune system’s response. The goal of these treatments is to slow down the collagen 
build-up and the progression of the disease.  
It is estimated that some 200,000-300,000 in the U.S. suffer from this illness, 
although estimates of prevalence from hospital-based data vary from 5 to 34 per 100,000 
of the population (Cooper, Bynum, & Somers, 2009). Given the challenges in diagnosis 
and the overlap with other conditions, it is difficult to provide an accurate count. Similar 
to other autoimmune diseases, it is four times more prevalent in women in general, and 
some 7-12 times higher in women between the ages of 30 and 55 (Gottesman, 2003). The 
rarity and the lack of experience of many health professionals with the disease result in a 
prolonged diagnostic phase, anecdotally 5 or 10 years, where patients have to see 
between “two to five doctors before receiving the diagnosis” (p. 2). Primarily treated by a 
rheumatologist, depending on the number of organs involved, most patients have to be 
under the care of multiple specialists (dermatologist, cardiologist, gastroenterologist, 
nephrologist, and pulmonologist) and undergo various tests (blood tests, lung function 
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tests, echo-cardiogram, CTs, etc.) on a regular basis. Some might need mental health 
professionals’ help to cope with the depression, stress, and the uncertainty of the disease. 
Tightening of the skin on hands leads to curling up of fingers, precipitating surgery for 
some patients. Skin tightening around the mouth necessitates seeing dentists with the 
knowledge and experience of working with such cases; pharmacists might have to be 
enlisted on how to manage prescription pills when the esophagus is affected.  
The extent of the medical care needed and its coordination, how very little is 
known about the disease itself, the experimental nature of medical interventions 
employed, the considerable variations in its manifestation, the disability and disfiguration 
that afflict some, and the unpredictable disease course place scleroderma in the category 
of complex chronic autoimmune diseases. The confluence of characteristics of chronicity, 
autoimmunity, complexity, and diversity in presentation of the disease makes 
scleroderma patients a novel population to study, as this population encompasses many 
characteristics of chronic illnesses in one setting. 
Chronicity 
A Centers for Disease Control and Prevention (CDC) report (Ward, Schiller, & 
Goodman, 2014) places 117 million people, that is about half of the U.S. adult 
population, as having one or more chronic conditions. Sperry (2006) defines a chronic 
disease as: 
a disease entity that usually does not have a single cause, a specific onset, or 
a stable set of symptoms. Such a disease state is largely an objective entity. 
Although a cure may be possible for mild levels, it is unlikely for moderate 
and advanced levels of disease process. The disease course tends to be 
marked by periods of exacerbation and remission as well as progressive 
degeneration. (p. 6) 
Scleroderma shares these defining characteristics with most chronic conditions. Lack of 
clarity on a cause(s), non-specificity of onset, a protean characteristic (absence of a set of 
stable symptoms), fluctuations in symptoms, and progressive nature of illness give rise to 
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subjective illness experiences such as a sense of uncertainty and confusion about the state 
of the disease and one’s prognosis; interruptions of routines and unpredictability of one’s 
health state due to fluctuation of symptoms; and stress and depression caused by the 
progression and downward decline of health. Although the intensity and timing of these 
experiences may vary among chronic disease sufferers, they do occur with all patients in 
some form or another, at one point or another, and may be viewed as shared 
commonalities among chronic disease patients. 
Autoimmunity 
Among the 117 million patients with chronic conditions, there are 23.5 million 
patients (National Institute of Health [NIH], 2012)—and by some accounts up to 50 
million (American Autoimmune Related Diseases Association [AARDA], 2017)—who 
suffer from some 80 autoimmune diseases, including the better-known ones like 
rheumatoid arthritis, diabetes mellitus (type 1), multiple sclerosis, lupus, Crohn’s disease, 
Hashimoto, celiac disease, Graves’ disease, inflammatory bowel disease, psoriasis, 
rheumatic fever, and rarer ones like scleroderma, Kawasaki, Sjogren’s and Still’s 
diseases. 
Autoimmunity, defined as the failure of body to distinguish between self and non-
self (Anderson & Mackay, 2014), was inconceivable and resisted as a concept in medical 
community until fairly recently: “1955-1965 [was] the decade marked by the question, 
does autoimmunity exist?” (Rose & Mackay, 1985, as cited by Silverstein, 2014, 
p. xxxiv). Once accepted, it has been instrumental in shaping a re-emergent perspective 
on the concept of disease and its treatment. Anderson and Mackay (2014) argue that: 
As the concept of autoimmunity emerged in the middle of twentieth 
century, it therefore represented to a degree the return to older physiological 
or biographical concept of disease causation … before the bacteriological 




This earlier “constitutional model” of being ill, according to Anderson and Mackay, 
relied on restoring body’s homeostats by individualizing, modulating, and adjusting 
medications, similar to how the modern approaches to autoimmune disease treatments 
have emerged and have been put into practice. These emergent holistic approaches have a 
better fit in chronic disease models and, it may be argued, provide a more natural context 
for expressions of involvement and active roles by patients. Studying patient involvement 
in scleroderma patients, thus, may prove to be a more meaningful undertaking due to this 
contextual factor, as opposed to inquiring into disorders where physicians come “to look 
for the disease, not the person” (p. 15). 
Complexity 
Scleroderma is a complex disease for a number of reasons, including multi-organ 
involvements. For patients with complex diseases, as Weiss (2007) notes, “clinical 
decision making and required care processes are not routine or standard. For complex 
patients, many recommendations from evidence-based medicine are unlikely to apply in a 
straightforward manner because of ‘exceptions’” (p. 375). Scleroderma patients are not 
alone in this regard. This complexity extends to patients with comorbidity, such as the 
25% of the U.S. adults who have two or more chronic conditions (Ward, Schiller, & 
Goodman, 2014). For these patients, providing information and involving them in self-
management practices are not straightforward due to ambiguity in behavioral changes to 
recommend, and a lack of evidence-based knowledge to impart, making patient 
involvement or lack thereof more challenging to pinpoint. Scleroderma, where 
complexity plays a major role not only in treatment but daily struggles of illness, 
provides opportunities to look at involvement from a more nuanced vantage point by 
forcing us to look to other ways patients in complex situations engage with illness, 




Variations among diseases may present themselves in areas such as onset and 
length of time one is afflicted (from birth, childhood, adulthood, or at old age); ease of 
identification and diagnoses; etiology; genetic contribution; availability and efficacy of 
treatment; stigma and public manifestations of disease; disruption to everyday life and 
morbidity; and the prognosis, progression, and mortality rates. Using some of these 
factors, chronic diseases may be roughly grouped into four categories of (a) life-
threatening diseases like cancer, (b) manageable condition such as diabetes, 
(c) progressively disabling diseases like Parkinson’s and lupus, and (d) the non-life-
threatening conditions with waxing and waning courses, such as fibromyalgia (Sperry, 
2006). In scleroderma, within a single disease, the characteristics of the above four 
categories are represented. Consequently, in a single patient population, the breadth of 
issues affecting patients’ involvement may be studied. 
Altogether, the above four characteristics of scleroderma form the main rationale 
and significance for this research and its chosen population and may be summarized as: 
•   Studying a complex autoimmune disease with applicability to 23.5 million 
patients dealing with autoimmune diseases, and possible relevance to 
117 million suffering from chronic conditions, a quarter of whom deal with the 
complexity of comorbidity.  
•   Studying involvement in an autoimmune disease where the conception of 
disease makes involvement a more natural occurrence, and where the diversity 
in presentation of the disease provides variability that generally requires studies 
across multiple disease populations. 
In addition, this study consists of: 
•   an under-studied patient population, 
•   a multi-disciplinary approach to understanding and framing of the concept of 
involvement by considering both the illness experience and learning. 
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Three specific research questions, as outlined in the next section, motivate this 
study. How learning may underlie the engagement of patients impels a second dimension 
of the research questions posed. 
Research Questions 
The following research questions informed this study: 
RQ1. How do scleroderma patients describe/understand their commitment to 
illness management? Did commitment to be involved change over time? If 
so, when and how? 
RQ2.  What strategies do scleroderma patients use to be involved, and how did 
they learn them? What do they perceive as impeding or facilitating their 
learning? How do they overcome the barriers? 
RQ3. How are social interactions, particularly support groups’ facilitations/ 
participations, perceived in terms of involvement and learning? 
Researcher’s Assumptions 
Detecting early malignancies on mammograms is extremely challenging. As part a 
research in digital mammography to understand how a radiologist determined 
malignancies on X-rays, the researcher had worked with an extraordinary radiologist at a 
teaching hospital. The researcher has attributed the radiologist’s high level of expertise 
and competence to how she was able to confirm or rule out her hunches by combining 
various sources of data: those derived from mammograms directly, the clinical and 
patient history data, her formal medical knowledge, her experiential and tacit knowledge 
of working with her patient population, as well as her openness to the observations and 
thoughts of patients themselves. Working with a population with a below average formal 
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education, talking to patients to get information, and not relying on what was written on 
forms were part of her routine. Observing how she engaged patients, in a specialty in 
which patient contact is not a normal part of the practice, led the researcher to believe 
that the medicine practiced well incorporates many sources of information and insights, 
including those from patients. Conversely, patients have to play their part in this 
exchange for better outcomes. 
Fast-forwarding ten years, one of researcher’s children was diagnosed with a 
serious condition. Contrary to advice given by a doctor, she researched the illness. Her 
research led to the recognition of misdiagnosis by the treating doctor, rejection of 
treatments offered, and seeking treatments at a specialty center, which diagnosed the 
illness as transitory and not needing medication. Since that encounter, the researcher has 
come across other parents with similar experiences who had learned on their own and had 
become experts in the conditions of their children. They had to learn how to navigate the 
healthcare system, what to demand, and how to actively be involved.  
Recently, a relative was diagnosed with scleroderma. Many years have passed 
since the earlier isolated experience of searching for information for the researcher’s 
child. This time, looking for information on scleroderma, the researcher was witnessing 
how other patients and caregivers grappled with similar issues through online 
communities. These experiences have led the researcher to assume: 
•   Patients want to be involved in their own care. 
•   Patients want to know about their diseases and treatment options. 
•   Whereas in acute illnesses a passive role may be a welcome option, with more 
serious conditions, most patients are compelled to become engaged with their 
illness. 
•   Commitment to illness management and involvement with one’s care is not 
easy. People learn through the process of doing it.  
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Definition of Terms 
Acute/Critical Condition—Illnesses that have curative or symptom-relieving treatments, 
or are self-limiting, and usually have short-term durations.  
Adherence—“The extent to which a person’s behaviour - taking medication, following a 
diet, and/or executing lifestyle changes, corresponds with agreed recommendations 
from a health care provider” (WHO, 2003, p. 3). 
Chronic Conditions—Disorders characterized by long durations, being not curable, or 
preventable by vaccines. 
Complex Disease—Diseases encompassing multiple chronic conditions, or a single 
chronic condition presenting unique needs in terms of functional limitations and 
disabilities (Bayliss et al., 2007) 
Contested illnesses—Syndromes characterized by a cluster of non-specific symptoms 
like pain, fatigue, and mood swings that cannot be attributed to any organic 
abnormality. Examples include fibromyalgia, chronic fatigue syndrome, and 
irritable bowel syndrome (Barker & Galardi, 2011). Illnesses where sufferers claim 
to have a specific disease that many physicians do not recognize or acknowledge as 
distinctly medical (Conrad & Barker, 2010). 
Disease—A physiological condition with possible corresponding therapeutic 
interventions to eliminate or ease the symptoms. 
Evidence-Based Guideline—“Systematically developed statement to assist practitioner 
and patient decisions about appropriate health care for specific clinical 
circumstances” (Institute of Medicine, 1990, p. 38). These guidelines are 
developed by a panel of experts within a medical field.  
Illness—The symptomatic human experience and suffering of having a disease. 
Illness experience—The working definition used in this study is: the combination of 
physical impacts of the disease on the body, the emotional/psychological toll it 
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engenders, and the social repercussions such as those relating to managing others 
and dealing with life work, employment, and finances. 
Patient Support Group (or Peer Support Group)— 
the provision of emotional, appraisal [affirmational], and informational 
assistance by a created social network member who possesses experiential 
knowledge of a specific behavior or stressor and similar characteristics as the 
target population, to address a health-related issue of a potentially or actually 
stressed focal person. (Dennis, 2003, p. 329) 
Rare or Orphan Diseases—The Orphan Drug Act of 1983 defines these as the illnesses 
that affect fewer than 200,000 people in the U.S. It is estimated that 25 million 
Americans and 250 million people worldwide are afflicted with one of 7,000 
orphan diseases (Lo, 2014). 
Scleroderma—Also known as Systemic Sclerosis (SSc), 
is a chronic connective tissue disease generally classified as one of the 
autoimmune rheumatic diseases. The word ‘scleroderma’ comes from two 
Greek words: ‘sclero’ meaning hard, and ‘derma’ meaning skin. Hardening 







The purpose of this study was to explore and describe, through scleroderma 
patients’ own perceptions and understanding, their commitment to illness management, 
including how they were involved in dealing with their illness and how they learned to do 
so. To carry out this research, a literature review was conducted.  
Patients’ active role is conceptualized under terminologies such as patient 
empowerment, involvement, participation, activation, and engagement, among others. In 
common parlance, these words are considered synonymous. For example, involvement is 
understood to mean being a participant embroiled or engaged in an issue or activity. In 
contrast to their common meanings, there is a lack of definitional clarity in a large body 
of literature that has explored these concepts. Gallivan, Burns, Bellows, and Eignseher 
(2012), in a literature search of studies between 1995 and 2010, found 15 different terms 
utilized. Fumagalli, Radaelli, Lettieri, Bertele, and Masella (2015) noted, “These 
concepts are sometimes treated as synonyms, other times in contraposition, yet others as 
unrelated concepts” (p. 385). Gallivan et al. (2012) observed that  
there is broad support for the idea that patients should be “involved” and 
should “take part” in health care, but no clear consensus exists about what 
precisely this means and how much or to what extent patients are included. 
Although these terms [patient involvement, partnership, collaboration, 
participation, engagement] are used in the literature, they are not readily 
defined in most papers and thus the reader is not necessarily clear as to what 
they mean. (para. 14) 
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The lack of clear definitions and consensus among researchers on what these terms mean 
and how to meaningfully operationalize them, referred to as a “conceptual muddle” by 
Forbat et al. (2009), are echoed by many, including Elwyn, Edwards, Mowle, and 
Wensing (2001), McCormack et al. (2011), and Staniszewska, Brett, and Mockford 
(2011), who stated: 
While there are some helpful definitions of involvement, the 
conceptualization or theorization of PPI [Patient and Public Involvement] 
has generally been poor. There have been some attempts to develop 
conceptual or theoretical frameworks, but there is no overall conceptual 
model of PPI impact that captures the essence of the concept and has been 
empirically tested. Such models can be very helpful because they can 
provide a blueprint for evaluation, identifying key areas for assessment. 
(p. 394) 
Beyond the conceptual confusion, the irony is not lost in combining the passively 
connoted term “patient” (Latin patiere, to bear or endure) with actively connoted words 
“involvement” (Latin involvere, to enwrap), “activation” (Latin activus, actus, agree, to 
drive, to do), “engagement” (Old French gager, to guarantee, as in to do something), or 
“participation” (Latin particip, to take). Nonetheless, these terms are used, sometimes 
interchangeably, in studies encompassing disciplines of nursing, psychology, social work, 
medical practice, public health, medical anthropology, medical sociology, health service 
delivery, policy studies, patient advocacy, illness phenomenology, ethics, and post-
modernity. Menichetti, Libreri, Lozza, and Graffigna (2014), in a review of some 60,000 
articles using the terms “patient activation,” “patient adherence,” “patient compliance,” 
“patient empowerment,” “patient engagement,” “patient involvement,” and “patient 
participation,” found that the majority of these papers (74%) were in the health domain 
(medicine and nursing). Higgins, Larson, and Schnall (2016) found a somewhat higher 
distribution of 96% in medicine and nursing among 722 articles they reviewed based on 
keyword “patient engagement.” 
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In conducting a literature review for this dissertation study, two approaches were 
taken. First, a review of five most commonly used terms—“patient empowerment,” 
“patient engagement,” “patient involvement,” “patient participation,” and “patient 
activation”—is presented in this chapter. Second, through parsing the relevant literature 
by differentiating between disease and illness, the notion of patient involvement in one’s 
care is scrutinized from these two perspectives. In addition, a review of adult learning 
literature is included, as learning is another focus of this study. Last, theories and models 
informing the conceptual framework of this study are presented in more depth in a 
separate section, followed by a chapter summary. Thus, this literature review chapter is 
structured in seven parts: 
1.   The various conceptualization of patients’ active roles 
2.   Disease versus Illness 
3.   Involvement as attending to disease in clinical interactions 
4.   Involvement as attending to illness in lifeworld 
5.   Theoretical Context: Adult learning theories 
6.   Conceptual Framework 
7.   Literature review summary 
Various Conceptualizations of Patients’ Active Roles 
Menichetti et al. (2014) reviewed 58,987 studies from 92,771 articles retrieved 
using the search terms “patient empowerment,” “patient involvement,” “patient 
participation,” “patient engagement,” “patient adherence,” “patient compliance,” and 
“patient activation” for the years 2002-2013. Studies focusing on the concept of patient 
compliance constituted 80% (47,042) of the articles, followed by those using the concept 
of patient participation (18%). The remaining concepts ranged from 1% to 3% of the total 
studies. A temporal analysis for the period between 2002 and 2013 showed a drop of 10% 
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in the frequency of using the term “patient compliance,” while the usage for “patient 
engagement” and “patient activation” increased 18-fold and 3-fold, respectively. 
Interpreting these changes from a historical perspective, Menichetti et al. viewed the 
period of 2002-2004 as being concerned with compliance and adherence. This was 
interpreted as an indication of the passive behavioral expectation for patients by 
providers. The period of 2006-2009 was interpreted as focusing on clinical encounters 
and patients’ involvement and participation in clinical settings. For the period 2010-2012, 
patient empowerment and notions of autonomy and self-determination took center-stage. 
Menichetti et al. contend that from 2013 onward concepts of activation and engagement 
have been the foci, suggesting a “consumer behavioural perspective” (p. 523) that goes 
beyond the subjective experience of illness and into relational and organizational realms. 
In particular, Menichetti et al. claim that the concept of patient engagement subsumes the 
other concepts (activation, involvement, participation, adherence, and compliance), 
which were “traditionally used to generally denote the role of patients in their care” 
(p. 524). 
Fumagalli et al. (2015) reviewed 286 studies from an initial list of 3,088 articles 
published between 1990 and 2013 addressing patient empowerment, patient involvement, 
patient participation, patient enablement, patient engagement, and patient activation. 
They found an explicit definition for these concepts was given only in “17% of studies 
about ‘patient involvement’, 29% about ‘patient engagement’, 30% about ‘patient 
enablement’, 42% about ‘patient empowerment’” (p. 385). Only studies about activation, 
adapting Hibbard et al.’s (2004) activation measure, reached a 72% level of definitional 
reporting. 
These five concepts—empowerment, engagement, involvement, participation, and 




Fumagalli et al. (2015) argued that patient empowerment was conceptualized in 
three ways in the literature: (a) as an emergent state (having knowledge, skills, self-
awareness, motivation, etc. that enabled patients to have an active role); (b) as a process 
leading to such a state (e.g., education, patient-centered care, etc. that facilitated active 
patient behavior); or (c) as patients’ behavior (the actual behavior that exploited their 
power in a given context). Considering patient activation, enablement, engagement, 
involvement, participation, and empowerment, Fumagalli et al. devised a concept map to 
indicate the relationships among these. Subsequently, they suggested a definition of 
empowerment based on this concept map: 
Patient empowerment is the acquisition of motivation (self-awareness 
and attitude through engagement) and ability (skill and knowledge through 
enablement) that patient might use to be involved or participate in decision-
making, thus creating an opportunity for higher levels of power in their 
relationship with professionals. (p. 390) 
In this definition, an engaged patient “deploys a strong motivation to become more 
knowledgeable (e.g. by preparing in advance question, gathering additional expert 
opinions) and more ‘powerful’ (e.g. by fortifying the relationship with professionals, by 
seeking more appropriate settings and providers” (p. 389). Enabled patients are those who 
“are able to participate in self-care or shared-decision making” (p. 389) through 
interventions accorded to them by their healthcare providers. An involved patient 
participates in decision making, or shared-decision making with his/her provider. The 
proposed definition of empowerment subsumes engagement, enablement, participation, 
and involvement.  
Patient Involvement and Patient Participation 
The terms “patient involvement” and “participation” are shortened phrases for the 
concepts of patient involvement in health delivery and participation in health care 
consultation. As such, they are associated with patient-physician interactions, provision 
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of information, and level of decision making. Thompson (2007) using patient interviews 
and focus groups arrived at a taxonomy of patient involvement and participation 
consisting of three levels of patient-determined, co-determined, and professional-
determined active roles. Within the patient-determined level, patient-desired degrees of 
involvement included non-involvement, information-seeking, information-giving, or 
autonomous decision-making. Thompson differentiated between involvement and 
participation by labeling the co-determined shared decision-making where providers 
surrendered some of their power as “participation.” In this definition, patient participation 
is a subset of patient involvement, although in many studies these two terms are used 
interchangeably. 
In Thompson’s conceptualization of involvement and participation, power is 
negotiated between patients and providers. At the lowest level of non-involvement, the 
provider assumes full power, while at the autonomous decision-making level, the patient 
enjoys full autonomy in decision making. Fumagalli et al. (2015) reported other 
interpretations of involvement in studies they reviewed, including: (a) involvement as a 
combination of participation in decision making and in self-care and treatment; and 
(b) involvement as activities helping patients to have a more active role regarding 
choices. They further concluded that these varied interpretations make patient 
involvement and participation either the antecedents or consequences of patient 
empowerment. 
Patient Activation 
The term “patient activation” is generally associated with Hibbard et al.’s (2004, 
2005) work in operationalizing the concept of “person’s ability to manage their health 
and health care” (Hibbard & Cunningham, 2008). This work has been influenced by Von 
Korff, Gruman, Schaefer, Curry, and Wagner (1997), who enumerated a set of behavioral 
principles involved in collaborative management of chronic illnesses. These included 
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self-directed behavior and learned skills to manage the illness; motivation and self-
efficacy in self-care; and monitoring and adaptation to emotions, symptoms, and disease 
states. They further asserted that in collaborative management of chronic illness, 
“providers as well as patients will benefit from active participation in this process” 
(p. 1099). Taking these assertions, Hibbard et al. (2004) inquired into the question of 
“what skills, knowledge, beliefs, and motivation do they [patients] need to become more 
effectual heath care actors?” (p. 1006). Relying on a literature review, expert consensus, 
and patient focus groups, they arrived at a definition of activation based on these 
elements: 
Those who are activated believe patients have important roles to play in 
self-managing care, collaborating with providers, and maintaining their 
health. They know how to manage their condition and maintain functioning 
and prevent health declines; and they have the skills and behavioral 
repertoire to manage their condition, collaborate with their health providers, 
maintain their health functioning, and access appropriate and high-quality 
care. (p. 1010) 
Based on this definition, Hibbard et al. developed a measure of activation, PAM (Patient 
Activation Measure), which measures a patient’s belief in the role they need to play, 
knowledge of the disease, and skills and confidence in enacting behavioral changes to 
manage the illness.  
Fumagalli et al. (2015) compared patient activation to patient empowerment and 
noted that both concepts are related to “an increased ability and motivation, and growing 
patient awareness of having an important role in the management of own healthcare” 
(p. 388). Given the overlap, they argued that empowerment has a broader scope, while 
activation “is more focused on precise and specific improvement goals” (p. 388) in the 
context of a disease. 
Graffigna, Barello, and Triberti (2015), on the other hand, drew a comparison 
between patient activation and patient engagement, asserting that “the concept of 
activation features numerous elements that resemble the characteristics of the patient 
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engagement process. Indeed, the two terms are often used synonymously in the scientific 
debate” (p. 19). Despite these similarities, they argued that the focus of patient activation 
is on “the conative dimension of the behavior of the patient, and assumes that the main 
driver of activation is the level of knowledge of the patient about the disease … [and] 
focuses on the behavior of patients as a reactive response to the healthcare system and to 
its organizational practices” (p. 20). Graffigna et al. argued that patient engagement, on 
the other hand, attends to non-institutional context of patients’ experience of an illness.  
Patient Engagement 
Fumagalli et al. (2015), in a review of related literature, noted that “patient 
engagement has rarely received an explicit and precise definition” (p. 389) and pointed to 
two interpretations in literature that often coexist in the same study: “patient engagement 
as the participation of patients in self or shared management,” and “the behavior that 
patient preform to improved their role in healthcare” (p. 389). 
Barello et al. (2014) sifted through 1,020 potential articles published between 2002 
and 2013, ultimately retaining 259 abstracts that “adjectively defined and contextualized” 
patient engagement. Using occurrence and co-occurrence of words and by employing chi-
square tests, Barello et al. attempted to determine how the meaning of patient 
engagement (semantic patterns) was constructed in these abstracts. The definitions 
assigned to patient engagement were reported within five fields of inquiry. In the 
biomedical field, engagement was conceptualized as “‘learnable’ and ‘malleable’ patient 
attitude” and a top-down strategy to help patients self-manage their disease. In nursing, 
engagement was viewed as patients’ self-awareness in expressing their physical and 
emotional needs and providers’ role in facilitating support, choice, and the desired 
interventions. In mental health, engagement was portrayed as fostering a collaborative 
approach and the alliance between patients and providers in the service of obtaining 
better outcomes. In the public health domain, engagement was seen as empowering 
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patients, orienting health policies, and promoting public health. In multidisciplinary 
health research, engagement was equated to disease self-management.  
Barello et al. (2014) concluded that “despite the widespread use of the term ‘patient 
engagement’ our study showed significant variations in its conceptualization, testifying 
that the debate on this issue is still in its infancy” (p. 4). Furthermore, they observed that 
“the voice of patients in defining what patient engagement is and what may favour it is 
still under-represented in the literature, thus suggesting the need for more research on 
patients’ perspectives” (p. 4).  
Higgins (2016) reviewed 722 published articles through mid-2014, over 90% of 
which were in medicine and nursing, to arrive at a definition of engagement through 
concept analysis. Out of 722 articles, ultimately 96 articles that defined or measured 
engagement or had it as their main subject were retained for further analysis. A large 
number of attributes (446), as characteristics of the engagement that were either directly 
or indirectly inferred, were identified and grouped into three general domains of 
“process” containing 43% of the attributes, “behavior” encompassing 33% of the 
attributes, and “environment” entailing 24% of the attributes. These domains, then, were 
organized thematically into six categories of time, activity, process, cognition/emotion, 
ethics, and communication, and finally were reduced to four overall themes of 
“personalization of the approach to care,” “access to necessary resources,” “commitment 
to pursuing quality care,” and “nurturing the relationships between actors in the 
encounter” (p. 57). Higgins contends that these themes are “the defining attributes of 
patient engagement as they describe the nature of the behaviors, processes and 
environments that support engagement” (p. 57). Separately, 34 antecedents to 
engagement (which were reduced to 12) and 21 consequences of engagement were 
collected from the 96 articles. These antecedents and consequences, together with the 
four overall themes, formed the basis of a definition of patient engagement as:  
  
30 
the desire and capability to actively choose to participate in care in a way 
uniquely appropriate to the individual in cooperation with a healthcare 
provider or institution for the purpose of maximizing outcomes or 
experiences of care. Patient engagement on the part of the provider is the 
effort to foster that desire and capability. (p. 62) 
To elaborate on this definition, Higgins defined the terms “desire,” “capability,” “active,” 
“choice,” “unique,” and “cooperation” used in the above definition of patient engagement 
as follows: 
•   Desire: “emotional and psychological factors such as past experiences or social 
support structures that shape their interest in exploiting the healthcare options 
that may be made available” (p. 63). 
•   Capability: “cognitive factors such as functional literacy, as well as social 
economic factors, that enable the patient to access those resources that support 
self-care” (p. 63). 
•   Active: “the belief or self-efficacy to participate in care, which is a central 
aspect of the concept of patient activation” (p. 63). 
•   Choice: “patient’s freedom to decided how and to what extent he/she wants to 
participate in shared decision making and the process of care’ (p. 63). 
•   Unique: “the unique circumstances of each patient such as patient’s personal 
preferences and health literacy status” (p. 63) 
•   Cooperation: “elements of the provider-caregiver-patient therapeutic alliance as 
a form of the human connection that provides psychological and social support 
to patient efforts to participate in care” (p. 63). 
These elaborations make the patient engagement definition proposed by Higgins a 
complex and compound construct defined based on six other compound constructs, 
which, in turn, include concepts such as experience, social support, functional literacy, 
self-care, self-efficacy, freedom to decide, health literacy, personal preference, and 
alliance with providers. 
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Whereas in the domain of nursing, Higgins’s (2016) concept of engagement is 
defined in terms of patients’ “desire and capability to actively choose to participate” and 
cooperate with health providers in order to “maximize[e] outcomes or experiences of 
care” (p. 62), Graffigna, Barello, and Triberti (2015) conceptualize engagement as a 
“psychosocial process” (p. 29) of decision making and negotiation with healthcare 
providers based on consumer psychology theories. These theories are concerned with 
“processes that individuals, groups, or organizations enact to select, secure, use, and 
dispose of products, services, experiences, or ideas, in order to satisfy their needs and to 
fulfill their goals and values” (p. 29). Thus, engagement may be seen as what patients are 
able to exhibit in terms of decision making, sense making, and negotiation with 
providers, given the particular confluences of patients’ feelings, thinking, and acting. 
Formally, engagement is defined as a conjoint cognitive, emotional, and conative 
orientation that patients take toward the management of their health.  
This orientation unravels sequentially as a process in four phases. Each dimension 
of cognition, emotion, and conation contributes, synergistically, in each phase. In the 
initial phase, patients are in a “blackout” state, and everything seems to be out of their 
control; they are passive recipients of care. In the second stage, although better-informed, 
patients are overwhelmed by emotions and “unable to self-manage their diseases and 
treatment prescriptions” (p. 31). In the third phase, patients have acquired disease 
knowledge and skills to follow medical interventions and cope with their condition, but 
are doing so passively and not as collaborators. In the last stage, patients come to the 
acceptance of their illness, are fully engaged, and can form partnerships with their 
providers. Arrival at this stage is dependent on a successful movement from one stage to 
the next. This movement is viewed as an “elaboration and reframing” (p. 36) of health 
experiences. To facilitate this movement, “the healthcare system needs to educate 
patients and improve their understanding of their health and related conditions” (p. 36) 
and “provide patients with occasions to improve their sense of self-efficacy and 
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confidence” (p. 37). In later stages, patients need to take up active social roles and 
incorporate their patient identity into their lives. These positive steps need “to be 
legitimized by the healthcare system” (p. 38). This model of engagement is 
operationalized in a Patient Health Engagement Scale (PHE) as a measure of patient 
engagement. 
Graffigna, Barello, and Triberti’s (2015) four stages of engagement are reminiscent 
of Hibbard et al.’s (2004, 2005) four levels of activations, although Graffigna et al. argue 
that these stages encompass more dimensions than Hibbard et al. behavioral focus. Given 
Graffigna et al.’s claim of a model designed to “see engagement from patients’ eyes” (p. 
28), there is a great amount of reliance on health providers and the healthcare system to 
help move patients from one stage to the next by “educating” and “legitimizing” their 
efforts.  
In concluding this section, several observations may be made given the above 
definitions for the five terms used to capture patients’ active roles: (a) these definitions 
and conceptualizations are defined, by the authors of these studies, as either overlapping 
or subsuming the other concepts, making for compound constructs that are difficult to 
tease out, measure, and operationalize; (b) in these definitions varying levels of agency 
and knowledge are afforded to patients; similarly, to varying degrees healthcare system 
and providers are seen as enablers of patients’ active roles; (c) the discipline within which 
a particular conceptualization is situated (e.g., psychology vs. nursing) exerts an 
influence in the definitional focus presented; and (d) some of the observed differences 
may be attributed to the underlying paradigmatic views of disorder either as a biomedical 
disease or an illness experience. 
Among these, the perspective of disease versus illness deemed to be the most 
important and relevant to this study, as one denotes the perspective of the professionals 
and, on the other hand, that of the patients. This distinction sets the stage for the expected 
roles for each. To represent patients’ voice in this discussion, therefore, it is important to 
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understand how approaches to patients’ active role are grounded on such a distinction. 
This is explored in the next section. Given the lack of clear definitions, the terms 
patients’ “active role,” “involvement,” and “engagement” are used interchangeably.  
Disease versus Illness 
The biomedical sciences adopt a positivist posture characterizing disease as an 
aberration or deviation from statistically determined biological, physiological, and 
pathological norms observed in aggregate of the human species. Larsen and Lubkin 
(2009) echo the prevailing sentiment that disease is an “alteration in structure and 
function” (p. 4). Campbell, Scadding, and Roberts (1979) identify disease as referring to 
“(a) a described and recognizable combination of symptoms and signs; (b) a phenomenon 
associated with a specified disorder of structure or function; or (c) a phenomenon due to a 
specific cause or causes” (p. 757). These definitions coexist with at least seven other 
views in biomedical literature identified by Boorse (1979). From these views, the body, 
or more precisely its functioning, is the main focus, and patient involvement may be 
viewed as compliance with the interventions that would restore normal conditions, or at 
least prevent deterioration of functions. The roles assigned to patients include cooperation 
in taking medication and doing home monitoring, undergoing procedures, keeping 
doctors’ and labs’ appointments for professional monitoring, and making lifestyle 
changes deemed to improve outcomes. 
On the other hand, social and psychological considerations prompt a distinction 
between disease (pathophysiologic) and illness (symptomatic human experience and 
suffering), extending the notion of an ailment from a purely biological deviation or 
abnormality to a psychologically and socially constructed one. A common thread among 
many perspectives on illness is the premise that the self has a social nature and the 
meaning given to illness is not inherent within it, but comes about through interactions 
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and relations of individuals within their social contexts. The notion of “sick role” coined 
by Talcott Parsons (1951), American sociologist, captures this idea that “our repertoire of 
responses to illness are governed by a set of social expectations and responsibilities” 
(Bissell, Travlsen, & Haugbolle, 2002, p. 60). These social norms allow, for example, 
exemption from work and an obligation to seek medical help when sick, and resumption 
of normal work, when better. Over time, attention to patient’s role turned to “illness 
behavior” and “health behavior” (Burnham, 2013). A major component in viewing illness 
became the nature of the altered relationship with one’s body when sick. This altered 
relationship occurs in the context of one’s social world giving way to a “loss of self” 
(Charmaz, 2003), or a “biographical disruption” (Bury, 1982, 1991) affecting a person’s 
sense of identity and the ability to fulfill roles in everyday life (Thorpe, 2009). Illness 
poses as a stressor, disrupting life’s steady state (Cohen & Lazarus, 1979; Moos & Tsu, 
1977), requiring patients’ proactive engagement with tasks as a means of adjustment. 
Coping strategies and self-regulating behavior based on one’s illness representation 
(Leventhal, Meyer, & Nerenz, 1980), and integration of illness into one’s life through 
biographical, illness, and everyday life work (Corbin & Strauss, 1988), among others, 
gave impetus to the notion of self-management behaviors and self-care activities as a 
more formalized approach to view and promote what patients engage with in between 
doctors’ visits. 
These two general strands reflecting the primacy given to the disease or the illness 
when considering the patients’ roles are reviewed next. 
Patients’ Active Role: Attending to Disease in Clinical Interactions  
In medical studies, engagement stems from the perspective of attending to disease 
condition and improving the physiological symptoms of a disorder. Therefore, patient 
engagement is viewed to take shape in the context of the patient-physician dyad in the 
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confines of clinical consultations and interactions. Two major components of such a 
construction are: (a) provisions of information, and (b) preference for control in decision 
making. Involvement is promoted by providing information to patients and encouraging 
their participation in decision making in treatments. 
Provision for Information 
In clinical settings with a focus on patient-physician interactions, patients’ need for 
information in order to make decisions regarding their illness is considered essential for 
involvement, yet studies examining the informational needs of patients are limited. 
Among studies in this area are those exploring the nature of informational materials given 
to patients and their impact, factors affecting information seeking, the nature of patient 
and physician exchanges of information, challenges in conveying risk information to 
patients, and the role of technology in patients’ information-gathering activities. 
In a discourse analysis of 1,000 patient-leaflets by Dixon-Woods (2001), only a 
small subset of patient-leaflets was characterized as having a patient empowerment 
discourse, while the majority were seen as having the traditional approach of treating 
patients as “passive” (p. 1417) recipients of information. Wetzels, Wensing, Van Weel, 
and Grol (2005) provided educational leaflets to patients prior to doctors’ visits as an 
intervention, and found no difference in terms of patients’ involvement, satisfaction, or 
enablement between intervention and control groups. Pegg (2003), in studying the 
difference between the impact of personalized information and general information, 
found that patients receiving personalized information on physical therapy had higher 
levels of participation and reported greater satisfaction. Aldoory (2001) looked for factors 
impacting patients’ engagement with health messages, specifically those influencing 
women’s involvement with public health messages (e.g., harm of smoking; caffeine in 
pregnancy, etc.). Receptivity to health messages was related to life roles and situations 
(motherhood, pregnancy, etc.), one’s sense of identity (racial, ethnic, economic, etc.), 
  
36 
source of information (media, celebrities, authority figures, etc.), and women’s own 
conceptions of health status. 
The face-to-face information transfer between doctors and patients was studied by 
Lee and Garvin (2003). They found that the “one-way model of information transfer” 
(p. 449) from professionals to patients was pervasive and relied on three problematic 
assumptions that privileged expert perspective, considered as appropriate in a one-way 
flow of information from doctor to patient, and focused on individual risk and behaviors 
without the consideration of structural barriers. Beisecker and Beisecker (1990), in a 
study of 106 patients, attributed patients’ information-seeking behavior to variables such 
as length of interaction, diagnosis, and reason for visit, and found that interactions with a 
duration of 19 minutes or longer were required for patients to engage with information-
seeking behavior. 
Increasingly, technology plays a role in acquisition of information and is altering 
the traditional information exchanges with doctors. Lee and Hawkins (2010) reported that 
women with breast cancer who perceived unmet informational and emotional support 
were more likely to engage with online sources. Synnot et al. (2016) found that MS 
patients perceiving “too much information” and “too little that applied to them” in their 
online searches, while Ginnossar (2016) reported age, education, ethnicity, and 
prevention orientation as predictors of information-seeking behavior in cancer 
prevention. Chung (2013) reported White, middle age, highly educated women as being 
more likely to go online for health information. In that study, only 30% of those 
searching online discussed the search results with their health providers, confirming other 
reports that only 20% to 30% of patients disclosed or discussed their online findings. 
Chung listed men and those concerned with quality of online information as being more 
likely to discuss their findings with doctors. In a review of 18 studies on the online 
information-seeking behavior of patients, Tan and Goonawardene (2017) found that 
patients used various strategies in sharing or verifying information they obtained online, 
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including directly disclosing findings, verifying silently, and bringing printouts to 
doctors’ offices. Having a family member present, doctors initiating questions, and 
advertisement seen in media facilitated office conversation on online health information, 
while fear of doctors perceiving online information as a challenge or insult, resistance 
and discouragement of doctors in use of online sources, embarrassment in patients’ 
abilities to relate the information to their own cases, and lack of time were seen as 
barriers to information sharing. 
Lastly, imparting information regarding risk and uncertainty of treatments 
increasingly is seen as essential for patients to make informed decisions (Smith, Street, 
Volk, & Fordis, 2013; Zikmund-Fisher, 2013). Han (2013) studied the challenges in 
conveying concepts such as meaning of probability (risk), ambiguity (reliability & 
credibility of information), and complexity (multiplicity of risk factors) related to 
treatments and procedures. He identified the key areas in need of future research as: 
conceptualizing uncertainty, identifying what and how much to communicate, devising a 
standardized language and methods of communication, and determining ways to take on 
a patient-centered approach.  
Among the above issues, the online information gathering and conveyance of risk 
and complicated medical concepts, exacerbated by limited time available at visits, have 
taken patients’ informational needs to uncharted territory. Providers and patients alike are 
not quite sure how to manage these situations. Inconsistent expectations from patients, 
variously conveyed by providers to be independently informed or not, are confusing to 
the patients. Similarly, unreliable online content and demands for interventions read on 
the Internet are frustrating to the providers. Additionally, the access to a wealth of 
information has transformed the notion of informational need to a need for discussion to 
evaluate and discriminate the relevancy and validity of information. This is occurring at a 
time when health providers are constrained by the amount of time they can devote to each 
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patient, and compensation models (fee-for-service, pay-for-performance, etc.) that 
discourage such engagement.  
Thus, access to online information has made the traditional notion of provision for 
information, as it has been explored in literature, outdated and moot. The nature of 
information exchange between patients and providers is, at best, a fluid one, as new 
norms are being established.  
Preference for Decision-Making  
Exerting influence in decision-making is the second notion most equated to 
involvement in the health domain literature. Storm and Edwards (2013) assert that “user 
involvement is intended to increase the actual and ‘real’ influence of patients on 
decisions about their treatments, to ensure that services are provided in accordance with 
patients’ needs and to enhance patients’ control over their health care” (p. 314). 
Arnstein’s (1969) ladder of control is frequently adopted to devise a hierarchy of control 
and influence in decision-making to describe patients’ sphere of influence. The best-
known hierarchy is that of Emanuel and Emanuel (1992), consisting of levels of 
paternalistic, informative, interpretive, and deliberative models. In the paternalistic 
model, physicians act as guardians articulating, persuading, and implementing what is 
best for patients. In the informative model, physicians are the experts providing facts 
patients need to decide. In the third interpretive model, physicians act as counselors in an 
advisory capacity by not only providing medical facts but also helping patients sort 
through their values and determine which treatments realize those values. Lastly, in the 
deliberative model, physicians are teachers who engage the patients in dialogue. Charles, 
Whelan, and Gafni (1999) suggest another configuration of similar levels consisting of 
three elements: the unilateral extremes of paternalistic and informed models, and a shared 
decision-making model where doctors and patients jointly arrive at decisions.  
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Thompson (2007) divides the hierarchy of control into two strands of 
“professional-determined patient involvement” and “patient-desired involvement.” The 
former includes a range consisting of “being excluded,” “paternalistic consultation and 
information giving,” “shared-decision making with professional-as-agent,” and 
“informed decision making” The patient-desired involvement, on the other hand, has five 
levels of “non-involvement,” “information seeking,” “information giving,” “shared 
decision-making,” and “autonomous decision-making.” Epstein and Gramling (2012) 
collapse these hierarchies into a collaborative emergent model of “shared mind,” where 
complexity and uncertainty of decisions in the context of a serious and life-threatening 
disease are tackled through interactions of all stakeholders (patients, family, and doctors). 
An array of instruments for measuring patients’ preferences for decision-making have 
been proposed. For the period of 1980-2005, Dy (2007) identified 11 instruments, 
including CPS—Control Preferences Scale (Degner, Sloan, & Venkatesh, 1997), 
PSDM—Problem-solving Decision Making Scale (Deber, Kraetschmer, & Irvine, 1996), 
API—Autonomy Preference Index (Ende, Kazis, Ash, & Moskowitz, 1989), and HOS—
Health Opinion Survey (Krantz, Baum, & Wideman, 1980). The focus of these 
instruments is on patients’ perceptions of role (how passive or active they want to be) and 
their preferences for information, and the amount and type of information desired using 
assessments such as scenarios and vignettes.  
Dy (2007) found two challenges in reviewing these instruments: the heterogeneity 
of domains in which the instruments were originally designed and tested, and a general 
lack of validity testing. In spite of these limitations, there is an abundance of studies in 
this area. Say, Murtagh, and Thomson (2006) reviewed 25 quantitative studies using the 
above measures, seven qualitative, and one mixed methods covering years 1975-2003. 
Seventeen out of 20 studies found associations between younger age and more active 
decision-making preferences. Five out of eight studies found that women were more 
likely to express a preference in having an active role. Sixteen out of twenty associated 
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higher education with involvement. Also, White patients were more likely to be more 
involved. Associations between involvement and marital status, class, occupation and 
income were more problematic to interpret. The severity of disease and the decision-
making involvement were inversely associated (the more severe a condition, and more 
serious a decision, less involvement was displayed). 
In a literature review of studies done between 1966 and 2009, Tariman, Berry, 
Cochrane, Doorenbos, and Schepp (2010) examined preferred and actual/perceived 
decision-making roles (autonomous, shared, passive) in cancer patients. Twenty out of 22 
studies used the CPS measure. These studies showed the level of control patients 
preferred, initially, was more than what they perceived as ultimately having occurred. 
Only three studies (all of prostate cancer patients) reported the reverse. Furthermore, the 
majority of patients wanted information, but only 2/3 desired active participation in 
decision-making. Gaston and Mitchell (2005), looking at studies between 1966 and 2003 
in late-stage cancer patients where palliative care rather than cure was the goal, found 
that advanced cancer patients had the same desire for information as early cancer 
patients, and about 2/3 of these patients wanted to be a part of the decision-making in 
some form. Furthermore, those whose conditions deteriorated wanted to surrender 
control; those who improved wanted more control. 
Chewning et al. (2012) conducted a systematic review of 115 studies done between 
1980 and 2007. These studies utilized measures of CPS in 44 studies, API in 16, HOS in 
5, PSDM in 6, and other measures in the remaining 49 studies. Across all studies, 63% 
found that most patients wanted to be a part of the decision-making process, and 22% 
found that the majority of patients wanted to delegate decision-making to their 
physicians. These included 75% of cancer and invasive-procedures patients, who 
indicated preference for decision-making, as opposed to 50% of those with other chronic 
conditions and in the general population. The authors concluded, “The choice of the 
study population contributes to contradictory findings in the literature” (p. 14). In 
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addition, “clear differences occurred in patients’ reported decision role preferences 
depending on the measure used” (p. 14). In particular, they found that instruments using 
hypothetical vignettes (such as API) had inconsistent results, and instruments that 
explicitly provided an option for shared or autonomous decision roles (CPS or PSDM) 
had a higher percentage of patients opting for them. Chewning et al. concluded that there 
was an important methodological issue in interpreting mean scores used by many 
measures, and pointed out the lack of psychometric data to assess reliability and validity 
of some of these tools. 
Frongillo, Feibelmann, Belkora, Lee, and Sepucha (2011), arguing a lack of 
“consensus over how to measure shared decision making or patient involvement” (p. 70), 
operationalized the perception of involvement for early stage breast cancer patients, by a 
score based on seven items in four categories measuring patients’ perceptions of whether 
a discussion of options (mastectomy or radiation) took place; the levels of “pro 
discussions” and “against discussions” for each option; and the extent of discussion 
concerning patients’ own preferences. Similarly, Ashraf et al. (2013) determined the 
nature of involvement by mapping survey questions, similar to the CPS measure, ranging 
from “I made the decision with little or no input from my doctors” to “My doctors made 
the decision with little or no input from me” (p. 666) to three levels of paternalistic, 
informed, and shared decision-making.  
A limited number of qualitative studies have examined how patients interpret 
decision-making. Ziebland, Evans, and McPherson (2006) interviewed 43 women 
between ages 33 and 80 with ovarian cancer in the U.K. regarding their involvement in 
treatment choices. Responses ranged from perceptions of not having any ‘real’ decisions 
to make to being confused about options and worrying about going against a doctor’s 
recommendations. Ziebland et al. concluded that giving patients choices could be 
interpreted as abandonment by some patients. In another qualitative study of 17 patients, 
Edwards and Elwyn (2006) found that, contrary to the emphasis placed on decision-
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making in the literature, it is of little importance to the patients; “it is the process of 
involvement that appeared to deliver benefits for patients, not the action of making the 
decision” (p. 317). Entwistle et al. (2008) found that diabetic patients’ involvement in 
decision-making was related to three aspects of “ethos and feel of healthcare encounters” 
(respectful and non-judgmental), “communication about health problems” (clear 
explanations, listened to), and “communication about treatments” (rationale for treatment 
and having a say) (p. 362). Based on these findings, they point to the “insufficiency of 
models and practices that focus narrowly on the exchange of information about treatment 
options and the activation of patients as choosers” (p. 373). Lastly, Joseph-Williams, 
Elwyn, and Edwards (2013), studying patients’ perceptions of enablers and barriers to 
involvement in decision-making, found two key factors of knowledge (of treatment 
options and personal preference) and power (“perceived capacity to influence the 
decision-making encounter,” p. 15) as instrumental for participation.  
Overall, these studies point to the role and power of providers in setting the tone 
for patients’ participation in decision-making. The severity of patients’ conditions, age, 
race, gender, and educational attainment were also implicated as factors impacting the 
desire to engage with decision-making. The diversity of disorders and contextual factors, 
such as confusion about choices and concerns for doctors’ reactions, make generalization 
of these studies challenging. Furthermore, the notion of involvement as a dynamic 
process, which may vary at different times during the course of illness, is missing from 
these studies. 
Patients’ Active Role: Attending to Illness in Lifeworld 
Whereas involvement in clinical settings and interactions is concerned with patient-
physician dyads, a second body of literature looks at patients’ active role as engagement 
with one’s care, occurring in between doctors’ visits, through management of symptoms 
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in everyday routines. This type of involvement is generally labeled as self-management 
or self-care. Again, neither concepts nor terminologies are precise. Jones, MacGillivray, 
Kroll, Zohor, and Connaghan (2011), in a review of studies between four decades of the 
1970s to the 2000s, found 139 definitions of self-care. Terms such as self-management, 
lay self-management, illness-management, self-care, participation, coping, and self-
regulation are used to discuss similar or overlapping ideas. Lorig and Holman (2000) 
write that “one of the first uses of the term self-management appeared in an article on 
asthma self-care written by Thomas Creer in the mid-1970’s” (p. 4), with self-care and 
self-management appearing synonymous in the same sentence. Godfrey et al. (2011), in a 
thematic analysis of conceptualization of self-care, self-management, and self-
management support, concluded that “these concepts can be differentially conceptualized 
according to the nature and level of networks involved, the level of imperative for action, 
and the types of goals to be achieved” (p. 183). Kralik et al. (2004) distinguish between 
coping, a “state of tolerating, minimizing, accepting, or ignoring,” and self-management 
as “activities people undertake to create order, discipline and control” (p. 260), and 
further contend that self-management may be taken to be a structure or a process. 
The frameworks looking at chronic conditions through the lens of patient 
experience espouse self-management as a way of life and a socially negotiated process 
that occurs within life world and the social contexts of family, work, and community, 
organically. Patients choose to be self-managing (Kendall, Ehrlich, Sunderland, 
Muenchberger, & Rushton, 2011) around “‘mundane’ reality of living with chronic 
disease” (Morden, Jinks, & Ong, 2011, p. 87). 
Motivations for such an engagement are attributed to outcomes. The personally 
important outcomes to patients are listed as: establishing normality, happiness, and well-
being (Vassilev et al., 2011), bringing order to life (Kralik et al., 2004), being able to 
discharge roles and social obligations (Morden et al., 2011), and creating balance in 
personal life (Hinder & Greenhalgh, 2012), while dealing with the burdens of disease. 
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These burdens include psychological ones such as lack of control over the disease, 
uncertain course of illness, and difficulty in maintaining a positive outlook (Cudney, 
Sullivan, Winters, Paul, & Oriet, 2005); and physical burdens like side effects of 
medication, time spent travelling to obtain care, attending to and monitoring symptoms, 
financial strains and impact on employment, and health services issues like lack of 
continuity of care (Sav et al., 2013).  
At the same time, the desired outcomes could be professionally determined, bio-
medical, normative, and disease-specific. They might include objectives such as regular 
symptoms’ monitoring, medication adherence, behavioral changes, and increasing self-
efficacy and psychological empowerment. Some contend the successful attainment of 
these objectives is predicated on acquiring disease knowledge and “learning and 
practicing the skills necessary” (Hibbard, Stockard, Mahoney, & Tusler, 2004; Lorig, 
1993) through programmatic and formal interventions. 
Looking for processes that are involved in self-management, Schulman-Green et al. 
(2012) conducted a meta-synthesis of 101 qualitative studies on self-management 
between 2000 and 2011. They identified tasks and skills associated with three categories 
of “focusing on illness needs,” “activating resources,” and “living with the chronic 
illness” (p. 5). In total 76 different skills were identified to accomplish 20 discrete tasks. 
These skills ranged from simple ones such as keeping appointments and taking 
medications to complex skills of communicating effectively and dealing with stigma.  
The various self-management/self-care models, in spite of overlaps, may be 
arranged broadly in a number of categories based on the core elements of their 
conceptualizations. 
Self-Management as Developing Skills 
Lorig and Holman (2000) conceptualize self-management based on the Corbin and 
Strauss (1989) model in combination with Bandura’s (1977) self-efficacy framework. 
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“Five core self-management skills:  problem-solving, decision-making, resource 
utilization, forming of a patient/healthcare provider partnership, and taking actions” (p. 2) 
form the core of this model. Based on these concepts, a self-management intervention 
program was developed for arthritis patients at Stanford University, which since then has 
been applied to other conditions (chronic pain, HIV) and further refined as a generic 
model called the Chronic Disease Self-Management Program (CDSMP).  
Self-Management as Problem-Solving 
Hill-Briggs (2003) combines three problem-solving theories from cognitive 
psychology, educational research, and social problem-solving to provide a theoretical 
framework for self-management as a problem-solving process. The four components of 
having a “problem-solving orientation,” acquiring the “problem-solving skills,” learning 
the “disease-specific knowledge,” and the “transfer of past experience” (p. 190) to new 
situations are deemed to lead to an effective outcome in self-management. 
Self-Management as Decision-Making and Learning  
Thorne, Paterson, and Russell (2003) have looked at the process of decision-
making as a means of gaining and assuming control over the management of illness. By 
decision-making they meant “all behaviors undertaken by affected individuals for the 
purpose of promoting or restoring their health” (p. 1339). Being in control was identified 
as “being able to mediate the effects of the disease so that they could live as ‘normally as 
possible’” (p. 1341). Three common processes were identified: (a) learning how to take 
charge of own life through learning about the disease, treatment, and body’s responses; 
body listening (“monitoring of the body’s sensations and functioning,” p. 1242), and 
reflecting on priorities and life meanings; (b) fine-tuning to the disease-specific context 
by managing social context, lifestyle changes, treatment, and healthcare interactions, all 




Self-Management as a Progressive Process with Distinct Phases 
Audulv (2013) argued that self-management behaviors do not develop as a simple 
chronological process of increasing knowledge and skills, or as fluctuating phases in 
response to life changes and illness experiences’ ebbs and flows. Rather, in her 
longitudinal study (2½ years), she observed four patterns of emerging self-management 
behaviors. These behaviors, labeled as consistent, episodic, on demand, and transitional, 
developed over time, each with its own goal and timeline. Consistent self-management 
behavior, such as taking medications, remained unchanged during the study period. 
Episodic behavior, characterized by periods of actions and inactions, consisted of 
behaviors that were difficult to sustain, such as smoking cessation or exercise, in spite of 
good intentions to do so. On demand behaviors were those addressing acute and short-
term crisis. Lastly, transitional self-management behaviors were those stemming from a 
change in one’s values, focus, or acceptance of a new situation. 
The progression in Whittemore and Dixon’s (2008) work is in the form of 
integration and assimilation through “a complex person-environment interaction whereby 
new life experiences are assimilated into the self and activities of daily living resulting in 
an overall life balance” (p. 179). They identified five phases of integration: “shifting 
sand,” “staying afloat,” “weathering the storms,” “rescuing oneself,” and “navigating a 
life” (pp. 181-182). These phases corresponded to the initial emotional response to the 
diagnosis, coming to terms with disease and understanding one’s self-management needs, 
dealing with barriers and setbacks, engaging with a meaningful life to weather the storm, 
and managing the oscillation between “living a life” and “living an illness” (p. 177). They 
further asserted that in addition to behavioral work necessary to manage a disease and the 
psychological work needed to cope with an illness, social/vocational work associated 
with one’s roles and existential work required in living a meaningful life were essential. 
Townsend, Wyke, and Hunt (2006) observed a similar concept to existential work in their 
study, identifying it as the core moral work of self-management. 
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Self-Management as Work 
Hinder and Greenhalgh (2012) noted that patients viewed their efforts in self-
management as work and used metaphors such as hassle, grief, and ballache to express 
the nature of physical, cognitive, and emotional work needed. Corbin and Strauss (1988), 
in their highly influential work, saw patients as engaging in three categories of “work”—
”illness work,” “biographical work,” and “everyday life work”—in managing their 
illness. Corbin and Strauss’s study has been influential in subsequent research and 
development of a number of self-management models. Their work forms a component of 
the conceptual framework of this study and is delved into in detail under “conceptual 
framework” later in this chapter. 
The above studies provided a range of characteristics that described the nature of 
patients’ involvement with their own care. These included development of skills, 
problem-solving, integration of life and illness, decision-making, and learning along a 
multi-dimensional process involving varying levels of engagement characterized as 
phases. There were overlaps in some articulations, among them the consideration of 
illness as a multi-faceted and dynamic entity. At the same time, each study accentuated 
particular features. The influence of the field of study within which the study was located 
accounted for this, coupled with study’s population and characteristics of chronic 
condition considered. Most studies were of patients with a single chronic condition. 
Patients with multi-morbidity, in advanced stages of diseases or age, or certain chronic 
conditions pose a more complex situation. Bayliss et al. (2007) argued that “the person 
with complex care must integrate numerous, and potentially conflicting, self-management 
tasks “(p. 168). Among the issues faced by these patients were: getting multiple and 
possibly conflicting self-management recommendations due to care from multiple 
providers, suffering from symptomatic depression hampering self-management abilities, 
dealing with compounding effects of multiple conditions and medications, being seen by 
poorly trained physicians with little expertise in managing complex care needs, and 
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having to contend with lack of care coordination. Other studies confirm that patients with 
multi-morbid conditions have more extensive learning needs for self-management skills. 
(Noel et al., 2007). These more complex situations do not fit neatly into self-management 
models focusing on formal knowledge and skill development as main approaches to 
illness management. 
Theoretical Context: Adult Learning Theories 
An ongoing illness precipitates an avalanche of issues and thrusts them into one’s 
life, often unexpectedly. These include existential threats, disabilities, and bodily 
dysfunctions; practical exigencies such as near-constant interactions with healthcare 
system, and vigilance with treatment regimens; interruptions in one’s roles and 
responsibilities; and alterations in familial and social relationships. These changes, 
alterations, and disruptions to one’s way of life bring with them enormous challenges and 
suffering, but also new experiences and potentials for learning and meaning-making. 
Many adult learning theories focus on experience and reflection on experience as the 
primary bases of learning. This view of learning is in contrast to learning theories that 
emphasize purely cognitive knowledge acquisition and recall or give primacy to 
behavior. This review will focus on experience, brought about by an illness, as the main 
impetus for learning. Among theories and models of learning from experience, informal 
and incidental learning, and somatic and embodied learning are highlighted. 
Learning from Experience 
Experience in the context of adult learning theories could mean: (a) a mental, 
physical, or emotional engagement in the moment; (b) a past, simulated, or introspective 
experience; or (c) one’s sense making through collaboration in a community (Merriam, 
Caffarella, & Baumgartner, 2007). In Dewey’s (1930) formulation, experience has 
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“peculiarly combined” active and passive elements: “On the active hand, experience is 
trying … on the passive, it is undergoing” (p. 163). By the peculiar combination, he 
meant there is a “backward and forward connection” where the “change made by action 
is reflected back into a change made in us … we learn something” (p. 163). Thus, in this 
view the experience of going through a chronic condition may be viewed as having the 
potential of undergoing a change that may be labeled as learning. 
Drawing on the work of Dewey, Lewin, and Piaget, Kolb (1984) elaborates one of 
the well-known models of experiential learning in the field. This model suggests that 
learning is involved with the resolution of two conflicting or opposing ways of dealing 
with the world. Learning becomes an adaptation in the process of reconciling the 
dialectics of the experience in a transaction between the individual (subject) and the 
environment (object). For a patient, the object or the environment may include the 
disease itself, medical interventions and treatments, physical, emotional, everyday 
changes, as well as family, workplace, healthcare, and social interactions. This 
experiential model has been promoted and used in the design of patient educational 
programs (Arndt & Underwood, 1990; Deakin, 2011; Montez-Ray, 2011; Sorin-Peters, 
2010), and in a study of dental patients’ decision-making (Jayson, 2000). Kolb’s model, 
having a reflective/constructivist perspective that focuses on the cognitive and rational 
processes within an autonomous agent, is criticized for its lack of adequate attention to 
the emotional, environmental, social, and historical contexts of experience, including 
issues of power (Fenwick, 2000; Heron, 1992; Jarvis, 2006).  
Jarvis (2006) addresses some of these shortcomings by including a person’s life 
history into his model and emphasizing the notion of a “disjuncture” (p. 9). Disjuncture 
occurs when our “biographical repertoire is no longer sufficient to cope automatically 
with our situation” and when “people are consciously aware that they do not know how 
to act. We have to think, to plan or to learn something new” (p. 9). For Jarvis, experience 
is not just a “segment of our life-world” that we happen to be focusing on, but also an 
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“episode in time.” It is at these intersections of person, life, and time that we learn 
through emotions, reflection, and action in the world. Collins (2012) used Jarvis’s model 
to frame an art-based HIV/AIDS adult education program, and Hakanson, Sahlberg-
Blom, Ternestedt, and Nyhlin (2012) explored the experience of patients with irritable 
bowel syndrome participating in a group-based patient education program through 
Jarvis’s model. 
For Mezirow (2009), the incongruity and continuous negotiation of “contested 
meanings” (p. 3) of our experiences is our human condition. When there is a disjuncture 
and incongruity between our sensory experiences of an event or a phenomenon, and our 
internal processes try to make the event meaningful, transformative learning occurs. 
Learning is viewed as transformative since it alters (expands, modifies, replaces) our 
meaning-making processes such that we do not process our experience of the world the 
same way as prior to learning. Such a perspective transformation is usually prompted by 
a “disorienting dilemma,” along an eleven-step process, and concluding with 
reintegration into one’s social life (Mezirow, 1994, p. 224). 
The mechanism through which we resolve or accommodate the incongruities in our 
experience is through critical reflection and dialogue. Critical reflection is differentiated 
from mere reflection and thinking. It is the kind of thinking that prompts examination and 
questioning of the underlying assumptions and suppositions that shape the way we 
process our experiences. By theorizing the underlying processes of change and meaning-
making, Mezirow’s theory is considered one of the most influential contributions to the 
field’s understanding of human experience. It has been applied in studying the 
transformative learning in HIV/AIDS patients (Courtenay, Merriam, & Reeves, 1998), a 
follow-up study of a sub-sample of these patients (Courtenay, Merriam, Reeves, & 
Baumgartner, 2000), rheumatoid arthritis patients (Dubouloz, Laporte, Hall, Ashe, & 
Smith, 2004), stroke patients (Kessler, Dubouloz, Urbanowski, & Egan, 2009), multiple 
sclerosis patients (Lewis, 2009; Taylor, 2008), and Tarlov cyst patients (Reasoner, 2010). 
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In addition, based on Mezirow’s theory, Brendel (2009) suggested a narrative-driven 
transformative framework to promote proactive and critical mindset in patients. Malkki 
(2012) has applied Mezirow’s theory to the context of infertility, as an emotionally 
chaotic experience, to explore the connection between disorienting dilemma and 
initiation of reflection. 
Informal and Incidental Learning 
Much of adult learning is understood to occur in life and work interactions, and 
experiences outside formal structures and institutions (Fenwick, 2000). In a study of 
organ transplant patients, Plunkett (2011) found that 44% of learning came from formal 
sources such as medical care professionals and conventions/seminars, while patients 
attributed the majority of their learning to sources such as other transplant patients (28%), 
Internet (15%), books and videos (11%), and magazines and other publications (2%). 
Eraut (2004) characterized such informal learning as “implicit, unintended, opportunistic 
and unstructured learning and the absence of a teacher” (p. 250). He further differentiated 
such informal learning on two dimensions of “levels of intentionality,” and the “focus on 
when the experience occurred” (i.e., past experience, present, or envisioned future). 
Three levels of intention were observed: implicit learning where the learner is not 
conscious of explicit knowledge, reactive or opportunistic learning where learning is 
more deliberate, but is near spontaneous in the middle of an action, and deliberate 
learning, either by setting definite learning goals, or through engagement of problem-
solving and planning activities. In this type of deliberate learning, “learners are aware 
that they are learning; learning with a definite, specific goal rather than generalized 
learning” (Boud, Keogh, & Walker, 1985, p.18), albeit in informal settings. Such 
informal learning in patients with chronic conditions has been studied from the 
perspective of self-directedness by Rager (2004) in breast cancer patients, Rager (2006) 
in prostate cancer patients, and Holland (1992) in multiple sclerosis patients.  
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Inquiring into learning that is not deliberate, but tacit and incidental, Marsick and 
Watkins (1990) state that such learning is “a byproduct of some other activity, such as 
task accomplishment, interpersonal interactions, sensing the organizational culture, or 
trial-and-error experimentation” (p. 12). Their model of informal and incidental learning 
is part of the conceptual framework of this study and is explained in detail later in this 
chapter. The notion of incidental and tacit learning in chronic patients has been studied 
by Keeping and English (2001) in end-stage renal disease patients, and Jackson (2006) in 
the context of lifelong learning. 
Somatic Learning 
Most learning from experience theories relies on cognitive bases of learning 
through critical reflection, inference, creativity and innovative thinking, problem-solving, 
and analogical reasoning. Experience in these theories is presented as an interaction with 
entities in one’s environment. Having a chronic disease, at one level, is the experience of 
a diseased body in the world. On another level, it is a somatic experience where the body 
is the object and subject of experience, all at once. 
Literature on embodiment considers the role of body in experience by questioning 
the dichotomy of mind-body in Western epistemology. This disengagement of mind from 
body makes experience and learning “disembodied.” To remedy this disembodiment, the 
body is recast as both “a lived, experiential structure” and “the context or milieu of 
cognitive mechanisms” (Varela, Thompson, & Kesch, 1993, p. xvi). Experiential learning 
is redefined as the “experience that re-members body and mind” (Michelson, 1998, 
p. 224), through a holistic process that takes into account somatic knowing (Crowdes, 
2000). Embodiment becomes “a way to construct knowledge through direct engagement 
in bodily experiences and inhabiting one’s body through being-in-the-world” (Freiler, 
2007, p. 6).  
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Somewhat differently, somatic learning is “directly experienced through bodily 
awareness and sensation during body-centered (somatic) approaches and movements” 
(Freiler, 2007, p. 5; Bennett, 2012). According to Heron and Reason (1997), such 
expressions through movements and other artistic presentations are “metaphors of 
aesthetic creation” (p. 281) and indicative of presentational knowing. This paper defines 
presentational knowing as an “intuitive grasp of the significance of our resonance with 
and imaging of our world” (p. 281). This intuitive grasp is based on and derived from 
experiential knowing, which is the direct encounter with the world. The two other forms 
of knowing, propositional knowing (conceptual) and practical knowing (knowing how do 
things), complete the four ways of knowing in Heron’s (1992) original epistemology. 
What Heron articulated was the existence of a perspective of knowing and learning that 
lies in between the knowing through a purely experiential encounter of physical reality on 
one hand, and knowing through conceptual and descriptive classification of things, where 
words are available to us to name things. Heron posited that these modes of knowing, in a 
hierarchical fashion, ground each other in one direction and consummate each other in 
the “up hierarchy” (Heron, 1992). This hierarchy provides for a more holistic and 
embodied way of knowing and learning.  
Having an illness creates an awareness of body and one’s state of health, which 
many patients find difficult to articulate in a propositional way. Somatic learning and 
Heron’s holistic model provide a lens to look for this type of knowing and learning. 
Conceptual Framework 
The conceptual framework for analysis of this study’s findings draws on the work 
of Corbin and Strauss (1988) in illness management, as well as Marsick and Watkins’s 
(2001) model of informal and incidental learning. Corbin and Strauss’s and Marsick and 
Watkins’s models are described in this section. This is followed with a rationale for 
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choosing these theoretical lenses to aid in conceptualizing notions of commitment to 
illness management through involvement with care and learning in this study’s sample. 
Corbin and Strauss Model of Illness Management 
Corbin and Strauss (1985, 1988) turn to theoretical perspectives on occupation and 
work, specifically work processes, to conceptualize management of a chronic illness in 
terms of the work and the task components that are performed by patients, spouses, 
partners, friends, etc. They define work “as a set of tasks performed by an individual or a 
couple, alone or in conjunction with others, to carry out a plan of action designed to 
manage one or more aspects of the illness and the lives of ill people and their partners” 
(Corbin & Strauss, 1988, p. 9). What differentiates this work from work done in 
professional settings (e.g., hospitals) is the nature of its inseparability from one’s life. 
Due to this intimate interconnection with life, three types of work are identified: 
•   Illness work—the disease management works of controlling and monitoring 
symptoms, preventing/managing crises, implementing regimens, rehabilitation 
work, and dealing with social isolation. 
•   Biographical work—for “defining and maintain an identity” (p. 10). This is 
done by: 
o   Contextualizing the illness into biography 
o   Coming to terms with limitations caused, and the possibility of death 
o   Restructuring new conceptions of self 
•   Work of everyday life—occupational, marital, domestic and child-rearing 
work. 
On a daily basis, Corbin and Strauss note that there are great variations in type, 
degree of difficulty, duration, frequency, and consistency of the work. This dynamic 
nature is exacerbated further by the fluctuation in the disease and its movement along an 
illness trajectory, providing a constant threat of instability. Even small changes and 
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perturbations can cause chaos. In order to bring a sense of relative stability and 
equilibrium to this, at times, chaotic system, strategies are needed. Corbin and Strauss 
describe these “adjustable and changeable” strategies as “management in process.” 
Strategy is often thought of as plans or methods to achieve goals or desired 
outcomes. As such, it is involved with goal setting, planning, figuring out the needed 
actions and resources, and execution. Bakir and Todorovic (2010) argue that when the 
means-end relationship is ambiguous, while maintaining the notions of intentionality and 
goals, strategy takes on an interpretative characteristic. As “goals persistently shift and 
change as a result of interactions, and the outcomes are predominantly emergent,” 
strategy formation becomes more of a “muddling through,” “incrementality,” “organized 
anarchy,” “strategy-as-practice,” “social action,” and dealing in “complexity” (p. 1050). 
That is, strategies in complex and uncertain environments, become emergent and 
opportunistic, similar to the type of strategy that Corbin and Strauss see needed in illness 
management. 
In addition to strategies, in Corbin and Strauss’s formulation, motivation is needed 
to allow patients to continue engaging with three lines of work. Three types of motivation 
are listed: commitment to engage with the illness, hope to carry on, and having 
biographical and trajectory schemes. The latter refers to having the will to live and 
having an indication of the course of illness and what might lie ahead. However, they 
acknowledge that, if uncertainty surrounding one’s condition is great, then maintaining 
motivation becomes challenging. 
In summary, Corbin and Strauss’s model has a number of features that can 
illuminate patients’ commitment to their illness management and their involvement:   
•   Illness is treated as a dynamic trajectory where the only constant is change. 
•   What patients do is described as work, consisting of intertwined and interacting 
strands of activities, which simultaneously, interact with the changes in disease 
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providing for a complex system. Maintaining a relative equilibrium in this 
system through emergent strategies becomes a goal. 
•   Achieving this goal and engaging with lines of work hinge on motivation, 
which in turn is predicated on having hope, commitment, and biographical and 
trajectory schemes.  
Marsick and Watkins Model of Informal and Incidental Learning 
Marsick and Watkins (1990) contend that informal and incidental learning is the 
type of learning that “almost always takes place although people are not always 
conscious of it” (p. 12); it is often taken it for granted, because of its tacit nature. They 
further argue that incidental learning is often “the result of a significant unplanned or 
unexpected event” (Marsick & Watkins, 2001, p. 27), where people have to figure out 
solutions and be inventive in techniques or strategies to achieve desired results and 
outcomes. Observing that “learning grows out of everyday encounters while working and 
living in a given context” and that “a new life experience may offer a challenge, a 
problem to be resolved, or a vision of a future state” (p. 29), Marsick and Watkins (2001) 
proposed a non-linear model of informal and incidental learning. The components of the 
model, not intended to be sequential or in a particular order, are listed as: 
1.   Learning begins with an internal or external trigger signaling “dissatisfaction 
with current ways of thinking or being.” 
2.   Interpretation of that experience and context by framing the experience and 
assessing what is problematic or challenging about it based on one’s 
worldview. 
3.   Interpretation leading to examination of alternative solutions by comparing the 
new situation with prior experience and search for potential model of actions. 
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4.   Employing learning strategies including acquisition of knowledge, acquiring 
resources and the needed skills, and motivating oneself to learn to achieve 
desired solution. 
5.   Proposing a solution and taking action. 
6.   Assessing outcome, the intended and unintended consequences. 
7.   Drawing lessons learned. 
8.   Using the lesson as new frame for future actions.  
Three conditions that enhance this type of learning are: 
•   “Critical reflection to surface tacit knowledge and belief, 
•   Stimulation of proactivity on the part of the learner to actively identify options 
and to learn new skills for implementing those options and solutions, 
•   And creativity to encourage a wider range of options” (p. 30). 
This model is suited to understand the type of unintended learning that occurs 
when attending to new and constantly changing experiences of dealing with an illness 
and resolving associated issues.  
Rationale for Conceptual Framework 
The Corbin and Strauss model of chronic illness management was chosen to 
encapsulate the notion of patients’ commitment to their illness management and their 
involvement in their own care. First, this model is based on interviews of patients and 
their partners forming “a body of grounded information about the problems such couples 
are up against” (Corbin & Strauss, 1988, p. xi). Thus, this is a patient-derived rather than 
a professional-derived model. Second, the notion of work, in all its variations, as a series 
of purposeful activities “to carry out a plan of action designed to manage one or more 
aspects of the illness and the lives of ill people and their partners” (p. 9), describes how 
one may be involved with management of one’s illness very concisely. Third, this model 
views a chronic illness and activities related to its management as dynamically changing, 
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resulting in a complex system that is more descriptive of the everyday experience of 
living with a chronic illness. This is an elegant model for a messy process that reflects the 
realities of a complex illness like scleroderma very well. 
The inclusion of Marsick and Watkins’s learning model is based on the following 
assumptions: First, being involved as a patient requires learning and working in multiple 
domains. This work changes in form, but is continuous. It involves doing (working and 
experiencing) and learning from it, and learning in order to do. One’s involvement 
resides in this space. Second, the majority of this learning is informal and incidental. The 
unexpected and jolting experience of being diagnosed with a serious chronic condition 
may provide the need, motivation, and opportunity for a great deal of learning. In 
addition, the disabilities and host of problems resulting from a lack of appropriate and 
responsive care structure mean that patients have to figure out solutions to their problems. 
Along the way, they learn from their experiences and learn through their bodies and 
socially with other patients in venues such as support groups.  
Last, many models and theories of informal and incidental learning are developed 
in the context of work as an unstructured environment where learning occurs. Eraut 
(2004) notes, “This (unstructured environment not designed for learning) is true of family 
and community contexts, which are even more difficult to research” (p. 247). Drawing 
similarities between the work of patients and those in a work environment, similar to the 
approach taken by Corbin and Strauss, makes the application of informal learning models 
to this study more appropriate. The alignment of Corbin and Strauss’s and Marsick and 
Watkins’s models also makes sense from this point of view.  
Conceptual Framework Components 
The Conceptual model consists of the following components: 
•   Illness Trajectory 
•   Management 
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o   Lines of Work (illness work, biographical work, everyday work) 
o   Creating Relative Equilibrium  
•   Buttress 
o   Strategies 
o   Motivation 
§   Commitment 
§   Hope 
§   Trajectory and Biographical Scheme 
•   Learning 
o   Incidental Learning 
These components are shown in Figure 2.1. In this representation, the dynamic and 
interacting illness trajectory and various forms of work are kept in an equilibrium by the 
buttress of strategy, learning, and motivation. 
Summary of Chapter II 
In this chapter, five concepts of patient empowerment, patient engagement, patient 
involvement and participation, and patient activation were reviewed. It was observed that 
these definitions and conceptualizations are either overlapping or subsuming the other 
concepts, making for compound constructs that are difficult to tease out, measure, and 
operationalize. The perspective of disease versus illness deemed to be an important 
distinction in defining these concepts, and it was suggested that these perspectives have 
shaped the way involvement is defined and explored, both in clinical interactions and  
patients’ lifeworld. The medical view of involvement as patients’ informational needs 
and preference for decision-making was presented. It was noted that patients’ access to 
online information has changed the notion of the need for information to the need for 





Figure 2.1. Conceptual model of study based on elements of Corbin and Strauss’s and 
Marsick and Watkins’s models. A relative equilibrium may be maintained, in this 
dynamic system, through motivation, learning and strategy. 
Severity, age, race, gender, education, confusion about choices, and concerns for doctors’ 
reactions impact decision-making preferences. The diversity of disorders and conflicting 
results made generalization of studies on decision-making preference challenging.  
Patient involvement as engagement with one’s care outside a clinical setting, 
sometimes framed as self-management and self-care, was presented as development of 
skills, problem-solving, integration of life and illness, decision-making and learning, 
work, and a multi-dimensional process involving varying levels of engagement occurring 
in phases. Some of these conceptualizations were deemed not sufficiently fitting patients 
with comorbidities and complex diseases. 
A selection of adult learning theories was presented to foreground the concept of 
learning as central to this study. Learning was portrayed as closely tied to our experiences 
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and includes informal, incidental, and somatic learning. The conceptual framework of the 
study, based on work of Corbin and Strauss and Marsick and Watkins, was elaborated 





This chapter outlines the details of the research design for inquiring into 
scleroderma patients’ commitment to illness management, including how they are 
involved in dealing with their illness and how they learned to do so. The chapter is 
organized into the following sections: 
•   Rationale for a mixed-methods qualitative framework 
•   Rationale for a descriptive qualitative component 
•   Rationale for a non-experimental fixed design quantitative component 
•   The research sample and the selection process 
•   Information needed to conduct the study 
•   The research design, including data collection, analysis and synthesis, ethical 
considerations, issues of trustworthiness, validity, and limitations and 
delimitations of the study 
•   Chapter summary 
Rationale for Mixed-Methods Qualitative Framework 
A mixed-methods research combines quantitative and qualitative data within a 
single study to answer research questions. In doing so, a mixed-methods approach 
acknowledges the paradigmatic characteristics of quantitative and qualitative modes of 
inquiry, assumes that each approach provides only a partial understanding of our social 
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world, and advocates a respectful dialogue and integration between the two (Schiazza, 
2013). These assumptions philosophically motivate the choice of a mixed-methods 
approach for inquiring into the complex phenomenon of patient involvement. On a 
practical level, scleroderma’s complexity gives rise to an array of illness experiences that 
are difficult to catalogue. Furthermore, the rarity of the disease makes the population 
from which a sample may be drawn small and difficult to access. Hence, a general 
understanding of population characteristics as a whole is sparse, and validated 
instruments for this patient population are rare. Given these limitations, it was this 
researcher’s contention that involvement of scleroderma patients was best understood 
when data from an individual perspective and data from a population perspective were 
brought together. Neither method, quantitative or qualitative, by itself would have 
adequately provided a clear picture of this population and the phenomenon under 
consideration. Therefore, a mixed-methods approach was deemed to be a more 
appropriate and fruitful strategy. 
Issues of purpose, implementation, and integration are given consideration in a 
mixed-methods strategy. Purpose has to do with the reasons for mixing methods; while 
implementation is concerned with the order (sequential or parallel) in which qualitative 
and quantitative data are collected and analyzed. Integration attends to the points in the 
design process where qualitative and quantitative data are connected or mixed. 
According to Greene, Caracelli, and Graham (1989), there are five purposes for 
conducting a mixed-methods analysis:  
•   Triangulation: to converge and corroborate results through different methods. 
•   Complementarity: to elaborate, clarify, enhance results from one method by the 
other. 
•   Development: using the results obtained from one method in the service of the 




•   Initiation: to discover paradoxes and contradictions. 
•   Expansion: to extend the breadth of inquiry, using different methods for 
different components. 
The mixed-methods strategy in this study served the purposes of development, 
complementarity, and triangulation. First, the survey data were used to inform the 
selection of patients for the qualitative portion, and the answers to survey questions were 
used to guide interviews. Second, the survey results were elaborated and clarified by 
interview findings, contributing to triangulation. Specifically, the prevalence and 
distribution of certain quantitative data made more sense and had added plausibility, 
when viewed in light of the interview findings. Last, the convergence of findings 
corroborated the findings from each method of inquiry where integration and 
interpretation across all findings occurred. The overall mixed-methods design may be 
shown as an overall convergent design, depicted in Figure 3.1. The dashed arrows 
indicate where mixing of data or results occurred. 
The overall convergent design of the study indicates separate collection and 
analysis steps for qualitative and quantitative data, followed by convergence of results in 
the last stage (Creswell, 2015). 
 
 
Figure 3.1. Mixed methods design of study. Solid arrow indicates the sequence of events. 
Dashed arrows, additionally, indicate exchange/mixing of findings or results. 
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The design deviated from a fully sequential, or fully parallel ordering due to 
practical constraints: a gap between the collection of survey data and their full analysis, 
followed by interviews of a geographically dispersed and qualitatively large sample of 
25 people would have jeopardized access to the interview sample and would have made a 
fully sequential approach impractical. At the same time, lack of any information on the 
population’s makeup and the need for a theoretical variation in the sample relative to 
involvement, coupled with need for a mechanism to identify the subset of participants 
willing to be interviewed would have made a fully parallel design unworkable. The 
modified design was a compromise given these constraints.  
Rationale for a Descriptive Qualitative Component  
Qualitative research with its inductive approach is well-suited to study perceptions 
and experiences of a sample. Ritchie and Lewis (2003) contend that a “major feature of 
qualitative methods is their facility to describe and display phenomena as experienced by 
the study population, in fine-tuned detail and in the study participants’ own terms” 
(p. 27). In their view, this would allow for unpacking issues relative to dimensions, 
features, meaning, and typologies related to the phenomenon under consideration. These 
descriptive and exploratory functions provide for a mechanism to examine and “portray 
an accurate profile” (Robson, 1993, p. 59) of a phenomenon. A descriptive or exploratory 
approach is a common approach in qualitative health care related studies (Kim, Sefcik, & 
Bradway, 2017; Polit & Beck, 2009), where studying the phenomenon in a natural state 
(observations or interviews), using a maximum variation sampling, connecting to work of 
other researchers in the field (as opposed to just theory), and tying “nicely with 
quantitative data” are some of the features (Neergaard, Olsen, & Andersen, 2009, p. 4; 
Sandelowski, 2000, 2010). 
In this study, the main focal point was the description of commitment to illness 
management and involvement and learning from patients’ points of view, obtained by 
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interviewing adult patients with an official diagnosis of scleroderma living in New York, 
New Jersey, or Connecticut areas (as indicated by being on the Scleroderma Foundation’s 
mailing list). A descriptive and exploratory approach was considered appropriate to 
obtain a direct portrayal. An initial assumption of the study was that heterogeneity in 
terms of involvement may be indicated by support group membership, giving the 
rationale for a maximum variation sampling (Patton, 2002, p. 243).  
Rationale for a Non-experimental Fixed Design Quantitative Component 
A non-experimental fixed design or a correlational study was chosen for the 
quantitative portion of the study. In such a design, the phenomenon under consideration 
is not manipulated by the researcher and is best suited for descriptive purposes (Robson, 
2007). Since the interest in the phenomenon of involvement in the scleroderma patients 
was that of understanding and describing the phenomenon coupled with a one-time 
opportunity to collect data, this methodology was deemed well-suited and is in alignment 
with the purposes of the qualitative portion.  
Furthermore, according to Robson (2007), a correlational design is useful in 
“establishing cause in the sense of providing supportive evidence for the operation 
mechanisms and for teasing out the particular situations and groups of people where 
enabling or disabling mechanisms have come into play” (p. 155). When associations are 
seen in the data, an opportunity is provided for integration of qualitative findings to shed 
light on the mechanisms involved. This made the choice of a correlational study design, 
as part of a mixed methodology, attractive. 
The Research Sample 
The Scleroderma Foundation is a 501(c)(3) nonprofit patient support, education, 
research, and advocacy organization for scleroderma. Twenty active chapters and 
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approximately 160 support groups nationwide function under this organization. The 
Scleroderma Foundation, Tri-State Chapter, based in Binghamton, NY is one of the semi-
autonomous and larger chapters in the country covering New York, New Jersey, and 
Connecticut. Some 20 patient-led support groups are associated with this chapter. This 
chapter is not a HIPAA (Health Insurance Portability and Accountability Act of 1996)-
covered entity and does not collect any health information. It has limited data on its 
membership, primarily consisting of contact information for the purpose of sending 
information on its activities (patient education, fund-raising, and legislative and policy 
advocacy). Scleroderma patients as the participants of this study were recruited through 
mail using a mailing list maintained by the Scleroderma Foundation, Tri-State Chapter. 
The inclusion in the mailing list might have occurred due to registration for patient 
educational programs sponsored by the Foundation, membership in a support group 
offered by the Foundation, participation in fund-raising walks and events and donations 
to the Foundation, or as a result of contact with the Foundation for information and 
support. Those on the mailing list receive the organization’s newsletter, educational 
program promotions, and fund-raising and membership appeals. This mailing list of 
1,000 names and addresses of potential participants was made available to the researcher 
in the form of mailing labels. Only names and addresses were available from this list. No 
other information regarding the population was shared. Information such as age, validity 
of addresses (use of non-profit bulk mail rate precludes knowledge of undelivered mail 
and invalid addresses), and whether the individual was a patient, caregiver, underage, or 
deceased were not reflected in the list, and had to be subsequently dealt with. 
Recruitment procedures were negotiated with the Scleroderma Foundation, Tri-
State Chapter, which provided mailing envelopes and labels. The agreement included the 
use of official Foundation envelopes, one-time mailing of recruitment materials, no 
duplication of names and addresses from the mailing labels, and the labeling of envelopes 
and their mailing done under observation of the Foundation’s staff. Protecting the privacy 
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of participants and a one-time solicitation attempt were the two major considerations for 
allowing access to this mailing list. 
The 1,000 mailed recruitment packets contained an invitation to take part in the 
study, along with an explanation of the study, the required IRB forms including a consent 
form, a demographic questionnaire, two instruments of PAM-13 and MOS-SSS, an 
interview interest form, and a return envelope with a dedicated P.O. Box address to 
which only the researcher had access. These were sent, using first class mail, to 678 
patients in NY, 214 in NJ, and 108 in CT, adding up to 1,000 in total. 
Simultaneously, an identical, password-protected online version of the above forms 
and questionnaires was provided through the Qualtrics survey tool, available from 
Teachers College. The link to the Qualtrics survey and the password to access it were 
provided in the recruitment packet. Thus, the participants were given the option of filling 
out the paper questionnaires and instruments and returning them to the researcher by mail 
to a dedicated P.O. Box address secured for this purpose, or going online and filling out 
the identical forms on the Qualtrics site.  
Seventy-five packets were returned to sender as undeliverable [6 (5.6%) CT, 17 
(7.9%) NJ, 52 (7.7%) NY)]. Presumably, 925 packets were successfully delivered. 
Twenty patients filled out the online version, and 192 mailed back the paper version. The 
online version had the completion date and time digitally recorded, and the paper 
versions were date-stamped upon arrival. A total of 205 (96.7%) responses were received 
within the 3 months after the mailing date of the recruitment materials. Another 7 (3.3%) 
trickled in several months later. This represented a 23% response rate for a sample of 212 
respondents. Since the main focus of the study was involvement, the process of engaging 
with the survey and responding to it, even writing notes on the margins and including 
additional letters and notes by some, might have indicated this sample was the more 
involved sub-population that the study needed to focus on. Thus, these respondents may 
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be viewed as representative of more involved patients on account of their response to this 
study. 
Among the 212 respondents, 86 patients expressed an interest to be contacted for 
an interview. These 86 patients were stratified by support group participation (leaders, 
members, non-members) and gender. Nine belonged to the “leaders” group, and seven 
were interviewed. From the 21 respondents in the “members” group, 4 females and 2 
males were randomly selected. From the 59 respondents in the “non-members” group, 10 
females and 2 males were randomly selected. In total, 7 leaders, 6 members, and 12 non-
members, consisting of 20 females and 5 males, were selected through this systematic 
sampling and were interviewed. 
The choice to include support group participation as part of the study design was 
based on the underlying rationale and logic for maximum variation sampling. The 
assumption was that support group membership status might have been indicative of 
higher levels of commitment and involvement, and having participants representing a 
theoretical variation including varying levels of participation could shed light on varied 
manifestations and perceptions of commitment and involvement. In addition, like most 
autoimmune diseases, scleroderma primarily afflicts women. A conscious choice was 
made to include at least a few men to increase the variation of the sample. 
Briefly, the 25 interview-participants were patients with variations in support group 
involvement and gender who were distributed proportionally between members and non-
members. The study respondents were a sample of 212 patients across NY, NJ, and CT. 
Details on sample characteristics for study respondents, survey participants, and 
interview participants are provided in Chapter IV.  
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Information Needed to Conduct the Study 
Information required to conduct this study consisted of (a) information needed to 
determine inclusion criteria, (b) quantitative data, and (c) qualitative data. These are 
summarized in Table 3.1 and described following the table. 
 
Table 3.1 
Information or Data Needed to Conduct the Study  
Data Source Procedure Purpose 
a) Inclusion Criteria  
Age 
Official SSc Diagnosis 
Desire to be interviewed 
 
b) Quantitative Data 
Patient Survey To identify study eligibility 
To identify interview eligibility & 
obtain permission & contact 
information for interviews 
Demographic  
   Personal data  
   Clinical data 






To Identify characteristic of sample 
and context within which involvement 
is studied in this sample. 
To develop criteria for interview 
sample selection 
Measurement Data    
   Involvement measure 




To obtain macro understanding of 
involvement and social support in 
sample  
c) Qualitative Data  
Perceptual 
Perceptions of: 
    Illness & its changes 
    Involvement per framework 
    Learning and its changes 
    Social support  
    Support group 
 
Patient Interview To obtain understanding of 
involvement and social support from 
individual perspective 
To understand connections among 
learning, involvement and social 
support  
Theoretical   
Conceptions of: 
    Involvement 
    Learning 
   Strategy 









To determine the status of what is 
known on topic. 
To obtain theoretical basis for data 
collection, analysis and interpretation. 
To obtain an understanding of disease 
and its treatments 
To locate the sample of this study 
among similar studies 
To identify gaps, contribution of this 
study, and areas of future research 
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Inclusion Criteria Information 
In order to determine the overall participation, two pieces of information: age 
(above 18 years of age) and an official diagnosis with scleroderma, were needed. 
Furthermore, to select interview participants, an indication of willingness to do an 
interview and contact information were required. 
Quantitative Data Needed 
In order to answer research questions 1 and 3, from a deductive perspective, 
demographic, clinical, support group status data, as well as measurement data 
operationalizing involvement and social support were needed. These categories were 
determined by review of other studies in this area and consideration of research 
questions. 
Demographic and clinical information. Data needed included personal data, 
clinical/disease-related data, indicators of ease of access and extent of care (number of 
doctors, how far patients travel to obtain care), an indicator of patients’ disease 
knowledge or illness status, and support group participation status. 
Patient measurements of an active role. The review of existing literature 
indicated that patient involvement was a difficult construct to operationalize. As such, 
only two known instruments for assessing some conceptualization of involvement were 
available: the Patient Activation Measure (PAM) and the Patient Health Engagement 
(PHE) scale. 
The Patient Activation Measure (PAM) (Hibbard et al., 2004) is a measure of 
patients’ “ability or readiness to engage in health behaviors that will maintain or improve 
their health status” (Wong, Peterson, & Black, 2011). This measure is based on a 
construct consisting of belief in one’s role in illness, knowledge of condition, and skills 
for obtaining high quality care (Hibbard et al., 2004).  
The Patient Health Engagement (PHE) scale (Graffigna, Barello & Triberti, 2015) 
operationalizes a somewhat different concept of patient engagement. Engagement is 
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defined as a multi-dimensional, process-like experience involving emotional, cognitive, 
and conative dimensions. The median of 5 item scores is transformed to one of four 
patient engagement positions, indicative of the psychological phase a patient is in and 
ensuing engagement with one’s health conditions (Graffigna, Barello, Bonanomi, & 
Lozza, 2015). This model was developed using a panel of Italian patients with chronic 
conditions, lacked validation with any U.S. patient population at the time of this 
dissertation’s design stage, and suffered from an absence of independently published 
results. For these reasons, the Patient Activation Measure (PAM) was chosen for this 
study and is detailed later in this chapter.  
Social support measures. In contrast to the paucity of patient involvement 
measures, many instruments to measure social support are available. Shumaker and 
Brownell (1984) define social support as “an exchange of resources between two 
individuals perceived by the provider or the recipient to be intended to enhance the 
wellbeing of the recipient” (p. 11). More nuanced conceptualizations have emerged 
through the years taking into consideration type of resources (material, emotional, 
informational, instrumental), the quantity of social connections (social network), the 
quality of ties between parties (formal, informal), along with notions of perceived and 
actual social supports indicating individuals’ appraisal of availability and adequacy of 
support (Lopez & Cooper, 2011). 
Social support instruments differ based on which of these aspects are the main 
focus. For example, the Multidimensional Scale of Perceived Social Support (MSPSS) 
(Zimet, Dahlem, Zimet, & Farley, 1988) assesses the source of support (family, friends, 
significant others), the Social Provisions Scale (SPS) (Cutrona & Russell, 1987) 
measures six dimensions of interpersonal relationship, such as guidance, reliable alliance, 
reassurance of worth, etc., while the Medical Outcomes Study: Social Support Survey, 
MOS-SSS (Sherbourne & Stewart, 1991) measures four dimensions of perceived support. 
The MOS-SSS measure was chosen for this study and is discussed later in this chapter. 
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Qualitative Data Needed 
The qualitative data needed for this study included demographic, contextual, 
perceptual, and theoretical data (Bloomberg & Volpe, 2012). The demographic and 
contextual data needs were addressed above, as shared data with the quantitative portion. 
In addition, descriptive contextual data concerning diagnosis, receiving care, interactions 
with medical professionals and family, and emotional and psychological states were 
needed. 
Perceptual data. Perceptual information in qualitative studies attends to the 
“participants’ descriptions of their experience” (Bloomberg & Volpe, p. 106) relative to 
the phenomenon being studied. Perceptual information, such as how patients viewed and 
described their involvement, the perception of learning that occurred or needed to occur, 
its changes during the course of illness, and the perception of support and its role in 
involvement including their views of support groups, was needed.  
Theoretical data. Theoretical information was obtained from research literature 
concerning the topic of inquiry. This included the state of knowledge about the topic, and 
theories utilized for conceptual framework and interpretation of results (Bloomberg & 
Volpe, 2012). In addition to the literature that was reviewed in Chapter II, ongoing 
review of other literature, specifically concerning studies of scleroderma patients, studies 
utilizing PAM-13 and MOS-SSS instruments, social support, and strategy, was conducted 
throughout the study process to guide the collection, analysis, and interpretation of data.  
Research Design 
The steps taken to conduct this research were as follows: 
•   A literature review of relevant literature was conducted and preliminary 
contacts with the Scleroderma National Foundation and the Scleroderma 
Foundation, Tri-State were made regarding access to study subjects. 
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•   A pilot study consisting of in-person interviews of a convenience sample of 
three patients with various chronic diseases and disabilities, and a caregiver of 
a patient with a chronic disease was conducted to test out interview questions 
and the conceptual frameworks that were under consideration. The interview 
questions were shortened and re-phrased as a result. 
•   Research license for use of the PAM-13 measure was obtained from Insignia 
Health. 
•   Upon reaching agreement with the Scleroderma Foundation, Tri-State for 
access to participants, and completion of a proposal defense, the IRB approval 
process was initiated. This process entailed careful consideration given to 
standards for human subject studies, and provisions of informed consent 
and participants’ confidentiality. IRB approved forms are attached in 
Appendices A-D. 
•   Upon IRB approval, recruitment materials were mailed to 1,000 potential 
participants. Over a period of 4 months, as responses were received 
electronically and through mail, the demographic data and instrument 
responses were captured in an Excel worksheet for a preliminary analysis. 
•   Based on the preliminary demographic data, an expressed desire to be 
interviewed by a subset of respondents, and through a stratified selection, 
potential interview participants were identified and contacted through email or 
phone and arrangements for conducting the interviews were made. 
•   Using an interview instrument, in-person interviews were conducted with 22 
scleroderma patients from the northernmost parts of New York State to New 
York City, and from eastern Connecticut to southern New Jersey. Three 
additional interviews were conducted over the phone.  
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•   MAXQDA 12 software and SPSS statistical package were obtained, and 
transcribed interview responses and instrument data were analyzed and 
subsequently integrated, synthesized, and reported. 
The overall design of the study is depicted, graphically in Figure 3.2. 
Figure 3.2. Overall design of study. Sequence and order of sample selection, data 
collection, analysis and mixing 
Data Collection Methods 
To collect data for this study, three methods of survey, scales, and interview were 
employed. Details of each method and the type of data collected are provided in this 
section. 
Survey. Surveys are a common means of collecting “a small amount of data in 
standardized form from a relatively large number of individuals” (Robson, 2007, p. 230). 
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explanatory purposes, while protecting the anonymity of respondents (Robson, 2007). As 
such, this was an appropriate fit for this study. To collect standardized demographic and a 
survey consisting of 13 questions encompassing the following demographic information 
was utilized: 
•   Personal data: gender, age, education, employment status 
•   Clinical data: SSc sub-type, disease duration, organs involved, co-morbidity, 
illness burden (fatigue, depression, pain, sleep disturbance, body image stress) 
•   Ease of access and extent of care: number of doctors seen, distance to travel to 
receive care 
•   Disease knowledge: knowledge of autoantibodies 
•   Support group participation: status as leader, member, non-member 
In addition, two questions to assess inclusion criteria in the study and the desire to be 
interviewed were included. An affirmative answer to a survey statement “Yes, I have 
been diagnosed with scleroderma by a doctor” was taken as an indicator of official 
diagnosis. To be included in the interview portion, the respondents were asked to check if 
they were participating in the survey part only or, if in addition, they desired to be 
interviewed. Contact information for those who desired to be interviewed was collected 
in a separate interview-interest form. This allowed for a separate mailing of the 
interview-interest form if the participants wanted to keep their survey and scale data 
anonymous.  
The Survey and the interview recruitment letters are included in Appendices D 
and E. All questions employed the standard ranges and categories for age, gender, 
education, employment, disease duration, and organ involvement, illness symptoms seen 
in similar types of studies, and the studies with scleroderma patients. The collected 
survey data were ordinal, nominal, and dichotomous (yes/no) in nature. Continuous type 
data (like exact age or disease duration) and certain categories (race/ethnicity, 
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geographical location) were deliberately not collected to safeguard against privacy 
violations, given the relative small size of the scleroderma community.  
Scales. Measuring instruments or scales are means to assess quantitatively 
individuals’ levels or standings relative to an attribute. Two common types of scales are 
the summated rating (Likert) and the cumulated (Guttman) scales. In the Likert scale, the 
instrument’s items are independent from each other and may relate to different 
dimensions of an attribute. Scores are added up to obtain a total score. In the Guttman 
scale, there is a cumulative order to the instrument’s items, so endorsing (agreement 
with) an item implies endorsement of all previous items, making for a unidimensional 
scale (Robson, 2007). 
To measure involvement and the perception of social support, two instruments—
the PAM-13 and the MOS-SSS—were used. The PAM-13 is a Guttman-like 
unidimensional scale with Likert scaling for each item (instead of just “agree” or 
“disagree” options, it has a range of five options), and the MOS-SSS is a Likert scale 
instrument. Each instrument is described, and the rationale for each choice is given next. 
PAM-13 measure. The PAM (Patient Activation Measure) developed by Hibbard 
et al. (2004), originally as a 22-item instrument and later reduced to a short form of 13 
items (Hibbard et al., 2005) (Appendix F), is intended to measure patient activation. In 
this model, patient activation is viewed as a construct, consisting of belief, knowledge, 
and skill domains, defined qualitatively through an expert panel and patient focus group 
study. It assumes that patients exhibit their activations through (a) the belief that they 
have a role to play, (b) the knowledge to manage their conditions and prevent decline, 
and (c) the skills to do so by obtaining high-quality care (Hibbard et al., 2004).  
This construct is operationalized through a one-dimensional, Guttman-like (i.e., a 
probabilistic Guttman) scale. The scale’s items are calibrated using a Rasch model and 
ordered accordingly by their difficulties. After item locations are determined, a person’s 
location (proficiency) on the scale may be estimated. In a Rasch model, the probability of 
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an expected answer for a given item is a (logit) function of person’s ability and the 
difficulty of that item on the scale. Thus, the higher the proficiency relative to an item’s 
difficulty, the higher the probability of the expected answer for that item will be. The 
expected value of the observation is the sum of the expected probability for all items 
given the response pattern, indicative of the proficiency or trait under consideration. 
Five possible response options of “strongly disagree,” “disagree,” “agree,” 
“strongly agree,” and “not applicable” are available for each item. The raw scores are 
normalized to a 0-100 range of theoretical activation score using a propriety algorithm, 
and are divided into four categories of activation according to pre-determined cut-off 
points. Table 3.2 depicts the levels, the cut-offs, the interpretation of activation levels, 
and each level’s associated items (Hibbard, Mahoney, Stock, & Tusler, 2007). Data 
collected through this instrument were entered in an Excel workbook, which was 
provided by Insignia Health as part of their licensing to calculate scores and levels.  
 
Table 3.2 
PAM Activation Levels, Cut-offs, and Interpretations of Level 
Level PAM Score Cut-
offs 
Interpretation of Level Instrument’s items 
1 Less than 47.0 “Passive recipient of care; not realizing importance of active 
role.” 
1-2 
2 47.1-55.1 “Lacks basic knowledge about condition, or its relevance to 
treatment.” 
3-8 
3 55.2-67.0 “Cognizant of key facts and beginning to take action, but 
lacks confidence and skills for new health behaviors.” 
9-11 
4 Greater than 67.1 “Taken action and have adopted new behavior, but might 
falter when under stress /facing health crises.” 
12-13 
 
This instrument has shown high internal consistency (Cronbach’s a= .87) and 
reliability (Skolasky et al., 2011), and has been validated with many chronic conditions, 
Multiple Sclerosis (MS), diabetes, Chronic Obstructive Pulmonary Disease (COPD), 
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chronic heart failure, chronic renal disease, spinal cord injuries, cancer, multi-morbid and 
mixed chronic and healthy general populations. It has also been translated and validated 
internationally in the U.K., the Netherlands, India, Germany, Norway, Finland, Turkey, 
Portugal, Australia, Italy, Israel, and South Africa (Insignia Health, 2017).  
The PAM-13 instrument was chosen over the only other available option, PHE 
(Graffigna et al., 2015), due to validation of the PAM-13 with MS patients, another 
autoimmune disease causing disability. A lack of clarity in calculating scores for PHE, 
and the absence of independent studies with a U.S. patient population at the time the 
choice was made were the other considerations.  
The PAM-13 measure was selected with the understanding that it addresses a 
narrower aspect of dealing with the physical impacts of the illness. Furthermore, it is 
assumed that in utilizing this measure, the physical impact of disease is considered to be 
the most direct and tangible consequence of having an illness, and an active involvement 
in physical aspects may be taken as an indicator of an overall involvement. 
The MOS-SSS measure. The Medical Outcome Study-Social Support Survey 
(MOS-SSS) is a multidimensional 19-item instrument covering four dimensions: 
emotional/informal support (EMI), tangible support (TAN), positive social interaction 
(POS), and affectionate support (AFF) (Appendix G). It was developed by Sherbourne 
and Stewart (1991) in a 2-year longitudinal study of chronic illness patients 
(hypertension, diabetes, coronary heart disease, depression) in three metropolitan areas 
encompassing some 2,987 patients. It operationalized the concept of social support in 
terms of the functional support that patients perceived was available to them. Functional 
support refers to “the degree to which interpersonal relationships serve particular 
functions,” (p. 705) such as the aforementioned dimensions of the instrument. The 
instrument has high construct validity overall, and for each dimension (Cronbach’s a= 
.91-.97) (Sherbourne & Stewart, 1991). 
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The emotional/informational (EMI) support dimension, captured by items 1-8, is 
related to offering of positive affect, understanding and empathy, and availability of 
information and feedback when seeking solution to problems. Tangible (TAN) or 
instrumental support is measured by items 9-12 and relates to availability of 
material/behavioral assistance. Affectionate (AFF) support (items 13-15) assesses the 
expression of love/affection available to a person. Positive social (POS) interaction 
references availability of fun social interactions (items 16-18), and together with an 
additional item (item19), it relates to “having someone to help get one’s mind off things.” 
The dimensions are rated on a 5-point Likert scale of: “(1) None of the time,” “(2) A little 
of the time,” “(3) Some of the time,” “(4) Most of the time,” and “(5) All the time.” The 
average of item scores in that subscale provides the raw score for that subscale. An 
overall index is calculated by taking the average of all items. These scores may be 
normalized to 0-100 (RAND Health Communications, 2002). The range of possible raw 
scores for each subscale are shown in Table 3.3. 
 
Table 3.3 
MOS-SSS Dimensions, Items, and the Range of Subscales’ Raw Scores 
Support Subscales   Raw Score Minimum Raw Score Maximum 
Emotional/Informational (EMI): items 1-8 8 40 
Tangible (TAN): items 9-12 4 20 
Affectionate (AFF): items 13-15 3 15 
Positive Social Interaction (POS): items 16-
18 
3 15 
Additional item 19 1 5 
 
The MOS-SSS differs from other instruments that view the notion of support in 
terms of structure of social network and number of connections to others. As the main 
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focus of this study relative to social support was on support groups and learning in that 
context, structure and social networks were less important than the perceived types of 
support garnered from support groups. Teasing out social support through multiple 
dimensions was an attractive feature of this instrument, as support groups are particularly 
strong in being an all-in-one source of the type of support measured by this instrument. In 
addition to strong psychometric properties, this instrument is relatively short, easily 
worded, and can be self-administered.  
Interview. Interviews are common data collection methods in social research 
where the meaning or perception of a phenomenon or its historical development is the 
focus of study (Robson, 2007). In addition to their primacy as a data collection tool in 
qualitative studies, they are well suited to mixed-methods research where insights and 
illustrations obtained through them can shed light on quantitative findings. The structure 
of an interview refers to the degree of formality, flexibility, and composition imposed on 
exchanges between researcher and subjects, resulting in a fully structured, semi-
structured, or unstructured interview. Robson defines a semi-structured interview as an 
interview that: 
has predetermined questions, but the order can be modified based upon the 
interviewer’s perception of what seems most appropriate. Question wording 
can be changed and explanations given; particular questions, which seem 
inappropriate with a particular interviewee can be omitted, or additional ones 
included. (p. 270)  
Regardless of format, the researcher seeks to illicit facts, discover behavior, or uncover 
beliefs and attitudes. To that end, a semi-structured format was adopted to collect data on 
perceptions of the participants regarding their involvement; learning; their actions in 
dealing with their illness; support group participation; and facts surrounding the reality 
and context of living with this illness. An interview protocol was developed 
(Appendix H) based on the literature review on the topic and, in particular, concepts in 
Corbin and Strauss’s (1998) and Thorne, Paterson, and Russell’s (2003) models. It was 
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piloted with a convenience sample of three patients with chronic conditions or 
disabilities, and one caregiver of such a patient. Based on the pilot study’s findings, the 
length of the protocol was reduced, and the initial multiple interview format was 
modified to one.  
The semi-structure of the protocol included an open-ended first question: “To the 
extent you like, please tell me your story of being diagnosed with scleroderma.” The 
open-ended format of this question was intentional to address a potential problem in the 
qualitative study of patients. Bury (2001) described the problem with illness narrative 
obtained from such interviews this way: “[Illness] narratives—which, by their very 
nature, require the presence of a listener (interviewer) and his/her questions and 
comments—may be more concerned with the repair and restoration of meaning than with 
conveying the ‘mundane aspects of experience’” (p. 283). To ameliorate the possibility of 
participants’ needs for telling their ‘stories’ taking precedence over the researcher’s 
questions, the open-ended question was asked first. The subsequent questions were 
modified or eliminated depending on how much relevant information was shared by 
participants as part of the open-ended question. Additionally, strong responses to the 
instrument’s items (e.g., a strong disagreement) were used as triggers for probing with 
follow-up questions.  
Using this protocol, 22 in-person interviews and 3 phone interviews were 
conducted. The researcher traveled to the participants’ locations. Eight interviews were 
conducted in the participant home, nine occurred in restaurants, and five took place at 
libraries, bookstores, or offices. On average, each interview took one hour and 20 
minutes. With the written consent of interviewees, all interviews were recorded. 
Subsequently, about 32 hours of interviews were transcribed and loaded to MAXDQA 
software for analysis. Subsequent to each interview, field notes were written to include 
general observations and striking features of the interview. Table 3.4 illustrates the 
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connection between the research questions and the interview questions intended to secure 
related data.  
 
Table 3.4 
Research Questions and Corresponding Interview Questions in Interview Protocol 
 
Research question Interview Questions Providing Answer 
1. How do SSc patients describe their experience of involvement? 
Did their involvement change overtime? If so when and how? 
1, 2, 3, 7, 10, 11, 12, 14, 
20, 22 
2. What strategies do SSc patients use to be involved? 
What facilitated or impeded this? How did they overcome these? 
4, 5, 6, 7, 8, 9, 10, 13, 
15, 16, 17, 18, 19, 21 
3. How are social interactions particularly, support groups’ 




As part of the interview, participants were asked about their support group 
involvement. All support groups in this study were affiliated with the Tri-State Chapter, 
encompassing states of the NY, NJ, and CT.  
Methods for Data Analysis and Synthesis 
This section describes the data set creation, cleaning, analysis, and synthesis for 
both quantitative and qualitative data. 
Quantitative data. The quantitative data, initially captured in an Excel file from 
survey and PAM-13 and MOS-SSS measures for preliminary analysis, were reviewed for 
eligibility and completeness.  
Data set creation and cleaning. Out of 212 responses, one online survey was 
determined to be a duplicate of a paper survey, as identical contact information was 
provided for both. The paper survey was retained. No other duplications were found. Five 
surveys were excluded for patients being either underage or deceased. In four cases, 
indicated by the response in the survey, someone other than the patient had filled out the 
surveys. These were eliminated due to a lack of clarity as to whose voices were reflected 
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in the questionnaires. One survey did not include demographic data and was eliminated. 
With the exclusion of these 11 responses, data from 201 participants, with complete 
demographic data, were retained for further processing to generate PAM-13 and 
MOS-SSS scores. 
When PAM-13 questionnaires were scrutinized for completeness and validity, 
seven were found to be completely blank, and four had more than three items marked as 
“N/A not applicable.” These were excluded. Seven additional responses were excluded 
by the PAM scoring algorithm, as it scrutinized the data for outliers (those marked as 
strongly agree/disagree for all items resulting in a score of 100) (Hibbard & Cunningham, 
2008; Rademakers, Nijman, Hoek, Heijman & Rijken, 2012; Wong et al., 2011). The net 
number of valid PAM scores available for analysis was, therefore, 183. The raw scores 
were normalized to a 0-100 range of theoretical activation score using a proprietary 
algorithm, and were divided into four categories of activation, according to pre-
determined cutoff points (see Table 3.2 for levels and cutoffs). This was done using an 
Excel worksheet containing PAM algorithm macros, which was provided by Insignia 
Health for this purpose.  
For all respondents with valid PAM scores (n=183), MOS-SSS scores were 
calculated using the algorithm provided by RAND Health Communications (2002). Prior 
to the calculation of scores, individual MOS responses were scrutinized for missing data. 
A total of 10 MOS responses were missing on average two items. For these 10 responses, 
the missing values were replaced with the average of remaining items. Three respondents 
with valid PAM scores did not answer any or most MOS questions. These were given a 
score of 0 for MOS dimensions. The average of raw scores in each of four subscales 
(EMI, TAN, AFF, POS) constituted that dimension’s score. The computed average of 19 
items provided an overall index of support. The raw subscales and the overall scale were 
transformed to a 0-100 scale.  
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Data analysis. The demographic data and calculated PAM-13 and MOS-SSS 
scores were imported into the SPSS statistical package version 24 in preparation for 
statistical analysis. Univariate analyses were conducted on continuous and categorical 
variables. Descriptive statistics (mean and standard deviation, minimum, maximum, 
range, and skewness) for continuous variables, and frequency and percentage for 
categorical variables, and appropriate tabular representations were generated. 
Distributions of data were checked for normality, and non-parametric tests were 
employed where a normal distribution could not be shown. 
In order to understand possible predictors for involvement, existence of 
relationships among the clinical variables and PAM levels, among MOS dimensions and 
PAM levels, and MOS dimensions and support group participation were explored. For 
these bivariate analyses, cross-tabulation and a Chi-square test of independence for 
significance associations among variables were performed, and appropriate tests to 
measure the strength of relationship, when one existed, were applied. These tests 
included Goodman and Kruskal’s Gamma (g) for clinical variables.  
Clinical variables were dichotomous variables indicating the presence or absence 
of symptoms or organ involvement. Dichotomous variables can be treated at any 
measurement level: categorical or interval. To treat them as ordinal and the choice of 
Gamma as association measure were warranted by small table size (2X2) and the sample 
size of (n=183). Whereas Gamma overestimates the degree of ordinal association when 
sample size is fairly large (over 250), for smaller samples and table sizes it represents a 
closer estimate of the association than other estimates such as Pearson r, Spearman’s rho, 
Kendall’s Tau-b or Tau-c, and Somers’ d (Goktas & Isci, 2011). In addition, Gamma is a 
symmetrical measure of association where its value is not based on identification of 
dependent or independent variables. Gamma has a range/direction of -1 to +1 and is 
defined as: (Ns- Nr)/(Ns+ Nr), where Ns is the number of same ordered pairs 
(concordant) and Nr (discordant) is the number of inverse ordered pairs. As a 
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Proportional Reduction of Error (PRE) measure, its value is interpreted as the 
improvement (reduction in prediction error) in predicting the dependent variable, 
knowing the values of the independent variable. The following ranges of magnitude were 
used for interpretation of results: .00-.24 “no relationship”; .25-.49 “weak relationship”; 
.50-.74 “moderate relationship”; .75-1.00 “strong relationship.” 
To explore the association, if any, between PAM activation levels and age, 
educational attainment, employment, disease duration, disease subtypes, presence of 
certain symptoms, and other demographic and clinical variables, the Chi-square test of 
independence was performed. The nominal and ordinal nature of variables, the unequal 
groupings of categories, skewed distribution of data, and mutually exclusive and 
independent categories made this choice appropriate. In order to meet the expected cell 
values assumption of the Chi-square test, the following categories were collapsed:  age 
category was collapsed into four groupings (18-49, 50–59, 60-69, >70), the employment 
category into two groupings (employed, not gainfully employed), education category into 
three groupings (some high school to some college, college graduate, postgraduate), 
disease duration into three groupings (1 to <5 years, 5-10 years, >10 years), number of 
doctors seen into three groupings (<=3, 4-5, >5), and four groupings for how far traveled 
to see a SSc expert (<24 miles, 25-99 miles, >100 miles, not seeing an expert). 
The Chi-square test was followed by calculation of Somers’ d (d) as a measure of 
strength of association. The activation level was the dependent variable. The measure 
Somers’ d is given as d= (Ns –Nr) / (Ns+ Nr + TD), where Ns is the number of 
concordant pairs, Nr is the number of discordant pairs, and TD is the number of pairs 
with tied ranks on the dependent variable. Somers’ d is an asymmetric measure with the 
magnitude range of -1 to 1, and is an appropriate choice when a distinction between a 
dependent and an independent variable is made.  
To test how the four PAM activation levels differed in degree of social support, as 
indicated by MOS variables, the Kruskal-Wallis H test was performed. The Kruskal-
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Wallis test, also known as one-way ANOVA on ranks, is a non-parametric test for 
determining differences among groups of an independent variable and ordinal or 
continuous dependent variables. This test is used when assumptions of one-way ANOVA 
do not hold. ANOVA’s assumptions include normality, no outliers, and balanced sample 
sizes. 
To test for normality, the Shapiro-Wilk test was performed on MOS data, grouped 
by PAM levels. Only the distributions of overall support and EMI for level 1 and level 2 
showed approximately normal distributions. Other dimensions, in particular TAN and 
POS scores in levels 3 and 4, were found to be skewed, with a larger number of 
participants claiming a high degree of support. The sample size for each activation level 
was also not balanced. Since the normality assumption did not hold across the board, and 
the sample size of level 3 was almost 3 times that of level 1, the Kruskal-Wallis H test 
was chosen instead. In this test, PAM activation was treated as the independent variable 
(grouping variable) and MOS variables as dependent for the purpose of determining if 
there was a difference in medians of MOS variables among four activation levels.  
The Kruskal-Wallis (1952) H test ranks each score of the dependent variable based 
on its value, without regard to its grouping. After this ranking is done for all scores, 
scores are summed and averaged within the groups they belong to, and a one-way 
ANOVA is applied to ranks (as opposed to the original observations). Formally the H 
statistic is calculated as: 
H=   
where T is sum of each group’s rank, n is the sample size in each group, and N is the total 
sample size. For number of groups (k) greater that three, and for five or more 
observations in each group, H approximates a Chi-Square distribution with degree of 
freedom (d = k-1). The acceptance or rejection of the null hypothesis is reported based on 
Chi-square critical value. The Kruskal-Wallis tests the similarity of distributions among 
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groups. If we can assume the distributions among groups are the same (i.e., groups have 
the same shape and dispersion and are only shifted up or down relative to a center point, 
i.e., median), then the null and alternative hypotheses may be stated as follows: 
H0: The population median among groups are equal. 
Ha: The population median among groups are not equal. 
Using boxplot and frequency histograms, distributions of MOS variables, among 
four PAM levels, were visually compared. While the level 3 group showed the highest 
frequencies, the shape and dispersions for all MOS variables were similar for all groups, 
as assessed by this visual inspection. Based on this determination, comparison of median 
scores was considered. When the Kruskal-Wallis test is significant and there are more 
than two groupings in the independent variable, a follow-up test to compare pairwise 
differences in the groups is usually conducted to determine which two groups are 
different from the others. Subsequent to the Kruskal-Wallis test, pairwise comparisons 
were conducted in SPSS. SPSS uses Dunn’s (1964) procedure, which includes 
Bonferroni correction. 
Qualitative data. Qualitative data consist of unstructured text. The data from 
interviews were converted to textual format through a transcription process. In qualitative 
analysis, each transcript represents one data source, and it is examined individually by the 
identification and classification of texts of interest therein (words, sentences, or 
paragraphs). Additionally, categories and concepts across all data sources are pulled 
together for comparison. One way to approach this process is through thematic analysis, 
defined as an approach to “identify commonalities and differences in qualitative data, 
before focusing on relationships between different parts of the data, thereby seeking to 
draw descriptive and/or explanatory conclusions clustered around themes” (Gale, Heath, 
Cameron, Rashid, & Redwood, 2013, p. 2). A strategy to make this process more 
methodical was developed by Ritchie and Spencer at the National Centre for Social 
Research in U.K. in the 1980s, known as the Framework Method. This method allows for 
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management of data and its structured representations and organizing, so data reduction 
and analysis may be performed in a more systemic way.  
The proposed analytical structure of Framework Method provides for three 
hierarchical stages or “viewing platforms” (Ritchie & Lewis, 2003, p. 213) to view and 
make sense of data, in progressively abstract terms. The first stage deals with 
development of a coding matrix, and assignment of data to themes and categories. The 
second stage is about refining themes and categories, and finding associations among 
themes; the third stage is associated with developing associations or patterns among 
concepts (Smith & Firth, 2011). These stages are by no means linear. Rather they are 
bi-directional, allowing for movements up and down to refine and link concepts among 
levels of abstraction. Notwithstanding these backward and forward iterative movements 
among stages, the essence of each stage is delineated below. 
•   Stage 1: Data management 
o   Creating a coding index: A subset of transcripts is carefully reviewed (open 
coding) to generate an index to identify initial labels or codes for texts of 
interest in transcripts, for the purpose of devising a coding index. Pre-
defined codes based on a conceptual framework may be used instead, or in 
conjunction with open coding.  
o   Creating a working analytical framework: Sorting and grouping of codes 
into broader categories and main themes to create a working analytical 
framework in order to index (code based on framework) all data sets. 
•   Stage 2: Descriptive Accounts 
o   Indexing of data set: The entire data set is indexed by using the working 
analytical framework. The framework is refined with each transcript coded 
in an iterative process, and is a fluid work in progress until the last 
transcript is indexed. 
  
90 
o   Creation of framework matrix: A framework matrix (a worksheet made of 
sample as rows, and categories as columns) is created; data is summarized 
(vs. verbatim text) by category for each transcript. References to illustrative 
quotations are retained. 
o   Detection of typologies: Association and typologies may be detected by 
examining non-overlapping categories and identifying discriminant factors 
or dimensions 
•   Stage 3: Explanatory Accounts 
o   Explanatory account: Explanatory accounts are developed based on patterns 
of associations or clustering of themes. 
The above approach was adopted in this study. 
Data set creation and reduction. All recorded interviews were transcribed and 
uploaded to MAXDQA software. Each interview was read several times in order for the 
researcher to become fully familiar with the transcripts. A handful of transcripts 
representing variations in transcripts were selected for coding. Starting with an initial and 
provisional coding index based on literature, these transcripts were coded. Codes related 
to contextual and background information surrounding diagnosis and each individual, 
absent in the initial coding index which relied on literature, were added as emergent 
codes. Subsequently, the resulting working analytical framework was applied to the 
entire data set of 25 interviews in an iterative process, going back and forth between 
transcripts, as new categories emerged and categories collapsed. Along the way, analytic 
memos (“the theorizing write-up of ideas about codes and their relationships as they 
strike the analyst while coding,” Glaser, 1978, pp. 83-84) were written. These included 
references to other transcripts, outlines of emerging typologies, and nuances or emerging 
features that seemed to define or characterize a code/category and its variations. 
MAXDQA provides for recording of memos per transcript and per category, allowing 
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observations and insights to be saved and associated with categories and transcripts in a 
systematic and convenient manner.  
Once the iterative process of indexing was deemed to have reached a satisfactory 
saturation and ran its course, the framework matrix was created. This was achieved 
conveniently in MAXDQA through the Summary Grid feature, providing a mechanism 
for summaries to be written for each coded segment. The wordings of summaries were 
kept as close to the original text as possible. At this stage, the data were reduced 
considerably and categorized, allowing for patterns and associations to become apparent, 
and typologies discovered, leading into an explanatory and interpretive process. These 
typologies are presented in Chapter IV. One such example is the modes of doctors’ 
interaction as perceived by patients, graphically shown in Figure 3.3. Additionally, a 
sample index and a sample framework matrix, resulting from the first two stages of the 
framework method, are provided in Appendices I and J. 
 
Figure 3.3. Example of a typology seen in data.  
Illustrative texts and participants’ own words from transcripts were included to 
support the reporting of findings. In order to safeguard the anonymity of participants, 
demographics and descriptive data were presented in aggregate; data tables were ordered 
by different variables to remove the possibility of linking them to each other. In addition, 
to protect the identities of interview participants, pseudonyms were used, and identifiable 
information was removed whenever participants were quoted.  
 
Dismissive Fatalistic Measured Supportive 
Patients’ Perceptions of Doctors’ Modes of Interaction 
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Analysis and synthesis. The categories, themes, and typologies obtained from 
stage two provided the descriptive accounts of the phenomenon under consideration, by 
making explicit the constituent components. To arrive at explanatory accounts, as Miles 
and Huberman (1994) quote Bernard, requires showing how these “component parts fit 
together according to some rule” (p. 90). These “rules” may come from participants’ 
explicitly stated logic and reasoning; from the researcher’s inferences based on evidence 
from data, common sense, or hunches; from other empirical research, or more formally 
from theoretical frameworks (Ritchie & Lewis, 2003). The goal is to decide on general 
findings that hold true for the data and examine them in light of the literature (Miles & 
Huberman, 1994). The problem of how components that were found fit together was 
tackled through all these means, “presentation of evidence,” and “consideration of 
alternative interpretations” (Yin, 2009, p. 127). Bloomberg and Volpe (2012) suggest to 
make this process explicit by: 
•   Providing answers to research questions through findings 
•   The synthesis of quantitative and qualitative data 
•   Showing the relevance of findings in the context of literature 
•   The appraisal of findings relative to researcher’s initial assumptions. 
These recommendations were followed and are presented in discussions and analysis, in 
Chapter V. 
Synthesis of quantitative results and qualitative findings. In a convergent 
mixed-methods design, the integration of the qualitative and quantitative data occurs 
when results from the respective methods are brought together and compared (Creswell, 
2015). One approach consists of discussing the results of each method, in sequence, in 
the discussion section of the study. This approach was taken in this study. Additionally, 
quantitative findings were elaborated and clarified by interview findings and vice versa, 




As part of the institutional Review Boards (IRB) approval requirements, safeguards 
regarding informed consent and the protection of the rights of the subjects were 
implemented. Statements of participant’s rights and informed consent for survey 
respondents were developed and included in the recruitment packet. The personally 
identifiable information and certain demographics related to race/ethnicity and geography 
were not collected from the survey participants. The completed surveys were collected 
through a dedicated post office box accessible only to the researcher, and the results of 
the surveys were reported as aggregates. 
Those interested in being interviewed were given the option of keeping their survey 
anonymous by mailing in their contact information separately. Statements of participants’ 
rights and informed consent for interview respondents were shared with interviewees, and 
written consent for conducting the interviews and audio recording was obtained prior to 
the interviews. Each participant in the study was assigned a pseudonym for 
confidentiality purposes and was identified as such in the research analysis and reporting. 
Any identifying references to the individuals disclosed during interviews was masked in 
reporting. Transcripts, coding, and data material were stored in a private, secure space, 
and digital files were password protected. Confidentiality was maintained by reports of 
aggregate data. Consent forms and statements of participants’ rights are included in 
Appendices A-C. 
Issues of Trustworthiness 
Trustworthiness of a study concerns the validity or credibility and dependability or 
reliability of results. Quantitative studies deal with threats to validity through controls 
built into the design before research commences, while in qualitative designs, most 
threats are addressed after the start of fieldwork and when tentative accounts are formed 
(Maxwell, 2005). Determination of validity is obtained through presentation of evidence 
and theory to support the interpretations of results or findings.  
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Validity and reliability related to results and assertions in this study are presented 
separately under quantitative and qualitative headings. 
Validity and reliability of the quantitatively obtained results. Trustworthiness 
in quantitative fixed designs encompasses construct validity (measuring of what is 
intended), reliability of measure (measuring the same consistently), and external validity 
(extent of generalizability). 
Three categories of data were collected in the quantitative portion of this study; 
two categories were collected through the use of PAM-13, MOS-SSS instruments, and 
for the third category, the demographic data including disease state and illness 
perceptions (depression, pain, fatigue, etc.) were self-reported.  
Construct validity and criterion validity analysis, conducted by the developers of 
the PAM measure, based on hypothesis related to the expected behavior consistent with 
high activation (e.g., engaging in self-care, seeking information, comparing medical 
options, having better functioning, less health fatalism, etc.) indicated considerable 
construct validity (Hibbard et al., 2004). Packer et al. (2016), using measures of health 
status and lifestyle (diet, activity, etc.), reported both a strong internal consistency, and a 
strong construct validity through comparison with these measures. 
 On the other hand, Graffigna et al. (2017) showed a correlation between the 
PAM-13 and her PHE (Patient Health Engagement) scale, indicating an overlap of 
activation and engagement constructs. Rademakers et al. (2012) reported a weak to 
moderate correlation between PAM and health literacy, a suspected factor in high 
activation, and concluded that more research in PAM validity with respect to health 
literacy is warranted. These highlight the ambiguities in drawing boundaries around 
concepts of activation, engagement, and involvement, bringing to mind Forbat et al.’s 
(2009) characterization of “the conceptual muddle with which involvement is articulated, 
understood and actioned” (p. 2553). In this dissertation, PAM is used as an 
approximation to patients’ commitment and involvement to manage their illness, while 
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acknowledging PAM covers a specific subset of such a concept. The inherent difficulty in 
defining and operationalizing concepts such as activation, involvement, and engagement 
was explored previously and was at the heart of the rationale for conducting this study. 
The difficulty in establishing construct validity in a clear and all-encompassing way is 
viewed as giving credence to the argument and purpose of this study.  
A source of validity evidence in use of scales is the “Response Process” to the 
instrument. Response process is defined as “actions and thought processes of test takers” 
(Cook & Beckman, 2006, p. e10) while taking the test, and is looked into through a 
“think aloud” approach. A number of participants in this study had written notes and 
comments on the margins of this instrument, indicative of their thought processes and 
their ambivalence with some items. Specifically, items 3 and 12 were more difficult to 
endorse, while items 7 and 6 were easier than expected to endorse. Other studies (Packer 
et al., 2016; Staerk, 2015; Stepleman, et al., 2010) have reported similar variations in 
scaling. In spite of such variations, these studies concluded that PAM is a reliable and 
valid instrument in assessing patients’ activation. The notion of the response process of 
this instrument was taken into consideration in interpreting the results.  
PAM-13 has shown to have high reliability across different levels of self-reported 
health status, age, race, education, household income, and nine chronic conditions 
(Hibbard et al., 2005). A high internal consistency with Cronbach’s a of above .84 has 
been reported by others in a wide range of chronic illnesses (Brenk-Franz, Hibbard, 
Herrmann, Freund, & Szecsenyi, 2013, in German patients; Moljord et al., 2015 in 
mental health; Packer et al., 2016 in neurological illnesses; Rademakers et al., 2012, in 
Dutch patients; Skolasky et al., 2011, in multi-morbid older adults; Stepleman et al., 
2010, in MS). 
The second instrument used in this study, MOS-SSS, has shown strong validity 
through confirmatory factor analysis of four dimensions (Sherbourne & Steward, 1991). 
The four dimensions were shown to be highly correlated (.69-.82), while number of 
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family or friends indicated low/moderate correlations (.19-.24) with these dimensions. 
Other factors such as family/marital functioning, mental/physical health, and social 
activity were positively correlated, while loneliness had a negative correlation. Other 
studies in patient populations (Kettman & Altmaier, 2008, in bone-marrow transplant 
patients; Rodin et al., 2007, in cancer) have shown a negative relationship between social 
support and depression. Sherbourne and Stewart (1991) have reported reliability 
coefficients of .97, .96, .92, .91, and .94 for overall support, EMI, TAN, AFF, and POS 
dimensions, respectively. 
The third category of data collected was self-reported information as to the 
existence of pain, depression, fatigue, sleep disturbance, body image stress, existence of 
comorbidity, and involvement of organs for the purpose of assessing disease severity. 
The self-reported nature of these data makes them susceptible to inaccuracies. At the 
same time, the anonymous design of the survey makes an intentional misreporting 
unlikely. The validity threats of this type may be avoided by drawing the sample from a 
medical setting, where access to clinical findings and official health status are available. 
Additionally, the presence and levels of many illness complaints, including those listed 
above (e.g., pain, depression, fatigue, etc.), may be measured by related instruments.  
Access to a sample from a medical setting was not available to this researcher, and 
inclusion of more instruments in the survey packets was deemed impractical and counter-
productive, given the degree of hand-disabilities in this population, and the increased risk 
of non-participation due to the length of survey. To mitigate some of the uncertainty 
about these data, an extensive review of studies reporting on these variables using scales 
in scleroderma patients was conducted to assess the presence of possible deviations and 
anomalies. The reported percentages in this dissertation fell within the ranges reported in 
other studies, with the exception of a slightly higher lung involvement reporting. 
Hypothesis as to this occurrence, as well as details related to other variables, are provided 
in Chapter IV. 
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In a cross-sectional study, causal inferences are not supported, and the results are 
considered descriptive of the sample. However, given the shared characteristic among 
chronic disease patients discussed previously, it is expected the results to be applicable to 
involvement in other illnesses as well. 
Credibility and dependability of the qualitatively obtained assertions. Maxwell 
(2005) contends that two main validity threats in qualitative studies are the selection of a 
sample that fits the researcher’s bias and preconceptions, and the influence of the 
researcher on study subjects (reactivity), making alternative hypotheses or rival 
explanations plausible. Therefore, the main task in dealing with validity issues in 
qualitative studies is to account for these threats to reduce the plausibility of other 
explanations, in order to increase confidence in interpretations, and lend credence to the 
reasonableness of the conclusions drawn. Among suggested strategies (Maxwell, 2005; 
Miles & Huberman, 1994), the following were utilized to reduce validity threats:  
•   Triangulation—collecting a diverse range of data by “data source, by method, 
by research, by theory, by data type” (Miles & Huberman, 1994, p. 267): 
Triangulation was incorporated by inclusion of a large number of participants 
(25), two types of data (qualitative, quantitative), considerations of theories 
from various fields of study, and obtaining inter-rater reliability through coding 
of transcripts by another colleague.  
•   Collection of rich data (“data that are detailed and varied enough that they 
provide a full and revealing picture of what is going on,” Maxwell, 2005, 
p. 110): Inclusion of open-ended questions, allowing for participants to tell 
their “stories” and particularly the recounting of specific instances and 
examples resulted in a rich set of data, and providing safeguards against a 
“uniform mistaken conclusion” (p. 110).  
•   Checking for representativeness by looking for outliers, observing the sample 
in other venues; increasing the number of the sample, including negative and 
  
98 
extreme cases, and stratifying the cases: Stratifying the sample based on 
support group membership was a strategy to increase the diversity of sample 
selection. Characteristics of outliers were noted in drawing interpretations. 
Scleroderma patients were observed in two national conferences and multiple 
educational forums. The number of participants for this interview (25) was 
twice as many as in most qualitatively conducted studies. 
•   Getting feedback from informants/member check: Interview-participants were 
given an opportunity to comment on findings, and those comments were 
considered in the interpretation of results. The summary of the interview 
findings along with the cumulative trajectory was emailed to all interview-
participants. Eight participants acknowledged the receipt of the email, and four 
included substantial feedback. These comments are included in the reflections 
section in Chapter V. 
•   Checking for researcher’s effects: “Researcher threatens or disrupts ongoing 
social and institutional relationships, insiders do not want outsiders in on most 
troubling/negative aspects” (Miles & Huberman, 1994, p. 265). The researcher 
was sensitive to the relationships between Scleroderma the Foundation, Tri-
States and its members and leaders. Use of the Foundation’s envelopes for 
mailing provided for some level of official sanction for the study. Disclosing 
the researcher’s interest in scleroderma due to having a relative with the disease 
facilitated the sharing of information.  
•   Bracketing researcher’s assumptions: When it came to the researcher’s 
assumptions and beliefs, having a relative with the disease was a double-edged 
sword. On the one hand, familiarity with the disease and an “insider” status 
provided advantages. On the other hand, assumptions of the researcher were 
formed by witnessing the lived experiences of one patient, most likely not 
typical of other patients. Journaling thoughts and assumptions, and discussing 
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these assumptions with the relative, observing other patients in educational 
forums, and hearing the staff at the Scleroderma Foundation, Tri-State, made 
these assumptions explicit; the researcher was cognizant of their impacts on the 
interpretations of results and checked against alternative interpretations.  
Reliability in qualitative studies has to do with reproducibility of the study’s 
results, and existence of an audit trail. To increase the reliability of this study, procedures, 
including sampling methods, interview protocol, and framework method, were delineated 
in detail to allow for duplication of study.  
External validity in qualitative studies, in the sense that it exists in quantitative 
studies, does not apply. However, Miles and Huberman (1994) suggest a number of 
features that may be considered to assess a broader application of the findings, including 
the full description of the sample to allow comparison to other samples, a theoretically 
diverse sampling to allow for broader applicability, congruency of results with prior 
theory and experiences of a range of readers, and generic descriptions of processes and 
outcomes to provide applicability to other settings. Attempts were made to provide this 
level of detail in writing this dissertation. 
Limitations and Delimitations 
The delimitations of this study extend to a number of areas. Among the six broad 
categories that patients take an active role and are involved in, this study focuses only on 
the concept of patients’ involvement in their own care, such as engagement with health 
information, participation in health care decisions, self-monitoring, etc. Furthermore, this 
study is an inquiry into involvement of a select group of patients, mostly middle-aged 
women with a rare disease living in three states in the northeast U.S. The rarity of the 
disease and certain unique characteristics of the disease may make the experience of 
living with this disease and the nature of involvement different, at some levels, from 
other chronic diseases.  
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A number of potential limitations exist for this study: Within the population of 
scleroderma patients, there is a wide variation in disease presentation, duration, and 
severity. It is possible that the full range of such presentations was not reflected in the 
study sample. In addition, no information regarding race/ethnicity or income was 
collected. The effect of these factors on the study’s results are unknown. Additionally, 
this study, in part, relies on the recollection of events and reporting of symptoms. Such 
self-reporting is liable to inaccuracies. The two instruments used for data collection have 
been validated with patients with some autoimmune diseases, but not specifically with 
scleroderma patients, posing validity and reliability threats. Furthermore, the correlational 
design of the quantitative portion does not allow for interpretation of associations among 
variables as causal relationships, and generalizability of results beyond the study sample 
might be problematic. Lastly, the researcher witnessing a relative with the disease might 
have introduced certain assumptions and biases into study’s design and interpretation of 
results. Efforts to minimize the effects of some of these limitations are described in the 
trustworthiness section in this chapter.  
Summary of Chapter III  
It is the researcher’s belief that patient involvement in their own care is best 
understood when data from the perspectives of individuals and those from collective 
beliefs and behaviors of the population are brought together; a mixed-methods approach 
best serves this purpose and was an appropriate choice, given that scleroderma has 
varying manifestations, the population is small and difficult to access and draw from, and 
the availability of validated scales is limited. A modified parallel design was adopted, and 
points at which the integration of data and results occurred were noted. A descriptive/ 
exploratory approach for the qualitative portion and a non-experimental fixed 
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correlational design for the quantitative portion were chosen, and the rationales for both 
were given.  
The sampling processes were delineated, and the study participants were described 
as 212 survey respondents, 86 of whom expressed an interest to be interviewed. A 
stratified random selection of 25 participants from this group constituted the interview 
sample. The information needed to conduct the study was outlined, and descriptions of 
data collection methods, including scales, survey, and interviews, were given. Methods 
for analysis of data were described for quantitative and qualitative data, and strategies for 
synthesis of data were outlined. Lastly, issues of trustworthiness, ethical considerations, 




RESULTS AND FINDINGS 
The quantitative results and the qualitative findings of this study are presented in 
this chapter. The quantitative results concerning survey data, including those of MOS and 
PAM measures, are reported first. The primary utilization of these results is in 
elaborating answers to research questions 1 and 3. These results obtained from a larger 
pool of 201 survey respondents impart a more expansive view of the population of this 
study, provide a quantitative measure of their levels of activation and engagement, and 
make explicit associations among activation and social support, and demographic and 
clinical attributes. Subsequent to presentation of the quantitative results, the qualitative 
findings are reported. These findings provide answers to research questions from the 
perspectives of 25 interview participants.  
This chapter is organized in two main sections and a number of sub-sections. 
•   Quantitative results 
o   Demographic, clinical characteristics, and support group participation 
o   PAM-13 and MOS-SSS results 
o   Bivariate analysis 
o   Summary of quantitative findings 
•   Qualitative findings 
o   Contextual description 
o   Patients’ work 
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o   Strategies 
o   Learning 
o   Motivation 
o   Social interactions 
o   Summary of qualitative findings 
Quantitative Results 
A total of 211 respondents (23%) out of 925 scleroderma patients with presumed 
valid addresses responded to the mailed survey packets. After elimination of disqualified 
returns, 201 responses with complete demographic information were retained and, 
henceforth, are referred to as respondents (n=201). Additionally, from among the 88 
(43.8%) of these patients who expressed an interest to be interviewed, 25 (28.4%) were 
chosen through a stratified random selection for interview, and henceforth are called 
interview-participants (n=25). The remaining 176 participants who were not interviewed 
are labeled as survey-participants (n=176).  
Demographics and Clinical Characteristics 
The demographic and clinical characteristics for all three categorizations of 
respondents (n=201), survey-participants (n=176), interview-participants (n=25) are 





Demographic and Clinical Characteristics  
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Table 4.1 (continued) 
 






Time since diagnosis of SSc 
<= 12 months 
1 to < 2 years 
2 to < 3 years 
3 to < 5 years 
5 to < 8 years 
8 to 10 years 

























































































































 *  - Participants could select multiple organs and symptoms. Responses do not add up to 100%. 
    
Among all respondents (n=201), 7% were below the age of 40 and another 7% over 
the age of 80, totaling 28 patients. Nearly one-third of all patients were 50-59 year-olds, 
followed by another one-fourth in the 60 to 69 age range. Thus, the 50-69 age group, 
together, constituted over half (55.3%) of the respondents. The respondents were 
overwhelmingly female, 180 (89.6%) vs. 21 (10.5%) male. They had an above-average 
educational attainment, with 67.2% having a college degree or above, and only 19.4% 
having a high school diploma or less. In terms of employment, 56.8% were either retired 
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or on disability or sick leave; about one-third were gainfully employed (26.9% full-time; 
8.5% part-time); and the rest were homemakers, unemployed, or “others.” 
The prevalence of self-reported disease subtypes among respondents included 9.5% 
localized; 43.3% limited cutaneous scleroderma (lcSSc); 34.3% diffuse cutaneous 
scleroderma (dcSSc); 5.0% scleroderma sine scleroderma (ssSSc); and 8.0% did not 
know their disease subtype. About 9% of them were diagnosed less than 3 years prior to 
the time of survey, 26.8% between 3 and 10 years, while 64.2% had lived with the 
disease for over 10 years. Some 34% of respondents indicated co-morbidity, 60% 
indicated none, while 6% did not know. 
About one-third of respondents, 33.8% (68), saw 2 to 3 doctors; another one-third, 
34.3% (69), saw 4 to 5 doctors; and a quarter of patients, 25.4% (51), saw more than 
5 doctors for their medical needs. Of these, 35.8% travelled more than 25 miles to see an 
SSc expert, 44.3% saw doctors locally, and 19.9% did not see a SSc expert at all (most 
likely saw a general rheumatologist). Of all the respondents, 30.8% (62) knew their SSc 
related antibodies, 45.3% (91) did not know, and 23.9% (48) were not sure. 
Eighty-three percent of all respondents suffered from Raynaud’s phenomenon 
(RP); over 79% had fatigue. Other reported symptoms included: skin issues (76%), 
gastrointestinal issues (71%), and joints/muscle problems (59%). The lung and heart 
involvements were reported at 52% and 27%, respectively, while kidney involvement 
was at 10.5%. Other disease impacts reported were: pain (69%), sleep disturbance (59%), 
body image stress (38%), and depression (34%). Respondents with the disease duration 
of less than 2 years reported the highest percentage of having pain (88%) and fatigue 
(100%), whereas from the second year onward, the pain was lower, with a mean of 
66.4% + 4.6. At the same time, fatigue fluctuated with a mean of 84.8% + 11.6. 
Similarly, those who indicated their employment status as “disabled or on sick-leave,” 
compared to those who were “employed” or “retired,” had substantially more pain 
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depressed (75% vs. 32.3%, 28%), suffered from a considerable degree of lung (70% vs. 
49.2%, 46.7%), heart (47.5% vs.,15.4%, 28.3%), gastrointestinal (82.5% vs., 67.7%, 
70%), and joint/muscle (77.5% vs., 50.8%, 56.7%) issues. 
When grouped as survey-participants and interview-participants, the latter was 
slightly younger (20% in 40-49 age group vs. 11.4% of survey group, and 12% in 70-79 
age range vs. 19.3% of survey group); more educated (36% post grad degrees vs. 25% of 
survey group), with a higher number of patients on disability or sick leave (32% vs. 
20.5% of survey group). The interview participants’ disease duration, number of treating 
doctors, and major disease subtypes (limited and diffuse) were comparable to the survey 
participants’. However, the interview participants differed from survey participants in 
number of patients travelling over 100 miles (presumably to scleroderma specialty health 
centers) (20% vs. 12.5%), and the number of patients knowing their antibodies (40% vs. 
29.5%). In addition, interview participants indicated more fatigue, pain, depression, joint 
and lung issues, but slightly fewer heart problems and comorbidities than survey 
participants. 
Support Group Participation 
When asked about their support group involvements, 67.7% (136) of respondents 
did not participate in a support group, while 23.9% (48) were support group members and 
8.5% (17) were support group leaders. Among survey participants, 23.9% (42) were 
support group members, 70.5% (124) did not participate in support groups, and 5.7% (10) 
acted as support group leaders. Among the interview participants, 32% (8) have not 
participated in any support groups beyond a few trial visits, if any; 16% (4) were 
associated with support groups in some capacity in the past, but have not been active or 
participating for a while; 28% (7) acted as support group leaders or co-leaders; and 24% 
(6) considered themselves members who attended meetings with some regularity. The 
interview participants were, therefore, considerably more active in support groups, both 
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Not a Member 136 (67.7%) 124 (70.5%) 8(32%) never participated/ 4(16%) did 
previously 
Member 48 (23.9%) 42 (23.9%) 6 (24%) 
Leader/Co-leader 17 (8.5%) 10 (5.7%) 7 (28%) 
 
When viewed by employment status, among those who were employed, 4.6% were 
leaders, 18.5% were members, and 76.9% were non-members. The participation (as 
leaders, members, and non-members, in that order) for those not-working or retired 
(6.8%, 25.7%, 67.6%) and those “disabled/on sick-leave” (15%, 30%, 55.8%) were 
progressively higher. Among all leaders, 42.9% were “disabled/on sick leave,” and 
35.7% were those who did not work.  
PAM-13 Results 
As was delineated in Chapter III, after detection and elimination of incomplete and 
invalid entries, the net number of valid PAM scores available for analysis was reduced to 
183. The calculated PAM scores had a range of 66.29 (24.40 to 90.69), with a mean of 
59.76 (+ 11.27) and a variance of 127.11, and subsequently were converted to four PAM 
activation levels.  
The distribution of levels in three sample groups is shown in Table 4.3 and 
includes 15.8% in level 1, 20.2% in level 2, 48.6% in level 3, and 15.3% in level 4, with a 
mean of 2.63, median of 3.0, and mode of 3 for respondents. Interview participants’ 
activation consisted of 12% at level 1 and level 4, and 32% and 44% at middle levels of 2 
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and 3, respectively. In comparison, almost 50% of survey-participants were in level 3, 
with a nearly equal distribution among the remaining levels. 
 
Table 4.3 









PAM Levels Frequency %  Frequency %  Frequency % 
1 29 15.8%  26 16.5%  3 12% 
2 37 20.2%  29 18.4%  8 32% 
3 89 48.6%  78 49.4%  11 44% 
4 28 15.3%  25 15.8%  3 12% 
Total 183 100%  158 100%  25 100% 
	  
Excluding those with unknown disease subtype, the majority of respondents fell into 
level three activation, irrespective of disease subtypes. Those with systemic-diffuse 
subtype had the highest percentage in level 3 and level 4, combined, as shown in Table 4.4. 
 
Table 4.4 
Distribution of PAM-13 Activation Levels by Disease Subtypes 
 
Disease Subtype Level 1 Level 2 Level 3 Level 4 Total (subtype) 
Localized 6.7% (1) 20.0% (3) 60.0% (9) 13.3% (2) 8.2% (15) 
Systemic-Limited 19.5% (16) 20.7% (17) 42.7% (35) 17.1% (14) 44.8% (82) 
Systemic-Diffuse 11.1% (7) 14.3% (9) 58.7% (37) 17.1% (10) 34.4% (63) 
Systemic-Sine 22.2% (2) 11.1% (1) 55.6% (5) 11.1% (1) 4.9% (9) 
Do not Know 21.4% (3) 50.0% (7) 21.4% (3) 7.1% (1) 7.7% (14) 
Total 15.8% (29) 20.2% (37) 48.6% (89) 15.3% (28) 100.0% (183) 
MOS-SSS Results 
For all dimensions of MOS-SSS, the following mean scores were observed for 
respondents: Overall (67.56), TAN (67.01), EMI (62.86), AFF (76.05), and POS (72.68), 
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with median ranging from 65.6 to 91.7 among all dimensions. All four dimensions 
showed negative skewness:  EMI (-.351), TAN (-.486), POS (-.747), and AFF ( -1.073), 
where 7.7% of EMI, 26.8% of TAN, 35.5% of POS, and 48.6% of AFF displayed the 
maximum score. Using the median as a cut-off, the reported high support consisted of 
50.3% for the overall support, 53% for TAN, 40.4% for EMI, 72.1% for AFF, and 61.7% 
for POS. Table 4.5 depicts MOS-SSS statistics by the sample’s groupings. The perceived 
overall, TAN, and POS supports for survey-participants and interview-participants were 
comparable. Interview participants, however, reported higher mean EMI and AFF 





MOS-SSS Statistics for Sample Groupings 
 





Dimensions  M SD Median  M SD Median  M SD Median 
Overall  67.6 24.9 72.0  67.2 25.4 71.5  69.5 21.2 74 
TAN  67.1 30.3 75.0  67.1 30.7 75  67.3 27.3 75 
EMI  62.9 25.6 66.0  62.4 26.3 66  66.2 20.8 63 
AFF  76.1 30.5 92.0  75.5 31.2 96  79.7 25.0 92 
POS  72.7 27.3 75.0  72.8 27.4 75  72.0 26.8 75 
Bivariate Analysis 
The bivariate analysis findings are presented by clinical variables, and PAM levels 
and MOS scores and their predictor variables. 
Clinical variables. Among clinical variables, a moderate association between pain 
and joint/muscle involvement, χ2 (1, N=183) = 17.418, p < .000 (l = .591, p < .000); a 
moderately high association between fatigue and joint/muscle involvement, 
χ2 (1, N=183) = 19.706, p < .000 (l = .708, p < .000); a moderate association between 
fatigue and lung involvement, χ2 (1, N=183) = 9.332, p < .002 (l = .542, p < .002); and a 
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moderate association between fatigue and heart involvement, χ2 (1, N=183) = 6.538, 
p < .011 (l = .634, p < .001) were detected.  
Among pain, fatigue, depression, body image distress, and sleep disturbance, the 
strongest associations were between fatigue and depression, χ2 (1, N=183) = 15.071, 
p < .000 (l = .835, p < .000); and fatigue and pain, χ2 (1, N=183) = 21.021, p < .000 
(l = .704, p < .000). In general, pain, fatigue, and depression seemed deeply intertwined 
and associated with each other. Sleep disturbance was moderately associated with pain, 
χ2 (1, N=183) = 16.497, p < .000 (l = .579, p < .000). Body image distress had a 
moderate association with depression, χ2 (1, N=183) = 18.737, p < .000 (l = .601, 
p < .000), and no association with any other physical symptoms and organ involvements. 
Also of note were lung and heart involvements, which strongly associated with each other 
(χ2 (1, N=183) = 34.948, p < .000 (l = .856, p < .000), as PAH (pulmonary arterial 
hypertension) is a heart and lung combined issue, which many patients identify as a heart 
problem. 
Overall, respondents who had joint/muscle issues had to deal with both pain and 
fatigue; those with lung and heart issues suffered from fatigue. Fatigue was associated 
with both pain and depression. In turn, pain was associated with sleep disturbance, and 
depression with body image distress. The significant associations among clinical 




Significant Associations among Clinical Variables 
 
 c2 df Significance Strength Measure l/ (significance) 
Pain     
      Fatigue 21.021 1 .000 .704 (.000)   
      Sleep Disturbance 16.497 1 .000 .579 (.000)    
      Depression 13.449 1 .000 .611 (.000) 
      Body Image 5.984 1 .014 .399 (.010) 
      Joint/Muscle 17.418 1 .000 .591 (.000) 
     
Fatigue     
      Depression 15.071 1 .000 .835 (.000) 
      Lung 9.332 1 .002 .542 (.002) 
      Heart 6.538 1 .011 .634 (.001) 
      Joint/Muscle 19.706 1 .000 .708 (.000) 
      Sleep Disturbance 7.886 1 .005 .491 (.007) 
     
Sleep Disturbance     
       Depression 11.028 1 .001 .512 (.000) 
      Gastro-Intestinal 6.142 1 .013 .389 (.015) 
       Joint/Muscle 8.505 1 .003 .422 (.003) 
     
Depression     
       Body image 18.737 1 .000 .601 (.000) 
       Joint/Muscle 5.134 1 .023 .358 (.019) 
     
Lung     
       Heart 34.948 1 .000 .856 (.000) 
      Gastro-Intestinal 13.283 1 .000 .553 (.000) 
       Raynaud 6.678 1 .010 .495 (.010) 
     
Heart     
      Gastro-Intestinal 9.859 1 .002 .633 (.000) 
       Joint/Muscle 12.128 1 .000 .592 (.000) 
       Kidney 6.557 1 .010 .534 (.035) 
     
Raynaud     
      Gastro-Intestinal 20.051 1 .000 .714 (.000) 
       Joint/Muscle 7.069 1 .008 .493 (.012) 
     
Gastro-Intestinal  3   
       Joint/Muscle 15.402 1 .000 .578 (.000) 
PAM levels and predictors. The association between PAM activation levels and 
demographic data (age, education, employment) and clinical data (disease duration and 
presence of symptoms) was sought. An association between activation and disease 
duration (years of having the disease), χ2 (6, N=183) = 16.438, p < .012 was seen. 
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However, the strength of this relationship was not statistically significant. When disease 
duration of less than 10 years, where more granular data for number of years having the 
disease were available, was scrutinized, an association, χ2 (3, N=68) = 11.601, p < .009, 
with the strength of the relationship given by Somers’ d (d =.371, p < .004) was detected. 
This statistically significant relationship between independent variable years of having 
the disease and dependent variable PAM activation levels indicates that within the first 
decade of disease, the longer disease duration was moderately associated with higher 
PAM activation levels. 
A weak association was seen between activation and educational attainment, 
χ2 (6, N=183) = 15.664, p < .016 (d = .123, p < .074). No significant associations were 
found between activation levels and other demographic variables (gender, age, 
employment), nor the clinical variables (disease subtypes, number of doctors seen, or 
knowledge of antibody, or any of symptoms and organs involved). 
MOS dimensions and predictors. When MOS dimensions were dichotomized, 
using the median as the cutoff for high and low values, only the association between 
PAM activation levels and TAN did not reach the level of significance: Overall support:  
χ2 (3, N=183) = 14.268, p < .003 (l = .405, p < .000) ; EMI: χ2 (3, N=183) = 8.137, 
p < .043 (l = .336, p < .003); POS: χ2 (3, N=183) = 9.368, p < .025 (l = .235, p < .044);  
AFF: χ2 (3, N=183) = 12.002, p < .007 (l = .328, p < .003).  
To test how respondents in the four PAM activation levels (level1, n=29; level 2, 
n=37; level 3, n=89; and level 4, n=28) differed in degrees of social support, as indicated 
by MOS variables, the Kruskal-Wallis H test (one-way ANOVA on ranks) was 
performed based on the following hypothesis: 
H0: The population median among groups (PAM levels) are equal. 
Ha: The population median among groups (PAM levels) are not equal. 
For all MOS measures, the median scores were significantly different across 
activation levels: Overall support: χ2 (3) =15.809, p =.001; EMI: χ2 (3) =14.511, p =.002; 
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TAN: χ2 (3) =8.216, p =.042; AFF: χ2 (3) =11.900, p =.008; POS: χ2 (3) =13.174, 
p =.004. Therefore, the null hypotheses were rejected. 
When the Kruskal-Wallis test is significant and there are more than two groupings 
in the independent variable, a follow-up test to compare pairwise differences in the 
groups is usually conducted to determine which two groups are different from the others. 
Subsequent to the Kruskal-Wallis test, pairwise comparisons were conducted using SPSS. 
Statistically significant differences were observed as a result. The overall MOS median 
score of level 4 was significantly higher than level 1 and level 2. The EMI score of 
level 4 activation was significantly higher than level 1 and level 2, and the POS median 
score of level 4 was significantly higher than level 2:  Overall MOS median scores 
between level 1 (73.62) and level 4 (118.52), p (.008); Overall MOS median scores 
between level 2 (73.70) and level 4 (118.52), p (.004); EMI median scores between level 
1 (71.05) and level 4 (117.1), p (.006); EMI median scores between level 2 (77.35) and 
level 4 (117.18), p (.016); POS median scores between level 2 (72.07) and level 4 
(111.7), p (.013). No other significant differences were detected among any other level 
pairings. 
When MOS dimensions were tested against depression, pain, fatigue, body image, 
stress, or sleep disturbance, all MOS dimensions were negatively associated with only 
depression: Overall: χ2 (1, N=183) =15.549, p < .000 (l = -.565, p < .000); TAN: 
χ2 (1, N=183) =8.575, p < .003 (l = -.432, p < .003); EMI: χ2 (1, N=183) =9.023, 
p < .003 (l = -.466, p < .001); POS: χ2 (1, N=183) =10.048, p < .002 (l = -.465, 
p < .002); AFF: χ2 (1, N=183) =7.232, p < .007 (l = -.404, p < .006). 
When MOS dimensions were analyzed within three categories of “support group 
leader,” “support group member,” and “support group non-member,” the means of all 
MOS dimensions were higher for leaders, followed by members, and then non-members, 
implying the perceived support received by patients in this sample was distinctly different 
when grouped by membership status. However, the Kruskal-Wallis H test failed to 
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determine a statistically significant association between support group participation and 
perceived social support.  
Summary of Quantitative Results 
Overall, the survey respondents of this study may be described as predominantly 
female, middle-aged, with an above average educational attainment, retired, or on 
disability/sick-leave. A majority of the respondents have lived with the disease for over a 
decade, and more than half did not have the systemic form of scleroderma. More than 
half were under the care of four or more doctors, and one-third traveled more than 25 
miles to see an SSc expert. Only a third was sure about their SSc related autoantibodies.  
Clinically, almost two-thirds suffered from RP, fatigue, and skin and 
gastrointestinal issues, while joint/muscle and lung problems were reported by over half 
of the sample. Those disabled or on sick leave had more pain, were more depressed, and 
had more lung, heart, gastrointestinal, and joint/muscle issues than employed 
respondents. 
The interview-participants indicated more fatigue, pain, depression, joint and lung 
issues, but slightly fewer heart problems and comorbidities than the survey-participants. 
The interview-participants were also slightly younger and more educated with a higher 
number on disability or sick leave. Clinical characteristics of both groups were 
comparable, but interview participants were more likely to travel over 100 miles, 
presumably to scleroderma specialty health centers, to obtain care, and were more likely 
to know their autoantibodies. 
Among the clinical variables, fatigue and joint/muscle issues, and fatigue and lung 
and heart involvement had high and moderate associations, respectively. Fatigue and 
depression, and fatigue and pain each had high association with each other, while pain 




Using the PAM-13 activation measure to describe involvement, 15.8% of 
respondents were classified as passive recipients of care (level 1), 20.2% of them were 
lacking knowledge of the disease (level 2), 48.6% of them were knowledgeable but 
lacked the necessary skills (level 3), and 15.3% of them were active (level 4). Overall, 
64% of respondents, in levels 3 and 4, may be classified as having high activation. Those 
with systemic diffuse subtype had the highest percentage of respondents in level 3 and 
level 4. A weak association between educational attainment and activation was discerned. 
A moderate positive association between activation and years of having the disease 
duration the first decade of disease was also found.  
The dichotomized MOS social support scores, with the median as the cutoff for 
high and low values, indicated 50.3% of respondents perceived having high overall 
support, 53% had high tangible (TAN) support, 72.1% had high affectionate (AFF) 
support, 61.7% had high positive (POS) support, but only 40.4% had high 
emotional/information (EMI) support. Except for TAN scores, the dichotomized MOS 
scores of all other dimensions had statistically significant associations with PAM 
activation levels. Furthermore, the perceived overall support, and EMI support for those 
in level 4 were significantly higher than those in level 1 and level 2. All MOS dimensions 
were negatively associated with depression. 
Almost 70% of respondents did not participate in a support group. Being employed 
was a barrier to support group participation, and being “disabled/on sick leave” was more 
conducive to active participation in support groups. No statistically significant 





The aggregate demographic and clinical characteristics of respondents, survey 
participants, along with those of interview-participants were reported in Table 4.1. 
Anonymized data for interview-participants, including additional demographic and 
clinical information gathered at the time of interview, are reported in this section in order 
to provide an overall context for the interview group and for each participant. 
Contextual Descriptions 
The 20 female and 5 male interview participants ranged in age from the mid-30s to 
85 years old, with 64% having a college degree or above. Those who worked full-time or 
part-time constituted 32% of the sample, while 56% were retired or on disability or sick 
leave. Except for two persons not disclosing, all held white-collar jobs such as teaching, 
accounting, sales, executive/managerial, administrative assistance, or research and health-
related work. Ethnically, 72% (18) were White American, 12% (3) White European, 4% 
(1) African American, 4% (1) Asian American, 4% (1) South American, and 4% (1) 
Asian. Table 4.7, ordered by age, captures these data.  
Interview participants reported their scleroderma subtypes as: 11 (44%) having 
limited cutaneous scleroderma (lcSSc), including 2 with overlap syndrome (i.e., other 
autoimmune diseases concurrently); 9 (36%) indicated diffuse cutaneous scleroderma 
(dcSSc), including 1 with overlap syndrome; 3 (12%) scleroderma sine scleroderma 
(ssSSc), with one overlap syndrome; and 2 (8%) who did not know the subtype of their 
disease. Five (20%) of participants were diagnosed when they were young, defined as 





Interview Participants’ Demographics, Ordered by Age 
 
Gender Age Race/Ethnicity Education Employment Status 
F 30-39 White European Post grad Working full-time 
M 40-49  White American College grad Working full-time 
F 40-49  White American College grad Disabled-Sick leave 
F 40-49  White American College grad Disabled-Sick leave 
F 40-49  White American Some college Disabled-Sick leave 
M 50-59 White European Post grad Disabled-Sick leave 
M 50-59 South American Some college Working full-time 
F 50-59 White American Post grad Working full-time 
F 50-59    White American College grad Working full-time 
F 50-59  Asian American College grad Working full-time 
M 50-59  Asian Caucasian Post grad Working full-time 
F 50-59  White American Some college Disabled-Sick leave 
F 60-69 White American Some college Not working 
M 60-69 White American HS grad Retired 
F 60-69   White American HS grad Retired 
F 60-69  White American HS grad Other 
F 60-69  White European College grad Not working 
F 60-69  White American Post grad Disabled-Sick leave 
F 60-69  White American Some post Disabled-Sick leave 
F 60-69  White American Some college Disabled-Sick leave 
F 60-69  White American Post grad Working part-time 
F 60-69  White American Post grad Retired 
F 70-79  White American Post grad Retired 
F 70-79  White American HS grad Retired 
F 80 or greater  African American Post grad Retired 
 
Ten (40%) were in their mid-40s to mid-50s, and four (16%) were older than 56 when 
diagnosed. Eleven (44%) participants were diagnosed within six months of seeing their 
doctors, two (8%) in a year, five (20%) in one and half years, two (8%) in two years, one 
(4%) in three years, and one (4%) was diagnosed in five years. Two participants were 
diagnosed due to other health issues unrelated to SSc, and one was self-diagnosed. On 
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average, these participants have lived with the disease for approximately 14.5 years, with 
the range given as of 2½ to 49 years (+ 10.2). Eliminating the 30 and 49 years of 
longevity as outliers, the average disease longevity was 12.2 years. Ordered by disease 




Interview Participants’ Disease Subtypes and Diagnosis Time, Ordered by Disease 
Duration 
 
Disease Duration SSc Subtype Time took to be diagnosed 
2.5 ssSSc Self-Diagnosed 
3 dcSSc 1-6 months 
3 ssSSc 1-6 months 
4 dcSSc 1 year 
5 dcSSc 1-6 months 
7 lcSSc 1-6 months 
7 dcSSc 1 ½ years 
10 ssSSc 1-6 months 
10 dcSSc 2 years 
10 lcSSc 1-6 months 
12 lcSSc 1 ½ years 
12 dcSSc 1-6 months 
12 lcSSc 1-6 months 
13 lcSSc 1-6 months 
15 ssSSc 1 ½ years 
15 lcSSc Coincidentally diagnosed due to other health issues 
16 lcSSc 5 years 
19 dcSSc 1-6 months 
19 dcSSc 1 year 
20 dcSSc Coincidentally diagnosed due to other health issues  
21 lcSSc 1-6 months 
22 lcSSc 3 years 
25 dcSSc 1 ½ years 
30 Don’t know 1-6 months 
49 Don’t know 2 years 
 
As to previous health conditions, 16 (64%) of the participants did not suffer from 
any chronic health condition prior to their SSc diagnosis, while 4 (16%) participants had 
other prior health issues. Nine (36%) had developed other conditions subsequent to SSc. 
Eleven participants (44%) made note of their excellent health status prior to their illness. 
Five were highly trained athletes at the level of marathon runners and sports trainers, 3 
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were highly active in sports and outdoor activities, and 3 considered themselves 
physically active with no prior history of health problems. 
Among the 25 interview participants, only 1 indicated ongoing medical issues since 
childhood. Growing up, 1 had a sibling with an autoimmune chronic condition (not SSc), 
1 had a sibling with diabetes, and 3 had a parent with autoimmune diseases (Lupus, 
Graves, SSc). Two had children who had major chronic conditions (not SSc) from early 
childhood. The other 16 (64%) patients did not indicate any major or long-term illnesses 
that they had to face personally, or had witnessed a close family member undergo. As to 
the familiarity with SSc, 3 patients mentioned a parent, an in-law, and a coworker with 
SSc. Thus, 88% of interviewees had never seen or heard of this disease prior to their own 
diagnosis. 
One patient had worked in the health field in clinical settings not related to chronic 
or immune diseases; one was in an administrative role in a health facility, and one had 
worked in a home care aid capacity in private settings dealing with chronic patients. Two 
people had expertise in the health field at policy and structural levels, and one patient had 
a spouse as a medical assistant working in a physician’s office. Four patients mentioned 
having family members or close friends in the medical field, as doctors and nurses, who 
provided some guidance related to medical decisions or navigating the healthcare system. 
Overall, this sample’s first-hand exposure to chronic conditions and the workings 
of health system, as indicated by their experiences of a prolonged disease or occupations 
within the industry, was limited. 
Patients’ Work 
The interview participants engaged with their illness experience through various 
types of work (Corbin & Strauss, 1998). These included what patients did in order to 
mediate the primary physical impact of the disease on their bodies, and the secondary 
tiers of impact encompassing the emotional, psychological, relational, and financial 
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aspects in their lives. Initially, this engagement was set in motion by efforts to find an 
explanation for baffling symptoms they were encountering. 
Obtaining a diagnosis. Initially, patients were taken off-guard, describing their 
symptoms as “strange” and “crazy,” and they did not know where to turn to other than 
their primary care doctors. For some, these doctors propelled them forward through the 
healthcare system. Others had to find the way through their own efforts. Accordingly, the 
starting point for patients’ involvement was their efforts to find a diagnosis, and this 
involvement was qualitatively different among the sample, indicating a difference in the 
intensity, duration, and persistence of effort that patients had to put forward to get a 
diagnosis. The diagnostic experiences of all patients were formed by a confluence of four 
elements, whch came together uniquely for each person. These elements consisted of the 
initial symptoms, the initial medical encounters, the rate of appearance of subsequent 
symptoms, and experiences with doctors early on.  
Initial symptoms. The early symptoms prompting participants to seek medical 
attention varied widely among the sample. Participants recalled feelings of general 
malaise, exhaustion, and fatigue; strange skin sensations and changes such as pins and 
needles, burning or being on fire, itchiness, dry and cracking skin, skin 
thickening/hardening, pigment changes (white spots), and red dots. Other complaints 
included swelling of fingers, joint tightening, pain, shortness of breath, and visual 
disturbance. Initially, some participants dismissed these complaints, instead attributing 
the symptoms such as dyspnea to being out of shape or being overweight, fatigue to 
overworking or aging, swelling and skin sensations as too minor. Two participants (8%) 
were diagnosed without them seeking a diagnosis when they were being evaluated for 
another condition/procedure. Due to abnormal blood work, they were referred to 
rheumatologists, who diagnosed them. The remaining 23 patients sought medical 
attention on their own. 
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Initial medical encounters. Six patients (24%) saw their primary doctors and were 
referred to rheumatologists because their doctors suspected some rheumatologic illness 
(arthritis, lupus, or even SSc). Another seven (28%) patients presented symptoms that 
were considered alarming, such as shortness of breath, very high or low blood pressures, 
or lack of motility. These were referred to hospitals or had lab work and tests done, 
expeditiously. Together these two groups of patients (52% in total) had official diagnoses 
that came fairly quickly within weeks or months (mean of 4 months), depending on how 
quickly lab work and appointments with rheumatologists were secured. For these 
patients, the initial experience of diagnosis, more or less, paralleled the general 
perception of how known chronic conditions (diabetes, heart disease, etc.) might be 
diagnosed by seeing a primary doctor who directs the patient to a specialist. They saw on 
average two doctors for diagnostic purposes; some sought a second or third opinion; and 
some were referred to other specialists (pulmonologist, cardiologist) to determine the 
extent of their disease, post diagnosis. 
Rate of appearance of symptoms. The remaining ten patients (40%) had a much 
more prolonged diagnostic process, due to non-specificity of their symptoms, or seeing 
doctors who did not have the expertise. Initially, some were told to take Tums for 
heartburn, iron supplement for anemia, cream for dry skin, diuretics or limited salt for 
hand/leg swellings. One person was told his/her symptoms were psychosomatic, and 
another was labeled as a “hysterical female” and was put on a tranquilizer. Not counting 
repeated visits to their primary physicians, they saw on average 4.6 doctors, and it took 
anywhere between 1 and 5 years before they were diagnosed. Being healthy up to that 
point and not having any prior experiences with a serious illness, one patient expressed 
that she did not even know what a rheumatologist did, let alone that it was the medical 
specialty she needed to seek. At some point in this process, either due to additional 
symptoms presenting themselves, or through luck, they came across a physician, a friend, 
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or a family member who guided them toward a rheumatologist. Table 4.9 summarizes the 




Interview Participants’ Diagnostic Experiences 
How 
Diagnosed 
By chance  Expedited Due to 
Alarming Symptoms 
Thru a primary doctor in 
short order 
 A prolonged Process 
(n)% of 
Patients 
2 (8%) 7 (28%) 6 (24%)  10 (40%) 
How Long A few weeks <= 1 month Mean of 4 months   1-5 years 
Number of 
doctors seen 
2 doctors for diagnosis + more to check extent of disease  4.6 
 
Experience with doctors early on. The symptoms and their rate of appearance 
dictated the person’s initial disease state and the extent of medical attention they 
received. One of the most salient parts of interview participants’ experiences of the early 
days of the illness, in the pre-diagnostic and the immediate post-diagnostic period, was 
their encounters with doctors. These initial encounters may be said to have been mostly 
of a convenient nature, in the sense that doctors might or might not have had the expertise 
to diagnose or treat such a complicated and rare disease; these doctors were the primary 
care physicians or general rheumatologists who were available locally. Later on, patients 
searched for doctors in a more discriminating way, which was influenced by these early 
encounters. The vivid descriptions of these early encounters conveyed four distinct 
perceptions of doctors’ responses: dismissive, fatalistic, measured, and supportive.  
Dismissive. Twelve patients (52%) perceived a dismissive attitude on the part of 
physicians they saw, in at least one of their encounters. Their perceptions were that 
doctors were not hearing them out, were refusing to do tests, were not taking seriously 
the extent of their suffering, and were dismissive of the evidence they were presenting. 
These patients needed to bring their doctors on board by showing their symptoms were 
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real and by being persistent. More often, they had to find other doctors who listened to 
them. This group of patients with a contested illness had to put forth the most efforts and 
persistence to get diagnosed, and their diagnoses generally took the longest. One patient 
who had travelled far and wide to well-known medical centers in search of a diagnosis 
and every time was told she was just anemic summed it up this way: 
I wasn’t happy that he was telling me this [diagnosing me with SSc] but 
I was happy that somebody was saying something other than “go home and 
take your iron.” (Rene) 
Fatalistic. Six (24%) of interview-participants saw doctors who diagnosed them 
correctly, but presented a pessimistic view of their prognoses, indicating there was 
nothing that could be done and predicted their imminent demise. These patients were 
given a life expectancy of 5 or 6 years and were told to get their lives in order. Two of 
these patients were diagnosed as early as 4 and 10 years ago, and the remaining four had 
an average of 17.5 years’ disease duration.  
Not succumbing to their doctors’ fatalistic pronouncements and finding other 
doctors who were willing to work with them in a more hopeful and responsive manner 
were approaches taken by these patients. The most dramatic story was that of Francis, 
who for a year and half had been going to various specialists with severe skin tightening 
and other internal symptoms. Nobody paid any attention to his skin. Finally, a doctor 
diagnosed him, but considering his case hopeless, refused to treat him and declined to 
refer him to another physician. Francis and another patient in this group, among all 
interviewees, showed the most determination and effort in finding doctors that treated 
them. 
Measured. In contrast to a fatalistic response, five patients (20%) described a 
measured approach, which left them unclear or confused as to the nature of their illness. 
These patients’ perceptions were that explanation of illness, indication of its severity, 
what can be done, or how it might progress were lacking. The main symptom for this 
  
125 
group of patients was related to their skin. With no or few other symptoms and no 
internal impact, doctors took a wait-and-see approach. This measured approach, intended 
not to alarm the patients, nevertheless left them uninformed about a progressive disease. 
For these patients, their understanding of the scope and nature of their illnesses came 
from living with the disease, reading on their own, and going to support groups.  
Supportive. Patients who saw SSc specialists and in a few instances other doctors 
reported the most positive experience of physicians’ encounters and the diagnostic 
process. Twenty-two patients (88%) have seen a scleroderma expert either initially or at 
some point. With one exception, patients described these encounters as affirming. 
Patients appreciated the knowledge and experience of their doctors; they felt heard, and 
given some clarity on the nature of disease and its progression. They also felt they were 
given hope and a sense that the doctor was accessible to them, so they were not alone in 
this journey; a number of patients were given doctors’ email addresses and could call 
them at any time.  
The sense of relief expressed by patients when they finally found such a doctor, 
who diagnosed them or gave them hope, answers, and a plan of action, was very distinct 
and palpable: 
I am lucky to have Dr. ___; again, thank God, I found her. I see Dr. ___ 
probably twice or three times a year, but every time I go there she has the 
right answers, the right questions. (Francis) 
Overall, 16 (64%) patients reported experiencing two or more of these four types of 
responses early in their disease in pursuit of the “right” doctor. For about half the 
patients, the rheumatologist who diagnosed them became their main doctor, and the rest 
moved on to others. 
These early experiences continued to exert an influence and were manifested in an 
ongoing search and alertness for finding doctors. Not being content with the nature of 
their interactions was one factor precipitating such a search. Other factors included 
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logistical issues such as relocation, doctors moving out of a practice/retirement/death; a 
need to add other specialists due to new organ involvement; the need to supplement their 
local doctors with an SSc expert or going to an SSc center due to the progression of the 
disease; and looking for doctors offering alternative therapies or clinical trials. No matter 
the reasons, finding and interacting with doctors took a considerable amount of time and 
effort in these patients’ lives. See Appendix L, Table L1 for patients’ accounts on 
obtaining a diagnosis. 
Managing relationship with doctors. One hundred percent of interview samples 
saw two or more doctors: nine (36%) patients saw 2-3 doctors, ten (40%) saw 4-5 
doctors, and six (24%) indicated seeing more than 5 doctors in various specialties. Many 
articulated a need to develop a relationship with doctors and their teams. Practically, all 
patients predicated the development of these relationships on finding doctors with 
medical expertise, communication skills, and respectful demeanors, but also their own 
willingness to express and advocate for their expectations, wants, and needs. Thus, 
interview-participants had developed a list of criteria as to what to look for in their 
doctors and clinical encounters, as well as a perception of their own role in this exchange. 
Expertise. Doctors’ expertise was the number one concern of all patients. Even the 
three who did not seek an SSc expert had made the determination that their 
rheumatologists were very knowledgeable about scleroderma. For many, the diagnostic 
experience had created a keen awareness that knowledge and experience in treating SSc 
was wanting, and they needed to find doctors who had the right credentials. Most were 
not hesitant to travel long distances to see one. They found these doctors through doctor 
referrals, their own research, but also through the experiences of other patients.  
Bedside manner is not so much, if I felt that they were really the person 
who had the most knowledge about it. Bedside manner is nice but I don’t 
think it’s something that would be the number one thing I’d look for in my 
doctor. I would look for the expertise first. The thing that bothered me about 
the doctor that I changed is that I didn’t have confidence in him. (Maddison) 
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I have a lot of people that thought I was crazy to travel to California to 
see a doctor. They’re like, “There are good doctors here.” That’s a special 
one. So, I run against what everybody else said, and I’m really glad I did. 
(Jenelle) 
Trustworthiness and competence. Patients did not merely seek knowledge in their 
doctors, but also a type of competency that engendered confidence and trust; a 
meticulousness and thoroughness that safeguarded against things falling through the 
cracks invoking a sense of safety for them. A number of patients noted that they do not 
even consider their doctors “nice,” but rather competent and trusted. 
This doctor is not even nice. I don’t even want to say nice. She’s just a 
smart and a good doctor and looks for everything … she just gets right 
through the crap, stops all the bullshit.… This is a crazy disease. You have to 
be comfortable with the doctor.... I feel so much safer with Dr. ____. It’s a 
good word. I feel safe where I feel like I’m going to be okay and if I’m not, 
she’s going to always take care of it. (Mackenzie) 
She is very, very meticulous. (Francis) 
Interview participants mostly spoke of one doctor that they had this trusting 
relationship with. It seems it was not necessary for all their doctors’ relationships to be of 
this nature, as long as there was one trusted doctor. Patients used terminology attributing 
a “North Star” quality to their trusted doctors. Not only were these doctors seen as 
showing the path, but they also acted as a reliable resource for keeping in check patients’ 
own pushbacks, for checking the soundness of other doctors’ recommendations, and for 
finding other good doctors. 
I got to [trust doctors]. I go crazy otherwise.… I trust them; you got to 
trust them. It is like, you know, getting here; you got to trust your GPS. 
(Ralph) 
Communication style. Interview participants wanted doctors whose 
communication style matched their expectations. By this, they meant finding a doctor 
who had the ability and willingness to convey information to them, who really listened to 
what they were saying, and answered their questions truthfully in a straightforward 
manner without being falsely hopeful, evasive, patronizing, or demeaning. 
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So, to me, I need to know if the doctor is listening to what I’m saying. 
(Jenelle) 
I expect him not to candy coat it; I just want to know what it is now and 
next and that is it. Tell me what it is, do not give me false hopes and as far as 
that goes you know, I know you are working on a cure and give me a call 
when you got it. Do not just tell me you are working on it. (Ralph) 
Non-verbal communication style. One non-verbal communication cue that patients 
took as belying trust was eye contact. “Looking them in the eyes when spoken to” had a 
significant meaning to many of these patients. As doctors increasingly look at their 
computer screens and tablets while attending to their patients, this was interpreted as 
either not seeing the patient as an individual, or as an inability to grapple with uncertainty 
and ambivalence about the prognosis or course of action to be taken. 
This pulmonologist who always said, “There’s nothing you can do.” He 
wouldn’t look at me. He never examined me. He would just sit and type and 
stare at his computer and I’m over here and he would give me bad news and 
not look at me. And I had to stop and then say, “Look at me and tell me that. 
I need you to stop typing and look at me.” (Jenelle) 
Even when patients did not take it negatively, they made a note of it: 
Sometimes, he’ll close his eyes but because he’s thinking. I can tell he’s 
thinking about what you’re saying. (Maddison) 
Patients’ role. Interview-participants’ perceptions of their own role included 
compliance with therapies and expression of their preferences. All patients claimed a 
very high level of compliance with medications and vigilance in keeping appointments 
for regular tests and checkups. Given the seriousness of their symptoms, patients felt 
compliance was necessary and expressed that they did not modify their regimen without 
consultation with their doctors. Within the boundaries of conventional medicine, 
however, they argued for choices. This included delaying or refusing certain treatments, 
taking minimal amount of medication, asking for certain medications, requesting 
inclusions in clinical trials, or refusing to participate in one. Patients expressed an 
awareness of voicing their questions or dissatisfaction, and asserting their wants and 
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expectations, and saw themselves as playing their part by having these conversations with 
their doctors: 
I said, “I’ll work with you but you got to work with me.”… I didn’t 
jump and all of a sudden voice all of this. First, I let him come in and ask and 
check me and do everything and then when it was time for me to talk, I 
explained about myself and my own feeling of how I want to wait taking 
medicine for this disease until I feel that I can’t function rather than the 
belief that “Catch it early. Go on all these.” (Lauren) 
My primary care used to say, “Let’s try this. Let’s try this. Take these 
drugs.” And every time we would do it, I would say, “Do I really have to do 
that? I don’t think I really have to do that?” He would say, “I think you 
should. I think you should start on this kind of a regimen and see where it 
goes.” And I would try to do that and I would come back and say, “I don’t 
want to do it. Let’s try something else.” (Kristeen) 
Patients attributed their assertiveness in expressing their preferences to their 
experiences of living with the disease and having confidence in their own knowledge, 
holding a non-intimidated view of doctors because of knowing relatives who were 
doctors, but also a belief that a good doctor would not be offended by their pushbacks. 
Such confidence in expressing wants and needs, and the expectations of mutuality, were 
more often articulated by patients with longer duration of the disease. They spoke of their 
relationship with their doctors in terms of friendship or partnership, or lamented the loss 
of one such relationship due to relocation, retirement, or death. In a similar vein, those 
with more complex cases were more likely to verbalize the greatest sense of trust and 
confidence in, and satisfaction with their doctors, irrespective of the length of illness. See 
Appendix L, Table L2 for patients’ accounts on managing doctors’ relationships. 
Pursuing effective therapies. Therapies for these patients, regardless of the 
subtype of scleroderma, were not a simple matter of taking proven pills or injections. 
Rather, it was an individual trial-and-error process where choices were dependent not just 
on the professional judgments of physicians, but also how much efforts patients were 
putting in to find the medications that worked for them. Based on their symptoms, 
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responses to the drug, rate of progression, organs involved, and the length of illness, 
patients described different experiences related to therapeutic interventions.  
The most drastic experience was that of Nicole with a rapidly deteriorating lung 
function, who went from six months of chemotherapy to autologous stem cell 
transplantation (ASCT) within a year of diagnosis. She was one of the handfuls of 
patients in a trial that was stopped shortly thereafter. A cohort of patients went through 
this trial in a serial fashion, each patient working closely with the one next in line, 
preparing her/him as to the sequence of events, procedures, reactions, and generally what 
to expect. She was coached by the person immediately preceding her, and coached the 
one succeeding her, both of whom passed away within a year.  
Unlike Nicole, the majority of patients went through therapies in isolation. In 
effect, they were a “medical trial of one,” all by themselves trying to assess their body’s 
responses to powerful medications over many months. When an effective medication was 
found, they needed to be persistent and continue their vigilance, looking for side effects, 
or diminished effectiveness over time as the disease progressed. Some had to try a 
cocktail of three or four drugs for maximum effectiveness.  
Patients spoke of onerous delivery mechanisms (e.g., pumps, or heavy oxygen 
tanks), complicated dosages and regiments (e.g., given high doses, weaned off and 
starting the cycle again, or having to maintain a precise concentration of drug in their 
bodies), compounded by physical changes, such as esophageal issues that made 
swallowing pills difficult, or hardening of skin that made injection needles penetrating 
skin an ordeal. These required a considerable degree of compliance commitment not only 
in the form of dedication and discipline in taking the medications as prescribed, but also 
by enacting changes in their lives to accommodate the therapies, such as modifying 
activities and changing eating and sleep patterns, etc. 
They have put me on Remodulin [a vasodilator for PAH in form of 
continuous subcutaneous infusion], which looked like I had an implant 
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hooked up to me. And so, I had to reevaluate how and when I did things 
because it was very sore so I was not as active as I could. It made that 
difficult in changing it and I was on it for about two years but now, I’m 
finally off the pump and they put me on the pill now. So now I feel free. I 
can take baths. I can go running. I can do a lot of activities that I was 
restricted to before. (Winola) 
Of note were two patients with exceptional disease longevity of 45 and 30 years. Very 
few medical options were available to them at the time. However, one continued seeing 
doctors and eventually was treated and, according to her, has been in remission; the other 
gave up on the medical profession and decided to “live her life.” She was the only 
exception in the sample that did not actively seek medical interventions early on, with 
detrimental effects.  
There wasn’t very much to do, not at all if you’re talking 30 years ago. 
It’s not like today. Today, they’re more aggressive…. Back then, it was 
strictly—they treat you with the high blood pressure medications.… So why 
am I going to go and get the same drill?… So, I just said I’m tired of it. I’ll 
just live my life, whatever befalls me- because you could spend your life at a 
doctor’s office getting picked and poked and I didn’t want. (Vanessa) 
One complication that some patients needed to manage was insurance drug 
coverage. Since many of medications for SSc were prescribed off-label, insurance 
companies generally did not cover them. Furthermore, they were subjected to formularies 
on a list of eligible drugs for a given plan. A handful of patients spoke of having to 
continue taking drugs that were not effective and/or had side effects for months in order 
to establish their inefficacy/harm for insurance purposes. Only then could they try other 
drugs, hoping, having built a case, the insurance would cover the cost of new 
medications. This put these patients in the difficult position of having to make decisions 
as to what therapies they could afford or were willing to take, in spite of the professional 
recommendation of their doctors. 
Patients’ engagement with therapies was most intense in the early and active 
phases of disease, but was also ongoing for many patients due to loss of effectiveness, 
toxicity, and progression needing to alter medications. Being alert about and engaged 
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with their medications was a constant endeavor throughout the course of illness. See 
Appendix L, Table L3 for patients’ accounts on pursuing effective therapies. 
Attending to emotional and psychological impact. Interview data indicated a 
range of ongoing emotional and psychological burdens in the course of illness, initiated 
by the fear of dying, and followed by fear of progression of disease, depression, and 
suicidal thoughts, frustration related to their disabilities, and distress over body image. 
Fear of dying. Whether through their own research, having known an SSc patient, 
or having information imparted to them by their doctors, the primary emotion shared by 
the overwhelming majority of patients was fear, in particular fear of dying. Out of 25 
patients, 1 person explicitly stated that she was not scared, 3 did not speak of their 
affective reactions, whereas the remaining 21 (84%) used one or more of the following 
words and phrases to describe their emotional states: scared, fearful, terrified, panicked, 
afraid, frightened, freaked out, petrified, upset, shocked, devastated, going to die, needing 
a bucket list, never will see my kids grow up/get married, sobbing, crying, tears pouring 
down my face. 
Fear. Fearful, just—I don’t think it was anger because I was just—
everything I read was just so devastating to me…. I didn’t know what it was. 
I couldn’t even say it [scleroderma], and then I saw pictures of people very 
disfigured. It’s hard not to be upset about it. (Brenda) 
I thought I am going to die. I had young children … I started to cry … I 
never heard of [SSc] and when I looked it up and said 80% of people 
diagnosed with it will die within 10 years. So, talk about a mid-life crisis, I 
had one. I had a bucket list a mile long. (Paula) 
First I was scared. Then I did the Internet thing, which is really stupid, 
because then you get a wide variety of information and people initially think 
it is a death sentence. (Stacee) 
Fear of progression. After the perception of an immediate death subsided, the fear 
of progression of the disease moved to the forefront. Patients took certain indicators as 
foreboding, signaling the worsening of their diseases or portending a decline in the near 
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future. These included appearances of new symptoms and lab and test results falling 
outside normal ranges, but also those they harnessed through body surveillances.  
 I did not cry through a lot of it at the beginning. I was sort of surprised. 
But when I got the diminished lung function, I was really devastated.… I 
thought that was sort of ‘oh gush it could be the beginning of the downturn’. 
(Willa) 
One of my biggest fears is that I’m going to end up having to go back on 
O2 [oxygen]. (Laurie) 
I really get worried when these nodules, they start scraping against each 
other and I’m worried they’re going to open up. I do know somebody that 
has all the open sores here and that’s another thing I’m scared of. I don’t 
want to look like that. (Mackenzie) 
Whereas the above measures indicated the short-term changes in the disease, the 
patients in more advanced stages whom one could see in support groups and other venues 
embodied the progression of the disease in the long term. Seeing these patients, in 
support groups or patient educational forums, was particularly difficult for many 
interview participants. Another way patients revealed their angst about progression was 
the uneasiness and ambivalence they had in differentiating between possible new 
symptoms and those related to aging, genetics, or other illnesses. Not knowing the 
attribution was particularly difficult for older patients, who were dealing with aging at the 
same time. 
Body image distress. Three patients in the sample had identified their subtype as 
scleroderma sine scleroderma, meaning they had no skin manifestations. The remaining 
22 (88%) had various degrees of skin thickening characterized by tightness, hardness, or 
leathery appearance of skin. Other visible changes included telangiectasia (red dots), 
discoloration of skin, changes to the shape of mouth and nose, rupturing of skin and 
ulcers on fingertips, and contraction of fingers. Out of 22 patients, seven (31.8%) 
considered their skin issues minimal and not concerning image-wise. For ten (45.5%) 
patients, there were sufficient physical changes to cause body image distress; this was 
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irrespective of gender. Among these were patients who deemed the changes so drastic 
that they were not recognizable from their old selves, prior to having the illness. A few 
characterized their concerns as vanity; others alluded to social expectations of women 
being pretty and men being athletic. Other signifiers of illness, including publicly visible 
therapies like oxygen tanks or loss of hair due to chemo, were also mentioned as sources 
of social anxiety. Presentation of self, altered by skin deformities, was particularly 
disconcerting for younger patients and was brought up in the context of dating by two 
patients. 
Ironically, the patients who did not have any noticeable disfigurements had a 
problem of their own. The phrase “but you do not look sick” was a detested statement 
that was repeated by several patients. This was especially true early in the disease process 
when the inflammation in skin, before it became hardened, eliminated the wrinkles and 
patients looked younger. The misalignment between how they felt and how they looked 
was perceived as needing to prove or legitimize their illness. This was a source of stress 
for a number of patients. 
Frustration, anger, and depression. Seventeen patients (68%) used words such as 
“frustration,” “angry,” and “upset” in describing issues they have faced. Twelve (48%) 
interview participants indicated in their survey that they had experienced depression. 
Among the patients with depression, seven spoke openly about their anxiety and suicidal 
thoughts during interviews. 
I was fearful and I just—it was weird because I actually got depressed 
and I suffered from depression and I don’t think that’s uncommon. (Brenda) 
I’d be driving home and I’d be in such pain…. I swear to God, I saw this 
building, a brick building, was like a cleaner, I came to this fork and I 
thought if I just kept going and crashing that building I could just end it all, 
and you would never think that you would think that way, but I did. It was 
torture. I loved my family and they needed me and I needed them, but I was 




Interview participants attributed disabilities, fatigue, and alteration or loss of roles as 
major contributing factors to their sense of frustration and depression. 
Disabilities and fatigue. The inability to be active as before or to do mundane 
chores was especially pronounced for patients with joint issues and contracted fingers. 
Ordinary tasks like opening a jar or a water bottle, turning a rotating light switch, a round 
doorknob, or faucet, turning on the car, or closing the trunk door became ordeals on a 
recurrent and daily basis. Even though the disability and physical limitations that patients 
were facing varied widely in type and severity, they implicated all patients in one form or 
another, contributing to their daily irritation. Complaints about Raynaud’s were universal. 
Stiff fingers and joints, pain, shortness of breath, and digestive and bowel issues, 
variously, affected patients. All of these complaints curtailed their activities and 
contributed to their frustrations. Kurt’s detailed description of cascading frustrations is 
instructive to understand the daily struggles of these patients: 
I told you about GI issues, you have SSc hand issues. You have [finger] 
contractions. Try being all bundled up in dead cold of winter here in ______ 
as it was and has been the last few years. First imagine that, then, imagine 
you’re outside in public area, you’re not at home and you got to go to the 
bathroom because your stomach is giving you a problem. Now, only have a 
short time to find a place—your fingers and hands aren’t working—you got 
to get yourself unbuttoned. You’re in a public restroom. What are you going 
to do with your clothes?… Your hands really don’t work. They’re frozen 
from the Raynaud’s. Try reaching for the toilet paper…. Think about those 
thin pieces of garbage that you’re given for toilet paper in the restroom. 
Think about trying to pull on that big roll. Think about trying to fold it. Now, 
think about reaching back when nothing is working in trying to clean 
yourself. (Kurt) 
Another universal complaint was fatigue. Both the disease itself and the use of 
immunosuppressant and chemotherapy drugs plagued the patients with constant 
weariness. 
Feeling crappy all the time. Being tired all the time. Before I got really 
sick, at work they used to call me the energizer bunny. I always kept going 
and I cannot do that anymore. I feel I lost my batteries. (Patricia) 
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These forced patients to give up on activities like doing housework, gardening, traveling, 
and the isolation that resulted from giving up their social lives and staying at home, 
because getting out was just too difficult in light of the disabilities they were facing. 
Other major sources of frustration for patients were the lack of understanding on the part 
of others regarding their illness, and the difficulties in dealing with the healthcare system 
and insurance coverage. Four patients used the word “anger” to indicate the intensity of 
their frustrations. These patients tended to be living with the disease for a shorter period 
of time, and their frustrations were related to dealing with issues outside their direct 
control like the healthcare system. 
Disruptions of roles and identities. Many patients had to give up their work, to take 
on less demanding jobs for which they were over-qualified, or to relinquish plans for 
advancing their education and moving up the career ladder. Two male patients openly 
lamented the loss of their identity as the provider, fixer, and protector of the family, while 
a third expressed anxiety in not being able to provide for his family financially. 
Disruptions in discharging parental roles weighed heavily on those with younger 
children; the unexpected physical and emotional unavailability due to fatigue and 
depression, failure to provide financially, and the possibility of not being there to rear 
their children to adulthood was devastating to all participants who were parents. 
A number of interviewees were athletes. The high levels of athletic ability 
developed over years of training being taken away and replaced by extensive physical 
limitations were heartbreaking to them. Other patients reported the loss of fine motor 
skills: one person spoke of her inability to play the piano, another talked about limitations 
in doing artwork, yet a third could not type on a computer keyboard, and a fourth had lost 
tactile ability to handle small instruments needed for work. Table 4.10 summarizes the 
extent of the main psychological stressors on patients. See Appendix L, Table L4 for 










Dying or Progression 
Depression Frustration & 
Anger 
Body Image Stress 
n (%) patients 21 (84%) 12 (48%) 17 (68%) 10 (40%) 
 
Approaches to coping. The interview participants presented various approaches to 
cope with and mediate the emotional and psychological burdens of disease, and to 
reframe their lives in light of the disabilities and disfigurements that precipitated some of 
their angsts and disquietudes. 
Seeking professional help. Seven patients (28%) indicated that they sought 
professional help and attributed their coping skills to years of therapy and medications.  
Keeping busy and being productive. Some interview participants found working 
and keeping their employment very helpful. 
Even the doctors recommended I stop working. My doctor, Dr. ___, told 
me even if it is only 2 or 3 months, I give you the paperwork whatever you 
need. I said, Dr. first of all financially I cannot afford and I want to keep 
active. I think that is what has helped me the most. Being active and going to 
work. (Francis) 
Doing for others and keeping busy in the process was another major theme in many 
patients’ lives. Seven patients (28%), in spite of their own conditions, were caregivers to 
aging or ailing spouses, parents, or children; three (12%) were helping raise 
grandchildren; and at least nine (36%) had cared for children at home while going 
through this illness. Seven (28%) had initiated a support group or taken on a leadership 
role, and a few volunteered for other causes and neighborhood organizations.  
Reducing daily irritations. On a practical level, many patients had found creative 
ways to ameliorate some of their disabilities in order to reduce daily irritations and 
frustration. One patient with joint issues in his hands had put his young children in charge 
of unbuttoning the shirts he was to wear for work; another had crafted a warming 
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beanbag for her steering wheels; yet another inserted cork stoppers in rotating light 
switches, and few put rubber bands around pens, brushes, and doorknobs, and used 
stemware for a better grasp. Others mentioned keeping a blanket in the car, a pair of cold 
weather gloves in every jacket, hand warmers, and rubber gloves in their bags (to grasp 
or turn things outside the home). Some have found modifying the type of clothing they 
wear (pants with elastics not zippers, wide-toe shoes, using insoles) as helpful. Through 
such small solutions, many had ushered a sense of control and reduced the constant 
irritations over mundane tasks in their daily lives.  
Controlling what they could control. Some patients found the secret in controlling 
what they could control like doing things that were helpful to their bodies, such as 
exercise and eating well, reducing their stress, and by not dwelling over things that have 
not happened: “Why borrow trouble?” 
It’s just managing how the disease makes you feel…. There’s a lot of 
SSc issues that we can’t do a thing about, but I think again, lifestyle changes. 
You’re just accepting that you can’t live your life the way that you would 
like to. There are limitations and just try to make the best when you do have 
a good day. You get out there, smell the roses, breathe the fresh air. (Laurie) 
I wake up every morning and say OK, put one foot in front of the other 
and keep going. Regardless of how you feel, everybody has those days that 
you feel horrible, you know, the aches and pains, my skin hurts and my 
lungs hurt, but then you make up your mind: am I going to make it through 
this day or am I going be miserable all day? I have a job to do; I have kids. 
So, I can either let it overtake everything I am, or I can plow on and hope for 
the best and keep going and that is what I do…. It is just a decision. It’s just 
a decision that you make. Am I going to be miserable? I am not. (Stacee) 
A handful of patients also acknowledged that not putting their disease front and center in 
their lives in terms of a constant preoccupation has been helpful. 
Reducing fear. For some patients, learning about the disease took away the fear and 
the hopelessness; for others, finding out about patients who successfully have managed 
their illness, or seeing patients who were worse off than them but were pushing through, 
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provided the courage. Yet, for others having someone to talk to and vent out, and drawing 
on faith and spiritual beliefs calmed their nerves and allayed their anxieties.  
The early critical years demanded the most from patients in mediating the 
emotional and psychological burdens of the disease. Notwithstanding that, the 
psychological burdens, like fear of progression, continued to be ongoing for patients 
requiring their full engagement throughout the course of illness. See Appendix L, 
Table L5 for patients’ accounts on approaches to coping. 
Dealing with employment and financial impact. The most consequential impact 
of the disabilities experienced by these patients was their inability to perform at work. 
Employment had a significant meaning for patients, not only as a means to make a living, 
but also instrumental in having medical insurance coverage and affording auxiliary 
services (physical therapy, home assistance, etc.). They and/or their spouses needed to 
work as long as possible, delay retirement to maintain medical insurance coverage, or 
earn enough credits to qualify for social security. 
Giving up work also was tantamount to a loss in one form or another. Some 
indicated it was a loss of identity tied to professional or expected roles. For others, it was 
a loss of a passion—giving up something they loved to do and were good at. For yet 
another group who had reached high levels in their careers, it was a premature loss of 
achievement. For a younger patient who was planning to further her education in her 
chosen field, having to give up those plans and find a less demanding job that she could 
do was a loss of dreams and hopes. 
The interview participants dealt with job and ensuing financial impact by 
continuing to work; retiring, or going on sick leave or disability; receiving assistance 
from family, including spouses delaying retirement, or financial assistance; and becoming 
a discriminating medical consumer. 
Continue working. Remaining productive as long as they could, both for financial 
and insurance reasons, was the approach taken by seven (28%) interviewees who had 
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continued with full-time work, and one with a part-time job. A handful of patients felt 
that keeping active and working not only was necessary financially, but also helped them 
psychologically, even when it was against their doctors’ recommendation. In order to 
continue working full-time, a number of patients had to switch jobs, finding work they 
could do, often at a great economic cost. Others had managed to keep their positions by 
asking for accommodations. Some employers were sympathetic and accommodating, and 
some were not. 
I need to do a little bit more work because of social security—I’m four 
credits short of getting my social security benefits when I’m 65. I’m 62 now 
… that’s my big concern at the moment is trying to earn these credits. 
(Laurie) 
I actually changed jobs because … I could not handle the instruments 
anymore. So, I had to change jobs to do something that did not require such 
a fine tactile movement…. So, I got a job doing something in an office 
setting rather than the ________. You know it is easier. I am not doing what 
I am trained to do; it is way downscale and I took a humongous pay cut. 
(Stacee) 
I was in the [this] business so they are not very giving on giving you 
extra time away and it was high stress, long hours and very physical work. 
So that made it very difficult. So, I was also working with a company that 
was not very sympathetic at all. So, I told them about my situation and I tried 
to get some accommodations which they wouldn’t do and then I went out on 
medical leave and then they wouldn’t let me back. (Jenelle) 
Retiring, sick-leave, disability insurance. Among the remaining patients, eight 
(32%) retired, or stopped working before retirement age, and another eight (32%) went 
on disability and sick leave. Debilitating fatigue, pain, hand deformities, and impacted 
tactile and fine motor skills were major culprits for these patients. 
I felt like I was made out of wood and the pain was excruciating … the 
pain was constant.… I couldn’t sleep. I needed to [work], because my 
husband was a teacher just to afford my three kids…. I kept working as long 




Those patients who went on disability insurance described it as a very difficult decision 
and undertaking symbolically, and logistically. Logistically, they found the process 
complicated; symbolically, it was the acceptance of their disability. 
If you don’t put the right things down, you’ll get denied. You just need 
to be very descriptive … chronically ill patients don’t talk about it that much. 
They either over talk about it or they don’t talk about what they really go 
through, and that’s really what has to be on this form. (Jenelle) 
It just did not seem, you know, and when I think of somebody young 
who is on disability [insurance], I have a friend who has an MS and she is in 
a wheelchair; that to me makes sense. It was not the image of me that I had 
in my head. (Sandy) 
Accepting family assistance. Patients with a partner had to rely on their spouses to 
continue to work and maintain their medical insurance for the foreseeable future. Single, 
or younger patients faced more challenging circumstances: working until their symptoms 
deteriorated enough to be eligible for disability coverage, or pushing through to the 
retirement age of 65 were the only viable paths for them. These were the patients who 
expressed the greatest financial uncertainty looking forward. A few patients had to accept 
financial assistance from extended families. 
Becoming discriminating medical consumers. Given these financial difficulties, 
patients had to become more aware and discriminating medical consumers and had to 
decide how, where, and what medical treatments they would seek or agree to in order to 
manage costs. 
I had that discussion [with doctor]. I said, “Well, I don’t want to take it 
[Methotrexate] in pill form. I have enough GI problems and [my local 
hospital] doesn’t do the injections. I get to pay a fortune, go out of state.” So, 
we discussed it and decided no Methotrexate type treatment. (Lauren) 
Five patients (20%) saw doctors in SSc specialty centers more than 100 miles away 
from home, while three (12%) had to travel 25-50 miles to see one. For most, the closest 
centers were located out-of-state and were out-of-network. At least three patients had 
learned that by splitting the medical encounters—seeing the expert at the centers, but 
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doing lab work or procedures locally—they could be partially covered by insurance. 
Sometimes this had put patients in an awkward position of asking doctors for special 
accommodation, and to push back on insurance companies and hospitals’ bureaucracy.  
Dealing with the financial fallout of their disease was a grave burden and concern 
of all patients. It required mental energy, as well as vigilance to deal, manage, and plan, 
regardless of patients’ financial situations. Overall, the younger and single patients had 
the most financial issues and concerns, as they had to face the brunt of this impact earlier 
in their careers and without the safety net of another wage-earner in their households. See 
Appendix L, Table L6 for patients’ accounts on dealing with employment and financial 
impacts. 
Handling familial relationships. The interview data revealed the impact of this 
constantly present illness on family members in at least three distinct arenas: 
(a) financial, which has already been touched upon, such as the loss of income, and when 
spouses were impacted by having to delay retirement; (b) psychological and emotional 
reactions of the family members to the illness itself; and (c) the role family members took 
on in relation to the patients. 
The interview participants expressed the psychological/emotional impact of their 
illness on their family members as those of fear, worry, concern, denial, and disbelief. 
Many patients not only had to deal with their own emotional state, but also needed to find 
ways to ameliorate the fear of their loved ones. 
They were very scared. They were really scared, and my kids saw that I 
was pretty upset. So that was upsetting to them. I never said to them, 
“Mommy is going to die.” My husband didn’t know what to do.… I think he 
was very afraid, but we worked through it, but it was hard. It was hard. 
(Brenda) 
The levels of engagement of family members, including their levels of knowledge 
of disease, varied greatly. Some took the lead in researching the disease, interventions, 
and doctors, exceeding those of the patients themselves. Others made no attempt to know 
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or understand, perhaps due to their own fears. Some family members took on an active 
role in supporting and engaging with the needs of patients, while others were more 
oblivious and removed. A handful of patients mentioned coming from large families (>5) 
or having close extended families. These patients expressed the most positive views of 
perceived support. Conversely, there were a small number of patients who spoke of stress 
and a lack of familial support that went beyond obliviousness. This, according to many 
patients in the sample who attended support groups, was not unheard of and was quite 
common. In supportive families, the roles members took on included: 
•   Information gathering, therapeutic suggestion, and finding physicians 
•   Accompanying patient to doctors, tests, and infusion sessions, support group, 
and educational forums 
•   Mental/emotional support, including decision making and reality checks 
•   Help with tasks/housework/driving/preparing healthy meals 
•   Monitoring for symptoms and changes 
•   Financial help (from parents, grown children, or siblings) 
Patients spoke appreciatively of these supports as expressions of love and 
commitment, especially coming from their spouses, daughters, and extended families, 
using phrases such as “being lucky,” “blessed,” “wonderful family,” “amazing support,” 
“always being there.” This was intertwined with feelings of guilt and being a burden for 
at least four patients. The most salient sentiment, however, was that of a disconnection. 
The overwhelming majority of patients felt that their illness experience was theirs alone.  
My sister doesn’t [understand], for however much she wants to try, 
because it doesn’t make sense unless you’re experiencing it, or seeing it 
every day or have another chronic illness that other people don’t understand. 
(Jenelle) 
Not only strangers, but also closest loved ones could not have possibly comprehended it. 
Patients’ descriptions indicated that life had dramatically changed for them, while it stood 
at a standstill for their families. This disconnection had created murky waters in which 
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notions of expectation, support, limits and boundaries, and dependence and independence 
were all submerged. Kristeen captured the essence of this most vividly. Her articulation is 
extensively presented below because it so critically and candidly reveals the intricacies of 
the familial relationships when a chronic illness is present. 
I’ve come from a very big family and it’s tough and so when I say, “I 
really can’t do this because I’m hurting so bad today, I can’t do it.” They 
think, “Oh, you’re wimping out” but they don’t understand. They don’t 
understand what it’s like … they don’t get it. Really, unless you have it, you 
don’t get it. I think my husband—I’ve been with him for 30 years—he 
doesn’t get it … they don’t get that every single day, you have it. It’s not 
something that you have in three days and then it goes away and life goes 
back. Life never goes back. They have that saying where the patient goes to 
the doctor and the doctor finds out that you have a chronic illness and 
another patient says, “What kind of chronic illness is this?” And you say, 
“Well, it’s good news and bad news. Good news is you’re going to live, bad 
news is you’re going to live.” I don’t know how else to [describe it]—but it’s 
every day. It’s every single day and they don’t understand it. It’s like, “you 
couldn’t come last week, how about today?” No, I still can’t. It’s like, “Can 
you come and help me paint?” I still can’t. Even on a good day, I can’t hold 
the brush. I can’t. Even when you mean to do, you can’t get through it. They 
want to understand. They want to, but it’s—I don’t know … I feel sorry for 
caregivers. I do because on one hand, they don’t understand, but on the other 
hand, I don’t want your help unless I really need your help…. How can a 
family member help you? I can say, Well, they can listen to me when I’m 
sad, they can try and go with me to the doctor, take me for a test but when 
I’m trying to get a scoop of ice cream out and it’s hard, leave me alone for a 
minute. Let me at least try, because if you start taking it out of my hand, I’m 
going to let you but then I lose that ability to even try anymore. So, it’s a 
really a fine line and I feel bad for caregivers. I haven’t been nasty to 
anybody but I’ve tried to say, you have to let me try and do it. Even with 
trips with family, they’ll say, “Can you do it?” I’m going to try. I really don’t 
want to miss it. I have bad knees and it hurts, but yes, I don’t want to give it 
up so let me try. Let me try and if today, I don’t feel like going on to the 
beach, I can sit on the deck and watch everybody. It’s a fine line, I 
understand and it’s hard because they have a life, too, and they want you part 
of their life and sometimes you can, sometimes, you can’t. (Kristeen) 
Being in and out of family activities, as the pendulum of good days and bad days 
swung, upended routines, schedules, plans, expectations, and commitments. This inability 
to predicate how and when they could be involved with family and social circles was a 
clear stressor on patients. In addition, many patients struggled with family’s and 
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caregivers’ suggestions, interventions, and information overloads as these contrasted with 
their own ideas of expectations, needs, and support. Patients confronted these in different 
ways: 
•   Putting the efforts into informing and educating the family 
•   Keeping the stress level on family members low by not complaining, 
maintaining independence, and being self-reliant 
•   Accepting their own limits, and clarifying the boundaries and their responses to 
others’ demands 
•   Stating clearly their expectations, and guarding against assumptions of support 
•   Limiting how much information they were willing to receive from family and 
friends 
•   Planning ahead and resting so they had energy to participate in activities and to 
keep their commitments; making it clear that spontaneous participation was 
difficult and they needed ample notice to prepare 
•   Not committing to one-on-one activities, giving them a way out: a group 
activity could go on without them, if they needed to excuse themselves from it 
without causing too much disappointment 
•    Modifying their lifestyles in terms of becoming “choosy” in their social 
circles, not getting entangled in family problems, and in some cases cutting off 
from their families and/or friends altogether 
Many of the issues that patients and their families were facing were not 
fundamentally different in nature from those most families face. However, the levels of 
stress, physical limitations, and uncertainty due to illness accentuated them. Furthermore, 
the assumption that patients had the benefit of a supportive home environment did not 
hold across the board for these patients. See Appendix L, Table L7 for patients’ accounts 




The motivation of patients to engage with their illness through various types of 
work was related to their acceptance of disease, and commitment and resolve to take 
ownership of the illness, which temporally took different forms for patients. This 
commitment was sustained by hope, a will to live, and imagining a future. 
Commitment. Participants described the difficulties of accepting the diagnosis. 
The disease was so scary and beyond anything they had known that it simply could not be 
true. All the intensity of seeking a diagnosis in a short period of time became a force of 
resistance.  
When he first diagnosed me, I told him he was crazy because I said I 
have a friend that has SSc, I do not have what he has. That is not true. So, I 
stayed away for a while, suffered and finally called him back one day and 
said I am sorry I was upset and I need this taken care of. (Ralph) 
It really took me two or three years to really [accept]. “This is it. This is 
what I have.” (Maddison) 
Those early days and months, post-diagnosis, were characterized as being shell-shocked. 
Some clearly defined a period of withdrawal, lasting several years, to wrap their heads 
around what had happened, to accept it, and to decide to move on. For others, equally 
shell-shocked, the decision came much earlier, within weeks or a few months.  
One statistic was 50% die within three to five years so that terrified me 
and had stuck in my heart. So, I think I stuck there, kind of like out of life, 
for a couple of years- not weeks but years.... I cried all the time. I didn’t 
want to do anything. I was terrified I was going to die tomorrow in my sleep 
and it was just awful. (Kristeen) 
In order to attend to their failing-bodies, they needed to pull themselves up by the 
bootstraps and get on with the business of tending to their illness. This was described as a 
commitment or resolve to take ownership of and to engage with the predicament they 
found themselves in. 
You need to be able to say, ‘I want to survive this. What can I do to 
survive this?’ (Kurt) 
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I went through a period of time where I was like, “Poor me. Poor me.” I 
had to snap out of that…. Somewhere around four or five [years into illness], 
I started saying, “I got to start living this. I got to live with this disease. I got 
to figure that out. (Mackenzie) 
Each patient had a reasoning of his/her own for this commitment. Some attributed 
it to their personality traits and characteristic such as proactivity, pragmatism, feistiness, 
and optimism and positivity. 
It was difficult in the beginning and then I realized either I do something 
about it and succeed, or I crawl into a ball, go to a corner, wait to die…. I 
knew, almost from the beginning, I had to take [charge of] it. I knew from 
the beginning because that’s who I am. I am an A-type and I hate that 
expression but that’s what people think of me. I always did take charge. 
(Kurt) 
I’m sort of an optimist about taking control of myself. So, personality 
has a lot to say. I didn’t get scared by it. (Lauren) 
I am not a quitter. I have an aggressive personality and I think that 
serves me well to some degree. I do not mean aggressive in a bad way—I am 
not afraid; I am not a scary cat. I think that serves me well because it would 
be very easy to sit in a corner and cry. Because it is weird; it is just weird. 
(Stacee) 
Other reasons included having children and families; the realization that life went on and 
their death was not immanent; the possibility that prognosis would not be as grave; 
stabilization of disease for some, and the worsening of symptoms for others; and the 
realization that confronting the disease was solely up to them. This perspective was 
expressed by three patients who believed no one would or could rescue them—not family 
or friend, nor medical professionals or pharmaceuticals.  
I just started to realize I was the only one. Nobody was going to come 
and save me from this. Nobody was going to figure out anything for me. I 
had to do it myself and I had to take responsibility. I’m not responsible for 
the disease but—Yeah, nobody was going to figure it out. I would have 
loved if they did and just told me what to do, but— (Kristeen) 
People expect the doctors to cure them. They expect the pharmaceuticals 
to come out with a magic capsule that will make their entire life better. Life 
doesn’t work that way … unlike most people, I don’t believe they’re going 
to find a cure in my lifetime.... (Kurt) 
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Medically, there could have been other contributing factors on how quickly 
patients needed or were compelled to take charge of their situations. Unlike the patients 
with a slower progression of disease, those with a rapid deterioration subsequent to initial 
symptoms had to race against time in terms of finding effective treatments to halt the 
progression of the disease. According to one study (Domsic, Lucas & Medsger, 2010), 
over 90% of organ involvements, in particular gastrointestinal, lung, heart, and kidney, 
experienced within the first 5 years of disease (as opposed to those that occur much later) 
occur during the first 2 years. Eleven participants (44%) reported this type of experience. 
Among these, five patients had rapid decreases in their lung functions, two patients faced 
heart issues, another was subject to a speedy and painful skin hardening, and the rest 
dealt with a combination of symptoms occurring in rapid succession. 
Thus, temporally, the experience of the disease placed the patients in two different 
camps. For 13 patients, the disease experience was characterized by a more drawn out 
phenomenon: being diagnosed with a serious and uncertain illness, some medical 
interventions, and a gradual involvement of organs overtime. On the other hand, about 12 
patients described a rapid onset of new symptoms within the first 2-3 years of the disease, 
needed to find SSc experts, had to make decisions on aggressive medical interventions 
such as chemotherapy, had to weigh experimental or unconventional treatments as 
options, saw more doctors to consult with, were subjected to more frequent procedures 
(CT scans, echocardiograms, right heart cauterization, pulmonary function tests, etc.) to 
check the status of their various organs, and overall had a greater sense of urgency. These 
differences might have been the other contributing factors propelling patients to take a 
position on how quickly they would engage with their illness. See Appendix L, Table L8 
for patients’ accounts on temporal dimensions of making a commitment. 
Sustaining this commitment was predicated on hope, finding a will to live, and 
imagining the future. 
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Hope. A few patients attributed their religious and spiritual beliefs as the source of 
hope; others to possibility of effective treatments and a cure happening soon. Most 
interview -participants described hope as given by their doctors’ assurance and 
explanations. 
“Yes, you have this and we can treat the symptoms. There’s really no 
one medication to take for the whole thing so we’re going to give you a great 
team. The team is going to work with you and we’re going to address the 
symptoms as they come up….” [He] was always there for whenever I needed 
him. (Winola) 
He wrote down so much and he asked so many questions and he did 
explain a lot to me, “Right now, you’re alright. You’re going to progress and 
we’re going to try and start things but for the moment, you’re okay.” And I 
think it helped me to hear somebody tell me that. (Kristeen) 
My current doctor, when I ask her about it [prognosis], she just gives me 
a hug and says, “I’m going to keep you alive until you’re in your 90s.” 
(Lauren) 
A will to live. The sustaining power to continue their commitment to illness was 
illustrated by the way participants looked for reasons to live. Having children that they 
needed to care and live for continued to be one of the most powerful reasons for 
interview participants. Being there for their children and seeing them grow up weighed 
heavily on patients, as 76% (19) of interview participants were parents. The ages of their 
children at the time of their diagnoses ranged from 4 years old to the early 20s. 
My priority was my two children and how this is going to affect their 
lives. (Brenda) 
My kids are the reason I keep going, pretty much, because I love my 
kids. (Stacee) 
Obligations to spouses and parents, and entertaining possibilities for a cure, 
remission, or arresting the progression of disease kept many participants going. The 
prospect of a shortened life was another impetus to live fully in the time they had. 
Patients tended to present “not dying,” “cure and remission,” and concerns about children 
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in their descriptions of earlier years with the disease. When speaking in later years, 
expressions of “slowing the progression” and “living their lives” were more prominent. 
I am not going to make myself crazy. There are too many other things in 
my life: we’ve got __ children and 8 grandchildren and we are very involved 
in our church and I need my energy for that. (Ralph) 
I have a job to do; I have kids. So, I can either let it overtake everything 
I am, or I can plow on and hope for the best and keep going and that is what 
I do. (Stacee) 
Make my money and then do what I like to do in life because I might 
not have a lot of time to do that. I might, I might not. You never know. I just 
do stuff even though it is a work night, I do not care. (Patricia) 
I’m looking for to be in remission again. (Vanessa) 
Imagining a future. The most difficult part of sustaining a commitment was the 
ambiguity and uncertainty surrounding the course of illness, and the interview-
participants’ expressed inability to visualize how the disease will progress and what lies 
ahead—in short, imagining a future. 
[The hardest part is] not knowing what to expect, what is going to 
happen next, what is going to be taken from you as a person. (Vanessa) 
I was told it could go two ways, limited or diffused.… She [Dr.] told me 
it might be years before I would be able to, probably know where it was 
going. One or two years later, she said, “I think it’s going to stay limited.” 
(Mackenzie) 
I relied on the doctors, but I did go to three different doctors … just to 
confirm if this [diagnosis] was true and my long-term prognosis was pretty 
uncertain. (Bryce) 
I do a lot but I’m not out of the woods. You’re never really cured from it 
and damage that it’s done doesn’t go away ... but you just never know what’s 
around the corner. (Rene) 
A number of participants had arrived at a point where they had accepted uncertainty as a 
feature of disease and had tried to live with it, in spite of the unease they felt. Others tried 
to learn as much as they could about the disease and other patients to help them chart a 
possible course for their illness. 
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Well, what are you going to do about it? You’re going to sit there, 
you’re going to take it and you’re going to live with it and you’re going to 
learn to deal with it. You sit like crying over spilled milk? Lighten up and 
move on…. It wasn’t my attitude in the first month. I can honestly say that. I 
had a very negative attitude the first month but then after that, I just learned 
when I started researching it more and finding people who are living longer 
with it then I had a very positive attitude and I still have a very positive 
attitude about this. (Winola) 
Strategies 
In order to cull the data on what strategies patients employed, a general definition 
of strategy as a guide to action was adopted. The following general strategies were 
identified: taking on a problem-solving/problem-avoidance orientation, utilizing 
resources and advocating for themselves, being transactional in evaluating care, being 
open to experimentation. 
Taking on a problem-avoidance/problem-solving orientation. A main strategy 
for many patients was a focus on problem solving and problem avoidance. Problems 
might have occurred in encounters to obtain care, brought about due to their disabilities, 
or manifested in social situations. This strategy included anticipating problems, thinking 
creatively, being persistent, and treating difficulties as challenges that needed reframing 
or a work-around: 
This does not work anymore, what do I have to do to make it work. It is 
just re-prioritizing, re-evaluating. I have not changed my priorities. I just 
changed the way I do things. Change the way you look at things. (Stacee) 
Interview participants used a problem-avoidance strategy in dealing with the 
healthcare system by anticipating what problems might occur during their doctor’s visits, 
such as previous records and lab results not being available to doctors, making their visits 
wasteful. Many patients spoke of unknowledgeable emergency room doctors and nurses, 
and how they had to preemptively be prepared for that. Practically all patients (80%) kept 
a medical file of lab reports and health records that they would carry along to their visits 
with doctors and hospitals. 
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I have found that having my own records is the best thing because if you 
go to a doctor and they, for some reason, they didn’t get your lab results or 
test results then sometimes, your whole visit is in vain. (Rene) 
Anticipating problems with their energy levels, access to medications, and 
difficulties outside of home were other areas in which patients showed watchfulness. For 
example, a strategy to deal with limited energy levels was to partition their days into 
good or bad days, which dictated how they regulated their activities. Those with a more 
sever fatigue used the spoon theory to allocate energy within a given day. Spoon theory 
quantifies the amount of energy a person has as the number of spoons that can be used in 
a given day, forcing patients to pace themselves and put a limit on what they planned to 
do. This strategy, in particular, minimized their withdrawals from family and social 
events and assured that they could take on more arduous tasks. 
Utilizing resources and advocating for themselves. Utilizing resources and 
harnessing the power of others to get what they needed was a strategy that was especially 
helpful to patients in navigating the healthcare system and other systemic bureaucracies. 
My insurance, there is a program connected with Blue Cross/Blue 
Shield called health advocate. I love it.… I called the university medical 
referral and they have kids there who just look at a book and give you the 
names of doctors and I wasn’t successful in finding a doctor then; they give 
you names but that’s all. Then you call the office, “We’re no longer taking 
new patients.” So anyway, this health advocate—…They gave me the names 
of three doctors and they said, “All three of them are taking new patients. 
Here are their names, their numbers. Call them and interview them.” And I 
did. (Marcia) 
Being transactional and evaluative in obtaining care. By taking on a 
transactional posture and considering metrics such as harm, benefit, futility, trade-off, 
positive return, cost, reliability, trustworthiness, availability, convenience, and personal 
preferences, patients were able to check the value propositions of choices in front of 
them. As such, they expected their doctors’ recommendations to produce results and 
reduce their symptoms; the tests and procedures they were subjected to have an 
actionable objective; for the side effects to not outweigh benefits; and the medical care 
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provided to them to meet certain cost, quality, convenience, and preference criteria. If 
they did not, patients would not assent to doing them. 
If I do not feel any positive return from anything that my doctor is 
doing, then, something is not right. (Sandy) 
[The test] is uncomfortable and then if they found out there is a problem 
what were they going to do about it? Could they do anything about it? No, 
not really. So, I did not do it. (Pricilla) 
My rheumatologist, I asked him, “Well, what’s the side effect?” And 
he’ll tell me and I’ll say, “I don’t want to do that yet” (Sharyl) 
Five patients (20%) saw doctors in SSc specialty centers more than 100 miles away 
from home, while three (12%) had to travel 25-50 miles to see one. For most, the closest 
centers were located out-of-state and were out-of-network. At least three patients had 
learned that by splitting the medical encounters—seeing the expert at the centers, but 
doing lab work or procedures locally—they could be partially covered by insurance. All 
patients, when asked if they evaluated the care they received, answered empathically yes, 
and proceeded to provide other examples. The criteria that many patients had developed 
to evaluate the quality of their doctors was one example. In addition, interview 
participants showed a high level of vigilance monitoring their doctors and were aware of 
factors such as preoccupation with research and travel to conferences, busy practices or 
family lives, retirement mode, or suboptimal office staffs and were ready to react either 
by expressing dismay or looking for another doctor. 
I did switch up from a very good primary to another primary. I finally 
found one that I liked a lot and the only reason I left the other primary is I 
had had him for so many years and I saw a change. He was in retirement 
mode in his focus and I knew I had to get a new, young doctor. (Lauren) 
I said I had some questions and I pull out my list…. She did take the 
sheet and look at it. She glanced and saw the amount of writing that was on 
it [half a page] and she said something about doctors are limited in the 
amount of time that they’re supposed to spend on you depending on 
whatever the insurance company pays or whatever and she said something 
about my time was up, and I should ask her the most important question. I 
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said, “They’re all important.” Anyway, I saw another doctor. I got another 
doctor. It wasn’t just that one incident. (Marcia) 
Being open to experimentation. Many patients expressed that they did not feel 
they had any control over the disease itself, but could control what they engage with. 
Patients viewed experimentation as an option wholly within their powers. They were 
acutely aware that little was known about the disease, making any treatment 
experimental, including the conventional medications they were given.  
To some extent, I mean, I’ve recognized that putting me on medication 
is not necessarily going to be the answer, because it’s trial and error and I 
recognize that. (Marcia) 
All patients claimed they were compliant with medications, meaning they followed 
doctors’ directions in determining the efficacy of prescribed drugs. At the same time, 
some patients would experiment with dosages of medications that they felt they had some 
leeway with, such as gastro-intestinal or pain medications. 
A lot of these medicines for stomach, I take them and I wait a couple of 
days and see how I feel about it. My stomach is easier to find out, if it is 
working or not, because I kind of know how I felt the day before and the day 
after. So, what I have done with these medicine, especially the stomach 
medicines, if I see a difference with me, I stop it for one day or two days, 
and if I am feeling better, I take it the next day—if something is wrong then I 
kind of come to the conclusion that it is the medicine. (Francis) 
Almost a third of patients, 7 (28%), have participated in nine clinical trials, and 3 
patients had actively pursued trials without success, due to strict inclusion criteria or a 
lack of insurance coverage through which some of the cost could be covered. 
He had tried the Remodulin on me. It just became a pump … I was the 
first one to get it and it was experimental and I said, “I’ll try it if it helps, if 
it’s going to help other people.” (Winola) 
As to experimenting with complementary and unconventional approaches, 18 
(72%) patients spoke of a range of treatments they have experimented with, including 
acupuncture, occupational and physical therapy, chiropractic medicine, massage therapy, 
yoga, meditation, nutritional approaches, high dose vitamin therapy, hot paraffin, stone 
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therapy, Reiki, collagen injection, hot tub, holistic medicine, herbal medicine, 
homeopathic, and Minocycline therapy (a controversial therapy not embraced by 
mainstream medicine). Acupuncture, yoga, and massage therapy were the top three 
choices, followed by nutritional and physical therapy. The main reasons for discontinuing 
were cost and ineligibility for insurance coverage.  
A third of the patients, 7 (28%), who were wary of alternative therapies and have 
never tried them, perceived the practices as having elements of “quackery” and “voodoo 
witch,” not research-driven, risky, or ineffective. On the other hand, the patients 
experimenting with alternative therapies believed therapies were not harmful and might 
have been helpful to varying degrees. Those who have done yoga or nutritional therapy 
were most enthusiastic about the efficacy of these interventions and a belief that they saw 
a difference. The sole patient who had done Minocycline therapy firmly believed it was 
the only intervention that worked in her case. Conversely, patients were less enthusiastic 
about results from some other choices, like Reiki and acupuncture. Acupuncture, in 
particular, did not work for many patients due to their skin hardening. 
One concern that patients repeatedly voiced was their aversion to taking 
medications and their desire to minimize the amounts they were prescribed. The 
willingness to experiment outside traditional Western medicine had availed some patients 
with relief from a purely pharmaceutical approach, an alternative to ineffective 
medications, and a sense of doing something natural for their bodies.  
If you do not want to do big pharmaceutical stuff because it makes you 
sick, what else can you do? I do chiropractic, which I was on meds for 
headaches that really did not do anything and I do not take it anymore, 
because I do not need them, I have my chiropractor. It works. (Patricia) 
Overall, when patients spoke of experimentation, their efforts were directed at 
medications, nutrition, exercise, and other lifestyle changes. These were the areas that 
patients had the most control over. Differentiating the controllable from uncontrollable, 
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patients were open to investigate alternative and potentially helpful ideas, wherever they 
could find them. See Appendix L, Table L9 for patients’ accounts on strategy. 
Learning 
Irrespective of the diagnostic path taken and the initial responses they got from 
doctors, once patients were diagnosed, they all arrived at the same spot, facing the reality 
of having a disease they had not heard of, an unknown. 
I went in and the doctor really said, “I think you have SSc.” And I said, 
“Okay,” because I had no idea what it was. (Nicole) 
Twenty-two (88%) patients had never heard of the disease. They had been handed 
an unfamiliar word—scleroderma—and they had to figure out how to make sense of the 
unknown, what it was, and more importantly what to do about it. 
In the beginning, it’s an unknown and you’re constantly searching and 
reading and looking and wondering and anything and everything, more 
doctors, more people [to talk to].… My first thought was I had to learn as 
much as I could when I knew that’s what I had. (Brittany) 
Patients, by and large, did not grasp the gravity of such a diagnosis until later when 
they were able to research it on their own. With no prior knowledge of disease and the 
limited experience with chronic diseases of any kind, most patients wanted as much 
information as they could find. These information-gathering activities were their first 
foray into learning. The key areas of learning in interview participants are detailed in this 
section. 
Informally. In their first attempts to gather as much information as possible, 
patients spoke of utilizing a variety of resources from the Internet in the more recent past, 
going to libraries, and seeking answers from social workers, nurses, or family or friends 
in the medical field. Some read brochures they were given, academic papers, and medical 
journals, and wrote to research scientists. Others contacted random SSc patients, miles 
away, that somebody who knew somebody had put them in touch with. A few reached 
out to various support groups (SSc Federation, SSc Foundation, Road Back Foundation, 
  
157 
Pulmonary Fibrosis Foundation), a handful went to educational gatherings, and some 
tried to learn by going from doctor to doctor. Regardless, most found more questions than 
answers, confusion, uncertainty, and fright in these efforts. 
Well, of course the first thing they say is don’t go on the Internet and 
that was the first thing I did. That night, I went and I looked it up on the 
internet and I started reading where it says the life expectancy and so on with 
SSc is only five years and then I started crying and I had to have my husband 
finish reading it…. The first initial reaction was I was going to die. (Winola 
When I was reading about SSc, I thought, “No way. I’m not even going 
to read about this.” It was scary. (Brittany) 
Two patients took the advice of their doctors and stayed away from the Internet and 
support groups altogether, leaving information gathering to other family members or 
none at all. For some, the search was empowering, never-ending, and became an ongoing 
feature of their lives. For a handful, it subsided after learning the basics, or as one patient 
put it, “I really believed I was living it. I didn’t need to read about it.” For a third group, 
the initial stages of search for information plagued them with debilitating emotions 
forcing them to pause; their search for information resumed once their symptoms became 
more stable. Thus, each group curated their informational needs in a particular way. The 
initial search for the most part was not informative and was the cause of panic and 
confusion. Over the course of the illness, the character of these searches, sources, and 
learning would change, best described as curating information.  
The word “curate” is used here to highlight the patients’ discriminating nature of 
information seeking, carefully managing and/or limiting the amount, type, or the sources 
of information. After the traumatic experience of going to the Internet, subsequent to 
their diagnosis and being flooded with statistics and tales that were difficult to sort 
through, patients became more discriminating about how they accessed information and 
how they got what they needed without getting overwhelmed. Having multiple sources of 
information was how most patients approached this task.  
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I speak to other people. I see what other people go through. I look at 
myself, what I have or have not gone through, and what I’m able to research. 
(Kurt) 
I would talk to [technicians], for example, during the pulmonary 
function tests; “Do other people have challenges with this one? Is this as 
hard for most patients as this one?” Just to try and find out how I stood 
compared to some other people. (Jenelle) 
There were four main sources of information for patients: (a) their doctors, nurses, nurse 
advocates at insurance companies, technicians, social workers, and researchers in the 
field; (b) websites, publications, patient brochures, conferences and educational forums 
of organizations such as the Scleroderma Foundation, Pulmonary Fibrosis Foundation, 
and well-known research institutions like the Mayo Clinic, the Cleveland Clinic, the 
National Health Institute, Johns Hopkins Medicine, and PubMed; (c) other patients, 
known either through participation in support groups or otherwise; (d) certain documents 
such as their lab reports and doctors’ notes. 
These sources not only allowed for triangulation of data, but satisfied disparate 
informational needs: from medical professionals and their medical records, they would 
get individualized and personally specific data, as well as hints of where they might fit 
relative to the other patients seen by the same doctors and technicians. From websites and 
organizations, they would obtain general knowledge, the latest research news, and reports 
of advances in the field. Other patients served as good informants for how the disease 
might progress, how it was managed, which doctors they saw and their opinions of them, 
tips on helpful gadgets, and experiences with taking medications and applying for 
disabilities.  
The majority of patients reported getting their lab reports and doctors’ notes; some 
had set up elaborate filing systems. By asking their doctors for explanations or looking up 
online, many had learned to read and understand these reports and would follow the 
trends and changes closely. 
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Interview participants provided different rationales for their information-seeking. 
Many equated having information with having knowledge as a means to: 
•   Understand what disease they had and what could be done about it 
•   Overcome their fears and feel in control 
•   Be a “good” patient and better manage their disease, especially as to 
medications’ side-effects 
•   Make informed decisions and negotiate treatments with doctors 
•   Face reality and prepare for what will be coming 
•   Keep tabs on their progression and monitor their health status 
•   Keep tabs on the quality of care they were getting and catch oversights 
•   Be aware of new research, medications, and trials for which they might qualify 
•   Be prepared when facing new doctors or emergencies to educate doctors and 
nurses 
•   Distinguish between changes that are SSc-related and those due to other causes 
These were summed in patients’ statements below that suggested that information 
seeking in part was to compensate for the inadequacy of a healthcare system that made 
dealing with this disease daunting: 
To me, information is power. Knowledge is power and I feel, as a 
patient, the more knowledge I can have, the better I feel about it and dealing 
with the disease. I think if you just go to the doctor, you’re given your pills, 
you take your pills and that’s the end of it, and life could be quite daunting 
having a disease like this … as I said, it’s up to the patient to really educate 
themselves and knowledge is power and it takes away the fear. (Laurie) 
And I think, over time, you hear about the mistakes and you experience 
the mistakes and then you say, “You know, I need to educate myself.” So, 
when I’m entering to this [situation], I know what I’m talking about, what I 
want the outcome to be, and how we got to get there. (Kristeen) 
Knowledge was a way to take some control over some aspect of their disease. At 
least one patient considered being knowledgeable an effective strategy in dealing with 
doctors, as she could speak their language.  
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Patients with vital internal organs affected or those at earlier stages of disease 
tended to utilize all or most of the resources above and expressed more vigilance and 
determination in keeping up with the advances and latest information in the field. 
I do research on the Internet. I read a lot of SSc research. I read medical 
journals and I talk to informed patients, which is very different than talking 
to—not all patients are informed. So, I make sure to talk to other patients 
that read research and might know something different than I do…. I’m 
online all the time looking for new treatments and touching base with 
doctors that either I’ve worked with in the past who have been my 
physicians in the past or doctors I worked with through the foundation that 
I’m still in touch with to see what research they’re doing that may be 
information that hasn’t been published, but anecdotal information they might 
have found. I have a little Google alert. Anytime SSc is in the news that day 
that comes to me. (Jenelle) 
Patients with a limited form of the disease or those who had the disease for a long 
time and were stable were more content with information their doctors provided at visits 
and less watchful for new developments; they considered it their doctors’ job to be on the 
lookout, and a few admitted that one becomes complacent overtime.  
Six patients (24%) indicated that they intentionally did not seek any information or 
limited what they read. In particular, they did not want to read the grim news and 
believed they were in good hands with trusted doctors. Some had other family members 
who had taken on the task. Having these watchful eyes has relieved the patients from the 
burden of keeping informed. Not wanting to project into the future and having a constant 
reminder of the disease were the most stated reasons for these patients: 
My husband filled a binder with stuff he printed for me to read, and I 
would never read it. I did get a couple of pamphlets about SSc form the 
doctor.… So, I had enough to know what is there and what it was but I did 
not want to read everybody’s story. (Nicole) 
No, I really don’t. I don’t get online a lot. Everything I read, sometimes, 
I find it’s worse to read it. I just don’t want to project into the future. 
(Mackenzie) 
Concerned about the traumatizing impact and relevancy of online information, 
doctors and patient organizations warned patients about indiscriminate Internet searches. 
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This had an impact on how some patients sought information, restricting themselves to 
websites sanctioned by the medical establishments and written for patients by 
professionals. 
Dr. ____’s first words to me were, “Stay off the Internet because what 
you read there, you’ll only hear the bad things.” So, I never once looked. 
(Nicole) 
[Using] Internet mainly, but very carefully. I was warned not to read 
everything. I was guided by the rheumatologist, and I was guided by him and 
her team. He had a wonderful, wonderful assistant who would give me links 
and then I would attend patient information days on a regular basis, which I 
found very, very helpful. (Laurie) 
A number of patients had access to both patient materials and academic technical 
journals, or to researchers in the field who were willing to communicate with them. The 
latter was not looked upon favorably for one patient: 
I wrote letters to different research scientists, because I was not getting 
anything from my doctors … and one day I went into his office and I started 
asking him about different things and he said, “How is it that you know 
about these things?” I said because I am interested in my own well-being and 
I did research on it. He said, “Well that is not for public consumption.” 
(Stacee) 
Contrary to this assumption of a lack of discernment on the part of patients in 
dealing with medical information, the majority of patients exhibited an awareness of the 
need to be discriminating about, contextualizing the information they were getting, and 
evaluating the trustworthiness of websites. 
Socially. The 13 (52%) interview participants who were involved with support 
groups, and the 4 (16%) who previously participated in some form described learning 
through and with other patients in these encounters. These learnings included exchanges 
of information on interventions and doctors. Recommendations on doctors and medical 
facilities from other patients themselves were considered valuable first-hand information. 
Other areas of vicarious learning from experiences of other patients were related to 
description of symptoms, progression, and reaction to medications. Obtaining practical 
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tips and solutions to deal with disabilities, including applying for disability insurance and 
helpful gadgets and apparel and where to shop for these, were other areas. Most 
importantly, through observing others, patients could learn where they might fit in the 
spectrum of disease. This learning occurred not only in support groups but also 
educational forums where patients could come in contact with other patients.  
Although not part of this study, a number of patients mentioned their learning 
through online exchanges. The Scleroderma Foundation’s portal was the primary site for 
patients to learn from each other. These online exchanges largely consisted of educating 
new patients by recommending doctors, discussing medications and nutrition, and giving 
and receiving hope and encouragement.  
Formally. Two major sources of formal education for patients were expert talks 
provided in support groups and various formal educational forums and national 
conferences with specific topics and programs. During the initial years of illness, when 
patients’ knowledge was limited and most subjects were of interest, these venues for 
learning were often attended. Many activities described by support group leaders could 
be characterized as problem anticipation and avoidance training. For example, patients 
learned about spoon theory and how to keep medical records in support groups. Patients’ 
awareness and uptake of a problem-avoidance/problem-solving orientation might be 
partially attributed to the formal learning in support groups. 
As patients’ level of general knowledge increased and their intentional learning 
took on a more focused approach, patients reported that these venues ceased to meet their 
needs and became repetitive or “pedantic.” For a number of interview participants, 
exposure to formal programs about the progression of disease, immediately after their 
diagnosis and before they had gained a footing, was traumatic and scared them away. 
These mismatches alluded to difficulties in providing formal learning programs for such a 
diverse patient population.  
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Experientially. For the most part, the interview participants learned experientially 
and incidentally. When asked about their learning, the majority would point to their 
information-gathering activities and formal learning, unaware of any incidental learning. 
However, in specific examples, they referenced experiences in which they had learned 
through trial-and-error, after facing upsetting mishaps, or facing limits imposed on them 
by bureaucratic systems These experiences had mostly to do with interactions with the 
healthcare system and dealing with disabilities, and seem to have given rise to the 
problem-solving and anticipation, and advocacy strategies that were covered under the 
Strategies section. Experiences through mishaps such as medical tests and procedures 
falling through the cracks, and dealing with inexperienced healthcare providers and staff 
were especially poignant.  
I had to learn it and I learned it the hard way by what didn’t work. So 
now, it’s 15 years in, I know…. I learned through seeing poor doctors … 
they had no idea what to do with me. And I know for those two years, I 
wasn’t getting the care that I needed. (Jenelle) 
I’ve learned, too, over the years that if they can’t get it [draw blood] on 
the first two tries, I have them get somebody else to draw the blood. 
(Winola) 
When you leave the doctor’s office, they give you this nice printout with 
all of this information on it. You’re finished with the doctor so you can’t ask 
any questions about it. So now, I started—the next doctor I see, the form that 
the previous doctor gave me, I’ll ask, “Explain this to me. What does this 
mean?” (Marcia) 
These experiences led to patients learning to advocate for their needs. Maddison, 
who had a pacemaker that was not working right, could not make any headway with her 
electrophysiologist and had to resign herself to “it’s as good as it is going to be, so let’s 
just leave it at that.” Talking to the doctor’s nurse, she found out “sometimes, the 
technician knows more about the device itself than the doctor.” Through a technician, she 
got the device adjusted. Learning from this experience, she got her SSc specialist to 
assign an intern to research pacemakers, “so when mine is due for the new battery in a 
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couple of years, he’s going to have a list of pacemakers to suggest to my 
electrophysiologist.” 
Learning from prior experiences unrelated to their illness was also instrumental in 
voicing their needs. Advocacy came easier to a handful of patients whose occupational 
skills transferred well for this purpose. 
Navigating the healthcare system—I guess I just know what to do, 
because of my work probably…. I know how to get people to help me if I 
need help like getting to and from endoscopy or getting information I know 
how – where to call, who reach out to. (Willa) 
I’m a [a client advocacy type of work], and I think I know how to 
advocate for myself or at least research and go and look for things, go to find 
me a decent doctor. I have no problem asking people … I just pick up the 
phone or I just advocate for—I’ll just do what I have to do. I think it’s 
because I have a good handle on what’s going on with the healthcare system 
now. (Mackenzie) 
Other patients expressed having learned from advocating for their children, and maturing 
and aging, in general, as helpful experiences. 
Another area where patients’ everyday experiences led to learning was in dealing 
with their disabilities and in trying to make their daily lives easier. Patients, in aggregate, 
had accumulated a host of knowledge in practical solutions, some of which were listed 
under problem-solving strategies.  
Somatically. A majority of patients characterized scleroderma as an illness with a 
unique combination of symptoms, a varying susceptibility to treatments, and differing 
from patient to patient. Thus, patients saw themselves as unique. 
Because our diseases have the same name does not mean it is the same 
disease. (Stacee) 
I do not have the skin issue but have a lot of the other symptoms. Most 
of the people when I went to the support group they had skin issues. They 
would not understand joint.… I think that is what makes me unique, you just 




I have different pain than anybody I’ve ever spoken to, and then right 
now, I’m having GI and lung issues that is different from what some other 
people I’ve talked to have experienced, but it’s nothing unusual. But to have 
the certain combination is weird and not to have— … I think the challenge 
with this disease is that it hits every single person differently. Nobody has 
the same symptoms. (Jenelle) 
Patients not only reported on the specific set of symptoms afflicting them, but also the 
changes (additions, reduction) of symptoms during the course of the disease, and waxes 
and wanes in shorter intervals, known as flares, making for a dynamic phenomenon. 
Given the perception of a unique and individualized illness, and the experience of a 
dynamically changing disease, many patients exhibited a high degree of somatic 
knowledge and a focused attention on their bodies as unique and different from those of 
other patients. In short, they “individualized” it. 
You need to individualize it, because our disease manifests individually 
in each person. (Kurt) 
I think this disease is really an individual disease and that it affects 
individuals very differently. (Maddison) 
Many, in particular, patients who were athletes prior to their illness, claimed they were 
always body-aware. One third of patients used the phrase “I know my body” in their 
interviews.  
I know my body and know what’s normal and what’s not normal and 
even with all the craziness that goes on, you know what isn’t right. (Jenelle) 
I’m a very attentive and intuitive for my own changes in my body and 
that’s a huge thing to recognize.… I probably do that too much. I do pay 
attention. The biggest thing for me is seeing how far I can stretch 
(physically) because that’s telling me whether I’m losing ground or not. 
(Lauren) 
Many patients knew that the onset of a flare-up (exasperation of symptoms), the 
sequence of symptoms occurring, could differentiate between pain and ache, or fatigue 
and being tired, but were not readily able to verbalize how. These were conveyed through 
imagery such as: flare-ups occurring like a cascade; the intensity of pain forcing one into 
a fetal position for days; being made out of wood; feeling my body is angry; and every 
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molecule of your body being tired. Sandy, being aware of her inability to express her 
somatic perception of fatigue, put it this way:  
I do not necessarily describe it [fatigue] in the medical format but as far 
as feeling: I was walking through the door and somebody smash my whole 
body, just overwhelming you are tired from inside out.…  I think that for me 
it is the biggest indicator [of disease], because like my body is not tired like 
oh I had a crazy day I am really beat. It is like a tired from full encompassing 
like your every molecule of your body. (Sandy) 
To some degree or another, all patients, through inexplicable internal mechanisms, 
or external observations and instruments, were gauging the changes in their bodies. Skin 
alterations entailed significant physical changes for many patients. These changes were 
visibly and tangibly available for examination in a more direct manner. Other variations, 
like changes in breathing or fatigue, were measured indirectly. Many had developed 
assessment methodologies, including using instruments such as blood pressure monitors, 
oximeters (oxygen saturation monitors), wearable health gadgets; taking pictures of skin 
changes overtime for comparison; tactile feel of their skin for degree of softness; using 
walks and exercises to appraise stamina and energy levels; and quantifying the amount of 
pain, skin discolorations, and extent of body stretch. Patients were particularly sensitive 
in regard to their breathing, using exercise and climbing stairs and general exertion as 
tools to detect changes. 
If you get winded and you exercise regularly, then there might be an 
issue with your lungs. But if you do not exercise regularly and you get 
winded you get confused whether it is being out of shape or it is PAH…. So 
that way I could distinguish. (Willa) 
Another marker was the quality of fatigue. Patients could make a qualitative 
distinction between fatigue from the illness and tiredness due to overexerting. Physical 
responses to medications, from Advil to chemo, were used to gauge the state of bodies. 
Those who fluctuated between flare-ups and periods of calm used the contrast between 
the two phases and how their bodies felt ramping up to a flare as a rubric.  
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A few patients expressed that they were bodily-aware even before their illness, but 
the majority attributed their somatic focus to the illness itself. Through body monitoring, 
they had learned and developed a niche expertise, based on which they could monitor the 
progression of the disease, determine the efficacy of medications, check against errors 
and mishaps with their medical care, and advocate for themselves when faced with 
unknowledgeable healthcare workers. 
I think he [Dr.] was on vacation as well, but I went to the emergency 
room. They didn’t help me at all, and because I know my body, I know 
what’s going on and I know what helps with the pain and they just looked at 
me like, “Oh, someone is here for just pain meds or something.” (Winola) 
Being attuned to their bodies and learning somatically, in addition to comparing 
themselves to other patients, were the mechanisms with which they individualize their 
illness.  
Learning informally, formally, socially, experientially, and somatically, patients 
made sense of their illness and developed high levels of knowledge and expertise. 
Empowered by their own knowledge, at least ten patients alluded to a possible shift in 
how they have come to view the nature of received knowledge. 
I think at the beginning, I just believed whatever they told me.... I don’t 
know when it just started to change, but I began to realize they get up in the 
morning and just like me every day and they may have gone to school for 
something but they don’t know everything and I’m living it—so maybe I 
know, too. (Kristeen) 
In addition, many patients became purveyors of information to other patients, 
friends, relatives, and medical professionals. The kind of expertise a number of patients 
had developed was in the area of tests and procedures, assessment of severity, and an 
ability to recognize undiagnosed individuals based on visible symptoms. Patients also 
reported educating emergency room doctors and medical students. Emergency rooms and 
unexpected hospital visits were particularly problematic for these patients, as healthcare 
professionals dealing with acute diseases and accidents were reported to be among the 
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least informed about SSc. All patients who had such a visit considered the experience 
painful and identified the occasion as an instant when they had to educate the doctors. In 
addition, their own rheumatologists at teaching hospitals had asked a number of patients 
to speak to, or be examined by, medical students. To these requests, they had happily 
responded. Their motivation was their annoyance with the lack of knowledge among 
healthcare workers, and their attempts to do something about it. 
Social Interactions in Support Groups 
Among the interviewees, eight (32%) have not participated in any support groups 
beyond a few trial visits, if any, four (16%) were associated with support groups in some 
capacity in the past, but have not been active or participating for a while, seven (28%) 
acted as support group leaders or co-leaders, and six (24%) considered themselves 
members who attended meetings with some regularity. Two of the leaders had served on 
the Chapter’s boards in two different states. 
Format. The leaders and members described the format of support groups in 
various ways, indicating there was not a pre-determined format followed by all groups. 
The number of attendees seemed to have determined the level of formality of format. In 
small groups, members updated each other of new problems and developments in 
informal settings, while larger groups had public meeting spaces and more formal 
programs with guest speakers and themes. Dealing with the psychological burden, 
making social connections, having positive interactions, and sharing information were the 
major themes. 
Members’ interests in topics and their suggestions shaped the programs, but leaders 
brought their own visions, perceptions of needs, personalities, strengths, and resources to 
how they conducted the meetings. For one leader, helping new patients was the priority; a 
second leader felt patients wanted to connect and needed opportunities to speak and get 
positive hope from others. A third leader believed in positive meetings based on fun and 
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laughing, and covered topics such as coping with holidays and stress, depression, getting 
your doctor to listen to you, and the best way to prepare for appointments. A fourth leader 
was against guest speakers, believing such information was available online. Instead, 
calling the approach psychological/emotional, that leader facilitated discussions around 
topics such as acceptance and guilt. Access to resources and educational background 
influenced some of these choices. For one leader who had worked in a health-related field 
and had contacts in the medical community, invited guest speakers were a regular feature; 
two others with psychology backgrounds had their focus on emotional aspects, while an 
outgoing leader had the focus on social aspects and inclusivity. Leaders made the point 
that they took feedback from their memberships in choosing topics and activities. A 
training manual was available from the Chapter’s office, and leaders spoke of an annual 
weekend retreat where group dynamics and facilitation skills training were offered. 
However, the leaders were volunteers and patients themselves, and they did what they 
could with the limited formal training available.  
Leaders’ involvement. Five of the eight leaders (7 current, 1 previous) had 
initiated a group, or took over one when no one was available to lead. The motivation for 
leading a group was expressed as sharing their experiences and knowledge with other 
patients in order to support them in this journey. Due to the length of their illness and the 
experiences they had accrued, a relevant educational background or skills, certain traits or 
personality, or a vision for a more effective group, they could contribute something of 
value to other patients.  
The first time I started a group was because I thought, “There are two 
people. There’s got to be more.” And they were scared and so I was helping 
them through it. (Leader 1) 
I do it because when I was first diagnosed with it, I wished there was 
one here for me to have someone to talk to that could understand what I was 
going through, someone that knew. (Leader 2) 
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I realized with all my qualms and all my frailties I am stronger than a lot 
of people. So that’s why I’m doing this. (Leader 4) 
I think the main reason is because so little was known about it. I was 
looking for other people to share with. (Leader 7) 
There are support groups, [the leader] starts every group pretty much, 
“We’re all going to die from this so let’s just talk about it. Let’s have a bitch 
session,” that’s not my way of doing it. I was, more, “You know what, we 
can talk about that and we can grumble about it but before we walk out the 
door, we’re going to be laughing and we’re going to find something that we 
can do today to make something better.” (Leader 8) 
Except for one person, all the leaders got involved with support groups in later 
stages of their disease when they felt stable, both physically and emotionally, to do so. 
Leaders viewed involvement of group members in managing their illness as a spectrum 
ranging from very involved to none. Involvement was described as being very informed, 
active, proactive, and showing strength and resilience, while the lack of involvement was 
characterized as being negatively impacted by fear and denial, trying things 
indiscriminately, inability to work with their doctors, and not being open to proven 
suggestions and guidance available at support groups. 
I think the majority of SSc patients are amazingly informed …  and then 
you got the other patients that really are just, “I’m not dealing with it. I’m 
just going to go on with my life.” (Leader 8) 
The people that tend to feel sorry for themselves are really the ones that 
don’t end up doing that well, because they kind of are in that mode of, “Poor 
me. I can’t do this. I can’t do that.” (Leader 7) 
There are those who are afraid to talk to their doctors about their 
symptoms—to those who think they know more than the doctors. (Leader 5) 
Some people become very strong all of a sudden. All of a sudden, they 
find their inner strength. I’ve seen people who you’d think nothing in the 
world would stop them. (Leader 4) 
Members’ involvement. The patients who had joined a support group 
characterized their involvements as an opportunity to (a) have social interactions with 
people who understood, (b) learn; and (c) join forces with others for a greater cause. 
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Social interactions were seen as an opportunity to converse with people who knew what 
one was going through; to make friends with people suffering from the same illness; to 
commiserate and give and get moral and emotional support; and to laugh and uplift one’s 
spirit. Learning included finding out about doctors and medications from other patients; 
observing other patients for symptoms, disease progression, and how others handle it; 
learning best practices from other patients; sharing of news and materials from 
conferences; accessing books and materials provided by the group; and partaking in 
discussions and talks given by guest speakers. To join forces with others for a greater 
cause or purpose included organizing events such as walks, fund-raising, public 
awareness to improve research and funding, and outreach to new patients. 
Non-members’ non-involvement. Interview participants presented a number of 
reasons for not joining a group or participating in educational programs organized by 
groups or the Chapter. These included logistical issues such as other commitments 
(children, working) and lack of time; fatigue and lack of energy to participate; distance 
and lack of transportation; and inconvenient meeting times or inconsistent meeting 
schedules. Personal issues consisted of not being ready for group interactions; being 
frightened by seeing members having severe disabilities or dying, or speakers talking 
about progression of disease; not wanting to know the worst, or projecting into future; not 
wanting to look at oneself as being sick (belonging to a patient community); not needing 
a constant reminder of illness through monthly group meetings; not wanting SSc to be 
all-consuming by doing yet another SSc-related activity; doctor recommended against it; 
and the belief that did not need it, or it is good for new patients or severe cases. Issues 
related to group dynamics consisted of not feeling the group is a good fit; whining and 
defeated attitudes of other patients; or too few people attending. Lastly, the content and 
programming issues encompassed meetings being perceived as social events, or not 
having enough opportunity to socialize; exchanges of unscientific or non-factual 
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information among members; the focus of materials on new patients; topics not of 
interest or repetitive. 
Among these, two reasons stood out as major impediments: 
•   Six (24%) patients stated the fear invoked by seeing other patients with severe 
disability, or hearing the worst from other patients or speakers, caused them to 
back away from participating: 
I was scared of what I might hear so I kind of stayed away. (Sharyl) 
Just the appearance of people, how you’re going to look, you picture 
yourself in there, it was too much for me to bear. (Vanessa) 
•   Eight (32%) patients considered negativity or the complaining demeanors of 
other members in the group as off-putting: 
A lot of patients, I could say this to you, whine too much and 
because I don’t feel that that helps us, I don’t want to hear it and I think it 
brings me down. (Lauren) 
I got into the support group and I really hated the whole thing. 
Because all they do is whine to each other about how bad they feel, and I 
do not find that to be helpful either. I am not going to let this disease 
control me. This is what I have, not who I am. (Stacee)  
Summary of Qualitative Findings 
From among respondents wanting to be interviewed, 25 SSc patients were selected 
for interview. These included 7 leaders of support groups, 6 members of support groups, 
and 12 non-members, consisting of 20 females, and 5 males. The sample was 
predominantly female (80%), White American (72%) who tended to be middle-aged 
(50-55), more educated, held white-collar jobs, and were more likely not to be gainfully 
employed at the time of interview. The average disease longevity was 14.5 years. The 
major self-reported SSc subtypes consisted of 11 (44%) limited cutaneous scleroderma 
(lcSSc) and 9 (36%) diffuse cutaneous scleroderma (dcSSc). Fourteen (56%) had major 
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internal organ (lung, heart, and kidney) involvements, while 11 (46%) had symptoms 
limited to skin, joint, gastro-intestinal, and musculo-skeletal systems.  
Patients engaged with various types of work or efforts to mitigate the physical and 
emotional/psychological, relational, and financial impacts of disease in their lives, 
including obtaining a diagnosis, managing relationships with doctors, pursuing effective 
therapies, attending to emotional and psychological impacts of the disease, dealing with 
employment and financial impacts, and handing familial relationships. The motivation to 
engage with these activities and work was predicated on a commitment to engage with 
the illness, and sustaining that commitment through hope, a will to live, and envisioning a 
future.  
Participants described four strategies as a guide to action: taking a problem-
solving/problem avoidance orientation; utilizing resources and advocating for 
themselves; being transactional and evaluative in obtaining care; and being open to 
experimentation. Participants learned informally by looking for information on the 
disease; socially in support groups; formally by attending talks and conferences; 
experientially through problem solving; and somatically by body-listening.  
Support groups’ format was described as informal and seen as an opportunity to 
not only facilitate voicing of experiences and concerns by members, but also allow 
leaders to share their own experiences, skills, and visions with other patients. Members 
saw support groups as providing opportunities to interact, learn, and join forces with 
other patients. Two major impediments to membership were described as fear invoked by 




DISCUSSION, INTERPRETATION, SYNTHESIS, AND CONCLUSIONS 
This chapter presents discussions, interpretations, and synthesis of results and 
findings in relation to the three research questions that this study had sought to answer. 
The discussion of quantitative findings consisting of the interpretations of results in the 
context of literature are presented first. This is followed by the interpretation of 
qualitative findings, mainly through the conceptual framework of the study and the 
related studies that were presented in Chapter II. The quantitative results and qualitative 
findings are integrated in answering research questions 1 and 3. 
The purpose of this study was to explore and describe, through scleroderma 
patients’ own perceptions and understanding, their commitment to illness management, 
including how they were involved in dealing with their illness and how they learned to do 
so. Additionally, an understanding of the role of social interactions, in particular, support 
group participation in their involvement, was sought. The two main discussion sections, 
quantitative results and qualitative findings, are organized by the three research questions 
of the study. 
Discussion and Interpretation of Quantitative Results 
The discussion and interpretation of the quantitative findings related to levels of 
activation, perceived social support, and any association with demographic and clinical 
attributes are presented in this section to elaborate on answers to research questions 1 and 
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3, and accordingly are organized by these two questions. These are prefaced by a 
discussion of the participants’ characteristics. 
Participants’ Characteristics 
The demographic and clinical variables of the study were compared to other studies 
of scleroderma patients to detect any differences that potentially might impact the 
discussion of results. 
Thirteen recent studies on scleroderma patients (Achaval, Kallen, & Mayes, 2013; 
Bauer, 2013; Elhai, Meune, & Avouac, 2012; Leavens, Patten, & Hudson, 2012; Merz 
et al., 2013; Muangchan, Canadian Scleroderma Research Group, Baron, & Pope, 2013; 
Muller, Rehberger, Gunther, & Schmitt, 2011; Radvanski, 2015; Richards et al., 2003; 
Sandusky, McGuire, & Smith, 2009; Singh, Clements, Furst, Maranian, & Khanna, 2012; 
Taillefer et al., 2010; Thombs et al., 2015) were considered. In addition, following 
scleroderma registries (EUSTAR—European Union SSc Trial & Research Group, the 
German Registry, and University of Pittsburg SSc database) were consulted indirectly 
through other studies (Meier, Frommer, & Dinser, 2012; Hunzelmann, Genth, & Krieg, 
2008; Steen, Domsic, & Lucas, 2012, respectively), and the Canadian SSc Research 
Group (CSRG, 2014) through its website, due to lack of a direct access. The demographic 
and clinical data from these studies are tabulated in three tables in Appendix K. 
Among studies reviewed, sample size and recruitment procedures encompassed a 
wide range, such as recruiting participants at SSc centers during doctor visits, patients in 
database registries during their annual visits, patients in a given geographic area served 
by certain clinics, patients attending support groups, conferences, and through mail, 
emails, magazines, and newsletter ads, as well as cross-sectional, retrospective meta-
studies and historical records, resulting in samplings that ranged from random to 
convenience sampling. In spite of variations in each study’s purpose and non-conformity 
in collected data and reporting formats, this broad spectrum of studies provided an 
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overview of the SSc population and helped locate this dissertation’s sample 
characteristics within this larger pool. 
Gender, age, general education, and employment characteristics of this dissertation 
study were well within the ranges presented in the 13 studies considered. The only 
exception was the percentage of college graduates, which was higher, at 34% vs. 27% of 
the reported upper range. Although within range, the mean age of this study’s participants 
was on the higher end of the spectrum, indicating that the population of this study was 
somewhat older. 
The distributions of disease subtypes were comparable to other studies, which did 
not recruit their samples from a medical setting. Among the 13 studies reviewed, those 
that recruited their participants at clinics, medical settings, or during doctors’ visits 
tended to have a larger diffuse subtype in the sample. This reflects the fact that, 
rheumatologically (hence medically), the interest in scleroderma is in its systemic form, 
not the localized subtype (Mays, 2008). On the other hand, studies using mail, ads, non-
clinical venues (conferences, support group meetings), or historical data had higher 
percentages of patients with limited subtype. This dissertation study, did not recruit 
through a medical setting and was prone to the sampling bias with more limited and 
localized respondents. This self-selection bias may be attributed to limited and localized 
patients having fewer internal organ involvements and presumably being more willing or 
able to participate in a study or survey outside a medical setting. On the other hand, those 
with diffuse have more frequent medical visits and are targeted for more recruitment 
during these visits. 
Among studies reviewed, a study by Radvanski (2015) conducted in the general 
geographical area of this research shared many similarities in its demographic 
compositions. In particular, Radvanski’s study of a random sample of 68 patients 
recruited from a scleroderma clinic at Rutgers University/Robert Wood Johnson Medical 
School reported a high educational attainment: 77% with “some college or above,” 
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similar to 80.6% of this study (53% having “some college or a college degree” similar to 
47.7% of this study, and 24% attended graduate school vs. 32.9% of this study). The 
higher educational attainment in both Radvanski’s study and this dissertation study may 
be attributed to the geographic area from which these two samples were drawn and whose 
residences rank among the top ten states in having college and advanced degrees. 
According to data from the United States Census Bureau (2009, 2011), 36.5% of adults 
25 years or older in Connecticut have a bachelor’s degree, followed by 35.8% in New 
Jersey and 33.2% in New York. Another 4.5% of Connecticut adults have an advanced 
degree, with New Jersey and New York at 4.1% and 3.8%, respectively. These statistics 
are as high as 50-60% for a bachelor’s degree in some counties within these states. Thus, 
the region of country from which this sample was drawn may partially account for the 
high educational attainment seen. 
In terms of disease subtype, Radvanski’s (2015) study had a 57.4% to 42.6% split 
between diffuse and limited, whereas in this study the distribution consisted of 34.3% 
diffuse; 43.3% limited; 5.0% sine; 9.5% were localized; and 8.0% did not know their 
disease subtype. The difference may be attributed to Radvanski’s recruitment at a 
scleroderma clinic where verifiable diagnoses were available through medical records, 
and where localized subtypes were excluded, versus the self-reported diagnosis for this 
study. During the interview portion of this study, some level of discrepancy between the 
disease subtypes reported and the descriptions of symptoms and progression of disease 
were observed for a handful of participants. It was apparent from interview participants 
that not all doctors made a clear distinction between disease subtypes to the patients. This 
is mainly due to the dynamic and uncertain progression of the disease early on (the first 
3-5 years), which made the classification difficult, and perhaps also due to a desire not to 
alarm the patients by typecasting them. In addition, not knowing the subtype was more 
prevalent among older participants or those who had the disease for a long time 
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(>20 years). Self-reporting of disease subtype, therefore, should be viewed with caution, 
especially in older patients and those with relatively long disease duration. 
This study’s mean age of 60.0 + 13.6, even though on the high side when 
compared to other studies, aligned well with Radvanski’s study mean age of 60.3 + 12.2. 
Scleroderma is mostly diagnosed in middle-age patients (40s to 50s age groups). The 
study sample was left-skewed by participants who had the disease for more than 10 years 
and hence the higher mean age of 60.0 at the time of survey. 
The employment status of Radvanski’s sample and this study was very similar 
(full-time 25.0% vs. 26.9, part-time 8.8% vs. 8.5%, homemaker 4.4% vs. 5.5%, retired 
36.8% vs. 34.8%, disabled 17.6% vs. 22%, and unemployed 5.9% vs. 2.5%). Over half 
the participants (56.8%) in this dissertation study were retired or on disability, and 
another 35.4% were employed full-time or part-time. While the percentage of those 
having a “college degree or above” was 67.2% of the sample, they constituted 72.2% of 
those working full-time or part-time. The higher educational attainment of this sample 
may imply a higher probability of holding white collar jobs with better benefits 
(retirement/pensions, insurance coverage, etc.). Such benefits might explain the 
employment status seen, where many could continue working due to less physical 
demands of their jobs and wanted to work for retaining the needed benefits. Sandqvist 
and Eklund (2008) reported that greater working ability was correlated to less physically 
demanding jobs in a study of SSc women. A number of interview participants holding 
white collar jobs reported accommodations (switching to less demanding positions, 
flexible hours, time off, etc.), which allowed them to continue to be employed. Nguyen, 
Poiraudeau, Mestre-Stanislas, and Rannou (2010), in a study of employment status and 
socio-economic burden of SSc in a French sample, suggested that employment status in 
SSc “could be related more to perceived health status and disability than to specific organ 
involvement” (p. 987). However, in this dissertation, those on disability or sick leave had 
more significant organ involvement than those holding employment: three times heart, 
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1.5 times lung and joint/muscle involvements. Age and disease duration distributions 
were similar for both groups. 
The findings from the interview portion of this dissertation study suggested other 
confounding factors, such as level of accommodation afforded by employers, the 
availability of insurance coverage and income through a spouse, and an impending 
retirement age factored in patients’ decisions to continue to work or not. Those who 
sought disability insurance found the process to be a difficult and complicated task 
requiring certain amount of savvy, knowhow, or financial resources to successfully 
navigate the program’s eligibility requirements. Having had a relationship with 
physicians who worked with patients to provide documentation for disability insurance 
application or having had access to legal resources were crucial in this process for a 
number of interview participants. Patients seeing scleroderma experts are more likely to 
get this type of support from their doctors, as these doctors are keenly aware of the 
burden faced by patients and are experienced with providing documentation for off-label 
use of medications to insurance companies. All these present a more nuanced picture of 
the employment status of SSc patients in the U.S. than was suggested by Nguyen et al.’s 
(2010) study. 
As to organ involvement, the reporting of lung and heart involvement was higher 
than in the 13 studies reviewed. The higher levels of lung and heart reporting may be 
explained by the larger number of older participants and the substantially larger number 
of participants with longer disease duration. The lungs and heart in SSc patients will be 
impacted with passage of time, even for those with the limited form. It is estimated that 
up to 90% of SSc patients develop some degree of lung disease detectable by high 
resolution CT scans, while in some 40-75% of patients, the changes will be seen in their 
pulmonary function tests (i.e., breathing tests) (Herzog et al., 2014; Solomon et al., 
2013). Since lung disease and pulmonary arterial hypertension (PAH) are considered the 
leading causes of death in SSc (Solomon et al., 2013, Steen & Medsger, 2007), patients 
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are screened carefully and regularly. By and large, patients have a clear understanding of 
the degree of impact of SSc on their lungs and heart and can accurately self-report them 
in surveys and questionnaires. Therefore, reporting of these organs’ involvement in this 
study may be viewed as reliable. 
The moderate association between fatigue and heart and lung problems found in 
this study, in light of higher reporting of lung and heart involvement, may explain the 
higher fatigue reporting. Another contributing factor may have been treatment with 
immunosuppressant drugs, which are known to cause fatigue. In lung and heart patients, 
due to the criticality of these organs, such treatments are prescribed more aggressively, 
which might have contributed to the higher reporting of fatigue in these participants. 
For this study, the numbers of participants reporting fatigue, pain, and depression 
were at 80%, 70%, and 34%, respectively; all three were associated with each other in 
this sample. This finding is corroborated by findings in a number of other studies, such as 
the correlation of fatigue, pain, and depression in a cross-sectional study of 659 Canadian 
patients (Thombs, Hudson, Bassel, & Taillefer, 2009), and correlation of pain and 
depressive symptoms in a study of 121 patients from Johns Hopkins and the University of 
Maryland Scleroderma Center (Benrud-Larson, Haythornthwaite, Heinberg, & Boling, 
2002). 
Another finding of this dissertation study was the moderate association between 
pain and joint/muscle and the moderately high association of fatigue and joint/muscle. 
Joint/muscle issues were reported by 77.3% of those who were “disabled/on sick leave,” 
who also reported suffering from pain (90.9%) and fatigue (93.2%). A study by Muller 
et al. (2012) of 84 patients in Germany found that those with musculoskeletal system 
involvement who were in pain had the greatest disability in performing everyday 
activities. In another study, pain was reported as “the single strongest predictor of 
physical functioning” (Benrud-Larson et al., 2002, p. 272). These reports seem to explain 
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the association of pain and joint/muscle issues and the levels of physical disability seen in 
this dissertation. 
Thombs, Bassel, McGurie, and Smith (2008) compared the fatigue levels in 106 
SSc patients with those levels reported in the general population, cancer, and rheumatic 
diseases. SSc fatigue levels were significantly higher than levels found in the general 
population, but were on par with levels seen in patients with rheumatic diseases or 
patients in cancer treatment. Lankveld, Vonk, Teunissen, and van den Hoogen (2007) 
found fatigue to be the “most annoying” stressor among 138 SSc patients in a study in the 
Netherlands, indicated on a 4-point scale ranging from “not annoying at all” to “very 
annoying.” In the interview portion of this dissertation study, almost all interview 
participants expressed a similar sentiment that fatigue and not pain was the most 
bothersome symptom they battled. In this dissertation study, fatigue was associated with 
both pain and depression. In turn, pain was associated with sleep disturbance 
In a meta-study of eight articles on depression in SSc, Thombs, Taillefer, Hudson, 
and Baron (2007) found consistently high levels of depression (36-65%) reported. The 
reporting of depression level in this dissertation study was within the above reported 
range (34%) overall, but reached as high as 56.8% in participants who had pain and were 
on sick leave. Lankveld et al. (2007) did not find any significant correlations between 
disease duration, education, employment, and depression in scleroderma patients, nor any 
difference in depression between limited and diffuse subtypes. However, they found a 
high correlation between depression and pain, and depression and fatigue. In this 
dissertation study, depression was moderately associated with body image distress and 
pain, and strongly with fatigue. 
In summary, this study’s participants were more educated and, although within 
range, were older. Higher educational attainment may be partially explained by the 
geographical location from where sample is drawn. Other disease characteristics and 
demographic make-up of this study fell within the general characteristic of SSc samples 
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of other studies, such as gender divisions and employment. The disease subtype 
distribution of this study was in line with studies recruiting in non-medical settings. 
Furthermore, the self-reports of fatigue, pain, and depression were comparable with a 
number of studies using measurement scales for these variables. In particular, self-reports 
of lung and heart issues, and prevalence of fatigue in these patients, may be considered 
reliable. Overall, the impact of higher educational attainment needs to be considered in 
the interpretations of results. 
Research Question 1: Description of Patients’ Commitment to Illness Management 
Research question 1 sought an answer to the following research question and 
sub-questions: How do scleroderma patients describe/understand their commitment to 
illness management? Did commitment to be involved change overtime? If so when and 
how? 
Using the PAM scores of the sample as a proxy for commitment and involvement 
of patients in their own care, the distribution of PAM activation levels provided a 
quantitative description and an overall sense of activation of the sample. The PAM 
activation construct is based on an individual’s belief, knowledge, motivation, and 
actions regarding their self-care. It assumes that activation is manifested by the belief that 
one has a role to play in one’s own care, and has the knowledge and skills to manage the 
condition and obtain quality care (Hibbard et al., 2004, 2005). Interpretation imposed on 
PAM levels placed 15.8% of the participants at the lowest level, indicating that these 
patients were passive recipients of care and were not cognizant of having an active role. 
At the next level, 20.2% of the participants were lacking fundamental knowledge of their 
disease and treatments. The third level had the highest proportions of participations 
(48.6%). These patients were knowledgeable about the key facts related to their condition 
and behaviorally showed signs of action, but lacked the skills and confidence to bring 
about new health behavior. The top 15.3% of the participants were those who took action 
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and adopted new health behaviors for the most part, perhaps finding the behaviors 
unsustainable only during a crisis or stress. 
PAM has been validated for a number of chronic diseases, including multiple 
sclerosis, which is also considered an autoimmune mediated disease. However, PAM has 
not been validated specifically for SSc, and no other study of scleroderma patients with 
this measure existed. Studies using PAM in chronic diseases and conditions, including 
MS (Staerk, 2015; Stepleman et al., 2010), diabetes (Remmers, 2008; Tabrizi, Wilson, & 
O’Rouke, 2010), COPD (Halding & Grov, 2017; Korpeshoek, Bos-touwen, de Man-Van 
Ginkel, & Lammers, 2016), chronic heart failure (Do, Young, Barnason, & Tran, 2015; 
Witt, Benson, Campbell, & Sillah, 2016), chronic renal disease (Bos-Touwen et al., 
2015), spinal cord injuries (Houlihan, Brody, Everhart-Skeels, Pernigotti, & Burnett, 
2017), cancer (Mazanec, Sattr, Delaney, & Daly, 2016; Salgado, Mackler, Severson, & 
Batra, 2017), as well as mixed chronic and healthy general populations (Hibbard & 
Cunningham, 2008; Skolasky et al., 2011; Wong et al., 2011) reported a range of PAM 
levels distributions that varied widely across studies. 
This dissertation study’s distribution levels of 15.8%, 20.2%, 48.6%, 15.1% were 
in the general range (64%-70% at active levels 3 and 4) of two studies with certain 
similarities in the sample populations: Blackmore et al. (2016), in a large sample of 3,636 
older patients over age 64 (mean age 75 + 6.8) found a distribution of 15%, 16%, 45%, 
25%). Witt et al. (2016), in a study of 157 women with heart conditions (mean age of 
63 + 10.8), reported a distribution of 14.6%, 12.7%, 38.9%, 28.7%. Similarities with Witt 
et al.’s study included age, gender, nature of issues faced with the illness, sample size, 
and inclusion of support group members, while older age and one or more chronic 
conditions and employment status were shared features with Blackmore et al.’s study. 
A number of studies indicated an association of education with higher activation 
(Salgado et al., 2017; Skolasky et al., 2011; Smith et al., 2013; Stepleman et al., 2010). In 
this dissertation, higher educational attainments had a weak association with higher 
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activation. The general high educational attainment of participants might have precluded 
the detection of a stronger association. In 16 PAM studies reviewed, gender was not 
reported as correlating with PAM levels, and reports of association of activations and 
age, race, disease duration, and comorbidity were mixed and inconclusive. Hibbard and 
Cunningham (2008) reported higher activations in patients with multiple chronic 
conditions or more serious illnesses like cancer. 
 In this study, a moderate association between disease duration within the first 
decade of illness and activation was detected. PAM is intended to measure “an 
individual’s self-concept as a self-manager” (Hibbard, 2014) and “reflects the degree to 
which one feels ‘in charge’ of one’s own health” (Hibbard & Cunningham, 2008, p. 3). It 
is shown to have a developmental and hieratical nature, and “patients need to sequentially 
pass through each of these stages on the way to becoming effective self-managers” 
(Hibbard et al., 2005, p. 1928), indicative of learning. This developmental aspect 
presumably, occurring over time and as a result of experience of dealing with the disease 
and learning, may explain the association found in this dissertation study between higher 
activation and longer disease duration within the first decade of the disease. 
Alternatively, the quantitative findings indicated the existence of a period of shock post-
diagnosis and lasting up to five years for some patients. During this period, patients were 
not able to engage with their illness in a meaningful way, as they needed to “wrap their 
heads around” the situation they found themselves in. Once patients got past this period, 
they would engage with their care in a more intense manner. 
Within a broader definition of patients taking an active role in their own care, PAM 
addresses aspects of engagement relating to the physical impacts of the disease. One 
assumption of this study was that physical impacts were the primary, most direct, and 
tangible consequences of having a disease, an active involvement in physical aspects was 
an indicator of an overall involvement, and the PAM instrument would capture the 
construct of active involvement. However, scleroderma is a complex disease, and some 
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items in the PAM-13 measure posed problems for patients, as indicated by their notes on 
the margins. 
Interview findings shed light on some of these difficulties. For example, item 8 (“I 
understand the nature and causes of my health conditions”) garnered comments such as 
“Doctors do not even know,” “Hard to answer,” or “Experts cannot be 100% confident.” 
For item 10 (“I know how to prevent further problems with my health condition”), the 
remarks indicated that the respondents knew what would be helpful (exercise, walk) but 
found it difficult to implement due to fatigue and/or pain. Therefore, non-adherence was 
caused by physical impediments. Item 3 (“I know what each of my prescribed 
medications does”) was more difficult to endorse by some patients than was expected. 
This might have been partially due to the experimental nature of treatments where 
medications are used off-label, making it difficult for patients to connect them to 
symptoms being addressed, even if they researched them. It also may be due to the 
systemic and overlapping nature of this disease entailing the vascular, connective, and 
immune systems that are difficult to disentangle for patients, either through their own 
research or doctors’ explanations. Patients saw the disease as one entity, whereas it was 
treated at different organ levels and body systems, pharmacologically. Item 12 (“I am 
confident that I can figure out solutions when new situations or problems arise with my 
health condition”) was harder to endorse than item 13 (“I am confident that I can 
maintain lifestyle changes, like diet and exercise, even during times of stress”) for this 
study’s sample, because the interview data revealed the ambivalence in differentiating 
between possible new symptoms and those related to aging, genetics, or other illnesses. 
This was particularly difficult for older patients, who were dealing with the effects of 
aging at the same time, and newly diagnosed patients, who perceived every new 
symptom as signaling the worsening of their conditions. Lastly, item 13 (“I am confident 
that I can maintain lifestyle changes, like diet and exercise, even during times of stress”) 
was problematic for some SSc patients to endorse because many had disabilities that 
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made adapting and adhering to lifestyle changes difficult. For others, since their disease 
waxes and wanes, the “times of stress” can easily be interpreted as flare-ups. Flare-ups 
can last for many months, could consist of debilitating cascades of symptoms, and may 
entail profound fatigue. Obviously, patients won’t be able to maintain lifestyle changes 
during such stressful periods of flares, and for many SSc patients, the “right” answer that 
more accurately reflected the realities of the disease might have indeed been to disagree 
with this item. 
On the other hand, some items were easier to endorse than the instrument’s scaling 
was predicting, such as items 6 and 7 (“I am confident I can tell when I need to go get 
medical care and when I can handle a health problem myself” and “I am confident that I 
can take actions that will help prevent or minimize some symptoms or problems 
associated with my health condition”). By and large, the interview sample had an 
awareness of the criticality of their conditions and the understanding that they could not 
ignore symptoms and problems. This, coupled with a similar understanding on the part of 
doctors, meant that many participants felt confident and were able to reach their doctors 
when symptoms or problems occurred. Furthermore, the reported treatment compliance 
by interview participants was at 100%. Participants may have interpreted their 
compliance with medication and doctor’s recommendations as taking actions to minimize 
and prevent symptoms.  
A number of other studies noted similar variations in scaling (Packer et al., 2016; 
Staerk, 2015; Stepleman et al., 2010), but concluded that PAM is a reliable and valid 
instrument in assessing patients’ activation. Nonetheless, these variations point to 
nuances that were difficult for respondents to resolve, which might have pushed some 
participants from higher activation levels to lower ones, resulting in some degree of 
under-reporting of activation. 
A different type of under-reporting was observed in interview patients. Six 
participants who exhibited high degrees of disease knowledge, awareness of and 
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utilization of expert and quality medical care, and displayed high levels of vigilance and 
initiative in care for themselves were scored at level 2 and level 3. These participants 
avoided the emphatic endorsements of items in general, and items 12 or 13 in particular. 
The expertise of these patients and awareness of the nuances of disease might have 
worked against endorsing items in the general sense that was intended in the instrument. 
These observations lead to a suspicion that activation levels of patients were higher than 
what was captured by the PAM instrument. 
The quantitative findings do not provide answers to question 2 of the study. 
Findings related to the third research question are discussed next. 
Research Question 3: Impact of Social Interactions on Involvement and Learning 
The third research question was concerned with the question: “How are social 
interactions, particularly, support group facilitation/participation, perceived in terms of 
involvement and learning?” 
The findings indicated that the mean and median for all dimensions of social 
support ranged from 67.01 to 76.68, and 65.6 to 91.7, respectively. The dichotomized 
MOS scores, with the median as the cut-off for high and low values, indicated that 50.3% 
of the respondents perceived having high overall support, 53% had high tangible (TAN) 
support, 72.1% had high affectionate (AFF) support, and 61.7% had high positive (POS) 
support, but only 40.4% had emotional/information (EMI) support. 
PAM activation levels had a significant association with all dimensions of support 
except for TAN. The Overall MOS and EMI median scores of level 4 were significantly 
higher than levels 1 and 2, while a POS median score of level 4 was significantly higher 
than level 2. All MOS dimensions were negatively associated with depression. 
Only about one-third (32.3%) of the respondents participated in support groups. 
Among non-members, 76.9% were employed, and 55.8% were on disability/sick leave. 
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No statistically significant association between support group participation and perceived 
social support was detected. 
The above-reported levels of support indicate that the majority of respondents 
benefited from friendship and personal and intimate relationships that afforded them 
expressions of love and affection (AFF), and fun social interactions (POS). In 
comparison, a considerably fewer respondents perceived practical (TAN), as well as 
emotional and informational (EMI) supports. The TAN refers to assistance and 
instrumental support, while EMI is related to understanding and empathy, and availability 
of information or feedback when seeking solutions to problems. (Sherbourne & Stewart, 
1991). 
Given the level of physical disability and fatigue in this population, the Tangible 
support (TAN) entailing actual material aid and behavioral assistance is of great 
significance for patients. Interview data indicated that this type of support was generally 
provided by family and friends, but could have also been institutionally provided. One 
interview participant lived not in a nursing home, but in a housing development that was 
specially designed for seniors, with an array of programs including onsite nurse and 
doctor visits, a peers checking-on-each-other system, shopping trips, and household help. 
In spite of living alone and having extensive disabilities, she had one of the highest 
perceived social support scores. Had the researcher not interviewed her at her residence, 
such a high score might have been viewed as an anomaly. Notwithstanding such 
arrangements, among interview participants, patients living alone were those with the 
most difficulties in obtaining assistive support of this kind. 
The interview data revealed four factors contributed to the perceived lack of 
tangible supports (TAN) by patients: (a) the lack of coverage for supportive services by 
insurance and social support programs; (b) the inability of patients to afford help such as 
house-cleaning services; (c) living arrangements not conducive to their disabilities; and 
(d) a general obliviousness on the part of family members to their needs. A number of 
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patients spoke of how their adult children and siblings, and even spouses, do not realize 
the extent of their disabilities and needs, and unless they ask for very specific assistance 
with tasks, they do not generally receive help as a matter of course. In addition, living on 
multiple floors and housing not designed for people with disabilities made their 
awareness of their need for assistance more pronounced. 
The high perception of TAN support was the only social support dimension not 
associated with higher activation levels. This may indicate that higher TAN support may 
make patients’ lives physically easier, but does not have the same significance as non-
physical support in terms of their involvement. Another interpretation based on the 
interview data may be made. For many patients, the need for help and assistance was 
intertwined with feelings of guilt, being a burden, and an ambivalence about taking help 
and expecting help. As such, TAN support is a complex concept in need of unpacking. 
Even when patients express that they have high support, there might be a substantial 
emotional undercurrent, such as guilt, involved. 
Emotional and Informational support (EMI) measures the perceived emotional and 
empathic interactions and responses to informational needs. The perceived lack of this 
type of support may be explained through the sentiments expressed by interview 
participants. The general sense of ambiguity, uncertainty, and lack of information to 
demystifying their illnesses may account for the perceived absence of informational 
support. The inability of the health profession to provide definite answers might have 
played a role in reinforcing this impression. This was expressed succinctly by one patient: 
“It is the most frustrating thing in the world for someone to say: ‘You have this. Up until 
this point it is pretty much fatal, there is no cure for it, and we cannot really answer your 
questions.’” 
The second aspect of this support, the affordance of understanding and empathy, 
relates to the general belief expressed by many interview-participants that unless one has 
experienced the disease personally, one cannot understand what patients go through and 
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be truly empathic. This could be the connection between EMI and TAN, as a true 
empathic understanding is needed for an offering of meaningful and consistent material 
assistance. 
One place that an authentic understanding might be offered is in support groups. 
The means of all MOS dimensions, although not reaching statistical significance, were 
higher for leaders, followed by members, and then non-members. However, 67.7% of 
respondents did not avail themselves of this resource for a host of reasons. Quantitative 
findings point to employment and level of disability as factors, as non-members included 
76.9% of employed and 55.8% of those on disability/sick leave. Other factors are detailed 
under qualitative findings. The low perception of EMI and POS in this sample may be 
partially attributed to absence of a connection to a community of patients. 
Health professionals are another source of support for patients. EMI support 
consists of “expression of positive affect, empathetic understanding, and the 
encouragement of expressions of feeling/offering of advice, information, guidance, or 
feedback” (Sherbourne & Stewart, 1991, p. 707). Positive patient-physician interactions 
entail such characteristics and could provide a particularly powerful form of EMI support 
for patients. Graffigna et al. (2017) found that “the perceived quality of patient/doctor 
relationship” played a role in “sustaining patient activation” (p. 12). Using the PAM 
measure, Alexander, Hearld, Mittler, and Harvey (2012) found that three variables of 
higher perception of interpersonal exchange with doctors, frequency of out-of-office 
contact, and reports of fair and respectful treatments free of bias (racial/ethnic, socio-
economical, gender, disease-specific misjudgments) were associated with higher patient 
activation. These factors were not measured in the quantitative portion, but are covered 
under the discussions of qualitative findings. 
When social support was viewed in light of activation, statistically significant 
associations between PAM activation levels and EMI, AFF, and POS were observed. 
Specifically, the overall, MOS, EMI, and POS median scores were significantly higher 
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for those in the highest level of activation, level 4, than those in the lowest levels (1 and 
2). Solberg et al. (2015) found that severely obese patients with high social support were 
more likely to have high activation and enjoyed high emotional well-being. Association 
of high social support and high activation has been reported in other chronic conditions. 
Witt et al. (2016) found that cardiac patients with high level of social support were more 
likely to have high activation levels (level 3 and 4). In Blackmore et al.’s (2016) study, 
those patients with multi-morbid conditions who had better social support had higher 
activation. Both these studies had used the ENRICHD Social Support instrument (ESSI) 
(Vaglio et al., 2004), which measures similar emotional, instrumental, and informational 
dimensions as MOS-SSS. 
Among study respondents, self-reported depression was negatively correlated with 
MOS dimensions. In a sample of autoimmune disease patients that included scleroderma 
patients, Taylor (2008) found that only depression and social support, and not disease 
severity, predicted healthy behaviors measured by the HPLP (Health Promoting Life 
Style Profile). Other studies (Blackmore et al., 2016; Mazanec et al., 2016; Smith et al., 
2013; Stepleman et al., 2010) using depression scales found depression to be strongly 
associated with lower activation. In this study, depression and lower activation were 
indirectly connected, through social support. The moderate association of depression and 
body image distress and pain and the strong association of depression with fatigue 
implicate pain, fatigue, body image concerns and depression as impacting patients’ 
activation. 
Summary of Quantitative Findings 
In summary, the answer to the first question, drawn from the quantitative findings, 
may be given as follows. Patients’ commitment to their illness management and their 
involvement in their own care, as represented by the activation construct, manifested in a 
range from passivity to high activation, with the majority of respondents being in the 
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upper range of activation. Increase in activation was related to disease duration in the first 
decade of the disease and was hypothesized to be attributed to the developmental nature 
of the illness experience. Other factors included the perception of social support and, 
indirectly through pain, fatigue, body image concerns, and depression. Disease severity, 
as it may be discerned by physical symptoms or disease subtypes, did not have an impact. 
To answer the third research question, higher activation was associated with higher 
perception of support; however, with almost 70% of respondent not participating in 
support groups, the role of a support group in respondents’ involvement was not clear. 
With 60% of respondents having a perception of low informational/emotional (EMI) 
support and almost half perceiving low tangible (TAN) support, there is a substantial void 
in the type of social support and interactions needed by these patients. 
Discussion and Interpretation of Qualitative Findings 
The qualitative findings of the study are discussed in light of the conceptual 
framework of the study and the related literature. The discussion of the findings is 
organized by the three research questions of the study and is presented after a brief 
contextual description of the participants. 
Contextual Description 
The participants of this study included 25 scleroderma patients (5 male and 20 
females), majority White -American, between the ages of mid-0s to 85, with 64% having 
a college degree or above, and 56% retired or on disability/sick-leave. Disease sub-types 
represented include 44% limited, 36% diffuse, 12% sine, and 8% unknown. Participants’ 
familiarity with prior chronic conditions and the healthcare system was limited, as the 
majority of participants (64%) enjoyed excellent health. For 40% of the participants, 
diagnoses occurred in their mid-40s to mid-50s. Forty-four percent of diagnoses occurred 
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within six months, while 56% took between a year and 5 years. The average disease 
longevity was approximately 12 years, excluding the two outliers with 30 and 49 years’ 
disease duration. 
In the next section, a summary of qualitative findings is followed by the discussion 
of the findings by the three research questions and the associated sub-questions of the 
study. 
Research Question 1: Description of Patients’ Commitment to Illness Management 
Research question 1 sought an answer to the following research question and 
sub-questions: How do scleroderma patients describe/understand their commitment to 
illness management? Did commitment to be involved change over time? If so, when and 
how? 
The findings related to question 1 described patients’ commitment to managing 
their illness in terms of work that patients did and the motivational factors that were 
needed to sustain this work. This included the work and the efforts put forth to mitigate 
the physical and emotional/psychological, relational, and financial impact of the disease 
in their lives. These efforts for the interview participants spanned across six categories of 
obtaining a diagnosis, managing relationships with doctors, pursuing effective therapies, 
attending to emotional and psychological impact, dealing with employment and financial 
impact, and handling familial relationships. 
To the extent that participants were motivated to do the above work, they were 
committed and involved. Their motivation was predicated on accepting the illness, and 
was sustained through hope, a will to live, and imagining a future. Patients spoke of 
needing time to accept their illness and certain periods when they were not fully engaged. 
In interpreting these findings, the starting point was to abstract a description of 
patients’ commitment and involvement from the interview-participants’ depictions of 
how they manage their illness. The notion of work suggested by Corbin and Strauss 
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(1988) was utilized for this purpose. Corbin and Strauss define work as the tasks that 
patients undertake in order to manage some aspects of their illness. Participants also used 
this terminology in referencing their activities as the full-time work of tending to the 
demands of the disease. Identifying the tasks that made up this work was one way of 
approaching the description of their commitment and involvement. Altogether, six major 
areas to which participants devoted their energies were singled out, and detailed themes 
regarding the nature of each engagement were listed. The salient features of these 
engagements are discussed in this section, using Corbin and Strauss’s model, which 
constitutes one part of the conceptual framework of this study. 
The six areas of tasks engaged in by participants aligned with the three categories 
of illness work, biographical work and everyday work of Corbin and Strauss’s (1988) 
model. The first three (obtaining a diagnosis, managing doctor’s relationship, and 
pursuing effective therapies) related to illness work; the fourth area (attending to 
emotional/psychological aspect of disease) consisted of biographical work; and the last 
two areas (managing employment and finances and familial relationships) fell under the 
everyday work of living one’s life. 
Participants’ descriptions indicated that the level of energy, effort, and attention 
given to these areas fluctuated along the illness course. Corbin and Strauss (1988) studied 
this temporal aspect and suggested the concept of an “involuntary illness trajectory” 
(p. 72) in order to describe the dynamic interactions between the three types of work and 
the fluctuating chronic disease progression. To create an equilibrium in this unpredictable 
system with interacting and moving parts, the model suggests that patients needed to 
come to terms with having a disease. Specifically, this was defined as a “movement 
toward an understanding and acceptance of the irrevocable quality of chronic illness, of 
the performance limitations accompanying it, of death, and of the biographical 
consequences it brings about such as lost jobs, failed marriages, and dependency” (p. 76). 
In this view, the imposed trajectory impels patients to take a position along a continuum, 
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ranging from non-acceptance to acceptance of disease, resulting in degrees of 
commitment to engage with the illness. Thorne et al. (2003) identified this commitment 
to engage as an act of taking control. They further reported that arrival at such a point is 
prompted by a realization that disease is chronic and ongoing; interventions may be 
limited and ineffective; one could prevent complications or improve outcomes; 
considerations of responsibilities toward others; and being the only one who can assume 
responsibility. Reaching such a mindset was characterized as a “philosophical shift” (p. 
1341) in patients’ relationship with the disease. 
Looking among the sample for either signs of a gradual movement or a shift 
revealed mixed results, as detailed in the findings. For some patients, a shift occurred 
early on in the form of a response, which was articulated as a mobilization to fight. The 
intensity and rapidity of symptoms creating an urgency, and a sense that their bodies 
were assaulted and needed a forceful response may be added to the precipitating factors 
mentioned by Thorne et al. (2003). On the other hand, for most patients, the process 
appeared to have been a gradual movement toward acceptance of the illness, especially in 
cases where progression of symptoms occurred more slowly. A few recalled a vivid and 
sudden shift, located within a prolonged struggle of resistance. The realization of the 
steady deterioration of their condition seemed to have been the main motivating factor in 
accepting and taking a stand regarding their disease. The quantitative findings regarding 
distribution of activation levels and their associations with disease duration in the first 
decade of disease may be given a different interpretation in light of notions of a 
philosophical shift and commitment: different levels of activation may be viewed as 
different degrees of commitment, and the increase in activation levels as a gradual shift in 
commitment as disease progressed in the first ten years of illness. 
In the early parts of the trajectory, biographical work, described in this study as 
what patients did to attend to the emotional and psychological impact of the illness, was 
particularly intense and demanding. Corbin and Strauss (1988) described the process as a 
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series of closures, breaking away from the past and what has been to take on what is here 
and will come, which might include grieving and depression. Many patients, in this 
study, described a period of grieving when they needed time to “feel sorry” for 
themselves, and “wrap their heads around” their diagnoses. Nearly 50% of the interview 
sample spoke of depression. Far from being episodic occurrences, depression was an 
ongoing feature for many, and patients toiled, irrespective of it, throughout their illness. 
At the root of these sufferings, Charmaz (1983) contends, is the “loss of self” 
(p. 168). From this view, self is socially constituted. The functional limitations, 
disabilities, and disfigurements for these patients may be interpreted as having caused a 
disruption in their concept of self (Charmaz, 1983; Corbin & Strauss, 1988). This 
disruption separated the past, present, and future, making unavailable the “experiences 
and meanings” (Charmaz, 1983, p. 168), or the “biography” (Corbin & Strauss, 1988, 
p. 50) upon which the former self-image was built, leaving the patients at a loss of self. 
Accordingly, many activities and work that patients engaged with in this area were 
attempts in appraising the extent of such a loss, contextualizing and accommodating 
disease, and reconstituting and repairing the shattered self. For some patients, the extent 
of the efforts was commensurate with the extent of the perceived loss and their 
determination to reconstitute it. For others, the discontinuity between the past (who one 
was), now (who one has become), and the future (who one imagined to be, but has to 
forgo) was parallelizing for various lengths of time. 
Given the variations in interview sample, the perceptions of such a loss spanned a 
wide range. Some of these were described under the theme of managing employment. 
The concept of loss expands this theme from a purely work and financial concern to an 
existential one. Those who were diagnosed later in life and closer to retirement age 
expressed less angst about loss of identity in terms of their professional roles. On the 
other hand, the sense of loss was very palpable for younger patients who had to give up 
their work, take on less demanding jobs for which they were over-qualified, or relinquish 
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plans for advancing their education and moving up the career ladder. The ability to 
continue to work, more or less as before, or retire in an expected timeframe provided for 
the continuity of professional self-image. On the other hand, for those having to go on 
disability, the perceived gap between the image of someone on disability and themselves 
needed to be bridged. As one patient put it, “When I think of somebody young who is on 
disability [like] I have a friend who has MS and she is on wheelchair, that to me makes 
sense. It was not the image of me that I had in my head.” 
Gender identity was another area where a disruption seemed to have occurred. Two 
male patients openly lamented the loss of their identity as the provider, fixer, and 
protector of family, while a third expressed anxiety in not being able to provide for his 
family financially. A few patients with visible skin and facial changes spoke of their 
appearance prior to the disease. One patient showed pictures of an extremely attractive 
person who was barely visible any longer; another patient spoke of bags of beautiful 
party attire that had to be given away, as “the previously known public, sociable 
presentation of self” (Charmaz, 1983, p. 179) was no longer available to her. Presentation 
of self, altered by skin deformities, was particularly disconcerting for two younger 
patients and was brought up in the context of dating. These findings corroborate the 
quantitative finding of the moderate association between body image stress and 
depression. 
Disruptions in discharging parental roles weighed heavily on those with younger 
children; the unexpected physical and emotional unavailability due to fatigue and 
depression, failure to provide financially, and the possibility of not being there to rear 
their children to adulthood were devastating to all participants who were parents. Again, 
the strong association of fatigue and depression in the quantitative findings may be, 
partially, explained by participants’ inability to fulfill their roles. 
The impact of pain and fatigue and associations with depression and joint issues 
were also on full display for many with joint and muscle issues. The high levels of 
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athletic ability developed over years of training being taken away and replaced by 
extensive physical limitations were spoken of wistfully. Other patients reported the loss 
of fine motor skills: one person spoke of her inability to play the piano, another talked 
about limitation in doing artwork, yet a third could not type on a computer keyboard, and 
a fourth had lost tactile ability to handle small instruments needed for work. Such losses, 
where the decline could be objectively measured, inflicted a harder blow on patients in 
two ways: not only a cherished part of who they were was taken away, but also the 
continued deterioration provided a constant reminder and measure of the downward 
trajectory of their disease. 
According to Corbin and Strauss (1988), one moves forward by letting go of what 
was lost and the past, and by integrating limitations imposed by the disease and 
reconstituting a new identity. Some of these were observed as participants described 
letting go of jobs they could not manage and the associated role identities they held dear; 
distinguishing between what could and could not be salvaged from the past like hobbies 
and pastimes that could still be performed; integrating their illness by discovering new 
ways they could feel productive and active, such as volunteering, tending to 
grandchildren, and working with other scleroderma patients; finding ways to lessen the 
intrusiveness of symptoms through creative inventions and gadgets, and the use of 
modified clothing; and lastly, respecting the limitations of their bodies by pacing 
themselves and altering social expectations and demands. Attempts to deal with these 
losses went across the six categories of tasks outlined earlier, highlighting the overlap and 
inter-relatedness of the tasks and work patients engaged with. 
In addition to biographical work, the vigilance in illness work—such as watching 
for new symptoms, medications’ side-effects and maintaining a cadre of competent 
specialists knowing that the threats of new organ involvement were looming—never let 
up for most patients in one form or another. Challenges in dealing with everyday work, in 
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light of the perceived lack of tangible support reported under quantitative findings, and 
the management and stress of familial relationships and finances, were not trivial. 
Given all these challenges, sustaining one’s commitment and engagement with 
work, according to the model, was predicated on hope, finding a will to live, and 
imagining a future. 
Hope was fundamental to this process: “hope for a better, albeit altered future… 
without hope, there is no incentive to move” (Corbin & Strauss, 1988, p. 77). By hope 
was meant the “perception of an exit—a way out of the present situation” (p. 77). “A way 
out” for the study sample included finding effective medications, seeing reduction of 
symptoms, going into remission, or believing a cure was possible in the near future. 
These perceptions were shifting ones. A number of patients stated that they no longer 
believed a cure was possible in their lifetime. A few believed they were in remission or 
have been, at some point, and could regain it. For most, managing symptoms, keeping 
stable, and arresting further deterioration were considered realistic and hopeful. At the 
same time, many acknowledged that a total resolution was out of reach, their time was 
limited, and at least one person saw the disease as “winning” the race. 
The need for signs of hope was detectable early on and did not seem to have abated 
in the course of illness for these patients. The vivid descriptions of interactions with 
diagnosing doctors may be interpreted in light of this need. Doctors exhibiting empathy 
and understanding, offering information and a plan of action, and engaging patients by 
experimenting with interventions, enrolling in clinical trials, or guiding them to adopt 
lifestyle changes were perceived as reassuring and hopeful, propelling patients to move 
forward with their illness. For those paralyzed by diagnosis, like a patient who had 
struggled for years being “stuck there, kind of like out of life,” and hearing her doctor 
explain that she was alright for the time being and there were interventions to try to 
dislodge her from the “stuck” position of being shell-shocked. Similar assurances by 
doctors, like the patient who asked about her prognosis and was told, “I’m going to keep 
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you alive until you are in your 90s,” provided for the possibility of an exit, and 
motivations to move on. This need to find reassuring doctors to sustain their engagement 
with their illness seems to have had a disproportionate role in their involvement. The 
needed characteristics of expertise, trustworthiness, and compatible communication styles 
listed by patients seem to speak to this aspect of patients’ relationship with their doctors, 
more than purely a rational list of criteria in getting the best medical care. 
Among the four motivational factors of commitment, hope, finding reasons to live, 
and imagining the future, the last one was the most difficult to address for the interview-
participants. Corbin and Strauss (1985) label the last two as biographical and trajectory 
schemes, and state, “Visualizing the illness course and some of its attendant medical 
work is usually the physician’s task. But the patient and spouse will have to discover all 
that is really entailed in carrying it out” (p. 238). In the slow progressing subtype with no 
major internal impact, a wait-and-see approach may be taken by doctors; the difficulty in 
classification of disease and a desire not to alarm the patients, combined with the 
unexpected trajectory and different responses to treatment, make visualizing the illness 
course for patients out of reach. Coupled with the unavailability of information or 
patients’ inability to sort through it, this creates a great amount of uncertainty and 
confusion. Corbin and Strauss assert: 
If there is a great deal of uncertainty about conditions, then the 
maintenance of biographical projection and updated schemes is problematic. 
How can you plan when you have only vague definitions of what the future 
will bring?… How much longer do I have to live? How disabled will I 
become? Will there be a flare up of the disease, complications? If so, when? 
What will bring it on? Why continue with the work when there seems to be 
no gain? (p. 239) 
While a few patients seemed to have learned to be at ease with uncertainty in a 
state of what the poet John Keats (1899) called negative capabilities: “when a man is 
capable of being in uncertainties, mysteries, doubts, without any irritable reaching after 
fact and reason” (p. 277), most patients described it as the most difficult aspect of living 
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with this disease. Mishel (1988) defines uncertainty in the context of an illness as “the 
inability to determine the meaning of illness-related events” (p. 225). 
The uncertainty management literature attributes uncertainty appraisal as the 
impetus for psychological and behavioral actions that are employed to manage 
uncertainty (Barbour, Rintamaki, Ramsey, & Brashers, 2012; Brashers, Hsieh, Neidig, & 
Reynolds, 2006; Mishel, 1990). These include actions such as seeking information when 
ignorance is perceived as harmful, and avoidance of information when one needs to deny 
or forestall undesirable outcomes, to avoid overexposure, or when knowing would not 
lead to any solution (Barbour et al., 2012). Both behaviors were observed, in an uneven 
proportion, across participants. The majority of patients looked for information, even if 
intermittently, throughout the illness trajectory. Those who did not perceived their 
doctors or knowledgeable relatives (in the medical field) as conduits for information. 
Whether seeking information or ignoring it, patients were taking an intentional 
approach in engaging with their situation in a way that allowed them to move on. Many 
patients took a similar stance toward information as they took toward patients in 
advanced stages of disease. For some, seeing such patients and observing the extent of 
disabilities and its management was useful information in anticipation of finding 
themselves in a similar situation in the future; for others, limiting exposure and 
forestalling the thoughts of such possibilities to a later time was the prudent way to deal 
with the enormity of the here and now. Information avoidance, far from being a passive 
posture, might have indeed been the appropriate behavior at a given moment in the illness 
trajectory. Barbour et al. (2012) argued that, in situations where information avoidance 
can reduce stress and limit anxiety, when circumstances may be made more manageable 
by waiting for the right time to act, or when one suspects the existence of flawed 
information or unreliable sources, information avoidance might be a sensible act. To this 
list may be added at least two other situations observed in this study. One has to do with 
the quality of information as being either inaccessible due to academic language and 
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terminology, or being overly simplified and basic, as in patient education materials or 
programs designed for new patients. Specific to scleroderma and other illnesses with 
phenotype plasticity is the variation in characteristics and presentation of the disease and 
its subtypes, which makes it nearly impossible for patients to locate themselves in the 
spectrum of the disease and cull relevant information specific to their disease presentation 
without a tremendous amount of work. 
Some of these factors contributed to some patients seeking information through 
their doctors. Doctors as “credible authorities” (Mishel, 1988, p. 228) could reduce 
uncertainty by explaining the disease and its course, creating a sense of stability, and 
controlling treatments decisions and providing a course of action (Brashers et al., 2006). 
At the same time, with a disease like scleroderma where medical knowledge is limited 
and treatments are experimental, a number of threats to the credible authority of health 
providers existed, undermining the stabilizing role it might have played in patients’ lives. 
Brashers et al. list threats such as invalidating patient’s experience by a lack of 
understanding and absence of empathy, a perceived lack of knowledge of the field, and 
violation of expectations in terms of objectivity of medical technologies and protocols 
that were used. For scleroderma patients, lack of knowledge, expertise, or competence 
was the most major threat to the credible authority of doctors, prompting a continued 
vigilance in finding the “right” doctors and maintaining complex relationships, at times, 
among many doctors they saw locally and in specialty centers. 
Particularly evident in descriptions of patients who were initially misdiagnosed or 
those whose symptoms were contested were their attempts to do their own independent 
research to hedge against this threat and to reduce uncertainty. Using a variety of 
resources, but mostly through the Internet and other patients, they sought information, 
which took some of the mystery of the disease away. The unedited and acontextual 
information thus obtained, however, was a double-edge sword. Mortality statistics and 
reported progression rates for scleroderma were devastating and overwhelming to most 
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patients, moving some to avoid or limit information seeking for a while, and come back 
to it at a later time, or to relegate the task to loved ones and doctors until they were able 
to do it themselves. 
These struggles with uncertainty and biographical interruptions, in tandem with 
fluctuation of the disease, seemed to have staged the commitment of patients to their 
illness management in the form of a trajectory. 
A cumulative commitment to illness management trajectory. An illness 
trajectory, incorporating the course of the disease and patients’ responses to it, may 
cumulatively and across all participants be discerned: 
1. The “deer in the headlight” period in the first months up to years, when 
patients were stunned by their diagnosis and the poor prognostic assessments. 
2. The immediate post-diagnostic phase, characterized as either a period of 
withdrawal for patients with slower progression lasting 2 to 5 years, or a 
period of aggressive treatment and frenzy for patients with rapid progression. 
3. The familiar and more stable phase, where some patients described a 
“calming” of their symptoms, some 5-6 years into illness. 
4. The late stage of the disease where organ involvement was most extensive and 
the symptoms most debilitating. 
This proposed illness trajectory is used to provide a descriptive account of patients’ 
commitment to their illness management and its changes. This is done by highlighting the 
type of work patients were more focused on at various phases of this trajectory. 
The “deer in the headlight” period. The focus of early involvement was on 
allowing oneself to grieve, overcoming fear, researching the disease, making sense of 
available options, sorting out recommendations for doctors, and finding scleroderma 
experts. Patients had to deal with their own fears and anxiety, as well as their loved ones. 
Searching on the Internet, halting it due to the shock and fear, and being propelled to 
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resume it were common. Concerns for children and the impact on them were 
overwhelming. 
The immediate post-diagnostic phase. After a doctor or a team of doctors was 
secured, those facing rapid progression had to undergo many tests and treatments. 
Perceptions of pain and fatigue were most intense and bothersome in this period. Finding 
their way through the healthcare system and getting to know their body’s reactions to 
treatments and tests were new learning experiences. Discovering how to evaluate the 
progression of the disease through body-listening and research, evaluating treatments, 
and finding alternative treatments like nutrition and exercise were among the work 
patients engaged with. If the initial medical providers were deemed not optimal, finding a 
trusted and competent doctor became a major focus of energy. Search for new treatments 
and clinical trials was ongoing. Vigilance for new and emerging symptoms was taxing. 
Patients spoke freely of their continued fears, anxiety, and depression. Dealing with the 
familial relationships and partners’ response to their illness was most intense, and 
attending to the psychological and emotional impact was considerable during this time. 
Participating in support groups and educational programs provided the needed support 
and information for some, while it frightened and overwhelmed others. For many, seeing 
patients in more advanced stages was unsettling and was avoided. With emerging 
disabilities, finding solutions to reduce the impact on their daily lives became important, 
and considerations of life-style changes including taking time off from work and 
switching to less demanding jobs took on an urgency. 
The familiar and more stable phase. With a shift to the middle stages of illness, 
the initial frenzy and confusion subsided, effective interventions were narrowed, some 
symptoms stabilized, patients’ understanding grew of the ebb and flow of their 
symptoms, the flares and calmer periods became clearer, their disease and somatic 
knowledge became more reliable, and medical visits and interventions became familiar, 
routine, and accepted. The focus of many shifted to improving the quality of life, the 
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management of symptoms, and the business of living with the disease beyond medical 
interventions, such as those related to solving daily problems, employment, increased 
disabilities, and family and social relations. Executing strategies to accomplish these 
goals, and researching and learning about the disease continued for many as regular 
features of their lives. 
As patients moved along, the focus of those with fewer disabilities became more 
outwardly. Whereas earlier on, contact with other patients felt overwhelming and 
avoided, in this stable period patients were reaching out to others. Many became active 
and involved in support groups and advocacy work, mostly to share their experiences and 
knowledge with other patients and the public, and also to learn from those in more 
progressive stages in anticipation of facing similar disabilities. The need for information 
and educational forums decreased, as patients felt these venues were geared toward new 
patients, and as they became more confident in their own knowledge. Some admitted to 
becoming complacent in keeping up with the latest information. For others, learning 
interests shifted from focusing on the disease to learning about new research and the 
management of disease. Attending venues, where patients with more severe cases could 
be seen, ceased to be jolting. Searching for what might have caused their illness lost 
importance; living and enjoying activities, being with loved ones that brought them joy 
and satisfactions, and eliminating situations and associations with people who put them 
or their bodies in stressful conditions took priority. 
The late stage. Distinguishing between new emerging symptoms and those related 
to aging or other causes became more confusing for some, as the threat of new organ 
involvement in later stages of disease increased. For some, new medical tests became part 
of their routines. Those with more progressive symptoms found themselves more limited 
and socially isolated and had their focus on attending to the increasing physical impact of 
the disease and managing the day-to-day difficulties. Some with slower progression 
  
206 
continued to be outwardly active by helping other patients through initiating support 
groups and mentoring them to take on more active roles. 
Throughout this illness trajectory, having access to competent and expert doctors 
was a paramount concern, and as doctors retired or moved, the effort to find new ones 
was ongoing. Body image distress and stresses associated with disabilities in public, at 
work, and in social situations were greatly burdensome; the economic issues and 
handling of employment, finances, medical expenses, and health insurance coverage 
weighed heavily on patients; and the negotiation of social interactions and management 
of familial stress were the added layers of strain in an already complex situation for 
many. Efforts to manage these complexities through problem solving, engaging 
creatively, and educating others were considerable. 
In the next section, a discussion on findings related to strategies and learning to 
answer the second research question is presented. 
Research Question 2: Patients’ Strategies and Their Learning 
The second research questions consisted of the following components: “What 
strategies do scleroderma patients use to be involved, and how did they learn them? What 
do they perceive as impeding or facilitating their learning? How do they overcome the 
barriers?” 
Four strategies utilized by the interview participants were identified: taking a 
problem-solving/problem avoidance orientation; utilizing resources and advocating for 
themselves; being transactional and evaluative in obtaining care; and being open to 
experimentation. The findings indicated that participants learned informally on their own; 
learned socially in support groups; learned formally in educational programs and support 
groups; learned somatically through their bodies; but mostly learned incidentally through 
experiences and trial-and-error processes when solving problems. The participants 
attributed trial-and-error; previous experiences; availability of sources like support 
  
207 
groups, the Scleroderma Foundation’s newsletters and website; doctors; other patients; 
and their own ability to research online as facilitating their learning. 
As the site of illness, the body is a complex biological system made up of 
subsystems of interacting components through biochemical, neural, and thermal feedback 
loops and pathways. When an autoimmune chronic disease, with unknown etiology, 
throws this complex system into disarray, patients find themselves in the surreal position 
of being at once the chaotic system at war with itself and the one who interacts with it, 
and the other complex systems (medical and social), in the hope of taming it. Complex 
systems exhibit highly variable behaviors, behaviors that are non-linear or chaotic 
(Brugnach et al., 2008). Examples include the wax and wane of symptoms, fluctuating 
intervals of stability and deterioration, and unpredictable responses to medication 
compounded by a multiplicity of interventions with unknown interactions. These account 
for some of the complexity seen in scleroderma. Corbin and Strauss (1985) observe 
another level of complexity that exists in the interactions of a dynamic disease course and 
enactments of various work. To create a relative equilibrium in this system, their model 
suggests, the management of illness needs “strategies and techniques for control which 
are adjustable and changeable, in response to various contingencies that arise … with an 
emphasis on adaption to change” (p. 240). This “management in process” is similar to 
“muddling through,” “incrementality,” “organized anarchy,” and “strategy-as-practice” 
argued by Bakir and Todorovic (2010) in situations where a means-end relationship is 
ambiguous. McCool, Freimund, and Breen (2015) suggest a number of approaches to 
engage with complexity. These include scenario planning to predict potential future 
problems and situations; using connections and networks and leveraging them to obtain 
desired outcomes; using models and simplifications (models could be as primitive as 
deferring to experts, or establishing routines); accepting and understanding complexity 
through experimentation; employing different forms of knowledge; and learning 
continuously. Using these as possible approaches, four strategies employed by the 
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interview participants were identified as: taking a problem-solving/problem avoidance 
orientation; utilizing resources and advocating for themselves; being transactional and 
evaluative in obtaining care; and being open to experimentation. These strategies are 
collectively discussed in the next section. 
Strategies. The four strategies identified as interview participants’ primary 
strategies had similarities with what McCool et al. (2015) suggested as approaches to deal 
with complexity. However, patients’ strategies lacked the intentionality and thought-out 
formalities of McCool et al.’s list. Participants’ strategies were themes identified in 
approaches that participants took when facing problems. As such they were by no means 
pre-meditated and consciously planned courses of action, but seemed to have emerged 
incidentally through trial and error and in response to specific problems. These may be 
viewed as learning processes and are discussed in that context. 
Five types of learning were reported in these patients (informal, formal, social, 
experiential, and somatic). While all these learning types played a role in patients’ 
involvement, learning experientially was most relevant in answering research question 2. 
Learning from experience, specifically Marsick and Watkins’s (1990, 2001) incidental 
learning lens, is utilized to explore the learning that might have precipitated the above 
strategies in order to answer this research question. 
Learning. For patients in this study, the burden of disease provided plenty of 
uncertainty, doubt, and problematic situations, and disjuncture when patients were 
“consciously aware that they do not know how to act” (Jarvis, 2006, p. 9). From the 
perspective of learning, a chronic illness provides an opportune venue for learning. This 
is so because not only it is “a context of experience in which problems naturally suggest 
themselves” (Dewey, 1930, p. 183), but also the “quality of problem it involves” (p. 183) 
is “a personal thing of such a nature as inherently to stimulate and direct observation of 
the connection involved, and to lead to inference and its testing” (p. 183). 
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At one level, the findings showed that almost all patients took an intentional 
approach to learning. This intentionality could be discerned through phrases such as 
“knowledge is power.” Generally, however, in daily encounters, learning was informal 
and incidental. The inability of patients to pinpoint how they learned hinted at the 
incidental nature of learning that went unnoticed. Marsick and Watkins (1990) defined 
incidental learning “as a byproduct of some other activity, such as task accomplishment, 
interpersonal interaction, sensing the organizational culture, trial-and-error 
experimentation, or even formal learning” (p. 12). They further added, such learning 
“almost always takes place although people are not always conscious of it” (p. 12). 
Marsick and Watkins’s (1990) informal and incidental leaning model relies on the 
problematics of a given situation and the ensuing cycles of trial and error as the impetus 
for learning that ultimately would bring about a solution. These problematics, starting 
with a trigger causing dissatisfaction, lead to reframing of experience by interpretation of 
the experience one is facing and consideration of alternative solutions through 
comparison to previous experiences. Other steps, not necessarily in a sequential manner, 
include the possible need for acquiring new knowledge, resources, or skills; taking action 
on the proposed solution; and assessing the consequences and drawing lessons, resulting 
in learning that would help in the reframing of new situations. 
The constant barrage of triggers from unsatisfactory responses of their own bodies, 
to inadequacies of healthcare system, inhospitable environments to their disabilities, 
including the weather, inaccessibility of public places, and social stigma due to their 
appearance were sources of dissatisfaction for participants. Many of these triggers did not 
go beyond frustration, anger, and feelings of helplessness. However, there were notable 
areas where patients were able to interpret their experiences by reframing the problem, 
finding solutions, and learning. The most prominent was in regard to receiving medical 
care. The frequency of doctors’ visits and lab work provided for repeated experiences that 
afforded patients opportunities to encounter problems and ultimately reframe their views 
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in the process of finding a solution. The criteria for the type of doctors they looked for, 
and what treatments and tests they were willing to undertake, for example, were arrived 
at from their assessments in problem-solving situations they encountered in their doctor 
visits and when subjected to medical procedures. Devising assessment criteria as learned 
lessons, in a tacit way, was a striking feature of learning in this context. 
As patients learned and gained experiences, established a reliable medical team, 
and got to know the staff, technicians, and procedures, the levels of dissatisfaction and 
problems that were shared by participants reduced considerably, only occurring when 
established medical routines were interrupted, such as when a doctor moved out of a 
practice, a need for a new specialist arose, patients found their doctors in retirement 
mode, or changes in insurance coverage occurred. Thus, learning in this area was most 
intense in the early years of the disease. 
On the other hand, with the passage of time and increased disabilities, participants 
were in more problematic situations in dealing with their disabilities and found ways to 
reduce or circumvent problems through practical solutions, gadgets, and approaches. 
Experimenting with unconventional therapies was one area in which they looked for 
alternative solutions outside what was offered by their medical team. 
Marsick, Watkins, Callahan, and Volpe (2008) posit that if the learner is stimulated 
to proactively look for options and acquire the skills to implement solutions, use 
creativity to exploit more options, and reflect critically to make the tacit beliefs and 
knowledge explicit, incidental learning would be enhanced. The varying levels of 
proactivity and efforts in finding creative solutions were a differentiating factor among 
interview participants. Proactivity relates to “a readiness to take initiative, an alertness to 
the environment and to opportunities it might afford learning” (p. 576). Creativity is what 
“enables people to imagine alternatives and think beyond their current circumstance or 
point of view” (p. 576). Nicolaides and Yorks (2008) attribute such a creativity to the 
interactivity aspect of experience, and its role of being “the catalysis for creativity and 
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innovation” (p. 2), especially in complex and dynamically changing environments. The 
proactive investigation of options and skills to implement solutions and use of creativity 
often went hand in hand. These were manifested, for example, in how patients found the 
right person to solve their problems, who in turn facilitated a creative solution. 
The ability to enlist others, including those in formal positions (nurses, insurance 
company representatives, etc.), to find solutions repeatedly showed up as a major strategy 
to solve problems for many participants, and it seems it was learned by replicating their 
experiences through assessing “similarities or differences and use interpretation to make 
sense of the new situation” (Marsick et al., 2008, p. 577). This is using analogies in the 
service of solving a problem. The strategy to advocate for their needs and leverage 
resources was one area in which this type of analogical reasoning could be seen. 
Gavetti and Rivkin (2005) stated that when people “reach back to an earlier 
experience for a solution, they are using analogy” (p. 56) and argued that analogical 
reasoning was the middle ground between the two extremes of trial and error (in 
ambiguous settings) and deduction (in information-rich settings). Yorks and Nicolaidas 
(2012) considered using analogies as a strategic learning tool. A number of patients used 
their experience in advocating for clients in their professional life as models to advocate 
for themselves. Some patients noted the experiences of having to advocate for their 
children as templates. Yet, many who were unable to pinpoint specific situations spoke of 
a cumulative learning in acquiring the skills and mindset needed for advocacy through 
living, or vicariously through watching family members operating in certain roles and 
positions, such as in the political arena. More generally, transferring knowledge and skills 
from their professional lives and looking for similarities in their illness situation to 
utilizing these skills were common practices. Another area where patients drew on their 
previous experiences to frame a new situation was in anticipating problems. Again, this 
approach was used in the context of medical problems, but also in regard to the 
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functioning of their own bodies and levels of fatigue in order to manage familial and 
social obligations. 
The ability to engage others to solve problems was not only about proactivity and 
reaching out, but also about a willingness to accept help. Generally, the perception of 
vulnerability by others accorded the patients legitimacy in asking for help, and such 
requests elicited more positive responses by others. At the same time, the perception of 
vulnerability by patients themselves and beliefs about how help should be given or taken 
was limiting to their proactivity. Some of these beliefs were alluded to in Chapter IV 
under relationships with family and friends. 
These types of unexamined assumptions and beliefs are major barriers to adult 
learning (Mezirow, 2009). Reflecting on the underlying tacit and taken-for-granted 
assumptions “may help learners rethink situation in which they find themselves and 
re-frame their understanding for the kind of learning they might need to undertake” 
(Marsick et al., 2008, p. 571).  
Verbalizing the tacit assumptions that one currently holds is a difficult task. It was 
much easier for patients to speak about the tacit assumptions they had previously held. 
Charmaz (1983) states, “Ill persons often become highly aware of previously taken-for-
granted aspects of self because they are altered or gone” (p. 170). This alteration in taken-
for-granted assumptions displayed itself in a few participants’ attitudes and beliefs 
regarding received medical knowledge. This was discussed previously under the threat to 
the credible authority of doctors. Such critical examination of one’s beliefs provides 
personal insight, and insight, Yorks and Nicolaidas (2012) argue, is “an essential 
foundation of strategic learning” (p. 186). Alhadeff-Jones (2016) suggests that life is not 
just a series of events; there exists a rhythm or pattern to our life experiences. A rhythm 
suggests continuity, discontinuity, and dimensions like “patterns,” “periodicity,” and 
“movement.” He contends that our strategies and responses, whether conscious or not, 
“tend to follow existing behaviors that repeat themselves,” (p. 274) and many times “so 
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much suffering comes indeed from the incapacity of individuals to change the strategies 
they mobilized in order to assert their own autonomy” (p. 275). The attention to and 
consciousness of these rhythmic patterns may frame one’s learning, specifically if it is 
transformative learning. In this light, utilization of some of the strategies seen in 
participants may fit a model of unconscious repetition of strategies that worked 
previously, not entailing substantial learning. Neither Alhadeff-Jones’s framework of 
rhythmic learning nor the transformative learning lens was utilized to collect or examine 
data; however, it was apparent that, for some participants, this illness was a disruption 
and discontinuity of a magnitude like no other in their lives, prompting a conscious 
reexamination of strategies and the adaptation of new ones. For most, this may be 
characterized as a situational awareness in certain context. One patient stood out, 
however, who repeatedly made contrast to her patterns of behavior and beliefs prior to 
her illness. The mere ability to draw these contrasts and to differentiate how her views 
and actions have changed in a systemic way hinted at transformational learning. 
Impediments and facilitators of learning. The incidental nature of learning in 
these patients and a conception of formal learning as the real learning held by the 
participants precluded arriving at a direct answer to what they perceived as impeding or 
facilitating their learning and a means to overcome the impediments directly. Outside 
general comments as to the availability of information, the usefulness of the Scleroderma 
Foundation’s newsletters and publications, helpfulness of support groups in providing 
materials, their own ability to research and find information on the Internet and through 
more formal means, the notion of learning and impediments, and facilitators to it were 
not available from these data. 
The inferences made using Marsick and Watkins’s model pointed to unsurfaced 
beliefs and assumptions, and the lack of proactivity and creativity as major impediments. 
As was illustrated previously, beliefs about the nature of help, how it was asked, and 
given were a major barrier for some patients. The inability of patient to place themselves 
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in the illness spectrum and the mindset of not exposing themselves to patients in more 
advanced stages as an avoidance strategy were another barrier. This was true in newly 
diagnosed patients, but also was seen in patients with more than a decade of living with 
the disease. Lack of proactivity, by relying on their doctors and assuming a passive role 
regarding information and experimentation with interventions, was another observed 
barrier. Some patients were more creative in devising tangible solutions for their 
disabilities through gadgets, while others were more creative socially in advocating for 
themselves. To the degree one was lacking the creativity in one area or another, their 
ability to deal with problems and learn through them was limited. 
In terms of structural barriers, doctors’ interactions played a substantial role. The 
more collaborative doctors provided for experimentation and mutual learning. Patients 
who reported that their health providers made time for conversation and discussion 
around symptoms and therapies and did not assume the mantle of total authority 
displayed engagement in the process of learning and figuring out their illness through 
these collaborations. On the other hand, the health providers who told patients they had to 
educate themselves but viewed that learning as something patients did outside their 
offices and on their own frustrated their patients’ attempts to learn. Providers who 
disregarded or trivialized patients’ information-seeking attempts by making them feel ill-
equipped to understand such information took away one means patients had to validate 
their understanding of their illness. This highlights the divide between the medical 
perception of care, and the illness care that patients of chronic illness expect from their 
providers. 
The structure of support groups and educational forums where patients were mixed 
regardless of their disease subtypes or other variables such as age and disease duration 
posed some challenges for patients, leading to their avoidance of such venues, where 
dialogue and sharing of experiences could have occurred and learning promoted. The 
nature of educational materials that address the needs of new patients, but have little to 
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offer to patients in later stages, is difficult to address and poses a barrier to learning. 
Another structural barrier is a lack of creativity in utilizing the expertise and learned 
lessons of experienced patients for the mutual benefit of newer patients in a format that 
goes beyond local interactions. 
In summary, through the incidental learning lens of the Marsick and Watkins’s 
model, the four strategies listed for the interview participants may be viewed as steps 
along a problem-solving process. These steps occurred in response to triggers and the 
appraisal of unsatisfactory situations leading to learning in the process of finding a 
solution to encountered problems. Learning occurred in some key areas important to 
managing the illness, particularly in interactions with the healthcare system. Surfacing 
tacit assumptions, creativity, and proactivity deemed to facilitate learning, while 
structural barriers, mostly outside patients’ direct control, played a role in impeding 
learning. 
Research Question 3: Impact of Social Interactions on Involvement and Learning 
The third research question was concerned with the question, “How are social 
interactions, particularly, support group facilitation/participation, perceived in terms of 
involvement and learning?” 
Participants discussed their involvement in support groups in terms of their 
contributions to and benefits from such participation. Leaders saw their involvement as 
sharing their experiences and vision, and utilizing their skills and resources for the benefit 
of other patients. Members described the involvement as an opportunity for learning, 
interacting with others, and joining forces for a greater cause, such as fundraising or 
helping other patients. Non-members described their non-involvement in support groups 
as being caused mainly by a fear invoked in seeing patients in more advanced stages, and 
the negativity and complaining demeanors of other members. 
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In interpreting these findings, two opportunities for significant interactions for 
patients were found to be those with doctors in and out of clinical settings and other 
patients in the context of support groups and educational forums. A third opportunity, 
electronically through patient portals, was not considered in this study. 
A total of 64% of the interview participants saw four or more doctors. Interaction 
with medical professional for scleroderma patients of this study, therefore, was extensive 
and made up a sizable portion of their illness experience. Using the PAM measure, 
Alexander et al. (2012) found that three variables—higher perception of interpersonal 
exchange with doctors, frequency of out-of-office contact, and reports of fair and 
respectful treatment free of bias (racial/ethnic, socio-economical, gender, disease-specific 
misjudgments) —were associated with higher patient activation. Interview patients 
indicated that characteristics such as listening, explaining, considering patient’s 
preferences, looking the patient in the eye, and spending adequate time in visits were 
among the most important metrics by which they judged the quality of their interactions. 
Some interview patients spoke of having cell phone numbers and email addresses 
of their doctors for out-of-office access, and reported instances when they included their 
doctors in fundraising events and walks, had them as speakers in support group meetings, 
or had lunch with them. This researcher, having attended two national scleroderma 
patient conferences and a number of educational forums, observed doctors as invited 
speakers in these venues to be accessible to patients after their talks and to be mingling 
informally with them throughout the events. A number of patients spoke of these doctors 
as their friends and partners in fighting the disease, and many considered scleroderma 
experts as “special” and uncommonly compassionate. Such out-of-office interactions are 
hypothesized to increase patients’ involvement by reducing the power differential and the 
levels of passive and paternalistic roles that patients and doctors may take on otherwise 
(Alexander et al., 2012; Roter, Larson, Sands, Ford, & Houston, 2008). 
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On the other hand, referencing doctors as “they,” expressions such as “they talk 
down to you, like you are stupid,” or “[saying] Trust me, that is not good enough 
[reason]” were indicative of patients’ negative perceptions of not being treated 
respectfully or without bias. Alexander et al. (2012) reported a 5.55-unit increase in 
patients’ activation per 1 unit increase in respectful treatment level, where a 4-6-unit 
differential was considered significant. As such, positive doctor interactions may be 
viewed as an important form of support, impacting patients’ activation and involvement. 
In this dissertation study, the perceived EMI (Emotional and Informational) 
support was associated with high activation. This type of support provides “expression of 
positive affect, empathetic understanding, and the encouragement of expressions of 
feeling/offering of advice, information, guidance, or feedback” (Sherbourne & Stewart, 
1991, p. 707). Positive patient-physician interactions entail such offerings and could 
provide a particularly powerful form of EMI support for patients. The role of doctors as 
credible authorities in providing hope and reducing the uncertainty of disease was 
previously discussed, and providing positive interaction is argued to be linked to patients’ 
activation. 
In addition to potential support by doctors, support groups can provide EMI and 
POS support. Fifty-two percent (13) of interview-participants were either leaders (7) or 
members (6) of support groups. These participants provided descriptions indicating that 
interacting with other patients who truly and empathically knew the experience of the 
illness was one of the most import reasons to join. POS support provided in support 
groups could be like no other, as expressed by a leader: “If you make jokes about being 
sick and debilitated, they [families] do not find it funny, but we do, and what a release 
[that is].” In addition, informational support in the form of practical information and 
guidance, in particular those related to doctors’ referral, medication side effects, and 
solutions to everyday difficulties through the subject-matter expertise of other patients, 
was deemed very valuable by most interview participants. 
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Specifically, leaders in this study indicated that sharing of experiences and utilizing 
their skills, knowledge, vision, and resources for the benefit of other patients were the 
main motivation for their involvement with support groups. For members to have social 
interactions with people who understood and were empathic, to learn, and join forces for 
a greater cause was the main reason. These findings were in agreement with Embuldeniya 
et al. (2013), who undertook a meta-study of 25 articles in chronic illness support group. 
In this study, mentors’ (peer leaders’) perceived impact of support group participation 
included the sharing of their experiential knowledge, sense of reciprocity, helping, role 
satisfaction, and emotional entanglement. The sense of connection, finding meaning, and 
reducing isolation were commonalities with members. 
These reasons, expressed by those connected to support groups, indicate their 
perceptions of their involvement as getting or giving support, or both, and learning 
through others’ experiences. A more nuanced understanding may be obtained by 
inquiring into reasons for not joining support groups, as the above reasons did not seem 
to have been motivating factors for 48% of the interview participants and nearly 68% of 
the survey participants. 
Reasons cited by the interview participants for not joining were grouped into four 
categories: logistical, personal, group dynamics, and programming. These categories 
were similar to three themes found by Gumuchian et al. (2017) in a three-factor model 
describing data obtained from 242 scleroderma respondents to a 21-item non-attendance 
survey: personal, practical (similar to logistical), and beliefs about support groups (e.g., 
too negative, similar to the group dynamics category). In that study, the two items with 
the most ratings of “important” or “very important” were “already having enough support 
from family” and “not knowing any scleroderma support groups offered in my area” 
(p. 4). Given that AFF (Affectionate) support was the highest form of support reported by 
survey-respondents (mean of 76.1 and median of 92.0) in this dissertation study, one may 
infer that Gumchian et al.’s sample may have enjoyed the same level of support and 
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equated this type of support received from family with what was offered in support 
groups. In contrast to Gumchian et al.’s findings, the two major reasons expressed by 
interview participants were the fear invoked by seeing patients in more advanced stages 
(expressed by 24% of participants) and the negativity of groups (32%). 
Mazanderani, Lock, and Powell (2012) observed the phenomenon of fear or stress 
invoked by seeing other patients among Parkinson’s and motor neurone disease (MND) 
patients. Similar to findings of this dissertation study, patients were seeing a deteriorated 
version of themselves in other patients, but simultaneously considered themselves 
different and unique. Mazanderani et al. argue that this creates an epistemic tension that 
patients need to resolve in order to value other patients’ experiences and have an 
empathic relationship with them. These conditions may be viewed as prerequisites for 
support group participation. Mazanderani et al. suggest that patients primarily negotiate 
this tension through the metaphor of being differently the same. This “cultivation of sense 
of difference” labeled in this dissertation as individualizing was previously reported as 
part of somatic knowing of the participants and is in agreement with Mazanderani et al.’s 
assertions. 
The findings of this dissertation study based on those who participated in support 
groups or educational forums, however, suggest that, ironically, one mechanism to 
determine one’s “difference” is through observations of other patients afforded in support 
group meetings and educational forums. These venues, by allowing patients to gauge the 
extent of their symptoms in comparison to other patients, provide for a mechanism to 
locate themselves in the spectrum of disease and, by extension, imagine a future. In this 
sense, interview participants who got involved with support groups were in two camps: 
those who could see themselves as different now but wanted to observe and learn how 
their illness might become, and those who knew they were different because they had 
lived with disease long enough to have developed a solid footing and wanted to help 




This study started off by inquiring into out what scleroderma patients’ commitment 
to their illness management looked like. In answering this question, the PAM-13 
measure, as one of the few available scales to measure patients’ active role, was utilized. 
At the outset, it was assumed that this measure would not capture all dimensions of 
patients’ commitment to their illness management. This assumption was proven correct 
through participants’ comments on the margins of questionnaires, the patterns of response 
to the measure’s items, and through the qualitative findings based on patients’ interviews. 
These findings indicated that patients’ commitment to the management of their illness 
entails attending to many concerns beyond those related to the physical impact of the 
disease, as discussed in this chapter. 
The existence of levels and stages of activation and engagement, as suggested by 
Hibbard et al. (2004, 2005) and Graffigna, Barello, Bonanomi, and Lozza (2015) was 
also detected in this study. However, whereas Hibbard et al. attributed these variations to 
differences in knowledge, skills, and beliefs among patients and Graffigna et al. saw 
psychosocial processes as the culprit, the findings of this study suggest a different 
framing. Specifically, the illness trajectory entwined with uncertainty and patients’ 
experiential learning in dealing with the illness-related problems and the use of strategies 
to surmount them shaped the patients’ commitment to their illness management. These 





Figure 5.1. Commitment to illness management 
 
In this sketch, commitment to illness management moves in tandem with illness 
trajectory and phases of the disease and the experiential learning of living with the 
illness. The mediating factors are strategies and uncertainty. Level of uncertainty is 
greater early on and may subside somewhat when patients feel more stable; it increases 
with deterioration of symptoms and fluctuates with the wax and wane of disease. As 
patients learn experientially to deal with their problems, their repertoire of strategies 
increases, helping them to better manage their illness in spite of increasing uncertainty 
due to the downward trend of disease and aging. The full development of a model was 
beyond the scope of this exploratory and descriptive study. In future work, this model 
will be fully developed, and a measure to assess patients’ commitment to the 
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This model does not merely propose a different semantics (learning vs. knowledge 
and skills, or uncertainty and strategies vs. psychosocial processes), but puts the patients’ 
experiences of illness front and center and frames commitment to illness management as 
a process of experiential learning in tandem with the needs of the disease as it is lived day 
in and day out, organically and holistically. Therefore, it confirms the agency of patients 
through their own learning processes as central to their engagement. 
This sample, by the virtue of having an illness with little known sanctioned medical 
knowledge and solutions and a lack of formal self-management program, was shown to 
have traversed different phases of their illness, organically and through their own 
learning. However, uncertainty and lack of knowledge about a disease are not unique to 
scleroderma. In their book on lupus patients, Price and Walker (2015) state: “Lupus is a 
condition that challenges the certainty for which contemporary medicine strives and 
throws into sharp relief the difficulties associated with diagnosing, treating and managing 
conditions that have uncertain and contested aetiologies, treatment approaches and 
prognoses” (p. 35). Other autoimmune diseases, like fibromyalgia (Johnson, Zautra, & 
Davis, 2006), also put patients under uncertain and ambiguous conditions. The fact that 
many of these patients are able to engage with and manage their illness does not deny the 
importance of programs and structures that can facilitate this process. A number of 
recommendations are provided in the next section that are aligned with a belief in the 
benefits of such instrumental and short-term interventions. However, the findings of this 
study questioned the fundamental issue at the heart of patient education programs and the 
care delivery systems that ignore the contribution of patients’ experiential learning and 
fail to incorporate patients’ illness experience into models of care. This includes models 
assessing patients’ engagement, activation, and involvement marketed to healthcare 
providers with the intention of promoting patient-centered interventions. Weeks and 
Weinstein (2016), in their book, Unraveled, quoted a cancer patient whose definition of 
patient-centered care was that of “patient better be in the center of and in charge of his 
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care, because no one is” (p. 42). Sadly, this indicates the cynicism of patients and how 
far-removed their experiences are from healthcare practices that claim they want them 
involved. English (2012) echoes the same, observing: 
Ideologies such as individual-focused health education, professional as 
all-knowing purveyors of health, and citizens as consumers of expert 
medicine have come to dominate the Western world. These ideologies have 
become hegemonized so that some citizens see themselves subject to the 
machinery of hospitals and evidence-based medicine in which their health 
needs are not always met. A revised theoretical approach, rooted in health 
promotion, works with learners in participatory ways to reclaim health. 
(p. 17) 
It was argued in the introductory chapter of this dissertation that the real-world problem 
of understanding how patients should or choose to have an active role in their own care is 
critical in addressing the mounting chronic disease problem faced by healthcare systems. 
Viewing patients as learners and engaging with them in collaborative and participatory 
ways that bring in their experiential knowing, as exemplified by some health providers of 
patients interviewed in this study, will be an important step in addressing this problem 
and reframing the nature of health delivery and health education. 
In the next section, reflection on research, and the conclusions and 
recommendations based on study’s findings and discussion are presented. 
Reflection on the Research 
When interview-participants were asked to comment on the findings of this study, 
the comments of one participant, who had extensive contact with patients in various 
capacities, seemed to indicate that the variations in the sample covered the breadth of 
patients in terms of their illness manifestations: “Thank you for sharing your findings. 
They are what I would expect and seem to run the gamut, which is typical because no two 
patients are alike.” Another participant expressed his views through a phone call. His 
critique of the study included the lack of educational and, by extension, socio-economic, 
  
224 
and racial/cultural diversity of the sample, and a want of attention to the suffering of 
scleroderma patients in terms of understanding and support within families. 
Another patient’s comments confirmed the critical role that trusted health providers 
play in encouraging and giving hope to patients to carry on, and also point to varying 
levels of comfort patients have with ambiguity. She saw the “wait and see approach” of 
her doctor 
as a positive because I had never thought in terms of “nothing could be done 
about it.” Now, as well as then, there still is no clear understanding of what 
the disease is or what can be done about it. Nevertheless, I do not recall 
experiencing any anxieties associated with lack of a well-defined protocol of 
treatment. I felt confidence in my doctor. In spite of the fact that my disease 
progressed to total disability, what I remember most is my doctor 
encouraging me to continue my life activities to the fullest extent of my 
ability. The result is that I have been able to have a full life, and now … am 
regarded by some doctors as possibly never having had scleroderma. Of 
course, they never saw me when I displayed the classic symptoms. Nor did 
they have access to my medical records when those symptoms were present. 
She concluded, “Your incisive summary makes me feel that the ways in which I have 
been involved with my ‘illness’ have been positive and appropriate.” 
Lastly, another patient’s comments indicated that the findings had resonated with 
her experience of illness: 
I thoroughly enjoyed reading your findings! I am interested in your 
future summaries and information.... I most often conclude that non-
Scleroderma affected people (those who are not sufferers of the disease) do 
not, and possibly never will, understand the way Scleroderma has changed 
us. Your conclusions have proven that I need to rethink my opinions! You 
seem to understand quite well!… You have successfully captured and shared 
the information given to you- good work and many thanks! 
These commentaries, although limited in number, provide some measure of 
assurance that the study has been on the right track and has captured the salient points of 
involvement with these patients. During the course of this study, this researcher has come 
to view scleroderma as a mighty river that patients found themselves thrown into, 
navigating its meandering and murky waters. Through this process of navigation, they 
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showed their commitment and involvement. The perseverance, resilience, ingenuity, and 
determination that were displayed by the 25 participants of this study were 
overwhelming, humbling and a testament to the human spirit. I feel privileged to have 
been welcomed to their homes, offices, and neighborhoods and to have been trusted with 
accounts of their struggles and experiences. 
This study started off with four general assumptions: Patients want to be involved 
in their own care; patients want to know about their diseases and treatment options; 
whereas in acute illnesses a passive role is a welcome option, with chronic conditions, 
most patients are compelled to become engaged with their illness; and commitment to 
illness management and becoming involved in one’s care are not easy, but people learn 
through the process of doing it. In conclusion of the study, this researcher has come to the 
realization that re-phrasing some of these assumptions is in order. Committing to be 
involved or not is not a binary choice. Patients are involved and involvement is a process 
that, like most processes in life, includes a good deal of learning in different forms, 
consciously or unconsciously, to discover the most effective ways of going about living 
and managing an illness. Learning about the disease constitutes a part of this learning, but 
by no means may it be equated to involvement; neither the unwillingness to learn at a 
given time nor the delegating of that task to others may be viewed as a lack of 
involvement. Involvement demands support by all those who can provide it to patients. 
Through family, health professionals, other patients, support groups, and educational 
entities, involvement takes shape. 
What sets scleroderma apart from more common illnesses is the degree to which 
there is a paucity of knowledge about it. From the perspective of the day-to-day living 
with the illness and its impact, however, there are commonalities with other immune 
diseases and chronic conditions. Fatigue, pain, disability, uncertainty, fear, stress, and 
depression are all the warp and weft of most illness fabrics. As such, many findings of 
this study do not stray far from what most patients with chronic diseases experience. 
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Conclusions and Recommendations 
Twenty-five scleroderma patients and 201 survey patients painted descriptions of a 
devastating and debilitating disease and their struggles to live with it and carry on. Their 
perceptions and descriptions informed this study in understanding their commitment to 
illness management, including how they were involved in dealing with their illness, how 
they learned to do so, and how social interactions and support groups impacted their 
involvement. Based on these findings and analysis, four conclusions are drawn. 
Conclusion One: Patient Commitment to Managing Their Illness is a Complex 
Process 
Scleroderma impacts the patients on three fronts: physically through an assault on 
the body, socially by altering roles and identities, and psychologically by engendering 
uncertainty. Patients’ commitment to manage their illness and strategies they use are 
concurrent attempts to mitigate these impacts and create a relative equilibrium in a 
complex situation. The degree of these impacts fluctuates throughout the illness 
trajectory. Far from a simplistic view that patients are either involved or not involved, 
involvement is a spectrum where at each point a patient may find him/herself in complex 
negotiation with these multiple needs in attending to his/her illness. Patients may become 
stuck at certain points or intervals, but overall forced to move, if for no other reason but 
the deterioration of their symptoms. Understanding this trajectory with its physical, social 
and psychological elements, the larger temporal view of where patients are at a given 
time and the appreciation of existence of a movement along this path will allow patient 
commitment and involvement to be viewed as a process and not a static patient 
characteristic. As such, it is rich in learning potential: learning in dealing with disease, 
learning in living with illness, and learning to develop and transform. 
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Conclusion Two: Importance of Managing Uncertainty 
The perception of uncertainty and challenges in dealing with this uncertainty are at 
the core of patients’ ability to engage with their illness. Patients have different levels of 
tolerance for ambiguity. For most patients, decreasing uncertainty is important. This 
study found that the patients’ own attempts to chart the progression of disease through 
information-seeking and drawing similarity or dissimilarity to other patients; passage of 
time, the learned patterns of wax and wane of symptoms, and occurrence of periods of 
stability; and health-providers’ willingness to provide assurances or share an assessment 
are the main means through which patients reduce their perceived levels of uncertainty. 
The first two put the onus on patients who have differing levels of skill and resources to 
manage these. Health professionals have a fundamental role to play by understanding the 
importance of uncertainty management in the care of their patients, and the ongoing need 
for hope and assurance, so patients can carry on and move forward. 
Conclusion Three: Role of Support Groups Needs Further Study 
Higher social support enhances patients’ commitment and involvement, but is 
undermined by the underutilization of support groups. Survey studies by others suggest 
that this underutilization is due to a perception of not needing support or a lack of 
knowledge of and access to these groups. The interview findings of this study point to an 
undercurrent that seems to have been overlooked: support groups are paradoxical for 
some scleroderma patients in negotiating notions of being different and being the same. 
Further understanding in this area is needed, as support groups are venues for social and 
experiential learning and the promotion of involvement for patients. 
Conclusion Four: Learning Occurs Through Problem-solving 
Patients learn informally, formally, socially, experientially, and somatically. 
However, they learn mostly informally and incidentally through solving problems. This 
learning occurs early in the illness trajectory facing dissatisfaction with the healthcare 
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system, and later in dealing with problems related to disability. Examining tacit 
assumptions and patterns of strategies that one utilizes can enhance patients’ learning. 
There were no indications that support and scaffolding to promote this type of 
examinations exist for this study’s participants. 
Based on these conclusions, the following recommendations for practice and 
further research are provided. 
Recommendations for Practice  
The following recommendations are applicable to patient education and advocacy 
practices, and professional development in dealing with scleroderma patients and other 
chronic conditions. The notion of illness trajectory and where a patient is located within 
this trajectory is an important concept to assess the needs of a patients, reduce 
uncertainty, integrate the illness, and learn to live with the physical impacts of the 
disease. Differentiating these needs, in addition to considerations of disease subtype, 
severity, age, and disease duration, may reveal programming content and presentation 
formats that are more conducive to meeting the needs and the learning of scleroderma 
patients. Facilitating critical thinking and examination of beliefs should be a part of these 
formats. 
Patients learn in multiple ways throughout their illness. The experience of a 
diseased body is an embodied experience like no other. Through the arts, movements, and 
other non-verbal methods, opportunities to express this embodied experience should be 
provided. These types of opportunities generally do not exist for patients, and efforts in 
creating programs to allow for patients’ participation in this manner should be advocated 
and encouraged. 
Given the extent of disabilities in these patients, helping patients integrate the 
disease into their lives by considering new roles and activities needs to be a part of 
patient education programs. Being active and feeling useful to others was one of the most 
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cited coping mechanisms mentioned by patients. Peer educators who successfully have 
done so and can share their own experiences, like many remarkable patients who were 
interviewed in this study, would be invaluable in this regard. 
Inclusion of opportunities in support group meetings to surface tacit beliefs and 
assumptions that are holding patients back would be more difficult to implement, but 
necessary to assist patients to enhance their learning and become more involved. 
Implementing training programs for group leaders to facilitate such discussions would be 
a first step in this process. 
Although having a chronic and life-threating disease at some level is a solitary 
process, the role that family, friends, doctors, other patients play in providing the types of 
support that engender more involvement cannot be separated from the patients’ journey. 
A difficult disease like scleroderma impacts the entire family. Family and caregivers’ 
education needs to go hand in hand with patient education. Facilitating discussions 
among patients and caregivers and family members, as well as providing specifically 
designed programs for caregivers, will go a long way in promoting the involvement of all 
stakeholders, in clarifying expectations and boundaries in familial relationships, and in 
allowing patients to learn without overly helpful caregivers taking away such 
opportunities. 
Professionals, from doctors and nurses to technicians and office staff, must also 
learn that patients’ needs for reassurance and hope, clarity and information, being heard 
and treated as individuals and collaborators, being believed, and being looked in the eyes 
are as real as their physical symptoms. Appropriate responses to these needs will provide 
for far more involved patients. 
Recommendations for Policy 
The Centers for Disease Control and Prevention (2015) have a four-pronged 
approach toward efforts in chronic diseases prevention and management: 
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(1) epidemiology and surveillance, (2) environmental approaches, (3) healthcare system 
interventions, and (4) community programs connected to clinical services. Based on this 
study’s findings, the following recommendations, aligned with the above approaches, are 
made: 
Fundamental health care system policy changes, specific to chronic conditions, are 
sorely needed. These include exemption from formulary restrictions, and deference given 
to physicians’ judgment and flexibility in the use of off-label medications when no tried 
and true intervention exists. Policies and regulations to prevent putting patients in the 
position of using ineffective drugs for months to prove inefficacy while dealing with 
onerous side effects need to be implemented. Removal of out-of-network limitations 
when patients have to cross state lines to specialty centers and to where clinical expertise 
exists will provide for more appropriate care and will remove major barriers to early 
diagnosis in cases that are difficult to diagnose. Furthermore, such policies would 
facilitate participation in clinical trials, as some clinical trials are not entirely free to 
patients and partial costs are expected to be passed to patients’ insurance. The out-of-
network coverage limits or eliminates access to these trials for many patients, not only by 
curtailing patients’ only viable option, but also by impeding the development of effective 
interventions in the long run. 
Coordination of care among multiple specialties is a major problem for patients 
with chronic illnesses and those with multi-morbidities. The current incompatibility of 
medical electronic systems put the burdens of dealing with systems’ inadequacies on 
patients themselves. Until technological advances and stakeholders’ cooperation allow 
for a seamless sharing of medical records, other intermediate measures to remove the 
onus from patients are needed. These measures may include more incentives for timely 
and automatic release and transfer of records to all care providers of a patient upon a visit 
or a major intervention; a system of regular training and education of office staff as to the 
existence of these systemic incompatibilities and their duties and procedures to remediate 
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the problems; and support and promotion of initiatives such as OpenNotes 
(www.opennotes.gov) and Blue Button (www.healthIT.gov), which provide for patients’ 
easy access to electronic health records.  
As was seen with the population of this study, the prevalent medical model of 
chronic care, with its focus on biological disease, leaves patients to themselves in dealing 
with the psychological impact of illness. An integrated approach, especially early on and 
in the form of teams of multi-specialty clinicians, social workers, and spiritual advisors 
working alongside physicians to heal the body and soothe the mind and soul, is 
desperately needed for all chronic illnesses. Examples of such multidisciplinary models 
need to be highlighted and promoted. 
Community interventions, such as self-management programs, have greater 
availability for certain chronic conditions like diabetes through local hospitals and health 
providers. By taking into consideration the commonalities in living a chronic disease and 
devising general programs to address common issues like disability, nutrition, exercise, 
fatigue, pain, and emotional and psychological issues, the isolation faced by many 
chronic patients may be reduced and educational resources may be shared more 
equitably. Local health entities need to be made aware of such needs and encouraged and 
enticed to implement such programs and outreach to patients whom they may not be fully 
aware of in their communities due to the smallness of their numbers and their needs for 
specialists outside local communities. 
As part of community design and interventions promoted by policies such as more 
walking/biking areas, physical education in schools, full-service groceries and farmers’ 
markets in underserved areas, attention to innovative designs in housing developments 
(outside nursing homes and care facilities) that take into account chronic illnesses as part 
of life and the aging process of majority of people need to be given consideration. Such 
innovative designs can facilitate elements of tangible support and self-sufficiency, which, 
in turn, could encourage a more active and involved posture toward one’s care. 
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Removing some of the daily agitations by providing more hospitable environments for 
living with disability may reduce the cost of care in the long term, as more patients opt to 
continue living in their own homes. 
Recommendations for Future Research 
This study inquired into the notion of patient commitment to managing their 
illness, primarily from the perspective of 25 patients with mixed scleroderma disease 
subtypes. Survey data of 201 patients provided additional insights into the role of support 
in involvement, and possible influences of factors such as educational attainment and 
disease duration in involvement. First, this study may be expanded in a number of ways 
by focusing on particular subgroups in the study such as those within a subtype of 
disease, a given age category, racial/ethnic make-up, or gender. The interview sample of 
this study, overall, had above-average education. The influence of education and income 
on patient engagement and involvement warrants further exploration in this population.  
The quantitative portion of this study collected categorical data and limited 
demographic information that generally are collected in this type of study. A more 
detailed questionnaire based on insights gained from this study may be developed, 
specifically for scleroderma patients. As an example, data related to disease duration need 
to go beyond the notions of early and late stages of disease perceived in biomedical 
research to what makes sense in the context of living with an illness. A nationwide 
outreach to have an adequate sample size is recommended. 
When this study was initiated, only one widely used instrument to measure some 
aspects of patients’ active role was available. Since then, a number of studies around a 
second instrument measuring patient engagement (Graffigna, Barello, & Triberti, 2015) 
have been published. Inquiry into the appropriateness of this instrument with this 
population of patients may prove to be a worthwhile effort. 
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Two male interview participants of this study had their spouses present while being 
interviewed. At times, these spouses offered unsolicited comments. Such participation 
was insightful in a number of ways, including the consideration of ownership of disease 
and involvement in its management as a shared project. A study to include patients and 
their partners or caregivers may provide not only more accurate and nuanced data, but 
additional insights into the role of caregivers and family members, and development of an 
expanded definition of involvement as a shared or familial enterprise. 
The notion of learning in this sample was explored mainly through the lens of 
informal and incidental, and experiential learning. A cursory look at somatic learning 
indicated that other ways of knowing were also involved in these patients’ encounters 
with their illness. This type of learning and knowing deserves further study, and this 
population seems to be a good candidate for such an exploration. Additionally, it was 
apparent that a number of interview participants had a transformative learning experience 
dealing with their illness, which had led to a sense of empowerment not seen in other 
participants. Utilizing the lens of Mezirow’s (1994) transformative learning theory to 
study these patients could provide another window into how such learning may occur in 
the context of a rare illness. In spite of studies in patient populations using transformative 
theory, the characteristic of this illness provides a unique situation unlike others 
previously explored. In addition, Alhadeff-Jones’s (2016) work in the rhythmic nature of 
learning in time might be an interesting framework to study this population, given the 
temporal nature of disease trajectory and its changing needs for learning. 
Similar to other autoimmune diseases, the majority of scleroderma patients are 
middle-aged women. Five men were included in this study, and the initial reaction of four 
of these men regarding their diagnosis consisted of doubt and disbelief of the expert 
opinion they were given. None of the women in the study expressed such a reaction. 
Belenky, Clinchy, Goldberger, and Tarule (1997) suggested five perspectives on 
women’s ways of knowing in developing a voice to be heard, and their choices as to 
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whom to hear. Women’s ways of knowing perspectives included silence, received, 
subjective, procedural, and constructed knowing. These perspectives collectively could 
provide another lens through which to explore learning as a developmental process, 
particularly as it relates to the notion of received knowledge in a disease where formal 
and expert knowledge is limited. 
Further research into various aspects of support groups is needed to discover 
factors inhibiting attendance, programming needs, and training of peer group leaders. The 
phenomenon of being different and being the same merits further investigation to unpack 
the nuances involved. Further research in understanding emotional factors in perception 
of tangible (TAN) support may also be helpful for support groups. 
Lastly, it was argued that living with scleroderma, even though a rare disease, 
shares many commonalities with other chronic illnesses. A formal study of these 
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PARTICIPANT’S RIGHTS 
Principal Investigator: Shohreh V. Anand 
Research Title: Learning to be involved: What does it mean for scleroderma patients? 
    I have read and discussed the Research Description with the researcher. I 
have had the opportunity to ask questions about the purposes and procedures 
regarding this study. 
 
    My participation in research is voluntary. I may refuse to participate or 
withdraw from participation at any time without jeopardy to future medical 
care, employment, student status or other entitlements. 
    The researcher may withdraw me from the research at his/her professional 
discretion. 
    If, during the course of the study, significant new information that has been 
developed becomes available which may relate to my willingness to continue 
to participate, the investigator will provide this information to me. 
    Any information derived from the research project that personally identifies me 
will not be voluntarily released or disclosed without my separate consent, 
except as specifically required by law. 
    If at any time, I have any questions regarding the research or my participation, I 
can contact the investigator, who will answer my questions. The investigator’s 
phone number is (914) xxx-xxxx. 
    If at any time I have comments, or concerns regarding the conduct of the 
research or questions about my rights as a research subject, I should contact the 
Teachers College, Columbia University Institutional Review Board /IRB. The 
phone number for the IRB is (212) 678-4105. Or, I can write to the IRB at 
Teachers College, Columbia University, 525 W. 120th  Street, New York, NY, 
10027, Box 151. 
    I should receive a copy of the Research Description and this 
Participant’s Rights document. 
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    If video and/or audio taping is part of this research, I ( ) consent to be 
audio/video taped. I ( ) do NOT consent to being video/audio taped. The written, 
video and/or audio taped materials will be viewed only by the principal 
investigator and members of the research team. 
    Written, video and/or audio taped materials ( ) may be viewed in an 
educational setting outside the research ( ) may NOT be viewed in an 
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Research Description and Informed Consent for Interviews 
 
 
525 West 120th Street New York NY 10027 212 678 3000 
www.tc.edu 
RESEARCH DESCRIPTION and INFORMED CONSENT FOR 
INTERVIEWS 
 
DESCRIPTION OF THE RESEARCH: Many experts agree that patient 
involvement and activation in their own care and management of their illness are 
important in chronic conditions. Our understanding of what patient involvement is 
and how patients learn to be involved, and what helps or hinders such learning are 
limited, especially when it comes to patients suffering from rare and complex 
conditions. You are invited to participate in a research survey and interviews that 
will explore the views of scleroderma patients on how they are involved in 
managing their illness, and how they learned to do so. Based on your experiences 
as a scleroderma patient, the researcher is interested in obtaining your points of 
view on: a) how you describe your experience of involvement; b) what you have 
learned; and c) if you are part of a support group how you view your support group 
engagements in terms of involvement and learning; The research will be conducted 
by a doctoral candidate. Two interviews lasting approximately 60-90 minutes each, 
will be scheduled based on your availability at a location of your choice. Interviews 
may be conducted over the phone or Skype, if an in-person interview cannot be 
arranged. These interviews will be informal and conversational in nature. At any 
point in time you can decline to answer a question, request what you have said be 
deleted, or withdraw from the study. If you have not completed the survey portion 
of this study, the researcher may ask you to fill out the survey prior to the 
interviews. 
 
RISKS AND BENEFITS: The interviews will be conversational in nature and will 
concern your personal experiences related to your involvement in managing your 
condition. The interviews will center on topics that you most likely have discussed 
or thought about before. Therefore, the researcher anticipates the risk of engaging 
in these conversations to be minimal. However, in the event of emotional distress 
related to these interviews, appropriate psychological counseling referrals will be 
provided. There are no direct benefits for participating in this study. 
 
PAYMENTS: There are no payments or other compensation for participation in the 
study. 
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DATA STORAGE TO PROTECT CONFIDENTIALITY. You will be assigned a 
pseudonym and will not be identified. Your interview and your survey data if you 
mailed it together with the pink sheet or have taken in person before the interviews 
will only be known to the researcher. 
 
For purposes of accuracy, the researcher requests that the interviews be audio 
recorded. Transcriptions and recordings, along with any handwritten notes, will be 
kept in a locked cabinet in the researcher’s office. All electronic files will be 
password protected. The researcher will destroy the tapes and surveys after she 
defends her dissertation. 
 
TIME INVOLVEMENT: Your interview participation will take approximately 2-3 
hours, to be distributed over two 60-90 minute interviews. Interviews will be 
scheduled based on your availability, and will be held in a convenient location to 
you, or may be conducted over the phone or Skype. If you have to take the survey 
again, it will take an additional 10-20 minutes. 
 
HOW WILL RESULTS BE USED:  The results of the study will be used to inform 
the 
researcher’s proposed dissertation research for completion of the doctoral degree. 
The research data may also be published in professional journals and/or articles, or 
be presented in professional conferences. The findings and aggregate data (but not 
the individual data) may be shared with the Scleroderma Tri-State Chapter. Since 
all study participants will be given pseudonyms, and all identifying information will 






Informed Consent for Survey 
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INFORMED CONSENT FOR SURVEY 
DESCRIPTION OF THE RESEARCH: Many experts agree that patient 
involvement and activation in their own care and management of their illness are 
important in chronic conditions. Our understanding of what patient involvement is 
and how patients learn to be involved, and what helps or hinders such learning are 
limited, especially when it comes to patients suffering from rare and complex 
conditions. You are invited to participate in a research survey. The research will be 
conducted by a doctoral candidate and will involve a two-part survey where you 
indicate your level of agreement/disagreement with a list of 13 statements, and the 
type of social support available to you when you need it. This survey is a part of a 
larger study that explores the involvement and learning of scleroderma patients. 
Your completing the survey and mailing it, or completing it online, indicates your 
consent in taking the survey and conveying your opinions. 
 
RISKS AND BENEFITS: The risks of participating in this study are minimal. 
If there is discomfort in answering a question, you may skip the question or 
abandon the survey altogether. There are no direct benefits for participating in 
this study. 
 
PAYMENTS: There are no payments or other compensation for participation in the 
study. 
 
DATA STORAGE TO PROTECT CONFIDENTIALITY: Your survey will be 
anonymous: there are no personally identifiable information collected; the 
researcher does not have access to your name or contact information, and there is 
no way to link your survey and demographic information back to you, either by me 
or the Scleroderma Foundation. All mailed surveys go to a dedicated P.O. box and 
only researcher has access to this mailbox. The online surveys will be password 
protected and is not accessible by anyone except the researcher. The results of the 
survey will be presented in a combined and aggregate form, not individually. Paper 
surveys and saved electronic surveys will be kept in a locked cabinet in the 
researcher’s office. All electronic files will be password protected. The researcher 




TIME INVOLVEMENT: The survey will take approximately 10 to 20 minutes to 
complete. 
 
HOW WILL RESULTS BE USED: The results of the study will be used to inform 
the researcher’s proposed dissertation research for completion of her doctoral 
degree. The research data may also be published in professional journals and/or 
articles, or be presented in professional conferences. The findings and aggregate 
data (but not the individual data) may be shared with the Scleroderma Tri-State 
Chapter. 
 
Since the surveys are anonymous, there will be no way to identify the subjects 
in the publication of the research data. 
 
CONTACT INFORMATION: If you have any questions about this study or your 
rights as a participant in this research, you can contact the Principal Investigator, 
Shohreh Anand, or the Institutional Review Board at Teachers College, Columbia 
University at the contact information listed below. 
 
Principal Investigator: Shohreh 
Anand Phone: 914-xxx-xxxx 
Teachers College Institutional Review 
Board 525 West 120th St. Box 151 





Interview Contact Form 
 
INTERVIEW CONTACT FORM (PINK FORM) 
 
If in addition to this survey, you are willing to be interviewed about your views on how 
you are involved in managing your illness and learned to do so, and what helps or hinders 
this process, please read this page. Otherwise ignore this page. 
The interview part of this research project will explore the views of scleroderma patients 
on how they are involved in managing their illness and how they learned to do so. 
 
I am very interested in your perspectives and experience. Your participation in this study 
is completely voluntary. If you decide to participate you will be asked to have two 
interviews between 60 to 90 minutes each, depending on your schedule and availability at 
a time and location convenient to you. These interviews will be informal and 
conversational in nature, and may also be conducted over the phone or Skype. Your 
interview comments will be completely confidential. 
 
If you are interested in participating in interviews, please return this page with your 
survey, or email me at sva2111@tc.columbia.edu, or call me at 914-xxx-xxxx. Please 
note if you return this form with you survey, your survey will not be anonymous, but it 
will be totally confidential (no one other than the researcher will know about your survey 
answers). I prefer to get your survey with this form to better tailor my interview questions 
and prepare for our conversation. However, if anonymity is a concern for your, please 
either mail this form separately, call or email me instead, or fill out the survey online. 
 
Your name:  ________________________________  
Your   email: ________________________________ 
Phone number: (          ) ________________________________ 
Address: ________________________________________________  
            ________________________________________________________ 
The best way to contact me is through: 
 
    Email 
    Phone, best time to call is:    





Dear Scleroderma Patient, 
 
My name is Shohreh Anand and I am a scleroderma caregiver. My husband is a 
scleroderma patient; you might have read his story in the Scleroderma Foundation Tri- 
State newsletter, Scleroderma Exchange, recently. I am reaching out to you for assistance 
on a study that I am conducting as part of my doctoral dissertation on the experiences of 
scleroderma patients in managing their illness and learning to do so. I became interested 
in this subject after my husband’s diagnosis and my own involvement in learning about 
this illness. 
 
Enclosed is a two-part survey that will ask about your agreement or disagreement with 13 
statements that people make when they talk about taking care of their health, and the type 
of assistance and support that is available to them when they need it. I will be grateful if 
you take a few minutes to fill out this survey and the demographic information sheet that 
goes with it, and return them in the envelope that is provided. Alternatively, you may fill 
out the survey online: Please use the password: colorteal and the link to survey: 
http://tinyurl.com/SclerodermaSurvey (please email me at sva2111@tc.columbia.edu 
and I will email you a link to click on, if you have problems with typing this in.) Taking 
part in this survey is totally voluntary and anonymous: there are no personally 
identifiable information collected; I do not have any access to your name or contact 
information, and there is no way to link your survey and demographic information back 
to you. In addition, the demographic information and answers you provide will be 
combined with everyone else’s and will be presented in an aggregate form, not 
individually. 
 
In addition to the survey, I would appreciate the opportunity to interview a few patients 
and support group leaders about the journey you have been on. My interest is in 
understanding how adults learn when faced with a challenging situation like the one 
many scleroderma patients face. In dealing with this disease, you have learned and have 
become experts in managing your condition. I would love to hear your views on what has 
been your learning. The interviews that I have in mind will be informal and 
conversational in nature, and totally confidential. If you decide to participate, I ask you to 
allow me two occasions for our conversation, between 60 to 90 minutes each, at a time 
and location convenient to you. Interviews may be conducted over the phone or Skype, if 
an in-person interview cannot be arranged. If you are willing to share your insights about 
your learning, and what helps or hinders this process, please contact me or provide your 
contact information on the enclosed pink page, and I will get in touch with you. 
 
Regardless of whether you want to be interviewed or not, I hope you take a 
few minutes to fill out the survey. I truly appreciate your time and 
willingness to assist me in this project. Please feel free to contact me if I can 
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Shohreh V. Anand 
Doctoral Candidate, Adult Learning & Leadership -Teachers College, Columbia 
University Email: sva2111@tc.columbia.edu 
Phone: 914-xxx-xxxx, 





Survey Demographic Information 
 
Please choose the best answer for each question and mark your choice with an X in the 
box with that choice. 
	  
1.   Are	  you	  a	  scleroderma	  patient?	  
£   a)	  Yes,	  I	  have	  been	  diagnosed	  with	  
scleroderma	  by	  a	  doctor.	  
£   b)	  No,	  I	  am	  not	  a	  scleroderma	  
patient.	  	  
o   I	  am	  a	  family	  caregiver	  
o   I	  am	  a	  friend	  
o   Other	  
	  
2.   How	  long	  ago	  were	  you	  diagnosed	  with	  
scleroderma?	  
£   a)	  12	  months	  or	  less	  	  
£   b)	  1	  to	  <	  2	  years	  ago	  
£   c)	  2	  to	  <	  3	  years	  ago	  
£   d)	  3	  to	  <	  5	  years	  ago	  
£   e)	  5	  to	  <	  8	  years	  ago	  
£   f)	  8	  to	  10	  years	  ago	  
£   e)	  More	  than	  10	  years	  ago.	  
	  
3.   Which	  of	  the	  following	  describes	  your	  
type	  of	  scleroderma?	  
£   a)	  Localized	  (Morphea,	  Linear,	  En	  
coup	  de	  sabre)	  
£   b)	  Systemic-­‐	  Limited	  or	  CREST	  
£   c)	  Systemic-­‐Diffuse	  
£   d)	  Systemic-­‐	  Sine	  Scleroderma	  	  
£   e)	  I	  do	  not	  know.	  
	  
4.   Do	  you	  know	  your	  auto-­‐antibodies?	  
£  	  a)	  Yes	  
£  	  b)	  No	  
£  	  C)	  I	  am	  not	  sure.	  
5.   Please	  indicate	  your	  gender:	  
£  	  a)	  Female	  
£  	  b)	  Male	  
	  
6.   Please	  indicate	  your	  age	  range:	  
£   a)	  18-­‐29	  years	  old	  
£   b)	  30-­‐39	  years	  old	  
£   c)	  40-­‐49	  years	  old	  
£   d)	  50-­‐59	  years	  old	  
£   e)	  60-­‐69	  years	  old	  
£   f)	  70-­‐79	  years	  old	  
£   g)	  80	  years	  and	  over	  
	  
7.   Please	  indicate	  the	  highest	  level	  of	  
education	  completed?	  
£   a)	  Some	  High	  School	  
£   b)	  High	  School	  graduate	  
£   c)	  Some	  College	  
£   d)	  College	  graduate	  
£   e)	  Some	  postgraduate	  work	  
£   f)	  Postgraduate	  degree	  
	  
8.   What	  is	  your	  employment	  status?	  
£   a)	  I	  am	  working	  full-­‐time	  
£   b)	  I	  am	  working	  part-­‐time	  
£   c)	  I	  am	  a	  non-­‐working	  homemaker	  
£   d)	  I	  am	  a	  student	  
£   e)	  I	  am	  retired	  
£   	  f)	  I	  am	  disabled	  or	  on	  sick	  leave	  
£   g)	  I	  am	  unemployed	  
£   h)	  Other	  
	  
9.   How	  many	  doctors	  do	  you	  see	  for	  your	  
medical	  care?	  
£   a)	  1	  
£   b)	  2-­‐3	  
£   c)	  4-­‐5	  
£   d)	  More	  than	  5.	  
	  
10.   If	  you	  see	  a	  scleroderma	  expert,	  how	  far	  
do	  you	  have	  to	  travel	  to	  see	  this	  
doctor?	  
£   a)	  Less	  than	  24	  miles	  	  
£   b)	  25	  to	  49	  miles	  
£   c)	  50	  to	  99	  miles	  
£   d)	  100	  miles	  or	  more	  
£   e)	  I	  do	  not	  see	  a	  scleroderma	  
expert.	  
	  
11.   Which	  of	  these	  symptoms	  do	  you	  
experience?	  Please	  check	  all	  that	  apply.	  
£   a)	  Pain	  
£   b)	  Fatigue	  
£   c)	  Sleep	  disturbance	  
£   d)	  Depression	  




12.   Which	  of	  these	  organs	  are	  involved	  in	  
your	  illness?	  Please	  check	  all	  that	  apply.	  
£   a)	  Lung	  
£   b)	  Heart	  
£   c)	  Digital	  Ulcer/Raynaud	  	  
£   d)	  Gastro-­‐intestinal	  	  
£   e)	  Musculo-­‐skeletal,	  joints	  
£   f)	  Kidney	  
£   g)	  Skin	  
£   h)	  Other	  
	  
13.   Do	  you	  have	  other	  medical	  conditions	  
unrelated	  to	  scleroderma	  such	  as	  
cancer,	  diabetes,	  etc.?	  
£  	  a)	  Yes	  
£  	  b)	  No	  
£  	  c)	  I	  am	  not	  sure	  
	  	  
14.   Are	  you	  part	  of	  a	  support	  group?	  
£   a)	  Yes,	  I	  am	  a	  Support	  Group	  
Leader	  or	  Co-­‐Leader	  
£   b)	  Yes,	  I	  am	  a	  Support	  Group	  
Member	  




Please check one: 
£   A)	  I	  am	  just	  participating	  in	  the	  survey	  
part	  of	  this	  study.	  
	  
£   B)	  I	  want	  to	  be	  contacted	  for	  
interviews	  and	  I	  am	  including	  the	  pink	  
form	  (interview	  interest	  form)	  with	  my	  
survey.	  I	  understand	  that	  my	  
information	  will	  be	  kept	  confidential	  
and	  only	  researcher	  will	  have	  access	  to	  
my	  survey,	  and	  my	  demographic	  and	  
contact	  information.	  
 
£   C)	  I	  want	  to	  be	  contacted	  for	  
interviews,	  but	  I	  want	  my	  survey	  to	  be	  
anonymous.	  Therefore,	  I	  will	  contact	  
the	  researcher	  by	  email	  or	  phone	  to	  be	  
included	  in	  the	  interviews,	  or	  will	  send	  







Below are some statements that people sometimes make when they talk about their 
health. Please indicate how much you agree or disagree with each statement as it 
applies to you personally by circling your answer. Your answers should be what is 
true for you and not just what you think others want you to say. If the statement 
does not apply to you, circle N/A 
 
1. When all is said and done, I am the person who is 
responsible for taking care of my health 
Disagree 
Strongly 
Disagree Agree Agree 
Strongly 
N/A 
2. Taking an active role in my own health care is the most 
important thing that affects my health 
Disagree 
Strongly 
Disagree Agree Agree 
Strongly 
N/A 
3. I am confident I can help prevent or reduce problems 
associated with my health 
Disagree 
Strongly 
Disagree Agree Agree 
Strongly 
N/A 
4. I know what each of my prescribed medications do Disagree 
Strongly 
Disagree Agree Agree 
Strongly 
N/A 
5. I am confident that I can tell whether I need to go to the 




Disagree Agree Agree 
Strongly 
N/A 
6. I am confident that I can tell a doctor concerns I have 
even when he or she does not ask 
Disagree 
Strongly 
Disagree Agree Agree 
Strongly 
N/A 
7. I am confident that I can follow through on medical 
treatments I may need to do at home 
Disagree 
Strongly 
Disagree Agree Agree 
Strongly 
N/A 
8. I understand my health problems and what causes them Disagree 
Strongly 
Disagree Agree Agree 
Strongly 
N/A 




Disagree Agree Agree 
Strongly 
N/A 
10. I have been able to maintain (keep up with) lifestyle 
changes, like eating right or exercising 
Disagree 
Strongly 
Disagree Agree Agree 
Strongly 
N/A 
11. I know how to prevent problems with my health Disagree 
Strongly 
Disagree Agree Agree 
Strongly 
N/A 
12. I am confident I can figure out solutions when new 
problems arise with my health 
Disagree 
Strongly 
Disagree Agree Agree 
Strongly 
N/A 
13. I am confident that I can maintain lifestyle changes, 
like eating right and exercising, 
even during times of stress 
Disagree 
Strongly 




Insignia Health. Patient Activation Measure; Copyright © 2003-2010, University of 
Oregon. All Rights reserved. Patient Activation Measure is reproduced here for use in 








People sometimes look to others for companionship, assistance, or other types of 
support. How often is each of the following kinds of support available to you if you 
need it? Circle one number in each line. 
 
MOS social support survey is reproduced here with permission from the RAND 
Corporation. Copyright © the RAND Corporation. RAND’s permission to reproduce the 
survey is not an endorsement of the products, services, or other uses in which the survey 


















Someone you can count on to listen to you when 
you need to talk 
1 2 3 4 5 
Someone to give you information to help you 
understand a situation 
1 2 3 4 5 
Someone to give you good advice about a crisis 1 2 3 4 5 
Someone to confide in or talk to about yourself or 
your problems  
1 2 3 4 5 
Someone whose advice you really want 1 2 3 4 5 
Someone to share your most private worries and 
fears with 
1 2 3 4 5 
Someone to turn to for suggestions about how to 
deal with a personal problem 
1 2 3 4 5 
Someone who understands your problems 1 2 3 4 5 
Someone to help you if you were confined to bed 1 2 3 4 5 
Someone to take you to the doctor if you needed it 1 2 3 4 5 
Someone to prepare your meals if you were unable 
to do it yourself 
1 2 3 4 5 
Someone to help with daily chores if you were sick  1 2 3 4 5 
Someone who shows you love and affection 1 2 3 4 5 
Someone to love and make you feel wanted 1 2 3 4 5 
Someone who hugs you 1 2 3 4 5 
Someone to have a good time with 1 2 3 4 5 
Someone to get together with for relaxation 1 2 3 4 5 
Someone to do something enjoyable with 1 2 3 4 5 
Someone to do things with to help you get your 
mind off things 






1)   Please tell me, to the extent you want to share, your story of being diagnosed and 
living with scleroderma. 
2)   Given your story, what did you think, then, about what you needed to do to take care 
of yourself? 
3)   Do you recall making a conscious decision to  ___  (make a plan, have a role, be 
involved, be active, be engage, take responsibility, be in charge, have control, or 
other words that may have been used by interviewee) in order to take care of 
yourself? Describe the situation & your thoughts then. 
a.   (If yes to #3) What (incidents, realization, thoughts, events, encounters, 
etc.) did prompt you to make this decision? Describe what happened. Who 
else was involved and in what way? 
b.    (If yes to #3) So you said you wanted to (have a role, be involved, to have 
control, to be active, to be in charge, to take responsibility, or other words 
used by interviewee). What does _______ (having a role, being in control, 
etc.) mean to you? Or how does it look like for you? 
4)   When you first started on this journey, how did you get information and learned 
about your illness and treatments? Who/what did you use as sources of information?  
5)   How did you make sense of information you got? Were there other people who you 
consulted or were helpful in making sense of it? 
6)   Has the way you go about getting information, stayed the same, or changed in the 
course of your illness? How? 
7)   Here I have a list of types of things that people say they do when they are involved 
in managing an illness (list at the end of the protocol). Please pick the top 5 that 
stand out for you, or are especially important for you to do, and describe in details 
what you do and why these are important.  
8)   Were there times when you had to change course and do things that you had not 
done before- maybe some of the items on the list? Thinking back over this time, 
were you in situations where you felt you did not have all the knowledge and skills 
that you needed or did not know what to do? What did you do then to gain what was 
missing? What did make it easy or difficult for you to learn what you needed to 
learn? 
9)   How do you describe the familiarity with scleroderma of health providers (nurses, 
therapists, pharmacist, etc.) that you have encountered? What did you do when you 
felt they were not familiar with your condition? 
10)  How did you choose your main doctor when you were diagnosed with this illness? 
Were you ever had to change doctors?  
11)  Can you describe your expectations about your main doctor’s role, and your doctor’s 
visits? 
12)  When your doctor recommended a treatment, how did you decide what to do? Who 
else helped you decide? What kinds of things you look for to decide if a 
recommended treatment is appropriate for you? 




things that you notice or feel? (Do you wait to check with the doctor? ask other 
patients, etc.)?  
14)   When you notice something unfamiliar, or a new health situation occurs, how do 
you decide what to do? 
15)   Some say each scleroderma patient is unique in the symptoms he/she has and the 
response to treatments. Do you agree with that? How do you know if something is 
unique to you? Can you give some examples of the criteria that you use?  
16)   Do you modify treatments in any way to suit your individual situation?  
17)   If you have made life style changes (nutrition, exercise, stress reduction, etc.), or 
have tried alternative medicine, what are your thoughts as why you needed to 
experiment with these? 
18)   Do priorities in life change because of such an illness? How? 
19)    I am interested in your thoughts about some of the strategies, some of the steps you 
have or could have taken along the way, or the lessons learned. If you have to write 
an advice book for other patients what are some of the strategies and tips that you 
would give them? 
20)    What are some of the qualities that have helped you in this journey?  What other 
qualities do you think a patient should have? What do you think is the best way to 
develop these?  
21)   Do you enlist others, family, friends, co-workers, and professionals (your doctor, 
therapist, etc.), in the work of your care? How?  
22)   Do you participate in advocacy activities (support groups, research fundraising, 
etc)? If yes why is that important to you? 
23)   Are you part of a support group? Why or why not? 
If yes: 
a)   Tell me, what does being a support group leader/member mean to you? 
Why do you do it? 
b)   In your observation, what does involvement mean to the people in the 
support group? Does it come up where you might discuss how they have 
been involved in their illness or how they are thinking about it? If it has come 
up, can you give an example? 




What Some Patients Do 
1.   I seek Information about my medical condition and possible treatments. 
2.   I attend patient educational programs. 
3.   I ask questions and consult with others (doctors, patients, etc.) about my illness. 
4.   I keep up with the latest research. 
5.   I comply with medical treatments my doctor prescribed. 
6.   Sometimes I decide not to comply with medical treatments. 
7.   I evaluate if a treatment is working for me. 
8.   I evaluate the expertise of my doctor and change doctors if needed. 
9.   I evaluate the quality of care I am getting from doctors, nurses, clinic, or the 




10.   I pay attention to my body and observe and monitor it. 
11.   I experiment with alternative therapy. 
12.   I hypothesize about the causes of my illness and what might make it better or 
worse and talk to my doctor or other patients about these hypotheses. 
13.   I make lifestyle changes. 
14.   I develop strategies to manage my care and navigate the healthcare system, and to 
get what I need. 
15.   I do advocacy work. 
16.   I know how to mobilize the resources I need, and ask for help. 
17.   I think and reflect about my medical condition and what I can do about it. 
18.   I have found ways to live with my limitations. 
19.   I think differently about my roles and my priorities in life after my illness. 
20.   I do things to bring a sense of control and balance to my life.  
21.   I Feel empowered that there are variety of ways of dealing with my health 
condition outside the conventional boundaries and expectations. 
22.   I expect my experiences and knowledge of my illness are listened to by health 
professional.  
23.   I am involved in making decisions about my treatments. 
24.   I use coping skills to manage, and minimize the physical and psychological 
burdens of my condition. 
25.   I participate in self-management activities to take responsibility for my own care. 






Sample Framework Analysis 
Participant Words from Transcript Initial Thoughts Initial Category 
 I do what I am told by my doctor because I have 
no one else to trust. And I wake up every morning 
and say ok, put one foot in front of the other and 
keep going…  I can either let it overtake 
everything I am or I can plow on and hope for the 
best and keep going and that is what I do.  
Trusts doctor, no 
choice; 
Pushes through; 
Hopes for the best 
Has to trust doctor. 
Has to push through. 
Has to have hope. 
Those will be the kind of things that will be really 
helpful in educational programs to give people 
standards by which they can sort of measure … he 
[Dr]is pinching my skin and he is looking at stuff 
and I asked what is he doing. He said I am just 
checking your skin. What are you checking for tell 
me. Tell me, it should not be a secret from me. I 
want to know what signs you are looking for, or 
what are your measurements. 
Helpful to have 
measures. 
Wants to know signs 
to look for 
Wants measure, and signs 
of disease 
 I think that is really interesting that you have the 
same symptoms that I do, yet you react differently 
to the drug than I do. It makes you mind go, ok, if 
this is the case, if we look at all the same things 
why can’t we figure out why you are reacting 
differently than me if we are having the same 
symptoms going into it…Cancer used to be the kiss 
of death and they found ways to treat that. I do not 
understand what is so elusive about the etiology of 
this disease. 
Same symptoms, but 





The same but different 
from other patients. 
Unknown etiology 
frustrating. 
I mean I suck up information. I belong to the page 
on Facebook on National SSc foundation and lot 
of time I post academic articles and I read all of 
them and I print them out. I have a binder of stuff 
and keep track of different - there is a, trying to 
remember the name of it, it is an international 
clearinghouse of research trials for different drugs 
and I am constantly on that looking for that I can 
jump on board for.  
Sucks up 
information; 
Active online; reads 
research articles 
Information seeking. 
Sources: online, research 
articles. 
That the day is going to look like based on when I 
wake up. Generally, pretty much I am on the mark. 
I have gotten good at predicting. Again, altering 
what you do makes a huge difference. If my knees 
hurt in the morning I am not wearing heels, 
because it is going to hurt worst.  
 
Predicts the day. 
Has become good at 
predicating; 
What she does 
makes a big 
difference. 
It is going to hurt 
Anticipating; 
Experience; 
Doing makes a difference; 






Sample Themes and Codes 
Initial Themes Initial Codes 
Assessing care Not a good feeling about the medication that was prescribed. 
 
The only thing that really, really worked. 
 
 didn’t like side effects; had it under control already. 
 
Getting team of doctors in a SSc center	  
Anticipating-Planning Attacking problems differently 
 
Noting where can sit when walks 
 
prepare for cold weather with RP 
 
Learning from mistake  knees hurting wearing wrong shoe 
 
 Mistake going to Mayo Clinic  
 
Doctor giving wrong medication.  
 
Wasted visit with lab results not there 
 
Nurses not knowing how to draw blood. 
 
Doctor not monitoring drugs - dangerous blood levels 
 
Ignoring infection and having to have surgery 
 
Blood tests not accurate. 
Overcoming fear no longer frightens by symptoms 
 
 less frightened, better knowing than wondering. 
 
less scared with device 
 
Individualizing  Asking technician how compared to others. 
 






Comparison to Other Scleroderma Studies 




Gender & Age Education Employment 
    




























































24% 11% 27% 24-
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 <100 (5 studies)  11+/-8 37-67% 9-63% 13%  
 100 -500 (4 studies) 8.7+/- 8.3 42-75% 25-58%   
> 500 (5 studies) 11.25+/-9.2 62-83% 26-42%   
EUSTAR as of 6/2011 7655  57.7% 36.9%   
CSRG as of 3/2007 1465  63% 37%   
German as of 2/2007 1483  45.5-48.2% 31.6-32.7%   
Univ. of Pittsburg 
1972-2007 Steen (2012) 
3148  48.45% 43%   
This study 202 11.4+/-10 43.3% 34.3% 5.0% 9.5/8.0 














































































Table K3. Comparison Data, Symptoms, and Organ Involvement 
 















    30 22  100 75 13  33 
 100 -500 
(4 studies) 
 76           
> 500  
(5 studies) 
56-75 56-76 53 51         
EUSTAR 
As of 6/2011 
7655             
CSRG 
As of 3/2007 
1465     34.5        
German 
As of 2/2007 





3148     45  18 98 62.5 79.5 95 9.75 
This study 202  69 80 59 34 52  27 83 71 59 76 11 










































Themes and Patients’ Accounts 
Table L1. Obtaining a Diagnosis: Perception of Initial Encounters with Doctors 
 
Patient’s Perceptions Selected Patients’ Words 
Dismissive 
•   Patients not being heard 
•   Symptoms not taken 
seriously 
•   Unwillingness to order lab 
work 
•   Discarding patients’ 
evidences or hunches 
Ralph: [complained about extreme pain all the time] It “kind of bothered me [that 
doctor did not believe him,] because you think I am lying to you.” 
 
Sharyl: [ saw an article in NY Times with pictures identical to what happened to 
her hands. Took the article to her doctor.] “My doctor, he threw the clipping on 
the side and he said, ‘Don’t tell me. I’m the doctor. You have dry hands.’  
 
Fatalistic 
•   Nothing can be done 
•   You will die in 5-6 years 
•   Get your life in order 
•   Will have lung/heart 
failure 
•   Invoked fear 
Harper: “He [doctor] said, I have SSc and there is not much we can do at this 
time. We usually have five years and we will lose you.” 
 
Jenelle: ‘You’re going to die,’ but I just wasn’t listening … doctors were still telling 
people you had at most, six years.”  
 
Francis: [After 1 ½ years of doctor hopping finally a doctor diagnosed him, but 
refused to treat him] saying, “these are very complicated medicines …they have 
side effects”. “I said you know I am dying. If I am going to die, I am going to die 
trying.”  
Measured 
•   No explanation of disease 
was given 
•   No indication how disease 
might progress  
•   Patients felt confused as 
what they had and what 
could be done. 
“Marcia: [Doctor] calmly, blithely announced to me—he didn’t say anything 
about it but then he said, ‘You have SSc.’ Well, I had never heard of it before and 
he gave me no indication that it was anything to be especially concerned about or 
alarmed about. So as far as I was concerned, he could have been telling me that I 
had a bad cold. “ 
 
Bryce: I didn’t even know what to make of it. I was like, “Okay, can I get a cream 
that I can put on my hands? What is it?” He’s like, “No, it’s a little bit more 
involved than that. It’s a disease. It’s tough to say,” and there were no answers as 
far as, “Okay. Is this going to shorten my life?” “Well, we can’t really say.” 
Really, everybody is different and they really couldn’t say what it would mean for 
me as far as my life experience from that point on. So, I was just a little confused. 
 
Supportive 
•   Doctors were attentive and 
listening taking note of all 
symptoms 
•   A confirmatory diagnosis 
was given, with no 
ambiguity  
•   Nature of disease was 
made clear. 
•   Patient was informed of   
symptomatic treatment, 
but no cure-all 
•   The need for a team of 
doctors was explained 
•   Previous damages cannot 
be fixed 
•   Patients felt hopeful 
 
Winola: [Dr. said]: “yes, you have this and we can treat the symptoms. There’s 
really no one medication to take for the whole thing so we’re going to give you a 
great team. The team is going to work with you and we’re going to address the 
symptoms as they come up…. “[He] was always there for whenever I needed him. 
If I had any kind of question, he’d call me back personally himself. If it was seven 
or eight o’clock at night, he’d call me back himself, so I always felt comfortable if 
I had a problem because I knew I could get a hold of him. 
 
Kristeen: He wrote down so much and he asked so many questions and he did 
explain a lot to me, “Right now, you’re alright. You’re going to progress and 
we’re going to try and start things but for the moment, you’re okay.” And I think 






Table L2. Managing Relationships with Doctors 
 
Issues Select Patients’ Words 
Expertise Nicole: I would say she’s not a warm and fuzzy person. However, she is very thorough. You 
walk in she goes through a list of things that she has checked. As far as my progress, she 
explains why she wants me to do the next pieces that she always has for me. You leave from 
there feeling like she’s keeping up and she wants to make sure you are too.  
 
Lauren: A lot of people don’t like my rheumatologist but I like her. I think she’s just busy and 
honest mainly because my rheumatologist will say, “Well, go to the SSc center and get looked 
at.” She recognizes the fact she doesn’t have all the answers and I sort of like that. That’s fine 
if the doctor says, “I don’t know. Can I get back to you?” Or, “I don’t know. I got to think 
about that.” That’s fine. I’m not afraid of a doctor saying that to me. I actually think that’s 
probably good advice. 





Kristeen: I think that they being patience with me helps and then I can also ask them 
questions and they don’t act like they think it’s a stupid question even if they do think it’s a 
stupid question. If they at least treat me with respect, I think that I will do the same… So, I 
think sometimes, asking questions rattles them but yet, if you have a good physician, they will 
drop the façade and talk to you. 
 
Ralph: I expect him not to candy coat it; I just want to know what it is now and next and that 
is it. Tell me what it is, do not give me false hopes and as far as that goes you know, I know 
you are working on a cure and give me a call when you got it. Do not just tell me you are 
working on it. 
Lauren: So, what I want him to do—and many doctors do this very, very well- is they can give 
me an example of what treatment, how they think it’s going to help me. I want my doctor to 
tell me, “How do you think it’s going to help me, how it’s going to help the skin or this and 
that? Why do you think this? Not because your computer said this is the protocol for SSc. 
Changing doctors Mackenzie: That’s why I think I changed my doctor, the rheumatologist, because she really 
wasn’t giving me a lot of information…. [The new doctor,] She’s straightforward and she 
really cares. …She makes me understand things. 
 
Willa: Most important thing to me is practical expertise. Second, would be personal rapport, 
the ability to communicate. If the doctor is a poor communicator I would switch. 
Looking in the 
eyes 
Lauren: Do they look me in the eye?... It’s okay if they don’t but in my mind, it’s like, Okay, 
this guy is not seeing me as a person and his eye is on his tablet and he’s so focused that he’s 
doing the standard protocol and he’s not seeing the individuality. 
 
Kristeen: Well, when I went to see the primary care that I see now—I’ve seen him for all these 
years now—he didn’t look me in the eye but he wrote down so much and he asked so many 
questions and he did explain a lot to me. 
Patients’ role-
Expressive of 
their wants & 
needs 
Ralph: Listen to me I am the patient. I need to not have this pain and I rather have bleeding 
…these are the side effects, but they are side effects I live with; I choose to live with. To me it 
was easier to buy Band-Aid and keep them in my backpack than to go off of Prednisone … He 
kind of finally one day said you are right, kind of milestone, a marker so to speak where he 
said you know your own body, there are no two ways about it and that was his reaction. 
 
Lauren: I said, “I’ll work with you but you got to work with me…  I didn’t jump and all of a 
sudden voice all of this. First, I let him come in and ask and check me and do everything and 
then when it was time for me to talk, I explained about myself and my own feeling of how I 
want to wait taking medicine for this disease until I feel that I can’t function rather than the 




Laurie: At the moment, I feel that my doctor has slipped a little bit. Now, I know it’s because 
of the pressures of work. I know what’s happening at that hospital and I also know that she 
was away teaching … but I do expect a level of response and speed, one, and in depth. When I 
have queries, especially when it comes to being on the new drug and to do the side effects, 
they need to get back to you ASAP… At the moment, I’m a little upset with my doctor because 
I feel that she’s being a little, not dismissive, but just overly busy and hasn’t responded to me 






Kristeen: Yeah, I think at the beginning, I just did whatever they told me. They used to scare 
me. The doctors would scare me but like I said, I don’t know when it just started to change 
but I began to realize they get up in the morning and just like me every day and they may have 
gone to school for something but they don’t know everything and I’m really like—so maybe I 
know, too, and maybe we have to work together instead of me just listening to you. 
 
Laurie: I know some people are intimidated, but I am not intimidated by medical experts, not 
in the least… Sometimes, they’re surprised at the number of questions and the depth of 
questions and sometimes, they’re not. Again, as I said, it’s up to the patient to really educate 
themselves and knowledge is power and it takes away the fear. 
 
Rene: some people are afraid that they’re going to—they’re afraid of the feelings that the 
rheumatologist may have if they go elsewhere [for a 2nd opinion or treatment], but my 
experience is anybody that is worth their salt—or however they say it—is not going to mind. 
In fact, they welcome it.  
 
Table L3. Pursuing Effective Therapies 
 
Engagement with Finding 
Therapies Selected Patients’ Words 
•   Tittering drug, looking 




•   Determining efficacy 





















•  Insurance drug coverage 
complications 
Marcia:  I work with the doctor in tittering, for example. The doctor doesn’t know what 
the dose is for me so, “Take this and let’s see how that goes. If there’s a wrong 
reaction, if you’re taking too much, we’ll reduce it, or if it’s not working, we’ll increase 
it  
 
Winola: He had me on Cellcept (an immunosuppressant) and I was taking that and 
taking it and I did not notice anything different, nothing changed, nothing improved, 
nothing got worse or better so after six months, I finally told him, ‘This is not for me. I 
don’t notice any kind of change. I still feel the same way. Nothing is improving.’  So, we 
moved on and tried something else. 
 
Laurie: There were five, maybe six medications for PAH (pulmonary arterial 
hypertension secondary to SSc) when I was first diagnosed in ___  and it was a matter 
of the doctor finding which cocktail of medications were going to help you most, 
because everyone reacts so differently. So, there was a trial period where I was on the 
Viagra, … then she changed me to the Cialis, … and then this other new drug came on 
the market, Letairis. It was available and she said, ‘Let’s throw Letairis into the mix 
and see how you do.’   
 
Willa: I remember trying different drugs [for Raynaud’s]. I tried everything from 
Norvasc, Prozac, and nothing worked, really. I think the last one I tried was Revatio 
and I finally told my doctor I do not want to do anything … Revatio gave me a 
headache. It opened up all blood vessels not just the ones in your hands. So, my face 
gets flushed, my head starts hurting. I said I do not want to suffer through this for my 
fingers.   
 
Sandy:  He [doctor] gives me choices, like Methotrexate. He said we can try that with 
something else, and I said no I do not want to stay on Methotrexate. It is not working for 
me. It is making me sick. It makes me feel like crap. I understand, like for me Rituxan (a 
chemo drug that destroys B cells) is insanely expensive. To get the approval, he said we 
have to go through the steps. To say we tried this, we tried that for the insurance to 
approve it. Ok, fine I understand the hoops you have to jump through, but beyond that I do 
not want to just test everything. Let’s try that one. Let’s just go and try it… we had to try x, 
y, z. If we can try the minimum of what we have to try to get that approved, I am not just 
going to say ok [to every drug], because it is my life. 
 
Stacee: I have done 6 months of chemo, because one of the drugs that he prescribed 
which was Cellcept (a pill), all of a sudden, they stopped covering it on my insurance. I 










Select Patients’ Words 
Fear of 
Progression 
Paula: One educational forum I went to in __, it was like an eye opener to me: these people with 
cripple hands, mouths that could not close. I was upset, you know what, that could be me in a 
couple of years. 
 
Sandy: I went to a research seminar … I was in a room filled with other SSc patients and seeing 
the vast difference and seeing people with that, I felt bad saying this, but I feel like it is like you 
were like bird people because the skin so, the mouth is smaller and makes their nose look 




Rene: I think one of the toughest things that—this shouldn’t be one of the toughest things- but 
the physical changes that SSc does to you and if you saw a picture of me before and a picture of 
me now, pretty significantly different. 
 
 Francis: When I first got sick, I had people that I have not seen every day, a month or two they 
had not seen me; they have come to me face-to-face and they would not recognize me. Even now, 
I have people that I have not seen in 2 or 3 years. People come to me. I had a customer that came 
to me and asked me face to face saying I am looking for  ____. Here I am. 
 
Don’t look Sick Lauren: I think they all think I look good. I’m an invisible health issue so they don’t know. I 
mean, they know but they don’t know.  
 
Brittany: When people looked at me, they did not know what I was feeling inside. They really 
couldn’t tell. It wasn’t obvious. I didn’t have wrinkles. I actually looked good for a while…they 
didn’t know the pain because it was an internal pain. Even now, people do not realize—if they 
don’t see my hands, nobody would know. 
Sandy: I find one of the biggest difficulties is that because I look normal that people do not get 
what it is that I am dealing with…. So, when people usually like peoples’ reactions when I do 
have that conversation with them is like “but you look so healthy” and I am like, well I guess I 
should be thankful for that, you know. 
 
started me on a course of Cytoxan (chemo) intravenously. So, it was 10 hours at a time. 
It was terrible. So, I go in the morning and strapped up to the thing and infused over 10 
hours…I did it every 2 weeks for six month. It was bad. Then my hair started falling off 
and then they stopped that and then my insurance changed and they covered the 
Cellcept, so I went back on that and now, of course, it is not covered again and I do not 
know who are the people who make all these decisions. I just got a letter last week that 




Table L5. Sample Approaches to Coping 
 
Table L6. Dealing with Employment and Financial Impact 
 
Job/Financial 
Related Impact Select Patients’ Words 
Forced to change 
jobs 
Stacee: I actually changed jobs because I could not, I was in the ____, and I could not handle 
the instruments anymore. So, I had to change jobs to do something that did not require such a 
fine tactile movement… So, I got a job doing something in an office setting rather than the 
________. You know it is easier. I am not doing what I am trained to do; it is way downscale 
and I took a humongous pay cut. 
Having to 
continue working 
Laurie: I need to do a little bit more work because of social security- I’m four credits short of 
getting my social security benefits when I’m 65 … that’s my big concern at the moment is trying 
to earn these credits. People say, “Well, why don’t you go on disability?” I don’t feel I’m sick 




Patricia: I have 2 heaters at work and a heated mouse. I used to share an office with other 
people and they complained that it was too hot. So, they made me move. In the [workplace], 
there are all these machines, so it was like 68 degrees, and I am like I cannot do this. So, they 
made me move to the other side of the hallway, which is nice, but it is temporary for 3 months. I 
do not know where they’re going to make me move then, so I can run my heaters, so nobody 
complains. I wear hoodie, with the hood up at work every day because it is cold. I don’t want to 
turn purple, and people just give me the stares.  
Jenelle: I was in the [this] business so they are not very giving on giving you extra time away 
Coping 
Approaches Select Patients’ Words 
Attitudinal tactics: 
control what you 
can, 
determination 
To carry on, being 
inspired by people 
worse off 
Laurie: It’s just managing how the disease makes you feel… There’s a lot of SSc issues that 
we can’t do a thing about, but I think again, lifestyle changes. You’re just accepting that you 
can’t live your life the way that you would like to. There are limitations and just try to make 
the best when you do have a good day. You get out there, smell the roses, breathe the fresh 
air. 
 
Stacee: I wake up every morning and say ok, put one foot in front of the other and keep going. 
Regardless of how you feel, everybody has those days that you feel horrible, you know, the 
aches and pains, my skin hurts and my lungs hurt, but then you make up your mind: am I 
going to make it through this day or am I going be miserable all day? I have a job to do; I 
have kids. So, I can either let it overtake everything I am, or I can plow on and hope for the 
best and keep going and that is what I do… It is just a decision. It’s just a decision that you 
make. Am I going to be miserable? I am not.  
 
Rene:  There were always people worse than I was. I mean, my hands are bad but not 
anywhere near as bad as people … they couldn’t open their hands at all… it doesn’t serve its 
purpose to feel sorry for yourself. Maybe that’s just my nature. I don’t think I’ve ever really 
done that. You just figure out to do what we have to do. Do your best doing that. I don’t know 
Doing for others Sharyl: But I think the secret, too, when you’re not feeling well is that you try to still do for 
others … you don’t feel so sorry for yourself if you have something to do…. So, I think—one 
of the things would just be—to help others and get out of your own feeling sorry for yourself. 
That’s what it is. 
Not dwelling on 
illness 
Willa: I kind of accepted it at this point. It is part of what I have to do. It is just like what I 
mentioned before: I have to go to the doctor; I have more doctors than people who do not 
have this condition …  I guess I think about it, but I do not dwell on it. 
 
Ralph: I am not going to make myself crazy. There are too many other things in my life: 
we’ve got __ children and__ grandchildren and we are very involved in our church and I 




and it was high stress, long hours and very physical work. So that made it very difficult. So, I 
was also working with a company that was not very sympathetic at all. So, I told them about my 
situation and I tried to get some accommodations which they wouldn’t do and then I went out on 




Rene: It wasn’t easy because I finally got my Master’s degree. I was the first woman promoted 
to be a supervisor. I finally reached that level and then kaboom, you know. So, it was hard, but it 
is what it is. 
 
Winola: It was very hard. It’s so hard. Since July ___ and it’s so hard. I used to be a 
workaholic. 
 
Sandy: I remember the day:  I almost dropped a ___. It was like I hurt really bad that day. My 
legs were killing me, my hips were killing me, I just was in so much pain and I could not focus 
mentally. I almost drop this ____ and something just clicked. It was like, I cannot do this 
anymore, or at least for now. …. When I realized that I had to stop working that was definitely 




Patricia: Pittsburg [Univ. of Pittsburg’s SSc Center] is hard. I really avoid going there because 
it is out of network. So, I have to save up my money to go there. The last time I went, I think, I 
spent like $400-$500 just to see the doctor and then the prescription of course it did not cover. 
So, I had to try to get that prescription from my other [local] rheumatologist and then you do 
not want to piss him off- to be like “oh I went to Pittsburg, oops”, you know. So that is hard. 
Then I had the surgery done for my finger; they referred me to a guy in [my town] that does it. 
Well, the guy was covered, but the surgery facility was not covered. So that was another 3 
grand. Just hard. It bothers me that insurance companies just do not understand that you do not 
fit the cookie-cutter view and they just don’t- I mean I had like appeals and everything and they 
are like “no, because you are going to go back there and we have to pay again.”  I am like this 
is my finger, don’t you understand? 
 
Stacee: I actually found and made an appointment with an [SSc] specialist [out of town] …they 
called me back and said you do realize that we do not take your insurance? It costs $600 to walk 
through the door and any additional tests you have to pay out-of-pocket for it; it is usually 
ranges around $2500 for the first visit”. I said thank you very much you can have your 
appointment. 
 
Table L7. Handling Familial Relationships 
 





Laurie: It was very upsetting especially for my husband. He went to pieces when I was 
diagnosed. 
 
Stacee: My husband does a lot of research, but he gets scared. He gets scared by the 
information, that is why I say do not read everything … he is naturally frightened. We have been 
married a long time, we have kids, and naturally he is frightened. 
Family’s 
Involvement 
Paula: My daughter definitely [is involved], my husband 85% of the time, my son is oblivious to 
the world, so I do not think so. 
 
Mackenzie: My son is a mess but my daughter is very in tuned to my situation  
Maddison: I have a very, very supportive family. I have five siblings and so we’re quite close. 
So, I get a lot of support from them, my children, and my husband. 
Family’s lack of 
understanding or 
support 
Patricia: I am married but like [he]does not understand., and just gets upset about it… I mean 
there is not too much support 
Sandy: I think I did have a situation with my stepmother and she just could not wrap her head 
around the fact, like how can she be sick, like she looks normal. 
 
Brittany: I found that my parents—my father ... he never really acknowledged my condition, 




hands if you tried, if you wanted to.” That hurts because he didn’t know the seriousness. He never 
looked up my disease. He never learned about it.. 
Tactics used 
with family 
Laurie: With regard in the family, it’s to bring the family and make sure that they understand 
what’s going on, that they understand the medications you’re on and possible side effects and 
how they make you feel and how the disease makes you feel so that they are not—they don’t have 
disappointments. Say, you make a plan to do a family activity and then that day you’re just 
feeling lousy, just want to go to bed, that you can say freely, “I can’t do this today.” 
 
Stacee: Some days I do want to be miserable, some days I am just cranky. But again, I do not 
feel that the disease I have should affect everyone around me. Yes, it does affect them and as a 
family we deal with that stuff. 
 
Brittany: I just have learned that I do what I want to do and if I can’t do it, don’t feel bad about 
it. Don’t apologize; just say it’s too much for me. I have to just listen to myself… Don’t expect 
help. Say what you need. Like I’ll say to my son, “my garbage pail is really heavy. Can you 
bring it down Monday night for me? I don’t think I can manage it.” Then yes, he will do it. Or, 
“can you pick me up this?” …You have to be exactly specific but to just sit back and think 
they’re going to offer and say, “Hey, Ma! Do you need anything? You want me to come help you 
do that. I’ll give you an hour of my time,” which is what I’d love them to say…. I don’t want to 
beg. So that’s a hard thing when you don’t get help. 
 
Nicole: I would tell them I don’t want to hear about it. He [husband] would try, continually, try. 
My sister and my husband focused on what was out there, what people were doing. So 
[husband] could name at the time every doctor in the United States and everywhere and what 
studies they were doing and he would try to tell me that. My sister, like I said, she was doing 
some of the same things, my aunt … 
 
Table L8. Temporal Dimensions of Commitment 
 
Patients’ Reactions Selected Patients’ Words 
 
Period of Withdrawal 
lasting several years: 
The statistics indicating 
a high mortality rate 
within 5-10 years, was 
paralyzing to many 
creating a scary, 
confusing time, 
requiring time to “wrap 
one’s head around it”, 
and accept it. 
Kristeen: One statistic was 50% die within three to five years so that terrified me and had 
stuck in my heart. So, I think I stuck there, kind of like out of life, for a couple of years- not 
weeks but years ... I cried all the time. I didn’t want to do anything. I was terrified I was 
going to die tomorrow in my sleep and it was just awful…And then I don’t know exactly 
what clicked in my brain. One day, I woke up and I said, “you know what, it’s Monday 
and my life is wasting away sitting here. Tuesday is going to come tomorrow, and then 
Wednesday and let’s just get on with it.” And I think it was my own personal turning point 
when I just started to say, ‘Let’s do this.’ 
 
Mackenzie: I went through a period of time where I was like, “Poor me. Poor me.” I had 
to snap out of that… Just by talking to myself, and my friends that said, “Stop living like 
that. Start living with the solution, not the problem.” … Somewhere around four or five 
[years into illness], I started saying, “I got to start living this. I got to live with this 
disease. I got to figure that out.” 
 
Brenda: I guess you have to find that new normal. So, I think it took me a couple of years 
… I think I was quite confused… After I found that stabilization, it fell into place 
 
Maddison: It really took me two or three years to really [accept] this is it. This is what I 





resolve to fight on 
Kurt: it was difficult in the beginning and then I realized either I do something about it 
and succeed, or I crawl into a ball, go to a corner, wait to die …  I knew, almost from the 
beginning, I had to take [charge of] it. I knew from the beginning because that’s who I 
am. … it means to me that I just need to find ways to cope and survive. That’s what it boils 
down to.  
 
Winola: Well, what are you going to do about it? You’re going to sit there, you’re going 
to take it and you’re going to live with it and you’re going to learn to deal with it. You sit 
like crying over spilled milk? Lighten up and move on…. It wasn’t my attitude in the first 
month. I can honestly say that. I had a very negative attitude the first month but then after 
that, I just learned when I started researching it more and finding people who are living 
longer with it then I had a very positive attitude and I still have a very positive attitude 
about this.  
 
 
Table L9. Strategies 
 





Rene: I have found that having my own records is the best thing because if you go to a doctor 
and they, for some reason, they didn’t get your lab results or test results then sometimes, your 
whole visit is in vain. 
 
Lauren: I’ve always been a problem solver. Some thing’s online that I look up and say, “I can 
make that.” I make heat sacks. I put in flax seed and I sew the heat sacks and heat them up in 
the winter. I have one for the leg, two for the hands.  
 
Patricia: It [her academic training] definitely helps me thinking about things analytically. Like 





Marcia: My insurance, there is a program connected with Blue Cross/Blue Shield called 
health advocate. I love it … I called the university medical referral and they have kids there 
who just look at a book and give you the names of doctors and I wasn’t successful in finding a 
doctor then; they give you names but that’s all. Then you call the office, “We’re no longer 
taking new patients.” So anyway, this health advocate—…They gave me the names of three 
doctors and they said, “All three of them are taking new patients. Here are their names, their 
numbers. Call them and interview them.” And I did.  
Transactional 
Posture 
Patricia: I guess if that [treatment] is working for me, it is good, if not we have to do 
something else…  it makes symptoms better and there is no side effect. So, minimal side effects, 
the side effects I can tolerate and it do not diminish my life.  
 
Brittany: The podiatrist told me—because I asked if he would recommend surgery for my feet 
and he said no … Once I learned that he didn’t recommend surgery, even the inserts I buy are 
better than the ones that he had specially made. S, I’m kind of my own judge. 
Open to 
Experimentation 
Rene: I did participate in two clinical research trials after that. One of them was for [name of 
treatment] …. That one, I don’t know how much that helped. The other one has a big deal 
study for relapsing, which they had high hope for. I did it through the University of  
 
Patricia: So, I think a lot of it is diet, and trying to get the correct nutrition & vitamins and 
everything. I mean U.S. has a lot of – like a lot of stuff that are ok to eat here, to sell here, eat 
here like back home- I am from [another country] - back home you could not do that. Back 
home I can eat wheat. I can eat stuff with eggs in it and I do not get sick. Here I cannot do it. 
 
